Single nucleotide polymorphisms in genes

ABSTRACT

The invention provides nucleic acid segments of the human genome, particularly nucleic acid segments from a gene, including polymorphic sites. Allele-specific primers and probes hybridizing to regions flanking or containing these sites are also provided. The nucleic acids, primers and probes are used in applications such as phenotype correlations, forensics, paternity testing, medicine and genetic analysis. A role for the thrombospondin gene(s) in vascular disease is also disclosed. Use of single nucleotide polymorphisms in the thrombospondin gene(s) for diagnosis, prediction of clinical course and treatment response, development of therapeutics and development of cell-culture-based and animal models for research and treatment are disclosed.

RELATED APPLICATIONS

This application is a divisional of U.S. application Ser. No.09/657,472, filed Sep. 7, 2000, which claims the benefit of U.S.Provisional Application Serial No. 60/153,357, filed Sep. 10, 1999, U.S.Provisional Application Serial No. 60/220,947, filed Jul. 26, 2000, andU.S. Provisional Application Serial No. 60/225,724, filed Aug. 16, 2000,the entire teachings of all of which are incorporated herein byreference.

BACKGROUND OF THE INVENTION

The genomes of all organisms undergo spontaneous mutation in the courseof their continuing evolution, generating variant forms of progenitornucleic acid sequences (Gusella, Ann. Rev. Biochem. 55, 831-854 (1986)).The variant form may confer an evolutionary advantage or disadvantagerelative to a progenitor form, or may be neutral. In some instances, avariant form confers a lethal disadvantage and is not transmitted tosubsequent generations of the organism. In other instances, a variantform confers an evolutionary advantage to the species and is eventuallyincorporated into the DNA of many or most members of the species andeffectively becomes the progenitor form. In many instances, bothprogenitor and variant form(s) survive and co-exist in a speciespopulation. The coexistence of multiple forms of a sequence gives riseto polymorphisms.

Several different types of polymorphism have been reported. Arestriction fragment length polymorphism (RFLP) is a variation in DNAsequence that alters the length of a restriction fragment (Botstein etal., Am. J. Hum. Genet. 32, 314-331 (1980)). The restriction fragmentlength polymorphism may create or delete a restriction site, thuschanging the length of the restriction fragment. RFLPs have been widelyused in human and animal genetic analyses (see WO 90/13668; W090/11369;Donis-Keller, Cell 51, 319-337 (1987); Lander et al., Genetics 121,85-99 (1989)). When a heritable trait can be linked to a particularRFLP, the presence of the RFLP in an individual can be used to predictthe likelihood that the animal will also exhibit the trait.

Other polymorphisms take the form of short tandem repeats (STRs) thatinclude tandem di-, tri- and tetra-nucleotide repeated motifs. Thesetandem repeats are also referred to as variable number tandem repeat(VNTR) polymorphisms. VNTRs have been used in identity and paternityanalysis (U.S. Pat. No. 5,075,217; Armour et al., FEBS Lett. 307,113-115 (1992); Horn et al., WO 91/14003; Jeffreys, EP 370,719), and ina large number of genetic mapping studies.

Other polymorphisms take the form of single nucleotide variationsbetween individuals of the same species. Such polymorphisms are far morefrequent than RFLPs, STRs and VNTRs. Some single nucleotidepolymorphisms (SNP) occur in protein-coding nucleic acid sequences(coding sequence SNP (cSNP)), in which case, one of the polymorphicforms may give rise to the expression of a defective or otherwisevariant protein and, potentially, a genetic disease. Examples of genesin which polymorphisms within coding sequences give rise to geneticdisease include β-globin (sickle cell anemia), apoE4 (Alzheimer'sDisease), Factor V Leiden (thrombosis), and CFTR (cystic fibrosis).cSNPs can alter the codon sequence of the gene and therefore specify analternative amino acid. Such changes are called “missense” when anotheramino acid is substituted, and “nonsense” when the alternative codonspecifies a stop signal in protein translation. When the cSNP does notalter the amino acid specified the cSNP is called “silent”.

Other single nucleotide polymorphisms occur in noncoding regions. Someof these polymorphisms may also result in defective protein expression(e.g., as a result of defective splicing). Other single nucleotidepolymorphisms have no phenotypic effects.

Single nucleotide polymorphisms can be used in the same manner as RFLPsand VNTRs, but offer several advantages. Single nucleotide polymorphismsoccur with greater frequency and are spaced more uniformly throughoutthe genome than other forms of polymorphism. The greater frequency anduniformity of single nucleotide polymorphisms means that there is agreater probability that such a polymorphism will be found in closeproximity to a genetic locus of interest than would be the case forother polymorphisms. The different forms of characterized singlenucleotide polymorphisms are often easier to distinguish than othertypes of polymorphism (e.g., by use of assays employing allele-specifichybridization probes or primers).

Only a small percentage of the total repository of polymorphisms inhumans and other organisms has been identified. The limited number ofpolymorphisms identified to date is due to the large amount of workrequired for their detection by conventional methods. For example, aconventional approach to identifying polymorphisms might be to sequencethe same stretch of DNA in a population of individuals by dideoxysequencing. In this type of approach, the amount of work increases inproportion to both the length of sequence and the number of individualsin a population and becomes impractical for large stretches of DNA orlarge numbers of persons.

SUMMARY OF THE INVENTION

Work described herein pertains to the identification of polymorphismswhich can predispose individuals to disease, by resequencing largenumbers of genes in a large number of individuals. Various genes from anumber of individuals have been resequenced as described herein, andSNPs in these genes have been discovered (see the Table and FIG. 3).Some of these SNPs are cSNPs which specify a different amino acidsequence, some of the SNPs are silent cSNPs and some of these cSNPsspecify a stop signal in protein translation. Some of the identifiedSNPs were located in non-coding regions.

The invention relates to a gene which comprises a single nucleotidepolymorphism at a specific location. In a particular embodiment theinvention relates to the variant allele of a gene having a singlenucleotide polymorphism, which variant allele differs from a referenceallele by one nucleotide at the site(s) identified in the Table and FIG.3. Complements of these nucleic acid sequences are also included. Thenucleic acid molecules can be DNA or RNA, and can be double- orsingle-stranded. Nucleic acid molecules can be, for example, 5-10, 5-15,10-20, 5-25, 10-30, 10-50 or 10-100 bases long.

The invention further provides allele-specific oligonucleotides thathybridize to the reference or variant allele of a gene comprising asingle nucleotide polymorphism or to the complement thereof. Theseoligonucleotides can be probes or primers.

The invention further provides a method of analyzing a nucleic acid froman individual. The method determines which base is present at any one ofthe polymorphic sites shown in the Table and/or FIG. 3. Optionally, aset of bases occupying a set of the polymorphic sites shown in the Tableand/or FIG. 3 is determined. This type of analysis can be performed on anumber of individuals, who are tested for the presence of a diseasephenotype. The presence or absence of disease phenotype is thencorrelated with a base or set of bases present at the polymorphic siteor sites in the individuals tested.

Thus, the invention further relates to a method of predicting thepresence, absence, likelihood of the presence or absence, or severity ofa particular phenotype or disorder associated with a particulargenotype. The method comprises obtaining a nucleic acid sample from anindividual and determining the identity of one or more bases(nucleotides) at polymorphic sites of genes described herein, whereinthe presence of a particular base is correlated with a specifiedphenotype or disorder, thereby predicting the presence, absence,likelihood of the presence or absence, or severity of the phenotype ordisorder in the individual.

The thrombospondins are a family of extracellular matrix (ECM)glycoproteins that modulate many cell behaviors including adhesion,migration, and proliferation. Thrombospondins (also known as thrombinsensitive proteins or TSPs) are large molecular weight glycoproteinscomposed of three identical disulfide-linked polypeptide chains. Theresults described herein also reveal an important association betweenalterations, particularly SNPs, in TSP genes, particularly TSP-1 andTSP-4, and vascular disease. In particular, SNPs in these genes whichare associated with premature coronary artery disease (CAD)(or coronaryheart disease) and myocardial infarction (MI) have been identified andrepresent a potentially vital marker of upstream biology influencing thecomplex process of atherosclerotic plaque generation and vulnerability.

Thus, the invention relates to the TSP gene SNPs identified as describedherein, both singly and in combination, as well as to the use of theseSNPs, and others in TSP genes, particularly those nearby in linkagedisequilibrium with these SNPs, for diagnosis, prediction of clinicalcourse and treatment response for vascular disease, development of newtreatments for vascular disease based upon comparison of the variant andnormal versions of the gene or gene product, and development ofcell-culture based and animal models for research and treatment ofvascular disease. The invention further relates to novel compounds andpharmaceutical compositions for use in the diagnosis and treatment ofsuch disorders. In preferred embodiments, the vascular disease is CAD orMI.

The invention relates to isolated nucleic acid molecules comprising allor a portion of the variant allele of TSP-1 (e.g., as exemplified by SEQID NO: 1), and to isolated nucleic acid molecules comprising all or aportion of the variant allele of TSP-4 (e.g., as exemplified by SEQ IDNO: 3). Preferred portions are at least 10 contiguous nucleotides andcomprise the polymorphic site, e.g., a portion of SEQ ID NO: 1 which isat least 10 contiguous nucleotides and comprises the “G” at position2210, or a portion of SEQ ID NO: 3 which is at least 10 contiguousnucleotides and comprises the “C” at position 1186. The inventionfurther relates to isolated gene products, e.g., polypeptides orproteins, which are encoded by a nucleic acid molecule comprising all ora portion of the variant allele of TSP-1 or TSP-4 (e.g., SEQ ID NO: 1 orSEQ ID NO: 3, respectively). The invention also relates to nucleic acidmolecules which hybridize to and/or share identity with the variantalleles identified herein (or their complements) and which also comprisethe variant nucleotide at the SNP site.

The invention further relates to isolated proteins or polypeptidescomprising all or a portion of the variant amino acid sequence of TSP-1(e.g., as exemplified by SEQ ID NO: 2), and to isolated proteins orpolypeptides comprising all or a portion of the variant amino acidsequence of TSP-4 (e.g., as exemplified by SEQ ID NO: 4). Preferredpolypeptides are at least 10 contiguous amino acids and comprise thepolymorphic amino acid, e.g., a portion of SEQ ID NO: 2 which is atleast 10 contiguous amino acids and comprises the serine at residue 700,or a portion of SEQ ID NO: 4 which is at least 10 contiguous amino acidsand comprises the proline at residue 387. The invention further relatesto isolated nucleic acid molecules encoding such proteins andpolypeptides, as well as to antibodies which bind, e.g., specifically,to such proteins and polypeptides.

The invention further relates to a method of diagnosing or aiding in thediagnosis of a disorder associated with the presence of one or more of(a) a G at nucleotide position 2210 of SEQ ID NO: 1; or (b) a C atnucleotide position 1186 of SEQ ID NO: 3 in an individual. The methodcomprises obtaining a nucleic acid sample from the individual anddetermining the nucleotide present at one or more of the indicatednucleotide positions, wherein presence of one or more of (a) a G atnucleotide position 2210 of SEQ ID NO: 1; or (b) a C at nucleotideposition 1186 of SEQ ID NO: 3 is indicative of increased likelihood ofsaid disorder in the individual as compared with an appropriate control,e.g., an individual having the reference nucleotide at one or more ofsaid positions. In a particular embodiment the disorder is a vasculardisease selected from the group consisting of atherosclerosis, coronaryheart or artery disease, MI, stroke, peripheral vascular diseases,venous thromboembolism and pulmonary embolism. In a preferredembodiment, the vascular disease is selected from the group consistingof CAD and MI.

The invention further relates to a method of diagnosing or aiding in thediagnosis of a disorder associated with one or more of (a) a G atnucleotide position 2210 of SEQ ID NO: 1; or (b) a C at nucleotideposition 1186 of SEQ ID NO: 3 in an individual. The method comprisesobtaining a nucleic acid sample from the individual and determining thenucleotide present at one or more of the indicated nucleotide positions,wherein presence of one or more of (a) an A at nucleotide position 2210of SEQ ID NO: 1; or (b) a G at nucleotide position 1186 of SEQ ID NO: 3is indicative of decreased likelihood of said disorder in the individualas compared with an appropriate control, e.g., an individual having thevariant nucleotide at said position. In a particular embodiment thedisorder is a vascular disease selected from the group consisting ofatherosclerosis, coronary heart or artery disease, MI, stroke,peripheral vascular diseases, venous thromboembolism and pulmonaryembolism. In a preferred embodiment, the vascular disease is selectedfrom the group consisting of CAD and MI.

In one embodiment, the invention relates to a method for predicting thelikelihood that an individual will have a vascular disease (or aiding inthe diagnosis of a vascular disease), comprising the steps of obtaininga DNA sample from an individual to be assessed and determining thenucleotide present at one or more of nucleotide positions 2210 of SEQ IDNO: 1 or 1186 of SEQ ID NO: 3. The presence of the reference nucleotideat one or more of these positions indicates that the individual has alower likelihood of having a vascular disease than an individual havingthe variant nucleotide at one or more of these positions, or a lowerlikelihood of having severe symptomology. In a particular embodiment,the individual is an individual at risk for development of a vasculardisease.

The invention further relates to a method of diagnosing or aiding in thediagnosis of a disorder associated with the presence of one or more of(a) a serine at amino acid position 700 of SEQ ID NO: 2; or (b) aproline at amino acid position 387 of SEQ ID NO: 4 in an individual. Themethod comprises obtaining a biological sample containing the TSP-1and/or TSP-4 protein or relevant portion thereof from the individual anddetermining the amino acid present at one or more of the indicated aminoacid positions, wherein presence of one or more of (a) a serine at aminoacid position 700 of SEQ ID NO: 2; or (b) a proline at amino acidposition 387 of SEQ ID NO: 4 is indicative of increased likelihood ofsaid disorder in the individual as compared with an appropriate control,e.g., an individual having the reference amino acid at one or more ofsaid positions.

The invention further relates to a method of diagnosing or aiding in thediagnosis of a disorder associated with one or more of (a) a serine atamino acid position 700 of SEQ ID NO: 2; or (b) a proline at amino acidposition 387 of SEQ ID NO: 4 in an individual. The method comprisesobtaining a biological sample containing the TSP-1 and/or TSP-4 proteinor relevant portion thereof from the individual and determining theamino acid present at one or more of the indicated amino acid positions,wherein presence of one or more of (a) an asparagine at amino acidposition 700 of SEQ ID NO: 2; or (b) an alanine at amino acid position387 of SEQ ID NO: 4 is indicative of decreased likelihood of saiddisorder in the individual as compared with an appropriate control,e.g., an individual having the variant amino acid at one or more of saidpositions.

In one embodiment, the invention relates to a method for predicting thelikelihood that an individual will have a vascular disease (or aiding inthe diagnosis of a vascular disease), comprising the steps of obtaininga biological sample comprising the TSP-1 and/or TSP-4 protein orrelevant portion thereof from an individual to be assessed anddetermining the amino acid present at one or more of amino acidpositions 700 of SEQ ID NO: 2 or 387 of SEQ ID NO: 4. The presence ofthe reference amino acid at one or more of these positions indicatesthat the individual has a lower likelihood of having a vascular diseasethan an individual having the variant amino acid at one or more of thesepositions, or a lower likelihood of having severe symptomology. In aparticular embodiment, the individual is an individual at risk fordevelopment of a vascular disease.

In another embodiment, the invention relates to pharmaceuticalcompositions comprising a reference TSP-1 and/or TSP-4 gene or geneproduct, or active portion thereof, for use in the treatment of vasculardiseases. The invention further relates to the use of agonists andantagonists of TSP-1 and TSP-4 activity for use in the treatment ofvascular diseases. In a particular embodiment the vascular disease isselected from the group consisting of atherosclerosis, coronary heart orartery disease, MI, stroke, peripheral vascular diseases, venousthromboembolism and pulmonary embolism. In a preferred embodiment, thevascular disease is selected from the group consisting of CAD and MI.

BRIEF DESCRIPTION OF THE DRAWINGS

FIGS. 1A-1D show the reference nucleotide (SEQ ID NO: 1) and amino acid(SEQ ID NO: 2) sequences for TSP-1.

FIGS. 2A-2C show the reference nucleotide (SEQ ID NO: 3) and amino acid(SEQ ID NO: 4) sequences for TSP-4.

FIG. 3 shows a table providing detailed information about the SNPsidentified herein. Column one shows the internal polymorphismidentifier. Column two shows the accession number for the referencesequence in the TIGR database which can be found on the world wide webat tigr.org/tdb/hgi/searching/hgigreports.html. Column three shows thenucleotide position for the SNP site. Column four shows the gene inwhich the polymorphism was identified. Column five shows the polymorphicsite and additional flanking sequence on each side of the polymorphism.Column six shows the type of mutation produced by the polymorphism.Columns seven and eight show the reference and alternate (variant)nucleotides, respectively, for the SNP. Columns nine and ten show thereference and alternate (variant) amino acids, respectively, encoded bythe alleles of the gene.

DETAILED DESCRIPTION OF THE INVENTION

The present invention relates to a gene which comprises a singlenucleotide polymorphism (SNP) at a specific location. The gene whichincludes the SNP has at least two alleles, referred to herein as thereference allele and the variant allele. The reference allele(prototypical or wild type allele) has been designated arbitrarily andtypically corresponds to the nucleotide sequence of the gene which hasbeen deposited with GenBank or TIGR under a given Accession number. Thevariant allele differs from the reference allele by one nucleotide atthe site(s) identified in the Table. The present invention also relatesto variant alleles of the described genes and to complements of thevariant alleles. The invention also relates to nucleic acid moleculeswhich hybridize to and/or share identity with the variant allelesidentified herein (or their complements) and which also comprise thevariant nucleotide at the SNP site.

The invention further relates to portions of the variant alleles andportions of complements of the variant alleles which comprise(encompass) the site of the SNP and are at least 5 nucleotides inlength. Portions can be, for example, 5-10, 5-15, 10-20, 5-25, 10-30,10-50 or 10-100 bases long. For example, a portion of a variant allelewhich is 21 nucleotides in length includes the single nucleotidepolymorphism (the nucleotide which differs from the reference allele atthat site) and twenty additional nucleotides which flank the site in thevariant allele. These nucleotides can be on one or both sides of thepolymorphism. Polymorphisms which are the subject of this invention aredefined in the Table with respect to the reference sequence deposited inGenBank or TIGR under the Accession number indicated. For example, theinvention relates to a portion of a gene (e.g., AT3) having a nucleotidesequence as deposited in GenBank (e.g., U11270) comprising a singlenucleotide polymorphism at a specific position (e.g., nucleotide 11918).The reference nucleotide for AT3 is shown in column 8, and the variantnucleotide is shown in column 9 of the Table. The nucleotide sequencesof the invention can be double- or single-stranded.

The invention further provides allele-specific oligonucleotides thathybridize to the reference or variant allele of a gene comprising asingle nucleotide polymorphism or to the complement thereof. Theseoligonucleotides can be probes or primers.

The invention further provides a method of analyzing a nucleic acid froman individual. The method determines which base is present at any one ofthe polymorphic sites shown in the Table and/or FIG. 3. Optionally, aset of bases occupying a set of the polymorphic sites shown in the Tableand/or FIG. 3 is determined. This type of analysis can be performed on anumber of individuals, who are tested for the presence of a diseasephenotype. The presence or absence of disease phenotype is thencorrelated with a base or set of bases present at the polymorphic siteor sites in the individuals tested.

Thus, the invention further relates to a method of predicting thepresence, absence, likelihood of the presence or absence, or severity ofa particular phenotype or disorder associated with a particulargenotype. The method comprises obtaining a nucleic acid sample from anindividual and determining the identity of one or more bases(nucleotides) at polymorphic sites of genes described herein, whereinthe presence of a particular base is correlated with a specifiedphenotype or disorder, thereby predicting the presence, absence,likelihood of the presence or absence, or severity of the phenotype ordisorder in the individual.

Definitions

A nucleic acid molecule or oligonucleotide can be DNA or RNA, andsingle- or double-stranded. Nucleic acid molecules and oligonucleotidescan be naturally occurring or synthetic, but are typically prepared bysynthetic means. Preferred nucleic acid molecules and oligonucleotidesof the invention include segments of DNA, or their complements, whichinclude any one of the polymorphic sites shown in the Table. Thesegments can be between 5 and 250 bases, and, in specific embodiments,are between 5-10, 5-20, 10-20, 10-50, 20-50 or 10-100 bases. Forexample, the segment can be 21 bases. The polymorphic site can occurwithin any position of the segment. The segments can be from any of theallelic forms of DNA shown in the Table.

As used herein, the terms “nucleotide”, “base” and “nucleic acid” areintended to be equivalent. The terms “nucleotide sequence”, “nucleicacid sequence”, “nucleic acid molecule” and “segment” are intended to beequivalent.

Hybridization probes are oligonucleotides which bind in a base-specificmanner to a complementary strand of nucleic acid. Such probes includepeptide nucleic acids, as described in Nielsen et al., Science 254,1497-1500 (1991). Probes can be any length suitable for specifichybridization to the target nucleic acid sequence. The most appropriatelength of the probe may vary depending upon the hybridization method inwhich it is being used; for example, particular lengths may be moreappropriate for use in microfabricated arrays, while other lengths maybe more suitable for use in classical hybridization methods. Suchoptimizations are known to the skilled artisan. Suitable probes andprimers can range from about 5 nucleotides to about 30 nucleotides inlength. For example, probes and primers can be 5, 6, 8, 10, 12, 14, 16,18, 20, 22, 24, 25, 26, 28 or 30 nucleotides in length. The probe orprimer preferably overlaps at least one polymorphic site occupied by anyof the possible variant nucleotides. The nucleotide sequence cancorrespond to the coding sequence of the allele or to the complement ofthe coding sequence of the allele.

As used herein, the term “primer” refers to a single-strandedoligonucleotide which acts as a point of initiation of template-directedDNA synthesis under appropriate conditions (e.g., in the presence offour different nucleoside triphosphates and an agent for polymerization,such as DNA or RNA polymerase or reverse transcriptase) in anappropriate buffer and at a suitable temperature. The appropriate lengthof a primer depends on the intended use of the primer, but typicallyranges from 15 to 30 nucleotides. Short primer molecules generallyrequire cooler temperatures to form sufficiently stable hybrid complexeswith the template. A primer need not reflect the exact sequence of thetemplate, but must be sufficiently complementary to hybridize with atemplate. The term primer site refers to the area of the target DNA towhich a primer hybridizes. The term primer pair refers to a set ofprimers including a 5′ (upstream) primer that hybridizes with the 5′ endof the DNA sequence to be amplified and a 3′ (downstream) primer thathybridizes with the complement of the 3′ end of the sequence to beamplified.

As used herein, linkage describes the tendency of genes, alleles, locior genetic markers to be inherited together as a result of theirlocation on the same chromosome. It can be measured by percentrecombination between the two genes, alleles, loci or genetic markers.

As used herein, polymorphism refers to the occurrence of two or moregenetically determined alternative sequences or alleles in a population.A polymorphic marker or site is the locus at which divergence occurs.Preferred markers have at least two alleles, each occurring at frequencyof greater than 1%, and more preferably greater than 10% or 20% of aselected population. A polymorphic locus may be as small as one basepair. Polymorphic markers include restriction fragment lengthpolymorphisms, variable number of tandem repeats (VNTR's), hypervariableregions, minisatellites, dinucleotide repeats, trinucleotide repeats,tetranucleotide repeats, simple sequence repeats, and insertion elementssuch as Alu. The first identified allelic form is arbitrarily designatedas the reference form and other allelic forms are designated asalternative or variant alleles. The allelic form occurring mostfrequently in a selected population is sometimes referred to as thewildtype form. Diploid organisms may be homozygous or heterozygous forallelic forms. A diallelic or biallelic polymorphism has two forms. Atriallelic polymorphism has three forms.

Work described herein pertains to the resequencing of large numbers ofgenes in a large number of individuals to identify polymorphisms whichcan predispose individuals to disease. For example, polymorphisms ingenes which are expressed in liver may predispose individuals todisorders of the liver. By altering amino acid sequence, SNPs may alterthe function of the encoded proteins. The discovery of the SNPfacilitates biochemical analysis of the variants and the development ofassays to characterize the variants and to screen for pharmaceuticalthat would interact directly with on or another form of the protein.SNPs (including silent SNPs) also enable the development of specificDNA, RNA, or protein-based diagnostics that detect the presence orabsence of the polymorphism in particular conditions.

A single nucleotide polymorphism occurs at a polymorphic site occupiedby a single nucleotide, which is the site of variation between allelicsequences. The site is usually preceded by and followed by highlyconserved sequences of the allele (e.g., sequences that vary in lessthan 1/100 or 1/1000 members of the populations).

A single nucleotide polymorphism usually arises due to substitution ofone nucleotide for another at the polymorphic site. A transition is thereplacement of one purine by another purine or one pyrimidine by anotherpyrimidine. A transversion is the replacement of a purine by apyrimidine or vice versa. Single nucleotide polymorphisms can also arisefrom a deletion of a nucleotide or an insertion of a nucleotide relativeto a reference allele. Typically the polymorphic site is occupied by abase other than the reference base. For example, where the referenceallele contains the base “T” at the polymorphic site, the altered allelecan contain a “C”, “G” or “A” at the polymorphic site.

The invention also relates to nucleic acid molecules which hybridize tothe variant alleles identified herein (or their complements) and whichalso comprise the variant nucleotide at the SNP site. Hybridizations areusually performed under stringent conditions, for example, at a saltconcentration of no more than 1 M and a temperature of at least 25° C.For example, conditions of 5×SSPE (750 mM NaCl, 50 mM NaPhosphate, 5 mMEDTA, pH 7.4) and a temperature of 25-30° C., or equivalent conditions,are suitable for allele-specific probe hybridizations. Equivalentconditions can be determined by varying one or more of the parametersgiven as an example, as known in the art, while maintaining a similardegree of identity or similarity between the target nucleotide sequenceand the primer or probe used.

The invention also relates to nucleic acid molecules which sharesubstantial sequence identity to the variant alleles identified herein(or their complements) and which also comprise the variant nucleotide atthe SNP site. Particularly preferred are nucleic acid molecules andfragments which have at least about 60%, preferably at least about 70,80 or 85%, more preferably at least about 90%, even more preferably atleast about 95%, and most preferably at least about 98% identity withnucleic acid molecules described herein. The percent identity of twonucleotide or amino acid sequences can be determined by aligning thesequences for optimal comparison purposes (e.g., gaps can be introducedin the sequence of a first sequence). The nucleotides or amino acids atcorresponding positions are then compared, and the percent identitybetween the two sequences is a function of the number of identicalpositions shared by the sequences (i.e., % identity=# of identicalpositions/total # of positions×100). In certain embodiments, the lengthof a sequence aligned for comparison purposes is at least 30%,preferably at least 40%, more preferably at least 60%, and even morepreferably at least 70%, 80% or 90% of the length of the referencesequence. The actual comparison of the two sequences can be accomplishedby well-known methods, for example, using a mathematical algorithm. Apreferred, non-limiting example of such a mathematical algorithm isdescribed in Karlin et al., Proc. Natl. Acad. Sci. USA, 90:5873-5877(1993). Such an algorithm is incorporated into the NBLAST and XBLASTprograms (version 2.0) as described in Altschul et al., Nucleic AcidsRes., 25:389-3402 (1997). When utilizing BLAST and Gapped BLASTprograms, the default parameters of the respective programs (e.g.,NBLAST) can be used. See the world wide web at ncbi.nlm.nih.gov. In oneembodiment, parameters for sequence comparison can be set at score=100,wordlength=12, or can be varied (e.g., W=5 or W=20).

The term “isolated” is used herein to indicate that the material inquestion exists in a physical milieu distinct from that in which itoccurs in nature. For example, an isolated nucleic acid of the inventionmay be substantially isolated with respect to the complex cellularmilieu in which it naturally occurs. In some instances, the isolatedmaterial will form part of a composition (for example, a crude extractcontaining other substances), buffer system or reagent mix. In othercircumstance, the material may be purified to essential homogeneity, forexample as determined by PAGE or column chromatography such as HPLC.Preferably, an isolated nucleic acid comprises at least about 50, 80 or90 percent (on a molar basis) of all macromolecular species present.

I. Novel Polymorphisms of the Invention

Some of the novel polymorphisms of the invention are shown in the Table.Columns one and two show designations for the indicated polymorphism.Column three shows the Genbank or TIGR Accession number for the wildtype (or reference) allele. Column four shows the location of thepolymorphic site in the nucleic acid sequence with reference to theGenbank or TIGR sequence shown in column three. Column five shows commonnames for the gene in which the polymorphism is located. Column sixshows the polymorphism and a portion of the 3′ and 5′ flanking sequenceof the gene. Column seven shows the type of mutation; N, non-sense, S,silent, M, missense. Columns eight and nine show the reference andalternate nucleotides, respectively, at the polymorphic site. Columnsten and eleven show the reference and alternate amino acids,respectively, encoded by the reference and variant, respectively,alleles. Other novel polymorphisms of the invention are shown in FIG. 3.

II. Analysis of Polymorphisms

A. Preparation of Samples

Polymorphisms are detected in a target nucleic acid from an individualbeing analyzed. For assay of genomic DNA, virtually any biologicalsample (other than pure red blood cells) is suitable. For example,convenient tissue samples include whole blood, semen, saliva, tears,urine, fecal material, sweat, buccal, skin and hair. For assay of cDNAor mRNA, the tissue sample must be obtained from an organ in which thetarget nucleic acid is expressed. For example, if the target nucleicacid is a cytochrome P450, the liver is a suitable source.

Many of the methods described below require amplification of DNA fromtarget samples. This can be accomplished by e.g., PCR. See generally PCRTechnology: Principles and Applications for DNA Amplification (ed. H. A.Erlich, Freeman Press, NY, N.Y., 1992); PCR Protocols: A Guide toMethods and Applications (eds. Innis, et al., Academic Press, San Diego,Calif., 1990); Mattila et al., Nucleic Acids Res. 19, 4967 (1991);Eckert et al., PCR Methods and Applications 1, 17 (1991); PCR (eds.McPherson et al., IRL Press, Oxford); and U.S. Pat. No. 4,683,202.

Other suitable amplification methods include the ligase chain reaction(LCR) (see Wu and Wallace, Genomics 4, 560 (1989), Landegren et al.,Science 241, 1077 (1988), transcription amplification (Kwoh et al.,Proc. Natl. Acad. Sci. USA 86, 1173 (1989)), and self-sustained sequencereplication (Guatelli et al., Proc. Nat. Acad. Sci. USA, 87, 1874(1990)) and nucleic acid based sequence amplification (NASBA). Thelatter two amplification methods involve isothermal reactions based onisothermal transcription, which produce both single stranded RNA (ssRNA)and double stranded DNA (dsDNA) as the amplification products in a ratioof about 30 or 100 to 1, respectively.

B. Detection of Polymorphisms in Target DNA

There are two distinct types of analysis of target DNA for detectingpolymorphisms. The first type of analysis, sometimes referred to as denovo characterization, is carried out to identify polymorphic sites notpreviously characterized (i.e., to identify new polymorphisms). Thisanalysis compares target sequences in different individuals to identifypoints of variation, i.e., polymorphic sites. By analyzing groups ofindividuals representing the greatest ethnic diversity among humans andgreatest breed and species variety in plants and animals, patternscharacteristic of the most common alleles/haplotypes of the locus can beidentified, and the frequencies of such alleles/haplotypes in thepopulation can be determined. Additional allelic frequencies can bedetermined for subpopulations characterized by criteria such asgeography, race, or gender. The de novo identification of polymorphismsof the invention is described in the Examples section. The second typeof analysis determines which form(s) of a characterized (known)polymorphism are present in individuals under test. There are a varietyof suitable procedures, which are discussed in turn.

1. Allele-Specific Probes

The design and use of allele-specific probes for analyzing polymorphismsis described by e.g., Saiki et al., Nature 324, 163-166 (1986);Dattagupta, EP 235,726, Saiki, WO 89/11548. Allele-specific probes canbe designed that hybridize to a segment of target DNA from oneindividual but do not hybridize to the corresponding segment fromanother individual due to the presence of different polymorphic forms inthe respective segments from the two individuals. Hybridizationconditions should be sufficiently stringent that there is a significantdifference in hybridization intensity between alleles, and preferably anessentially binary response, whereby a probe hybridizes to only one ofthe alleles. Some probes are designed to hybridize to a segment oftarget DNA such that the polymorphic site aligns with a central position(e.g., in a 15-mer at the 7 position; in a 16-mer, at either the 8 or 9position) of the probe. This design of probe achieves gooddiscrimination in hybridization between different allelic forms.

Allele-specific probes are often used in pairs, one member of a pairshowing a perfect match to a reference form of a target sequence and theother member showing a perfect match to a variant form. Several pairs ofprobes can then be immobilized on the same support for simultaneousanalysis of multiple polymorphisms within the same target sequence.

2. Tiling Arrays

The polymorphisms can also be identified by hybridization to nucleicacid arrays, some examples of which are described in WO 95/11995. Oneform of such arrays is described in the Examples section in connectionwith de novo identification of polymorphisms. The same array or adifferent array can be used for analysis of characterized polymorphisms.WO 95/11995 also describes subarrays that are optimized for detection ofa variant form of a precharacterized polymorphism. Such a subarraycontains probes designed to be complementary to a second referencesequence, which is an allelic variant of the first reference sequence.The second group of probes is designed by the same principles asdescribed in the Examples, except that the probes exhibitcomplementarity to the second reference sequence. The inclusion of asecond group (or further groups) can be particularly useful foranalyzing short subsequences of the primary reference sequence in whichmultiple mutations are expected to occur within a short distancecommensurate with the length of the probes (e.g., two or more mutationswithin 9 to 21 bases).

3. Allele-Specific Primers

An allele-specific primer hybridizes to a site on target DNA overlappinga polymorphism and only primes amplification of an allelic form to whichthe primer exhibits perfect complementarity. See Gibbs, Nucleic AcidRes. 17, 2427-2448 (1989). This primer is used in conjunction with asecond primer which hybridizes at a distal site. Amplification proceedsfrom the two primers, resulting in a detectable product which indicatesthe particular allelic form is present. A control is usually performedwith a second pair of primers, one of which shows a single base mismatchat the polymorphic site and the other of which exhibits perfectcomplementarity to a distal site. The single-base mismatch preventsamplification and no detectable product is formed. The method works bestwhen the mismatch is included in the 3′-most position of theoligonucleotide aligned with the polymorphism because this position ismost destabilizing to elongation from the primer (see, e.g., WO93/22456).

4. Direct-Sequencing

The direct analysis of the sequence of polymorphisms of the presentinvention can be accomplished using either the dideoxy chain terminationmethod or the Maxam-Gilbert method (see Sambrook et al., MolecularCloning, A Laboratory Manual (2nd Ed., CSHP, New York 1989); Zyskind etal., Recombinant DNA Laboratory Manual, (Acad. Press, 1988)).

5. Denaturing Gradient Gel Electrophoresis

Amplification products generated using the polymerase chain reaction canbe analyzed by the use of denaturing gradient gel electrophoresis.Different alleles can be identified based on the differentsequence-dependent melting properties and electrophoretic migration ofDNA in solution. Erlich, ed., PCR Technology, Principles andApplications for DNA Amplification, (W. H. Freeman and Co, New York,1992), Chapter 7.

6. Single-Strand Conformation Polymorphism Analysis

Alleles of target sequences can be differentiated using single-strandconformation polymorphism analysis, which identifies base differences byalteration in electrophoretic migration of single stranded PCR products,as described in Orita et al., Proc. Nat. Acad. Sci. 86, 2766-2770(1989). Amplified PCR products can be generated as described above, andheated or otherwise denatured, to form single stranded amplificationproducts. Single-stranded nucleic acids may refold or form secondarystructures which are partially dependent on the base sequence. Thedifferent electrophoretic mobilities of single-stranded amplificationproducts can be related to base-sequence differences between alleles oftarget sequences.

7. Single-Base Extension

An alternative method for identifying and analyzing polymorphisms isbased on single-base extension (SBE) of a fluorescently-labeled primercoupled with fluorescence resonance energy transfer (FRET) between thelabel of the added base and the label of the primer. Typically, themethod, such as that described by Chen et al., (PNAS 94:10756-61 (1997),incorporated herein by reference) uses a locus-specific oligonucleotideprimer labeled on the 5′ terminus with 5-carboxyfluorescein (FAM). Thislabeled primer is designed so that the 3′ end is immediately adjacent tothe polymorphic site of interest. The labeled primer is hybridized tothe locus, and single base extension of the labeled primer is performedwith fluorescently labeled dideoxyribonucleotides (ddNTPs) indye-terminator sequencing fashion, except that no deoxyribonucleotidesare present. An increase in fluorescence of the added ddNTP in responseto excitation at the wavelength of the labeled primer is used to inferthe identity of the added nucleotide.

III. Methods of Use

After determining polymorphic form(s) present in an individual at one ormore polymorphic sites, this information can be used in a number ofmethods.

A. Forensics

Determination of which polymorphic forms occupy a set of polymorphicsites in an individual identifies a set of polymorphic forms thatdistinguishes the individual. See generally National Research Council,The Evaluation of Forensic DNA Evidence (Eds. Pollard et al., NationalAcademy Press, DC, 1996). The more sites that are analyzed, the lowerthe probability that the set of polymorphic forms in one individual isthe same as that in an unrelated individual. Preferably, if multiplesites are analyzed, the sites are unlinked. Thus, polymorphisms of theinvention are often used in conjunction with polymorphisms in distalgenes. Preferred polymorphisms for use in forensics are biallelicbecause the population frequencies of two polymorphic forms can usuallybe determined with greater accuracy than those of multiple polymorphicforms at multi-allelic loci.

The capacity to identify a distinguishing or unique set of forensicmarkers in an individual is useful for forensic analysis. For example,one can determine whether a blood sample from a suspect matches a bloodor other tissue sample from a crime scene by determining whether the setof polymorphic forms occupying selected polymorphic sites is the same inthe suspect and the sample. If the set of polymorphic markers does notmatch between a suspect and a sample, it can be concluded (barringexperimental error) that the suspect was not the source of the sample.If the set of markers does match, one can conclude that the DNA from thesuspect is consistent with that found at the crime scene. If frequenciesof the polymorphic forms at the loci tested have been determined (e.g.,by analysis of a suitable population of individuals), one can perform astatistical analysis to determine the probability that a match ofsuspect and crime scene sample would occur by chance.

p(ID) is the probability that two random individuals have the samepolymorphic or allelic form at a given polymorphic site. In biallelicloci, four genotypes are possible: AA, AB, BA, and BB. If alleles A andB occur in a haploid genome of the organism with frequencies x and y,the probability of each genotype in a diploid organism is (see WO95/12607):

-   -   Homozygote: p(AA)=x²    -   Homozygote: p(BB)=y²=(1−x)²    -   Single Heterozygote: p(AB)=p(BA)=xy=x(1−x)    -   Both Heterozygotes: p(AB+BA)=2xy=2x(1−x)

The probability of identity at one locus (i.e, the probability that twoindividuals, picked at random from a population will have identicalpolymorphic forms at a given locus) is given by the equation:p(ID)=(x ²)²+(2xy)²+(y²)².

These calculations can be extended for any number of polymnorphic formsat a given locus. For example, the probability of identity p(ID) for a3-allele system where the alleles have the frequencies in the populationof x, y and z, respectively, is equal to the sum of the squares of thegenotype frequencies:p(ID)=x ⁴+(2xy)²+(2yz)²+(2xz)² +z ⁴ +y ⁴

In a locus of n alleles, the appropriate binomial expansion is used tocalculate p(ID) and p(exc).

The cumulative probability of identity (cum p(ID)) for each of multipleunlinked loci is determined by multiplying the probabilities provided byeach locus.cum p(ID)=p(ID1)p(ID2)p(ID3) . . . p(IDn)

The cumulative probability of non-identity for n loci (i.e. theprobability that two random individuals will be different at 1 or moreloci) is given by the equation:cump(nonID)=1−cump(ID).

If several polymorphic loci are tested, the cumulative probability ofnon-identity for random individuals becomes very high (e.g., one billionto one). Such probabilities can be taken into account together withother evidence in determining the guilt or innocence of the suspect.

B. Paternity Testing

The object of paternity testing is usually to determine whether a maleis the father of a child. In most cases, the mother of the child isknown and thus, the mother's contribution to the child's genotype can betraced. Paternity testing investigates whether the part of the child'sgenotype not attributable to the mother is consistent with that of theputative father. Paternity testing can be performed by analyzing sets ofpolymorphisms in the putative father and the child.

If the set of polymorphisms in the child attributable to the father doesnot match the set of polymorphisms of the putative father, it can beconcluded, barring experimental error, that the putative father is notthe real father. If the set of polymorphisms in the child attributableto the father does match the set of polymorphisms of the putativefather, a statistical calculation can be performed to determine theprobability of coincidental match.

The probability of parentage exclusion (representing the probabilitythat a random male will have a polymorphic form at a given polymorphicsite that makes him incompatible as the father) is given by the equation(see WO 95/12607):p(exc)=xy(1−xy)where x and y are the population frequencies of alleles A and B of abiallelic polymorphic site.

(At a triallelic site p(exc)=xy(1−xy)+yz(1−yz)+xz(1−xz)+3xyz(1−xyz))),where x, y and z and the respective population frequencies of alleles A,B and C).

The probability of non-exclusion isp(non-exc)=1−p(exc)

The cumulative probability of non-exclusion (representing the valueobtained when n loci are used) is thus:cump(non-exc)=p(non-exc1)p(non-exc2)p(non-exc3) . . . p(non-excn)

The cumulative probability of exclusion for n loci (representing theprobability that a random male will be excluded)cump(exc)=1−cump(non-exc).

If several polymorphic loci are included in the analysis, the cumulativeprobability of exclusion of a random male is very high. This probabilitycan be taken into account in assessing the liability of a putativefather whose polymorphic marker set matches the child's polymorphicmarker set attributable to his/her father.

C. Correlation of Polymorphisms with Phenotypic Traits

The polymorphisms of the invention may contribute to the phenotype of anorganism in different ways. Some polymorphisms occur within a proteincoding sequence and contribute to phenotype by affecting proteinstructure. The effect may be neutral, beneficial or detrimental, or bothbeneficial and detrimental, depending on the circumstances. For example,a heterozygous sickle cell mutationi confers resistance to malaria, buta homozygous sickle cell mutation is usually lethal. Other polymorphismsoccur in noncoding regions but may exert phenotypic effects indirectlyvia influence on replication, transcription, and translation. A singlepolymorphism may affect more than one phenotypic trait. Likewise, asingle phenotypic trait may be affected by polymorphisms in differentgenes. Further, some polymorphisms predispose an individual to adistinct mutation that is causally related to a certain phenotype.

Phenotypic traits include diseases that have known but hitherto unmappedgenetic components (e.g., agammaglobulimenia, diabetes insipidus,Lesch-Nyhan syndrome, muscular dystrophy, Wiskott-Aldrich syndrome,Fabry's disease, familial hypercholesterolemia, polycystic kidneydisease, hereditary spherocytosis, von Willebrand's disease, tuberoussclerosis, hereditary hemorrhagic telangiectasia, familial colonicpolyposis, Ehlers-Danlos syndrome, osteogenesis imperfecta, and acuteintermittent porphyria). Phenotypic traits also include symptoms of, orsusceptibility to, multifactorial diseases of which a component is ormay be genetic, such as autoimmune diseases, inflammation, cancer,diseases of the nervous system, and infection by pathogenicmicroorganisms. Some examples of autoimmune diseases include rheumatoidarthritis, multiple sclerosis, diabetes (insulin-dependent andnon-independent), systemic lupus erythematosus and Graves disease. Someexamples of cancers include cancers of the bladder, brain, breast,colon, esophagus, kidney, leukemia, liver, lung, oral cavity, ovary,pancreas, prostate, skin, stomach and uterus. Phenotypic traits alsoinclude characteristics such as longevity, appearance (e.g., baldness,obesity), strength, speed, endurance, fertility, and susceptibility orreceptivity to particular drugs or therapeutic treatments.

The correlation of one or more polymorphisms with phenotypic traits canbe facilitated by knowledge of the gene product of the wild type(reference) gene. The genes in which cSNPs of the present invention havebeen identified are genes which have been previously sequenced andcharacterized in one of their allelic forms.

Correlation is performed for a population of individuals who have beentested for the presence or absence of a phenotypic trait of interest andfor polymorphic markers sets. To perform such analysis, the presence orabsence of a set of polymorphisms (i.e. a polymorphic set) is determinedfor a set of the individuals, some of whom exhibit a particular trait,and some of which exhibit lack of the trait. The alleles of eachpolymorphism of the set are then reviewed to determine whether thepresence or absence of a particular allele is associated with the traitof interest. Correlation can be performed by standard statisticalmethods such as a κ-squared test and statistically significantcorrelations between polymorphic form(s) and phenotypic characteristicsare noted. For example, it might be found that the presence of allele A1at polymorphism A correlates with heart disease. As a further example,it might be found that the combined presence of allele A1 atpolymorphism A and allele B1 at polymorphism B correlates with increasedmilk production of a farm animal.

Such correlations can be exploited in several ways. In the case of astrong correlation between a set of one or more polymorphic forms and adisease for which treatment is available, detection of the polymorphicform set in a human or animal patient may justify immediateadministration of treatment, or at least the institution of regularmonitoring of the patient. Detection of a polymorphic form correlatedwith serious disease in a couple contemplating a family may also bevaluable to the couple in their reproductive decisions. For example, thefemale partner might elect to undergo in vitro fertilization to avoidthe possibility of transmitting such a polymorphism from her husband toher offspring. In the case of a weaker, but still statisticallysignificant correlation between a polymorphic set and human disease,immediate therapeutic intervention or monitoring may not be justified.Nevertheless, the patient can be motivated to begin simple life-stylechanges (e.g., diet, exercise) that can be accomplished at little costto the patient but confer potential benefits in reducing the risk ofconditions to which the patient may have increased susceptibility byvirtue of variant alleles. Identification of a polymorphic set in apatient correlated with enhanced receptiveness to one of severaltreatment regimes for a disease indicates that this treatment regimeshould be followed.

For animals and plants, correlations between characteristics andphenotype are useful for breeding for desired characteristics. Forexample, Beitz et al., U.S. Pat. No. 5,292,639 discuss use of bovinemitochondrial polymorphisms in a breeding program to improve milkproduction in cows. To evaluate the effect of mtDNA D-loop sequencepolymorphism on milk production, each cow was assigned a value of 1 ifvariant or 0 if wildtype with respect to a prototypical mitochondrialDNA sequence at each of 17 locations considered. Each production traitwas analyzed individually with the following animal model:Y _(ijkpn) =μ+YS _(i) +P _(j) +X _(k)+β₁+ . . . β₁₇ +PE _(n) +a _(n) +e_(p)where Y_(ijknp) is the milk, fat, fat percentage, SNF, SNF percentage,energy concentration, or lactation energy record; μ is an overall mean;YS_(i) is the effect common to all cows calving in year-season; X_(k) isthe effect common to cows in either the high or average selection line;β₁ to β₁₇ are the binomial regressions of production record on mtDNAD-loop sequence polymorphisms; PE_(n) is permanent environmental effectcommon to all records of cow n; a_(n) is effect of animal n and iscomposed of the additive genetic contribution of sire and dam breedingvalues and a Mendelian sampling effect; and e_(p) is a random residual.It was found that eleven of seventeen polymorphisms tested influenced atleast one production trait. Bovines having the best polymorphic formsfor milk production at these eleven loci are used as parents forbreeding the next generation of the herd.

D. Genetic Mapping of Phenotypic Traits

The previous section concerns identifying correlations betweenphenotypic traits and polymorphisms that directly or indirectlycontribute to those traits. The present section describes identificationof a physical linkage between a genetic locus associated with a trait ofinterest and polymorphic markers that are not associated with the trait,but are in physical proximity with the genetic locus responsible for thetrait and co-segregate with it. Such analysis is useful for mapping agenetic locus associated with a phenotypic trait to a chromosomalposition, and thereby cloning gene(s) responsible for the trait. SeeLander et al., Proc. Natl. Acad. Sci. (USA) 83, 7353-7357 (1986); Landeret al., Proc. Natl. Acad. Sci. (USA) 84, 2363-2367 (1987); Donis-Kelleret al., Cell 51, 319-337 (1987); Lander et al., Genetics 121, 185-199(1989)). Genes localized by linkage can be cloned by a process known asdirectional cloning. See Wainwright, Med. J. Australia 159, 170-174(1993); Collins, Nature Genetics 1, 3-6 (1992).

Linkage studies are typically performed on members of a family.Available members of the family are characterized for the presence orabsence of a phenotypic trait and for a set of polymorphic markers. Thedistribution of polymorphic markers in an informative meiosis is thenanalyzed to determine which polymorphic markers co-segregate with aphenotypic trait. See, e.g., Kerem et al., Science 245, 1073-1080(1989); Monaco et al., Nature 316, 842 (1985); Yamoka et al., Neurology40, 222-226 (1990); Rossiter et al., FASEB Journal 5, 21-27 (1991).

Linkage is analyzed by calculation of LOD (log of the odds) values. Alod value is the relative likelihood of obtaining observed segregationdata for a marker and a genetic locus when the two are located at arecombination fraction θ, versus the situation in which the two are notlinked, and thus segregating independently (Thompson & Thompson,Genetics in Medicine (5th ed, W. B. Saunders Company, Philadelphia,1991); Strachan, “Mapping the human genome” in The Human Genome (BIOSScientific Publishers Ltd, Oxford), Chapter 4). A series of likelihoodratios are calculated at various recombination fractions (θ), rangingfrom θ=0.0 (coincident loci) to θ=0.50 (unlinked). Thus, the likelihoodat a given value of θ is: probability of data if loci linked at θ toprobability of data if loci unlinked. The computed likelihoods areusually expressed as the log₁₀ of this ratio (i.e., a lod score). Forexample, a lod score of 3 indicates 1000:1 odds against an apparentobserved linkage being a coincidence. The use of logarithms allows datacollected from different families to be combined by simple addition.Computer programs are available for the calculation of lod scores fordiffering values of θ (e.g., LIPED, MLINK (Lathrop, Proc. Nat. Acad.Sci. (USA) 81, 3443-3446 (1984)). For any particular lod score, arecombination fraction may be determined from mathematical tables. SeeSmith et al., Mathematical tables for research workers in human genetics(Churchill, London, 1961); Smith, Ann. Hum. Genet. 32, 127-150 (1968).The value of θ at which the lod score is the highest is considered to bethe best estimate of the recombination fraction.

Positive lod score values suggest that the two loci are linked, whereasnegative values suggest that linkage is less likely (at that value of θ)than the possibility that the two loci are unlinked. By convention, acombined lod score of +3 or greater (equivalent to greater than 1000:1odds in favor of linkage) is considered definitive evidence that twoloci are linked. Similarly, by convention, a negative lod score of −2 orless is taken as definitive evidence against linkage of the two locibeing compared. Negative linkage data are useful in excluding achromosome or a segment thereof from consideration. The search focuseson the remaining non-excluded chromosomal locations.

IV. Modified Polypeptides and Gene Sequences

The invention further provides variant forms of nucleic acids andcorresponding proteins. The nucleic acids comprise one of the sequencesdescribed in the Table, column 5, in which the polymorphic position isoccupied by one of the alternative bases for that position. Some nucleicacids encode full-length variant forms of proteins. Similarly, variantproteins have the prototypical amino acid sequences encoded by nucleicacid sequences shown in the Table, column 5, (read so as to be in-framewith the full-length coding sequence of which it is a component) exceptat an amino acid encoded by a codon including one of the polymorphicpositions shown in the Table. That position is occupied by the aminoacid coded by the corresponding codon in any of the alternative formsshown in the Table.

Variant genes can be expressed in an expression vector in which avariant gene is operably linked to a native or other promoter. Usually,the promoter is a eukaryotic promoter for expression in a mammaliancell. The transcription regulation sequences typically include aheterologous promoter and optionally an enhancer which is recognized bythe host. The selection of an appropriate promoter, for example trp,lac, phage promoters, glycolytic enzyme promoters and tRNA promoters,depends on the host selected. Commercially available expression vectorscan be used. Vectors can include host-recognized replication systems,amplifiable genes, selectable markers, host sequences useful forinsertion into the host genome, and the like.

The means of introducing the expression construct into a host cellvaries depending upon the particular construction and the target host.Suitable means include fusion, conjugation, transfection, transduction,electroporation or injection, as described in Sambrook, supra. A widevariety of host cells can be employed for expression of the variantgene, both prokaryotic and eukaryotic. Suitable host cells includebacteria such as E. coli, yeast, filamentous fuigi, insect cells,mammalian cells, typically immortalized, e.g., mouse, CHO, human andmonkey cell lines and derivatives thereof. Preferred host cells are ableto process the variant gene product to produce an appropriate maturepolypeptide. Processing includes glycosylation, ubiquitination,disulfide bond formation, general post-translational modification, andthe like. As used herein, “gene product” includes mRNA, peptide andprotein products.

The protein may be isolated by conventional means of proteinbiochemistry and purification to obtain a substantially pure product,i.e., 80, 95 or 99% free of cell component contaminants, as described inJacoby, Methods in Enzymology Volume 104, Academic Press, New York(1984); Scopes, Protein Purification, Principles and Practice, 2ndEdition, Springer-Verlag, New York (1987); and Deutscher (ed), Guide toProtein Purification, Methods in Enzymology, Vol. 182 (1990). If theprotein is secreted, it can be isolated from the supernatant in whichthe host cell is grown. If not secreted, the protein can be isolatedfrom a lysate of the host cells.

The invention further provides transgenic nonhuman animals capable ofexpressing an exogenous variant gene and/or having one or both allelesof an endogenous variant gene inactivated. Expression of an exogenousvariant gene is usually achieved by operably linking the gene to apromoter and optionally an enhancer, and microinjecting the constructinto a zygote. See Hogan et al., “Manipulating the Mouse Embryo, ALaboratory Manual,” Cold Spring Harbor Laboratory. Inactivation ofendogenous variant genes can be achieved by forming a transgene in whicha cloned variant gene is inactivated by insertion of a positiveselection marker. See Capecchi, Science 244, 1288-1292 (1989). Thetransgene is then introduced into an embryonic stem cell, where itundergoes homologous recombination with an endogenous variant gene. Miceand other rodents are preferred animals. Such animals provide usefuldrug screening systems.

In addition to substantially full-length polypeptides expressed byvariant genes, the present invention includes biologically activefragments of the polypeptides, or analogs thereof, including organicmolecules which simulate the interactions of the peptides. Biologicallyactive fragments include any portion of the full-length polypeptidewhich confers a biological function on the variant gene product,including ligand binding, and antibody binding. Ligand binding includesbinding by nucleic acids, proteins or polypeptides, small biologicallyactive molecules, or large cellular structures.

Polyclonal and/or monoclonal antibodies that specifically bind tovariant gene products but not to corresponding prototypical geneproducts are also provided. Antibodies can be made by injecting mice orother animals with the variant gene product or synthetic peptidefragments thereof. Monoclonal antibodies are screened as are described,for example, in Harlow & Lane, Antibodies, A Laboratory Manual, ColdSpring Harbor Press, New York (1988); Goding, Monoclonal antibodies,Principles and Practice (2d ed.) Academic Press, New York (1986).Monoclonal antibodies are tested for specific immunoreactivity with avariant gene product and lack of immunoreactivity to the correspondingprototypical gene product. These antibodies are useful in diagnosticassays for detection of the variant form, or as an active ingredient ina pharmaceutical composition.

V. Kits

The invention further provides kits comprising at least oneallele-specific oligonucleotide as described herein. Often, the kitscontain one or more pairs of allele-specific oligonucleotideshybridizing to different forms of a polymorphism. In some kits, theallele-specific oligonucleotides are provided immobilized to asubstrate. For example, the same substrate can comprise allele-specificoligonucleotide probes for detecting at least 10, 100 or all of thepolymorphisms shown in the Table. Optional additional components of thekit include, for example, restriction enzymes, reverse-transcriptase orpolymerase, the substrate nucleoside triphosphates, means used to label(for example, an avidin-enzyme conjugate and enzyme substrate andchromogen if the label is biotin), and the appropriate buffers forreverse transcription, PCR, or hybridization reactions. Usually, the kitalso contains instructions for carrying out the methods.

The thrombospondins are a family of extracellular matrix (ECM)glycoproteins that modulate many cell behaviors including adhesion,migration, and proliferation. Thrombospondins (also known as thrombinsensitive proteins or TSPs) are large molecular weight glycoproteinscomposed of three identical disulfide-linked polypeptide chains. TSPsare stored in the alpha-granules of platelets and secreted by a varietyof mesenchymal and epithelial cells (Majack et al., Cell Membrane3:57-77 (1987)). Platelets secrete TSPs when activated in the blood bysuch physiological agonists such as thrombin. TSPs have lectinproperties and a broad function in the regulation of fibrinolysis and asa component of the ECM, and are one of a group of ECM proteins whichhave adhesive properties. TSPs bind to fibronectin and fibrinogen (Lahavet al., Eur J Biochem 145:151-6 (1984)), and these proteins are known tobe involved in platelet adhesion to substratum and platelet aggregation(Leung, J Clin Invest 74:1764-1772 (1986)).

Recent work has implicated TSPs in response of cells to growth factors.Submitogenic doses of PDGF induce a rapid but transitory, increase inTSP synthesis and secretion by rat aortic smooth muscle cells (Majack etal., J Biol Chem 101: 1059-70 (1985)). PDGF responsiveness to TSPsynthesis in glial cells has also been shown (Asch et al., Proc NatlAcad Sci 83:2904-8 (1986)). TSP mRNA levels rise rapidly in response toPDGF (Majack et al., J. Biol Chem 262:8821-5 (1987)). TSPs actsynergistically with epidermal growth factor to increase DNA synthesisin smooth muscle cells (Majack et al., Proc Natl Acad Sci 83:9050-4(1986)), and monoclonal antibodies to TSPs inhibit smooth muscle cellproliferation (Majack et al., J Biol Chem 106:415-22 (1988)). TSPsmodulate local adhesions in endothelial cells, and TSPs, particularlyTSP-1 primarily derived from platelet granules, are known to be animportant activator of transforming growth factor beta-1 (TGFB-1)(Crawford et al., Cell 93:1159 (1998)) and appear to be a potential linkbetween platelet-thrombosis and development of atherosclerosis.

To determine pivotal genes associated with premature coronary arterydisease, we analyzed DNA from 347 patients with MI or coronaryrevascularization before age 40 (men) or 45 (women) and 422 generalpopulation controls. Cases were drawn (one per family) from aretrospective collection of sibling pairs with premature CAD. Controlswere ascertained through random-digit dialing. Both cases and controlswere Caucasian. A complete database of phenotypic and laboratoryvariables for the affected patients afforded logistic regression tocontrol for age, diabetes, body mass index, gender.

Thrombospondin (TSP) 4 and 1 emerged as important SNPs associated withpremature CAD and MI. For CAD, 148 of 347 patients carried at least onecopy of the TSP-4 variant compared with 142 of 422 control subjects;adjusted odds ratio 1.47, p=0.01. For premature MI, the association waseven stronger: 91 of 187 cases vs. 142 of 422 controls had the variant;adjusted odds ratio 2.08, p=0.0003. The TSP-1 SNP was rare. Nonetheless,homozygosity for the variant allele gave an adjusted odds ratio of 9.5,p=0.04.

Specific reference nucleotide (SEQ ID NO: 1) and amino acid (SEQ ID NO:2) sequences for TSP-1 are shown in FIGS. 1A-1D. Specific referencenucleotide (SEQ ID NO: 3) and amino acid (SEQ ID NO: 4) sequences forTSP-4 are shown in FIGS. 2A-2C. It is understood that the invention isnot limited by these exemplified reference sequences, as variants ofthese sequences which differ at locations other than the SNP sitesidentified herein can also be utilized. The skilled artisan can readilydetermine the SNP sites in these other reference sequences whichcorrespond to the SNP sites identified herein by aligning the sequenceof interest with the reference sequences specifically disclosed herein,and programs for performing such alignments are commercially available.For example, the ALIGN program in the GCG software package can be used,utilizing a PAM120 weight residue table, a gap length penalty of 12 anda gap penalty of 4, for example.

Two SNPs have been specifically studied as described herein. The first(G334u4) is a change from A (reference nucleotide) to G (alternate orvariant nucleotide) at nucleotide position 2210 of the nucleic acidsequence of TSP—I (FIGS. 1A-1D), resulting in a missense amino acidmutation from asparagine (reference) to serine (alternate) at amino acid700. The second SNP (G355u2) is a change from G (reference) to C(alternate) at nucleotide position 1186 of the nucleic acid sequence ofTSP-4 (FIGS. 2A-2C), resulting in a missense amino acid alteration fromalanine (reference) to proline (alternate) at amino acid 387. Withrespect to the G355u2 SNP, individuals with CAD carried at least onecopy of the variant “C” allele more frequently than control individuals(43% as compared with 34%). With respect to the G355u2 SNP, individualswith MI carried at least one copy of the variant “C” allele morefrequently than control individuals (49% as compared with 34%). Withrespect to the G334u4 SNP, individuals with CAD carried two copies ofthe variant “G” allele more frequently than control individuals (1.7% ascompared with 0.2%). With respect to the G334u4 SNP, individuals with MIcarried two copies of the variant “G” allele more frequently thancontrol individuals (2% as compared with 0.2%).

As used herein, the term “polymorphism” refers to the occurrence of twoor more genetically determined alternative sequences or alleles in apopulation. A polymorphic marker or site is the locus at whichdivergence occurs. Preferred markers have at least two alleles, eachoccurring at frequency of greater than 1%, and more preferably greaterthan 10% or 20% of a selected population. A polymorphic locus may be assmall as one base pair, in which case it is referred to as a singlenucleotide polymorphism (SNP).

Thus, the invention relates to a method for predicting the likelihoodthat an individual will have a vascular disease, or for aiding in thediagnosis of a vascular disease, or predicting the likelihood of havingaltered symptomology associated with a vascular disease, comprising thesteps of obtaining a DNA sample from an individual to be assessed anddetermining the nucleotide present at one or more of nucleotidepositions 2210 of the TSP-1 gene or 1186 of the TSP-4 gene. In apreferred embodiment, the nucleotides present at both of thesenucleotide positions are determined. In one embodiment the TSP-1 genehas the nucleotide sequence of SEQ ID NO: 1 and the TSP-4 gene has thenucleotide sequence of SEQ ID NO: 3. The presence of one or more of a G(the variant nucleotide) at position 2210 of SEQ ID NO: 1 or a C (thevariant nucleotide) at position 1186 of SEQ ID NO: 1186 indicates thatthe individual has a greater likelihood of having a vascular disease, ora greater likelihood of having severe symptomology associated with avascular disease, than if that individual had the reference nucleotideat one or more of these positions. Conversely, the presence of one ormore of an A (the reference nucleotide) at position 2210 of SEQ ID NO: 1or a G (the reference nucleotide) at position 1186 of SEQ ID NO: 3indicates that the individual has a reduced likelihood of having avascular disease or a likelihood of having reduced symptomologyassociated with a vascular disease than if that individual had thevariant nucleotide at one or more of these positions.

In a particular embodiment, the individual is an individual at risk fordevelopment of a vascular disease. In another embodiment the individualexhibits clinical symptomology associated with a vascular disease. Inone embodiment, the individual has been clinically diagnosed as having avascular disease. Vascular diseases include, but are not limited to,atherosclerosis, coronary heart disease, myocardial infarction (MI),stroke, peripheral vascular diseases, venous thromboembolism andpuhnonary embolism. In preferred embodiments, the vascular disease isCAD or MI.

The genetic material to be assessed can be obtained from any nucleatedcell from the individual. For assay of genomic DNA, virtually anybiological sample (other than pure red blood cells) is suitable. Forexample, convenient tissue samples include whole blood, semen, saliva,tears, urine, fecal material, sweat, skin and hair. For assay of cDNA ormRNA, the tissue sample must be obtained from a tissue or organ in whichthe target nucleic acid is expressed.

Many of the methods described herein require amplification of DNA fromtarget samples. This can be accomplished by e.g., PCR. See generally PCRTechnology: Principles and Applications for DNA Amplification (ed. H. A.Erlich, Freeman Press, NY, N.Y., 1992); PCR Protocols: A Guide toMethods and Applications (eds. Innis, et al., Academic Press, San Diego,Calif., 1990); Mattila et al., Nucleic Acids Res. 19, 4967 (1991);Eckert et al., PCR Methods and Applications 1, 17 (1991); PCR (eds.McPherson et al., IRL Press, Oxford); and U.S. Pat. No. 4,683,202.

Other suitable amplification methods include the ligase chain reaction(LCR) (see Wu and Wallace, Genomics 4, 560 (1989), Landegren et al.,Science 241, 1077 (1988), transcription amplification (Kwoh et al.,Proc. Natl. Acad. Sci. USA 86, 1173 (1989)), and self-sustained sequencereplication (Guatelli et al., Proc. Nat. Acad. Sci. USA, 87, 1874(1990)) and nucleic acid based sequence amplification (NASBA). Thelatter two amplification methods involve isothermal reactions based onisothermal transcription, which produce both single stranded RNA (ssRNA)and double stranded DNA (dsDNA) as the amplification products in a ratioof about 30 or 100 to 1, respectively.

The nucleotide which occupies the polymorphic site of interest (e.g.,nucleotide position 2210 in TSP-1 and/or nucleotide position 1186 inTSP-4) can be identified by a variety of methods, such as Southernanalysis of genomic DNA; direct mutation analysis by restriction enzymedigestion; Northern analysis of RNA; denaturing high pressure liquidchromatography (DHPLC); gene isolation and sequencing; hybridization ofan allele-specific oligonucleotide with amplified gene products; singlebase extension (SBE). In a preferred embodiment, determination of theallelic form of TSP is carried out using SBE-FRET methods as describedherein, or using chip-based oligonucleotide arrays as described herein.

The invention also relates to a method for predicting the likelihoodthat an individual will have a vascular disease, or for aiding in thediagnosis of a vascular disease, or predicting the likelihood of havingaltered symptomology associated with a vascular disease, comprising thesteps of obtaining a biological sample comprising TSP-1 and/or TSP-4protein or relevant portion thereof from an individual to be assessedand determining the amino acid present at one or more of amino acidpositions 700 of the TSP-1 gene product (e.g., as exemplified by SEQ IDNO: 2) or 387 of the TSP-4 gene product (e.g., as exemplified by SEQ IDNO: 4). In a preferred embodiment, the amino acids present at both ofthese amino acid positions are determined. As used herein, the term“relevant portion” of the TSP-1 and TSP-4 proteins is intended toencompass any portion of the protein which comprises the polymorphicamino acid positions. The presence of one or more of a serine (thevariant amino acid) at position 700 of SEQ ID NO: 2, or a proline (thevariant amino acid) at position 387 of SEQ ID NO: 4 indicates that theindividual has a greater likelihood of having a vascular disease, or agreater likelihood of having severe symptomology associated with avascular disease, than if that individual had the reference amino acidat one or more of these positions. Conversely, the presence of one ormore of an asparagine (the reference amino acid) at position 700 of SEQID NO: 2, or an alanine (the reference amino acid) at position 387 ofSEQ ID NO: 4 indicates that the individual has a reduced likelihood ofhaving a vascular disease or a likelihood of having reduced symptomologyassociated with a vascular disease, than if that individual had thevaraint amino acid at one or more of these positions.

In a particular embodiment, the individual is an individual at risk fordevelopment of a vascular disease. In another embodiment the individualexhibits clinical symptomology associated with a vascular disease. Inone embodiment, the individual has been clinically diagnosed as having avascular disease.

In this embodiment of the invention, the biological sample containsprotein molecules from the test subject. In vitro techniques fordetection of protein include enzyme linked immunosorbent assays(ELISAs), Western blots, immunoprecipitations and immunofluorescence.Furthermore, in vivo techniques for detection of protein includeintroducing into a subject a labeled anti-protein antibody. For example,the antibody can be labeled with a radioactive marker whose presence andlocation in a subject can be detected by standard imaging techniques.Polyclonal and/or monoclonal antibodies that specifically bind tovariant gene products but not to corresponding reference gene products,and vice versa, are also provided. Antibodies can be made by injectingmice or other animals with the variant gene product or synthetic peptidefragments thereof comprising the variant portion. Monoclonal antibodiesare screened as are described, for example, in Harlow & Lane,Antibodies, A Laboratory Manual, Cold Spring Harbor Press, New York(1988); Goding, Monoclonal antibodies, Principles and Practice (2d ed.)Academic Press, New York (1986). Monoclonal antibodies are tested forspecific immunoreactivity with a variant gene product and lack ofimmunoreactivity to the corresponding prototypical gene product. Theseantibodies are useful in diagnostic assays for detection of the variantform, or as an active ingredient in a pharmaceutical composition.

The polymorphisms of the invention may be associated with vasculardisease in different ways. The polymorphisms may exert phenotypiceffects indirectly via influence on replication, transcription, andtranslation. Additionally, the described polymorphisms may predispose anindividual to a distinct mutation that is causally related to a certainphenotype, such as susceptibility or resistance to vascular disease andrelated disorders. The discovery of the polymorphisms and theircorrelation with CAD and MI facilitates biochemical analysis of thevariant and reference forms and the development of assays tocharacterize the variant and reference forms and to screen forpharmaceutical agents that interact directly with one or another form ofthe protein.

Alternatively, these particular polymorphisms may belong to a group oftwo or more polymorphisms in the TSP gene(s) which contributes to thepresence, absence or severity of vascular disease. An assessment ofother polymorphisms within the TSP gene(s) can be undertaken, and theseparate and combined effects of these polymorphisms, as well asalternations in other, distinct genes, on the vascular disease phenotypecan be assessed.

Correlation between a particular phenotype, e.g., the CAD or MIphenotype, and the presence or absence of a particular allele isperformed for a population of individuals who have been tested for thepresence or absence of the phenotype. Correlation can be performed bystandard statistical methods such as a Chi-squared test andstatistically significant correlations between polymorphic form(s) andphenotypic characteristics are noted. This correlation can be exploitedin several ways. In the case of a strong correlation between aparticular polymorphic form, e.g., the variant allele for TSP-1 and/orTSP-4, and a disease for which treatment is available, detection of thepolymorphic form in an individual may justify immediate administrationof treatment, or at least the institution of regular monitoring of theindividual. Detection of a polymorphic form correlated with a disorderin a couple contemplating a family may also be valuable to the couple intheir reproductive decisions. For example, the female partner mightelect to undergo in vitro fertilization to avoid the possibility oftransmitting such a polymorphism from her husband to her offspring. Inthe case of a weaker, but still statistically significant correlationbetween a polymorphic form and a particular disorder, immediatetherapeutic intervention or monitoring may not be justified.Nevertheless, the individual can be motivated to begin simple life-stylechanges (e.g., diet modification, therapy or counseling) that can beaccomplished at little cost to the individual but confer potentialbenefits in reducing the risk of conditions to which the individual mayhave increased susceptibility by virtue of the particular allele.Furthermore, identification of a polymorphic form correlated withenhanced receptiveness to one of several treatment regimes for adisorder indicates that this treatment regimen should be followed forthe individual in question.

Furthermore, it may be possible to identify a physical linkage between agenetic locus associated with a trait of interest (e.g., CAD or MI) andpolymorphic markers that are or are not associated with the trait, butare in physical proximity with the genetic locus responsible for thetrait and co-segregate with it. Such analysis is useful for mapping agenetic locus associated with a phenotypic trait to a chromosomalposition, and thereby cloning gene(s) responsible for the trait. SeeLander et al., Proc. Natl. Acad. Sci. (USA) 83, 7353-7357 (1986); Landeret al., Proc. Natl. Acad. Sci. (USA) 84, 2363-2367 (1987); Donis-Kelleret al., Cell 51, 319-337 (1987); Lander et al., Genetics 121, 185-199(1989)). Genes localized by linkage can be cloned by a process known asdirectional cloning. See Wainwright, Med. J Australia 159, 170-174(1993); Collins, Nature Genetics 1, 3-6 (1992). Linkage studies arediscussed in more detail above.

In another embodiment, the invention relates to pharmaceuticalcompositions comprising a reference TSP-1 and/or TSP-4 gene or geneproduct for use in the treatment of vascular disease, e.g., CAD and MI.As used herein, a reference TSP gene product is intended to mean geneproducts which are encoded by the reference allele of the TSP gene. Inaddition to substantially full-length polypeptides expressed by thegenes, the present invention includes biologically active fragments ofthe polypeptides, or analogs thereof, including organic molecules whichsimulate the interactions of the peptides. Biologically active fragmentsinclude any portion of the full-length polypeptide which confers abiological function on the variant gene product, including ligandbinding, and antibody binding. Ligand binding includes binding bynucleic acids, proteins or polypeptides, small biologically activemolecules, or large cellular structures.

For instance, the polypeptide or protein, or fragment thereof, of thepresent invention can be formulated with a physiologically acceptablemedium to prepare a pharmaceutical composition. The particularphysiological medium may include, but is not limited to, water, bufferedsaline, polyols (e.g., glycerol, propylene glycol, liquid polyethyleneglycol) and dextrose solutions. The optimum concentration of the activeingredient(s) in the chosen medium can be determined empirically,according to procedures well known to medicinal chemists, and willdepend on the ultimate pharmaceutical formulation desired. Methods ofintroduction of exogenous peptides at the site of treatment include, butare not limited to, intradernal, intramuscular, intraperitoneal,intravenous, subcutaneous, oral and intranasal. Other suitable methodsof introduction can also include rechargeable or biodegradable devicesand slow release polymeric devices. The pharmaceutical compositions ofthis invention can also be administered as part of a combinatorialtherapy with other agents and treatment regimens.

The invention further pertains to compositions, e.g., vectors,comprising a nucleotide sequence encoding reference or variant TSP-1and/or TSP-4 gene products. For example, reference genes can beexpressed in an expression vector in which a reference gene is operablylinked to a native or other promoter. Usually, the promoter is aeukaryotic promoter for expression in a mammalian cell. Thetranscription regulation sequences typically include a heterologouspromoter and optionally an enhancer which is recognized by the host. Theselection of an appropriate promoter, for example trp, lac, phagepromoters, glycolytic enzyme promoters and tRNA promoters, depends onthe host selected. Commercially available expression vectors can beused. Vectors can include host-recognized replication systems,amplifiable genes, selectable markers, host sequences useful forinsertion into the host genome, and the like.

The means of introducing the expression construct into a host cellvaries depending upon the particular construction and the target host.Suitable means include fusion, conjugation, transfection, transduction,electroporation or injection, as described in Sambrook, supra. A widevariety of host cells can be employed for expression of the variantgene, both prokaryotic and eukaryotic. Suitable host cells includebacteria such as E. coli, yeast, filamentous fungi, insect cells,mammalian cells, typically immortalized, e.g., mouse, CHO, human andmonkey cell lines and derivatives thereof. Preferred host cells are ableto process the variant gene product to produce an appropriate maturepolypeptide. Processing includes glycosylation, ubiquitination,disulfide bond formation, general post-translational modification, andthe like.

It is also contemplated that cells can be engineered to express thereference allele of the invention by gene therapy methods. For example,DNA encoding the reference TSP gene product, or an active fragment orderivative thereof, can be introduced into an expression vector, such asa viral vector, and the vector can be introduced into appropriate cellsin an animal. In such a method, the cell population can be engineered toinducibly or constitutively express active reference TSP gene product.In a preferred embodiment, the vector is delivered to the bone marrow,for example as described in Corey et al. (Science 244:1275-1281 (1989)).

The invention further relates to the use of compositions (i.e.,agonists) which enhance or increase the activity of the reference (orvariant) TSP (e.g., TSP-1 or TSP-4) gene product, or a functionalportion thereof, for use in the treatment of vascular disease. Theinvention also relates to the use of compositions (i.e., antagonists)which reduce or decrease the activity of the variant (or reference) TSP(e.g., TSP-1 or TSP-4) gene product, or a functional portion thereof,for use in the treatment of vascular disease.

The invention also relates to constructs which comprise a vector intowhich a sequence of the invention has been inserted in a sense orantisense orientation. For example, a vector comprising a nucleotidesequence which is antisense to the variant TSP-1 or TSP-4 allele may beused as an antagonist of the activity of the TSP-1 or TSP-4 variantallele. Alternatively, a vector comprising a nucleotide sequence of theTSP-1 or TSP-4 reference allele may be used therapeutically to treatvascular diseases. As used herein, the term “vector” refers to a nucleicacid molecule capable of transporting another nucleic acid to which ithas been linked. One type of vector is a “plasmid”, which refers to acircular double stranded DNA loop into which additional DNA segments canbe ligated. Another type of vector is a viral vector, wherein additionalDNA segments can be ligated into the viral genome. Certain vectors arecapable of autonomous replication in a host cell into which they areintroduced (e.g., bacterial vectors having a bacterial origin ofreplication and episomal mammalian vectors). Other vectors (e.g.,non-episomal mammalian vectors) are integrated into the genome of a hostcell upon introduction into the host cell, and thereby are replicatedalong with the host genome. Moreover, certain vectors, expressionvectors, are capable of directing the expression of genes to which theyare operably linked. In general, expression vectors of utility inrecombinant DNA techniques are often in the form of plasmids (vectors).However, the invention is intended to include such other forms ofexpression vectors, such as viral vectors (e.g., replication defectiveretroviruses, adenoviruses and adeno-associated viruses) that serveequivalent functions.

Preferred recombinant expression vectors of the invention comprise anucleic acid of the invention in a form suitable for expression of thenucleic acid in a host cell. This means that the recombinant expressionvectors include one or more regulatory sequences, selected on the basisof the host cells to be used for expression, which is operably linked tothe nucleic acid sequence to be expressed. Within a recombinantexpression vector, “operably linked” is intended to mean that thenucleotide sequence of interest is linked to the regulatory sequence(s)in a manner which allows for expression of the nucleotide sequence(e.g., in an in vitro transcription/translation system or in a host cellwhen the vector is introduced into the host cell). The term “regulatorysequence” is intended to include promoters, enhancers and otherexpression control elements (e.g., polyadenylation signals). Suchregulatory sequences are described, for example, in Goeddel, GeneExpression Technology: Methods in Enzymology 185, Academic Press, SanDiego, Calif. (1990). Regulatory sequences include those which directconstitutive expression of a nucleotide sequence in many types of hostcell and those which direct expression of the nucleotide sequence onlyin certain host cells (e.g., tissue-specific regulatory sequences). Itwill be appreciated by those skilled in the art that the design of theexpression vector can depend on such factors as the choice of the hostcell to be transformed, the level of expression of protein desired, etc.

The expression vectors of the invention can be introduced into hostcells to thereby produce proteins or peptides, including fusion proteinsor peptides, encoded by nucleic acids as described herein. Therecombinant expression vectors of the invention can be designed forexpression of a polypeptide of the invention in prokaryotic oreukaryotic cells, e.g., bacterial cells such as E. coli, insect cells(using baculovirus expression vectors), yeast cells or mammalian cells.Suitable host cells are discussed further in Goeddel, supra.Alternatively, the recombinant expression vector can be transcribed andtranslated in vitro, for example using T7 promoter regulatory sequencesand T7 polymerase.

Another aspect of the invention pertains to host cells into which arecombinant expression vector of the invention has been introduced. Theterms “host cell” and “recombinant host cell” are used interchangeablyherein. It is understood that such terms refer not only to theparticular subject cell but also to the progeny or potential progeny ofsuch a cell. Because certain modifications may occur in succeedinggenerations due to either mutation or environmental influences, suchprogeny may not, in fact, be identical to the parent cell, but are stillincluded within the scope of the term as used herein. A host cell can beany prokaryotic or eukaryotic cell. For example, a nucleic acid of theinvention can be expressed in bacterial cells (e.g., E. coli), insectcells, yeast or mammalian cells (such as Chinese hamster ovary cells(CHO) or COS cells). Other suitable host cells are known to thoseskilled in the art.

Vector DNA can be introduced into prokaryotic or eukaryotic cells viaconventional transformation or transfection techniques. As used herein,the terms “transformation” and “transfection” are intended to refer to avariety of art-recognized techniques for introducing foreign nucleicacid (e.g., DNA) into a host cell, including calcium phosphate orcalcium chloride co-precipitation, DEAE-dextran-mediated transfection,lipofection, or electroporation. Suitable methods for transforming ortransfecting host cells can be found in Sambrook, et al. (supra), andother laboratory manuals.

A host cell of the invention, such as a prokaryotic or eukaryotic hostcell in culture, can be used to produce (i.e., express) a polypeptide ofthe invention. Accordingly, the invention further provides methods forproducing a polypeptide using the host cells of the invention. In oneembodiment, the method comprises culturing the host cell of theinvention (into which a recombinant expression vector encoding apolypeptide of the invention has been introduced) in a suitable mediumsuch that the polypeptide is produced. In another embodiment, the methodfurther comprises isolating the polypeptide from the medium or the hostcell.

The host cells of the invention can also be used to produce nonhumantransgenic animals. For example, in one embodiment, a host cell of theinvention is a fertilized oocyte or an embryonic stem cell into which anucleic acid of the invention has been introduced. Such host cells canthen be used to create non-human transgenic animals in which exogenousnucleotide sequences have been introduced into their genome orhomologous recombinant animals in which endogenous nucleotide sequenceshave been altered. Such animals are useful for studying the functionand/or activity of the nucleotide sequence and polypeptide encoded bythe sequence and for identifying and/or evaluating modulators of theiractivity. As used herein, a “transgenic animal” is a non-human animal,preferably a mammal, more preferably a rodent such as a rat or mouse, inwhich one or more of the cells of the animal includes a transgene. Otherexamples of transgenic animals include non-human primates, sheep, dogs,cows, goats, chickens, amphibians, etc. A transgene is exogenous DNAwhich is integrated into the genome of a cell from which a transgenicanimal develops and which remains in the genome of the mature animal,thereby directing the expression of an encoded gene product in one ormore cell types or tissues of the transgenic animal. As used herein, an“homologous recombinant animal” is a non-human animal, preferably amammal, more preferably a mouse, in which an endogenous gene has beenaltered by homologous recombination between the endogenous gene and anexogenous DNA molecule introduced into a cell of the animal, e.g., anembryonic cell of the animal, prior to development of the animal.

A transgenic animal of the invention can be created by introducing anucleic acid of the invention into the male pronuclei of a fertilizedoocyte, e.g., by microinjection, retroviral infection, and allowing theoocyte to develop in a pseudopregnant female foster animal. The sequencecan be introduced as a transgene into the genome of a non-human animal.Intronic sequences and polyadenylation signals can also be included inthe transgene to increase the efficiency of expression of the transgene.A tissue-specific regulatory sequence(s) can be operably linked to thetransgene to direct expression of a polypeptide in particular cells.Methods for generating transgenic animals via embryo manipulation andmicroinjection, particularly animals such as mice, have becomeconventional in the art and are described, for example, in U.S. Pat.Nos. 4,736,866 and 4,870,009, U.S. Pat. No. 4,873,191 and in Hogan,Manipulating the Mouse Embryo (Cold Spring Harbor Laboratory Press, ColdSpring Harbor, N.Y., 1986). Similar methods are used for production ofother transgenic animals. A transgenic founder animal can be identifiedbased upon the presence of the transgene in its genome and/or expressionof mRNA in tissues or cells of the animals. A transgenic founder animalcan then be used to breed additional animals carrying the transgene.Moreover, transgenic animals carrying a transgene encoding the transgenecan further be bred to other transgenic animals carrying othertransgenes.

The invention also relates to the use of the variant and reference geneproducts to guide efforts to identify the causative mutation forvascular diseases or to identify or synthesize agents useful in thetreatment of vascular diseases, e.g., CAD and MI. Amino acids that areessential for function can be identified by methods known in the art,such as site-directed mutagenesis or alanine-scanning mutagenesis(Cunningham et al., Science, 244:1081-1085 (1989)). The latter procedureintroduces single alanine mutations at every residue in the molecule.The resulting mutant molecules are then tested for biological activityin vitro, or in vitro activity. Sites that are critical for polypeptideactivity can also be determined by structural analysis such ascrystallization, nuclear magnetic resonance or photoaffinity labeling(Smith et al., J. Mol. Biol., 224:899-904 (1992); de Vos et al. Science,255:306-312 (1992)).

Another aspect of the invention pertains to monitoring the influence ofagents (e.g., drugs, compounds) on the expression or activity ofproteins of the invention in clinical trials. An exemplary method fordetecting the presence or absence of proteins or nucleic acids of theinvention in a biological sample involves obtaining a biological samplefrom a test subject and contacting the biological sample with a compoundor an agent capable of detecting the protein, or nucleic acid (e.g.,mRNA, genomic DNA) that encodes the protein, such that the presence ofthe protein or nucleic acid is detected in the biological sample. Apreferred agent for detecting mRNA or genomic DNA is a labeled nucleicacid probe capable of hybridizing to mRNA or genomic DNA sequencesdescribed herein, preferably in an allele-specific manner. The nucleicacid probe can be, for example, a full-length nucleic acid, or a portionthereof, such as an oligonucleotide of at least 15, 30, 50, 100, 250 or500 nucleotides in length and sufficient to specifically hybridize understringent conditions to appropriate mRNA or genomic DNA. Other suitableprobes for use in the diagnostic assays of the invention are describedherein.

The invention also encompasses kits for detecting the presence ofproteins or nucleic acid molecules of the invention in a biologicalsample. For example, the kit can comprise a labeled compound or agent(e.g., nucleic acid probe) capable of detecting protein or mRNA in abiological sample; means for determining the amount of protein or mRNAin the sample; and means for comparing the amount of protein or mRNA inthe sample with a standard. The compound or agent can be packaged in asuitable container. The kit can further comprise instructions for usingthe kit to detect protein or nucleic acid.

The following Examples are offered for the purpose of illustrating thepresent invention and are not to be construed to limit the scope of thisinvention. The teachings of all references cited herein are herebyincorporated herein by reference.

EXAMPLES

Identification of Single Nucleotide Polymorphisms

The polymorphisms shown in the Table were identified by resequencing oftarget sequences from individuals of diverse ethnic and geographicbackgrounds by hybridization to probes immobilized to microfabricatedarrays. The strategy and principles for design and use of such arraysare generally described in WO 95/11995.

A typical probe array used in this analysis has two groups of four setsof probes that respectively tile both strands of a reference sequence. Afirst probe set comprises a plurality of probes exhibiting perfectcomplementarily with one of the reference sequences. Each probe in thefirst probe set has an interrogation position that corresponds to anucleotide in the reference sequence. That is, the interrogationposition is aligned with the corresponding nucleotide in the referencesequence, when the probe and reference sequence are aligned to maximizecomplementarily between the two. For each probe in the first set, thereare three corresponding probes from three additional probe sets. Thus,there are four probes corresponding to each nucleotide in the referencesequence. The probes from the three additional probe sets are identicalto the corresponding probe from the first probe set except at theinterrogation position, which occurs in the same position in each of thefour corresponding probes from the four probe sets, and is occupied by adifferent nucleotide in the four probe sets. In the present analysis,probes were 25 nucleotides long. Arrays tiled for multiple differentreferences sequences were included on the same substrate.

Publicly available sequences for a given gene were assembled into Gap4,which can be found on the world wide web atbiozentrum.unibas.ch/biocomp/staden/Overview.html. PCR primers coveringeach exon were designed using Primer 3, which can be found on the worldwide web at genome.wi.mit.edu/cgi-bin/primer/primer3.cgi. Primers werenot designed in regions where there were sequence discrepancies betweenreads. Genomic DNA was amplified in at least 50 individuals using 2.5pmol each primer, 1.5 mM MgCl₂, 100 μM dNTPs, 0.75 μM AmpliTaq GOLDpolymerase, and 19 ng DNA in a 15 μl reaction. Reactions were assembledusing a PACKARD MultiPROBE robotic pipetting station and then put in MJ96-well tetrad thermocyclers (96° C. for 10 minutes, followed by 35cycles of 96° C. for 30 seconds, 59° C. for 2 minutes, and 72° C. for 2minutes). A subset of the PCR assays for each individual were run on 3%NuSieve gels in 0.5×TBE to confirm that the reaction worked.

For a given DNA, 5 μL (about 50 ng) of each PCR or RT-PCR product werepooled (Final volume=150-200 μl). The products were purified usingQiaQuick PCR purification from Qiagen. The samples were eluted once in35 μl sterile water and 4 μl 10× One-Phor-All buffer (Pharmacia). Thepooled samples were digested with 0.2μ DNaseI (Promega) for 10 minutesat 37° C. and then labeled with 0.5 mmols biotin-N-6-ddATP and 15μTerminal Transferase (GibcoBRL Life Technology) for 60 minutes at 37° C.Both fragmentation and labeling reactions were terminated by incubatingthe pooled sample for 15 minutes at 100° C.

Low-density DNA chips (Affymetrix, Calif.) were hybridized following themanufacturer's instructions. Briefly, the hybridization cocktailconsisted of 3M TMACl, 10 mM Tris pH 7.8, 0.01% Triton X-100, 100 mg/mlherring sperm DNA (Gibco BRL), 200 pM control biotin-labeled oligo. Theprocessed PCR products were denatured for 7 minutes at 100° C. and thenadded to prewarmed (37° C.) hybridization solution. The chips werehybridized overnight at 44° C. Chips were washed in 1×SSPET and 6×SSPETfollowed by staining with 2 μg/ml SARPE and 0.5 mg/ml acetylated BSA in200 μl of 6×SSPET for 8 minutes at room temperature. Chips were scannedusing a Molecular Dynamics scanner.

Chip image files were analyzed using Ulysses (Affymetrix, Calif.) whichuses four algorithms to identify potential polymorphisms. Candidatepolymorphisms were visually inspected and assigned a confidence value:high confidence candidates displayed all three genotypes, while likelycandidates showed only two genotypes (homozygous for reference sequenceand heterozygous for reference and variant). Some of the candidatepolymorphisms were confirmed by ABI sequencing. Identified polymorphismswere compared to several databases to determine if they were novel.Results are shown in the Table.

Association of Thrombospondin Gene Polymorphisms with Vascular Disease

To determine pivotal genes associated with premature coronary arterydisease, we analyzed DNA from 347 patients with MI or coronaryrevascularization before age 40 (men) or 45 (women) and 422 generalpopulation controls. Cases were drawn (one per family) from aretrospective collection of sibling pairs with premature CAD. Controlswere ascertained through random-digit dialing. Both cases and controlswere Caucasian. A complete database of phenotypic and laboratoryvariables for the affected patients afforded logistic regression tocontrol for age, diabetes, body mass index, gender.

Thrombospondin (TSP) 4 and 1 emerged as important SNPs associated withpremature CAD and MI. For CAD, 148 of 347 patients carried at least onecopy of the TSP-4 variant compared with 142 of 422 control subjects;adjusted odds ratio 1.47, p=0.01. For premature MI, the association waseven stronger: 91 of 187 cases vs. 142 of 422 controls had the variant;adjusted odds ratio 2.08, p=0.0003. The TSP-1 SNP was rare. Nonetheless,homozygosity for the variant allele gave an adjusted odds ratio of 9.5,p=0.04. Genbank or TIGR Position Muta- Poly WIAF Accession in GeneFlanking tion Ref Alt Ref Alt ID ID Number Sequence Description Seq TypeNT NT AA AA AT3a7 WIAF-13246 U11270 11918 AT3, CTGCAGGAGT[G/A]GCTGGATGAAN G A W * antithrombin III DRD5u22 WIAF-12913 M67439 310 DRD1,CATCTGGACC[C/T]TGCTGGGCAA S C T L L dopamine receptor D1 DRD5u23WIAF-12914 M67439 332 DRD1, GTGCTGGTGT[G/C]CGCAGCCATC M G C C S dopaminereceptor D1 DRD5u24 WIAF-12915 M67439 369 DRD1,TGCGCGCCAA[C/G]ATGACCAACG M C G N K dopamine receptor D1 DRD5u25WIAF-12916 M67439 522 DRD1, TGTGCTCCAC[T/C]GCCTCCATCC S T C T T dopaminereceptor D1 DRD5u26 WIAF-12917 M67439 953 DRD1,GCAGAGCACG[C/T]GCAGAGCTGC M C T A V dopamine receptor D1 DRD5u27WIAF-12918 M67439 635 DRD1, ATGGTCGGCC[T/C]GGCATGGACC M T C L P dopaminereceptor D1 DRD5u2B WIAF-129l9 M67439 606 DRD1,GCAAGATGAC[T/C]CAGCGCATGG S T C T T dopamine receptor D1 DRD5u29WIAF-12920 M67439 845 DRD1, TCGCTCATCA[G/A]CTTCTACATC M G A S N dopaminereceptor D1 DRD5u30 WIAF-12921 M67439 720 DRD1,CGGGCCGGCT[G/T]GACCTGCCAA S G T L L dopamine receptor D1 DRD5u31WIAF-12922 M67439 1044 DRD1, AGACCCTGTC[G/A]GTGATCATGG S G A S Sdopamine receptor D1 DRD5u32 WIAF-12923 M67439 766 DRD1,GGAGGAGGAC[T/G]TTTGGGAGCC M T G F V dopamine receptor D1 DRD5u33WIAF-12924 N67439 777 DRD1, TTTCCGAOCC[C/T]GACCTCAATG S C T P P dopaminereceptor D1 DRD5u34 WIAF-12925 M67439 786 DRD1,CCGACGTGAA[T/C]GCACACAACT M T G N K dopamine receptor D1 DRD5u35WIAF-12926 M67439 881 DRD1, ACCTACACGC[G/A]CATCTACCGC M G A R H dopaminereceptor D1 DRD5u36 WIAF-12927 M67439 1279 DRD1,GTGCACCCAC[T/G]TCTGCTCCCG M T G F V dopamine receptor D1 DRD5u37WIAF-12928 M67439 1370 DRD1, GAAATCGCAG[C/T]TGCCTACATC M C T A Vdopamine receptor D1 DRD5u38 WIAF-12929 M67439 1500 DRD1,ACCCTGTTGC[T/A]GAGTCTGTCT S T A A A dopamine receptor D1 DRD5u39WIAF-12930 M67439 1338 DRD1, TCTCCTACAA[C/T]CAAGACATCG S C T N Ndopamine receptor D1 DRD5u40 WIAF-12931 M67439 1215 DRD1,CACTCAACCC[C/A]CTCATCTATG S C A P P dopamine receptor D1 DRD5u41WIAF-12932 M67439 1242 DRD1, ACGCCGACTT[T/C]CAGAAGGTGT S T C P Fdopamine receptor D1 DRD5u42 WIAF-12933 M67439 1441 DRD1,CGAGGAGGAC[G/A]GTCCTTTCGA M G A G S dopamine receptor D1 DRD5u43WIAF-12934 M67439 1460 DRD1, GATCGCATGT[T/C]CCAGATCTAT M T C F Sdopamine receptor D1 DRD5u44 WIAF-12960 M67439 399 DRD1,TGTCTCTGGC[C/T]GTGTCTGACC S C T A A dopamine receptor D1 DRD5u45WIAF-12961 M46743 9162 DRD1, TGCCGCCAGC[C/G]AGcAAcOCCA S C G G Gdopamine receptor D1 DRD5u46 WIAF-12962 M67439 195 DRD1,GGCAGTTCGC[T/G]CTATACCAGC S T G A A dopamine receptor D1 DRD5u47WIAF-12963 M67439 264 DRD1, TGGGGCCCTC[A/C]CAGCTCCTCA S A G S S dopaminereceptor D1 DRD5u48 WIAF-12964 M61439 465 DRD1,TGGCCGGTTA[C/T]TGCCCCTTTC S C T Y Y dopamine receptor D1 DRD5u49WIAF-12965 M67439 511 DRD1, CTTCGACATC[A/T]TGTGCTCCAC M A T M L dopaminereceptor D1 DRD5u50 WIAF-12966 M67439 557 DRD1,ATCAGCGTGG[A/C]CCCCTACTGG M A G D G dopamine receptor D1 DRD5u51WIAF-12967 M67439 476 DRD1, TGGCCCTTTG[C/A]AGCGTTCTGC M G A G E dopaminereceptor D1 DRD5u52 WIAF-12968 M67439 1004 DRD1,AGCCTGCGCG[C/T]TTCCATCAAC M C T A V dopamine receptor D1 DRD5u53WIAF-12969 M67439 1036 DRD1, GGTTCTCAAG[A/C]CCCTGTCGGT M A C T Pdopamine receptor D1 DRD5u54 WIAF-12970 M67439 859 DRD1,CTACATCCCC[G/A]TTGCCATCAT M G A V I dopamine receptor D1 DRD5u55WIAF-12971 M67439 931 DRD1, GATTTCCTCC[C/T]TGGAGAGGGC S C T L L dopaminereceptor D1 G10u1 WIAF-10234 J04111 1308 JUN, v-jun avianCCCTCAACGC[C/T]TCGTTCCTCC S C T A A sarcoma virus 17 oncogene homologG10u2 WIAF-10235 J04111 1471 JUN, v-jun avian GCTGCTCAAG[C/T]TGGCGTCGCCS C T L L sarcoma virus 17 oncogene homolog G10u3 WIAF-10253 J04111 2010JUN, v-jun avian TGGAGTCCCA[G/A]GAGCCGATCA S G A Q Q sarcoma virus 17oncogene homolog G1001u1 WIAF-13746 D26135 993 DGKG, diacyl-CCCCAGTCGT[C/A]TACCTGAAGG S G A V V glycerol kinase, gamma (90 kD)G1001u2 WIAF-13764 D26135 2313 DGKG, diacyl- ATGTGATGAG[A/T]GAGAAACATC MA T R S glycerol kinase, gamma (90 kD) G1002u1 WIAF-13918 X57206 334ITPKB, inositol CCCCAACATC[A/C]GGACAAGCCT M A C Q P 1,4,5-trisphosphate3-kinase B G1002u2 WIAF-13925 X57206 575 ITPKB, inositolCCAACTCAGC[T/C]TTCCTGCATA S T C A A 1,4,5-trisphosphate 3-kinase BG1004u1 WIAF-13567 L36151 1854 PIK4CA, phospha-GCCGCTCAGA[C/T]TCCGAGGATG S C T D D tidylinositol 4- kinase, catalytic,alpha polypeptide G1006u1 WIAF-12375 HT2690 858 PRKCA, proteinGGTACAAGTT[G/A]CTTAACCAAG S G A L L kinase C, alpha G1008u1 WIAF-12397HT2136 300 PRKCZ, protein CTGGCCTGCC[A/C]TCTCCCCGAC S A G P P kinase C,zeta C1008u2 WIAF-12398 HT2136 246 PRKCZ, proteinAGTGCAGGGA[T/C]GAAGGCCTCA S T C D D kinase C, zeta G1008u3 WIAF-12399HT2136 504 PRKCZ, protein GCTCCCACCC[C/T]CTCGTCCCCC S C T G G kinase C,zeta G1008u4 WIAF-12403 HT2136 807 PRKCZ, proteinAGAAGAATGA[C/T]CAAATTTACG S C T D D kinase C, zeta G1008u5 WIAF-12404HT2136 1514 PRKCZ, protein GGATTTTCTG[A/T]CATCAACTCC M A T D V kinase C,zeta G1008u6 WIAF-12412 HT2136 166 PRKCZ, proteinCAAGTGGGTC[C/A]ACACCGAAGG M G A D N kinase C, zeta C1008u7 WIAF-12418HT2136 560 PRKCZ, protein TCCCAACAGC[C/T]TCCACTACAC M C T P L kinase C,zeta C1009u1 WIAF-12396 L05186 2495 PTK2, PTK2 proteinTCATCAACAA[G/A]ATGAAACTCG S G A K K tyrosine kinase 2 G1011u1 WIAF-11988X07876 1250 WNT2, wingless-type TCCCATCTCA[C/A]CCGCATGACC M C A T N MMTVintegration site family member 2 G1011u2 WIAF-11997 X07876 788 WNT2,wingless-type CACTATGGGA[T/C]CAAATTTGCC M T C I T MMTV integration sitefamily member 2 G1011u3 WIAF-12014 X07876 1338 WNT2, wingless-typeTGCACACATG[C/A]AAGGCCCCCA N C A C * MMTV integration site family member2 C1011u4 WIAF-13475 X07876 856 WNT2, wingless-typeCCTGATGAAT[C/T]TTCACAACAA M C T L F MMTV integration site family member2 C1011u5 WIAF-13476 X07876 958 WNT2, wingless-typeGACATGCTGG[C/T]TGGCCATGGC S C T L L MMTV integration site family member2 G1011u6 WIAF-13477 X07876 789 WNT2, wingless-typeACTATCCGAT[C/T]AAATTTCCCC S C T I I MMTV integration site family member2 G1011u7 WIAF-13478 X07876 823 WNT2, wingless-typeTGCAAAGGAA[A/C]GCAAACCAAA M A G R G MMTV integration site family member2 G1012u1 WIAF-12408 HT48910 1574 WNT2B, wingless-typeATACTTGCAA[A/C]GCCCCCAAGA S A G K K MMTV integration site family, member2B G1016a1 WIAF-12125 Z22534 793 ACVR1, activin ACCCAAGCCGA[A/C]AATGTTCCCG S A G E E receptor, type I G1016u2 WIAF-12392Z22534 373 ACVR1, activin A CTGGCCAACC[T/C]GTGGACTGCT S T C A Areceptor, type I G1018u1 WIAF-12413 X74210 1150 ADCY2, adenylateCAAATTCCGA[C/T]TGCGTATTAA M G T V L cyclase 2 (brain) G1019u1 WIAF-12394U83867 5475 SPTAN1, spectrin, GCGACCTAAC[T/C]CGCCTCCACA S T C T T alpha,nonerythro- cytic 1 (alpha- fodrin) G1019u2 WIAF-12406 U83867 1223SPTAN1, spectrin, GCCCTCATCA[A/G]TGCACATCAC M A G N S alpha, nonerythro-cytic 1 (alpha- fodrin) G1019u3 WIAF-12409 U83867 3555 SPTAN1, spectrin,CTCAAGCTCT[T/C]ATCCCACACC S T C L L alpha, nonerythro- cytic 1 (alpha-fodrin) G1019u4 WIAF-12415 U83867 3369 SPTAN1, spectrin,TCCCTCAACC[C/A]AATGAACTAC S G A A A alpha, nonerythro- cytic 1 (alpha-fodrin) C1019u5 WIAF-12417 U83867 5839 SPTAN1, spectrin,TCACACACAC[T/A]TCACCCTCCA M T A F I alpha, nonerythro- cytic 1 (alpha-fodrin) G1022u1 WIAF-12393 U45945 631 ATP1B2, ATPase,CATCAATCTT[A/C]CCTCTCCTCC M A G T A Na+/K+ transporting, beta 2polypeptide G1022u2 WIAF-12400 U45945 432 ATP1B2, ATPase,GCCGCCCTGG[G/A]CGCTATTACG S G A G G Na+/K+ transporting, beta 2polypeptide G1023u1 WIAF-12401 D89722 395 ARNTL, aryl hydro-AACATTAAGA[C/C]GTGCCACCAA M G C G R carbon receptor nucleartranslocator-like G1023u2 WIAF-12407 D89722 681 ARNTL, aryl hydro-CTCATAGATC[C/T]AAAAACTGGA M C T A V carbon receptor nucleartranslocator-like G1024u1 WIAF-12410 U85946 731 Homo sapiens brainCATACATTTT[C/T]ACAACTTAAA M C T S L secretory protein hSec10p (HSEC10)mRNA, complete cds. G1027u1 WIAF-12402 L47647 1135 CKB, creatineTCGAGATGGA[A/G]CAGCGGCTGG S A G E E kinase, brain G1027u2 WIAF-12405L47647 499 CKB, creatine CCGAGCCCCG[A/C]GCCATCGACA S A C R R kinase,brain G103u1 WIAF-10427 HT2269 335 ERCC5, excisionGGGATCCCCA[T/C]CCGAACTCAA S T C H H repair cross- complementing rodentrepair deficiency, complementation group 5 (xeroderma pigmentosum,complementation group G (Cockayne syndrome)) G103u2 WIAF-10429 HT22691221 ERCC5, excision CCCTCCTTCT[C/T]CAAGAACTTT M C T P S repair cross-complementing rodent repair deficiency, complementation group 5(xeroderma pigmentosum, complementation group G (Cockayne syndrome))G103u3 WIAF-10431 HT2269 1783 ERCC5, excision TCTCCAACTT[C/C]TACAAATTCTM G C C S repair cross- complementing rodent repair deficiency,complementation group 5 (xeroderma pigmentosum, complenientation group G(Cockayne syndrome)) G103u4 WIAF-10432 HT2269 2077 ERCC5, excisionACTGAATCTG[C/A]AGGCCAGGAT M C A A E repair cross- complementing rodentrepair deficiency, complementation group 5 (xeroderma pigmentosum,complementation group G (Cockayne syndrome)) G103u5 WIAF-10446 HT22693338 ERCC5, excision AATTTGAGCT[A/T]CTTGATAAGG S A T L L repair cross-complementing rodent repair deficiency, complementation group 5(xeroderma pigmentosum, complementation group G (Cockayne syndrome))G103u6 WIAF-10447 HT2269 3487 ERCC5, excision TCAGAATCAT[C/T]TGATGGATCTM C T S F repair cross- complementing rodent repair deficiency,complementation group 5 (xeroderma pigmentosum, complementation group G(Cockayne syndrome)) G103u7 WIAF-10448 HT2269 3507 ERCC5, excisionTTCAAGTGAA[C/G]ATGCTGAAAG M C G H D repair cross- complementing rodentrepair deficiency, complementation group 5 (xeroderma pigmentosum,complementation group G (Cockayne syndrome)) G103u8 WIAF-10457 HT22691388 ERCC5, excision CTCTTCACGAE[T/G]CACCAAGATC M T G D E repair cross-complementing rodent repair deficiency, complementation group 5(xeroderma- pigmentosum, complementation group G (Cockayne syndrome))G103u9 WIAF-10458 HT2269 1362 ERCC5, excision CCGGACTCTT[T/C]CAGCCATTAAM T C S P repair cross- complementing rodent repair deficiency,complementation group 5 (xeroderma pigmentosum, complementation group G(Cockayne syndrome)) G103u10 WIAF-10459 HT2269 2357 ERCC5, excisionCTGAGAAAGA[T/C]GCCGAACATT S T C D D repair cross- complementing rodentrepair deficiency, complementation group 5 (xeroderma pigmentosum,complementation group G (Cockayne syndrome)) G103u11 WIAF-10462 HT22693109 ERCC5, excision TGGAACAGAA[C/T]GAAGACAGAT M C T T M repair cross-complementing rodent repair deficiency, complementation group 5(xeroderma pigmentosum, complementation group G (Cockayne syndrome))G103u12 WIAF-10463 HT2269 3138 ERCC5, excision GTTTCCTGTA[T/C]TAAAGCAACTS T C L L repair cross- complementing rodent repair deficiency,complementation group 5 (xeroderma pigmentosum, complementation group G(Cockayne syndrome)) G103u14 WIAF-10484 HT2269 3553 ERCC5, excisionAGAACAGCTG[C/T]GAAAGAGCCA M C T A V repair cross- complementing rodentrepair deficiency, complementation group 5 (xeroderma pigmentosum,complementation group G (Cockayne syndrome)) G103u15 WIAF-10485 HT22691429 ERCC5, excision CATCTCCACA[C/T]CCGACCGCCA M C T T M repair cross-complementing rodent repair deficiency, complementation group 5(xeroderma pigmentosum, complementation group G (Cockayne syndrome))G103a16 WIAF-12097 HT2269 3335 ERCC5, excision AACAATTTGA[G/T]CTACTTCATAM G T E D repair cross- complementing rodent repair deficiency,complementation group 5 (xeroderma pigmentosum, complementation group G(Cockayne syndrome)) G1030u1 WIAF-12411 U07358 203 ZPK, zipperACACTTCTGA[C/T]TGCACTCCCG S C T D D (leucine) protein kinase G1030u2WIAF-12416 U07358 1806 ZPK, zipper GCCACCCCAT[G/T]AACCTGGACG N G T E *(leucine) protein kinase G1031a1 WIAF-12124 U87460 2825 GPR37, Gprotein- GAGTCACCAC[C/T]TTCACCTTAT S C T T T coupled receptor 37(endothelin receptor type B-like) G1032u1 WIAF-12381 U57911 926 C110RF8,chromosome ACGTACATCA[A/C]TGCCTCGACG M A C N T 11 open reading frame 8G1033u1 WIAF-12437 M65188 431 GJA1, gap junctionTCTGTACCCA[C/T]ACTCTTCTAC M C T T I protein, alpha 1, 43 kD (connexin43) G1033u2 WIAF-12438 M65188 169 GJA1, gap junctionACGCAACATG[G/C]GTGACTGGAG M G C G R protein, alpha 1, 43 kD (connexin43) G1033u3 WIAF-12439 M65188 467 GJA1, gap junctionTATCTCATGC[C/A]AAAGGAACAG M G A R Q protein, alpha 1, 43 kD (connexin43) G1033u4 WIAF-12440 M65188 263 GJA1, gap junctionTTCATTTTCC[C/A]AATCCTGCTG M C A R Q protein, alpha 1, 43 kD (connexin43) G1033u5 WIAF-12441 M65188 218 GJA1, gap junctionCAAGCCTACT[C/T]AACTGCTCGA M C T S L protein, alpha 1, 43 kD (connexin43) G1033u6 WIAF-12442 M65188 498 GJA1, gap junctionAGAAAGAGGA[A/G]GAACTCAAGC S A G E E protein, alpha 1, 43 kD (connexin43) G1033u7 WIAF-12465 M65188 550 GJA1, gap junctionGCACTTGAAG[C/A]AGATTGAGAT M C A Q K protein, alpha 1, 43 kD (connexin43) G1033u8 WIAF-12466 M65188 548 GJA1, gap junctionATGCACTTGA[A/G]GCACATTGAC M A G K R protein, alpha 1, 43 kD (connexin43) G1033u9 WIAF-12486 M65188 933 GJA1, gap junctionCCCTGAGCCC[T/C]GCCAAACACT S T C P P protein, alpha 1, 43 kD (connexin43) G1033u10 WIAF-12487 M65188 990 GJA1, gap junctionCCTCACCAAC[C/T]GCTCCCCTCT S C T T T protein, alpha 1, 43 kD (connexin43) G1033u11 WIAF-12488 M65188 1034 GJA1, gap junctionAACCTGCTTA[C/A]TCGCGACAGA M C A T N protein, alpha 1, 43 kD (connexin43) G1033u12 WIAF-12489 M65188 1158 GJA1, gap junctionCTAACTCCCA[T/C]CCACAGCCTT S T C H H protein, alpha 1, 43 kD (connexin43) G1033u13 WIAF-12490 M65188 1222 GJA1, gap junctionTGGACATGAA[T/C]TACAGCCACT S T C L L protein, alpha 1, 43 kD (connexin43) G1033u14 WIAF-12491 M65188 1069 GJA1, gap junctionCCGCAATTAC[A/C]ACAAGCAAGC M A G N D protein, alpha 1, 43 kD (connexin43) G1033u15 WIAF-12492 M65188 1250 GJA1, gap junctionCTCCACCACC[G/A]ACCTTCAAGC M G A R Q protein, alpha 1, 43 kD (connexin43) G1033u16 WIAF-12496 M65188 423 GJA1, gap junctionTATTTCTCTC[T/C]GTACCCACAC S T C S S protein, alpha 1, 43 kD (connexin43) G1033u17 WIAF-12503 M65188 880 GJA1, gap junctionCCTTAAGGAT[C/T]GGGTTAACCG M C T R W protein, alpha 1, 43 kD (connexin43) G1033u18 WIAF-12504 M65188 855 GJA1, gap junctionAACTCTTCTA[T/C]GTTTTCTTCA S T C Y Y protein, alpha 1, 43 kD (connexin43) G1033u19 WIAF-12505 M65188 576 GJA1, gap junctionAGTTCAAGTA[C/T]GGTATTGAAG S C T Y Y protein, alpha 1, 43 kD (connexin43) G1033u20 WIAF-12512 M65188 1255 GJA1, gap junctionCCACCCACCT[T/G]CAACCACACC M T G S A protein, alpha 1, 43 kD (connexin43) G1033u21 WIAF-12513 M65188 1078 GJA1, gap junctionCAACAAGCAA[C/A]CAAGTGACCA M G A A T protein, alpha 1, 43 kD (connexin43) G1033u22 WIAF-12514 M65188 1097 GJA1, gap junctionCAAAACTCCG[C/G]TAATTACACT M C G A G protein, alpha 1, 43 kD (connexin43) G1034u1 WIAF-12443 J03544 1201 PYGB, phosphory-AGACCTGTGC[A/G]TACACCAACC S A G A A lase, glycogen; brain G1034u2WIAF-12469 J03544 771 PYGB, phosphory- GACACCCCAG[T/C]CCCCGGCTAC M T C VA lase, glycogen; brain G1034u3 WIAF-12470 J03544 1465 PYGB, phosphory-TCCACTCCGA[C/C]ATCGTCAAAC M G C E D lase, glycogen; brain G1034u4WIAF-12471 J03544 1583 PYGB, phosphory- CCCGCTCCCC[G/A]ATACCATCCT M G AD N lase, glycogen; brain G1034u5 WIAF-12472 J03544 1774 PYGB,phosphory- CCATGTTCGA[T/C]GTGCATGTGA S T C D D lase, glycogen; brainG1034u6 WIAF-12474 J03544 2449 PYGB, phosphory-AGGTGGACCA[G/A]CTGTACCGGA S G A Q Q lase, glycogen; brain G1034u7WIAF-12508 J03544 718 PYGB, phosphory- CCCCCGACGG[C/T]GTGAAGTGGC S C T GG lase, glycogen; brain G1035u1 WIAF-12484 U97105 1962 DPYSL2, dihydro-GCAGAGGAGC[A/G]GCAGACGATC M A G Q R pyrimidinase-like 2 G1035u2WIAF-12485 U97105 2842 DPYSL2, dihydro- ATGACGGACC[T/C]GTGTGTGAAG S T CP P pyrimidinase-like 2 G1035u3 WIAF-12511 U97105 2062 DPYSL2, dihydro-CCATCACCAT[C/T]GCCAACCAGA S C T I I pyrimidinase-like 2 G1036u1WIAF-12444 D88460 311 WASL, Wiskott- ACGTGGGGTC[C/T]CTGTTGCTCA S C T S SAldrich syndrome like G1038u1 WIAF-12445 HT2746 994 PCTK2, PCTAIRETAGAAGAAAG[C/A]TATTGCATCG M G A V I protein kinase 2 G1039u1 WIAF-12429HT2747 955 serine/threonine ATCCAAGAGT[C/T]GCATGTCAGC M C T R C kinase,PCTAIRE-3 G1039u2 WIAF-12458 HT2747 808 serine/threonineCACAGAAGAG[A/T]CGTGGCCCGG M A T T S kinase, PCTAIRE-3 G1041u1 WIAF-12459X72886 544 H.sapiens TYRO3 CAAGTGGCTG[G/C]CCCTGGAGAG M G C A P mRNA.G1041u2 WIAF-12460 X72886 693 H.sapiens TYRO3 TTGGCGGGAA[C/T]CGCCTGAAACS C T N N mRNA. G1041u3 WIAF-12502 X72886 561 H.sapiens TYRO3AGAGCCTGGC[C/T]GACAACCTGT S C T A A mRNA. G1043u1 WIAF-12448 M94055 5481Human voltage-gated CTCTGAGTGA[G/A]GATGACTTTG S G A E E sodium channelmRNA, complete cds. G1043u2 WIAF-12449 M94055 5205 Human voltage-gatedTTGACACCTT[T/C]GGCAACAGCA S T C F F sodium channel mRNA, complete cds.G1043u3 WIAF-12450 M94055 5224 Human voltage-gatedCATGATCTGC[C/T]TGTTCCAAAT S C T L L sodium channel mRNA, complete cds.G1043u4 WIAF-12451 M94055 5514 Human voltage-gatedAGGTTTGGGA[C/A]AACTTTCATC S C A E E sodium channel mRNA, complete cds.G1043u5 WIAF-12452 M94055 5217 Human voltage-gatedCCAACAGCAT[G/C]ATCTCCCTGT M G C M I sodium channel mRNA, complete cds.G1043u6 WIAF-12453 M94055 5334 Human voltage-gatedCCTCACTTAA[A/G]CCAGACTCTG S A G K K sodium channel mRNA, complete cds.G1043u7 WIAF-12454 M54055 5424 Human voltage-gatedTGTACATCGC[G/C]GTCATCCTGG S G C A A sodium channel mRNA, complete cds.G1043u8 WIAF-12455 M94055 5322 Human voltage-gatedATCACCCTGG[A/C]AGCTCAGTTA S A C G G sodium channel mRNA, complete cds.G1043u9 WIAF-12456 M94055 1200 Human voltage-gatedATGGCTACAC[G/A]AGCTTTGACA S G A T T sodium channel mRNA, complete cds.G1043u10 WIAF-12499 M94055 1170 Human voltage-gatedTCTGTGTGAA[G/T]GCTCGTAGAA M G T K N sodium channel mRNA, complete cds.G1046a1 WIAF-13187 U50352 267 ACCN1, amiloride-TCCCACCTGT[C/A]ACCCTCTCTA S G A V V sensitive cation channel 1, neuronal(degenerin) G1046a2 WIAF-13188 U50352 282 ACCN1, amiloride-TCTGTAACCT[C/g]AATGGCTTCC S C g L L sensitive cation channel 1, neuronal(degenerin) G1046a3 WIAF-13189 U50352 315 ACCN1, amiloride-TCACCACCAA[C/t]CACCTGTACC S C t N N sensitive cation channel 1, neuronal(degenerin) G1046a4 WIAF-13190 U50352 386 ACCN1, amiloride-CCCCATCTGG[C/a]TGACCCCTCC M C a A D sensitive cation channel 1, neuronal(degenerin) G1046a5 WIAF-13191 U50352 417 ACCN1, amiloride-CCCTCCGGCA[C/A]AACCCCAACT S G A Q Q sensitive cation channel 1, neuronal(degenerin) G1048u1 WIAF-12641 HT5174S 3214 REST, RE1-silencingCAGTCAAACC[G/A]CCTAAGGCAC S G A A A transcription factor G1048u2WIAF-12642 HT5174S 3199 REST, RE1-silencing CAAAGGAAGC[C/G]TTGGCAGTCA SC G A A transcription factor G1048u3 WIAF-12657 HT5174S 2125 REST,RE1-silencing CTCCCATCGA[C/T]ACTCCTCAGA M G T E D transcription factorG1048u4 WIAF-12660 HT5174S 2333 REST, RE1-silencingCGAACCTCTT[A/C]ACATACACCT M A C K Q transcription factor G1051u1WIAF-12431 HT28321 658 SCNN1G, sodium ATGACACCTC[C/T]GACTGTGCCA S C T SS channel, non- voltage gated 1, gamma G1051u2 WIAF-12434 HT28321 1735SCNN1G, sodium AAGCCAAGGA[G/A]TGGTCCGCCT S C A E E channel, non- voltagegated 1, gamma G1051u3 WIAF-12473 HT28321 409 SCNN1G, sodiumAGTCCCTGTA[T/C]GCCTTTCCAC S T C Y Y channel, non- voltage gated 1, gammaG1051u4 WIAF-12475 HT28321 953 SCNN1G, sodium AGTCATTTTG[T/C]ACATAAACGAM T C Y H channel, non- voltage gated 1, gamma G1051u5 WIAF-12476HT28321 975 SCNN1G, sodium GAGCAATACA[A/C]CCCATTCCTC M A G N S channel,non- voltage gated 1, gamma G1051u6 WIAF-12477 HT28321 1192 SCNN1G,sodium CTGCCTACTC[C/A]CTCCAGATCT S G A S S channel, non- voltage gated1, gamma G1053a1 WIAF-13192 HT2201 4085 SCN5A, sodiumCGTCCTCTGA[C/A]AGCTCTCTCA M G A R K channel, voltage- gated, type V,alpha polypeptide (long (electro- cardiographic) QT syndrome 3) G1053a2WIAF-13193 HT2201 5607 SCN5A, sodium ACTTTCCCCA[C/T]CCCCTGTCTG S C T D Dchannel, voltage- gated, type V, alpha polypeptide (long (electro-cardiographic) QT syndrome 3) G1053a3 WIAF-13194 HT2201 5828 SCN5A,sodium GACCCCATCA[C/T]CACCACACTC M C T T I channel, voltage- gated, typeV, alpha polypeptide (long (electro- cardiographic) QT syndrome 3)G1053a4 WIAF-13202 HT2201 713 SCN5A, sodium GCGTTCACTT[T/A]CCTTCCGGAC MT A F Y channel, voltage- gated, type V, alpha polypeptide (long(electro- cardiographic) QT syndrome 3) G1053a5 WIAF-13203 HT2201 6148SCN5A, sodium CCACACTGAA[G/T]ATCTCGCCGA M G T D Y channel, voltage-gated, type V, alpha polypeptide (long (electro- cardiographic) QTsyndrome 3) G1053a6 WIAF-13204 HT2201 6217 SCN5A, sodiumGCCCTCGCTC[C/T]CCACGACACA — G T — — channel, voltage- gated, type V,alpha polypeptide (long (electro- cardiographic) QT syndrome 3) G1053a7WIAF-13205 HT2201 6324 SCN5A, sodium AATCCCCCTC[G/A]CCCCCGCCCA — G A — —channel, voltage- gated, type V, alpha polypeptide (long (electro-cardiographic) QT syndrome 3) G1054u1 WIAF-12419 HT2202 2252 SCN4A,sodium TTGGCAAGAG[C/T]TACAAGGAGT S C T S S channel, voltage- gated, typeIV, alpha polypeptide G1054u2 WIAF-12423 HT2202 4559 SCN4A, sodiumTGGTCATGTT[C/T]ATCTACTCCA S C T F F channel, voltage- gated, type IV,alpha polypeptide G1054u3 WIAF-12424 HT2202 4856 SCN4A, sodiumTCAACATGTA[C/G]ATCGCCATCA N C G Y * channel, voltage- gated, type IV,alpha polypeptide G1054u4 WIAF-12425 HT2202 4777 SCN4A, sodiumGTCAAGGCTC[A/G]CTGCGGCAAC M A G D G channel, voltage- gated, type IV,alpha polypeptide G1054u5 WIAF-12426 HT2202 4863 SCN4A, sodiumGTACATCGCC[A/G]TCATCCTGGA M A G I V channel, voltage- gated, type IV,alpha polypeptide G1054u6 WIAF-12427 HT2202 4566 SCN4A, sodiumGTTCATCTAC[T/G]CCATCTTCGG M T G S A channel, voltage- gated, type IV,alpha polypeptide G1054u7 WIAF-12428 HT2202 4923 SCN4A, sodiumTGGTGAAGAT[G/T]ACTTTGAGAT M G T D Y channel, voltage- gated, type IV,alpha polypeptide G1054u8 WIAF-12446 HT2202 3595 SCN4A, sodiumTTCTGGCTGA[T/C]CTTCAGCATC M T C I T channel, voltage- gated, type IV,alpha polypeptide G1054u9 WIAF-12447 HT2202 4203 SCN4A, sodiumGGAGACAGAC[G/A]ACCAGAGCCA M G A D N channel, voltage- gated, type IV,alpha polypeptide G1054u10 WIAF-12495 HT2202 4811 SCN4A, sodiumTCTGCTTCTT[C/A]TGCAGCTATA M C A F L channel, voltage- gated, type IV,alpha polypeptide G1054u11 WIAF-12497 HT2202 5555 SCN4A, sodiumCAGGGCAGAC[T/G]GTGCGCCCAG S T G T T channel, voltage- gated, type IV,alpha polypeptide G1054u12 WIAF-12498 HT2202 5480 SCN4A, sodiumCACGGGACGC[C/T]GGACCCACTA S C T A A channel, voltage- gated, type IV,alpha polypeptide G1059u1 WIAF-12432 HT33704 112 APLP1, amyloid betaCGCTGCTGCT[G/A]CCACTATTGC S G A L L (A4) precursor-like protein 1G1059u2 WIAF-12433 HT33704 140 APLP1, amyloid betaTCTGCGCGCG[C/T]AGCCCGCCAT N C T Q * (A4) precursor-like protein 1G1059u3 WIAF-12435 HT33704 1344 APLP1, amyloid betaCACCATGTGG[C/T]CGCCCTGGAT M C T A V (A4) precursor-like protein 1G1059u4 WIAF-12457 HT33704 1687 APLP1, amyloid betaATCACCGAAA[C/A]CTGAATGCGT S C A K K (A4) precursor-like protein 1G1059u5 WIAF-12500 HT33704 976 APLP1, amyloid betaCGTTCCTGAG[A/C]GCCAAGATGG S A G R R (A4) precursor-like protein 1G1059u6 WIAF-12501 HT33704 1786 APLP1, amyloid betaGTCAGGCTCT[A/G]TCGGGTCTGC S A G V V (A4) precursor-like protein 1G1060u1 WIAF-12436 HT1418 1744 APLP2, amyloid betaCCAAGAAATT[C/C]AAGAGGAAAT M C G Q E (A4) precursor-like protein 2G1060u2 WIAF-12467 HT1418 2213 APLP2, amyloid betaATCACCCTGC[T/C]GATGCTGACC M T G V G (A4) precursor-like protein 2G1060u3 WIAF-12468 HT1418 2256 APLP2, amyloid betaGCCACGGGAT[C/T]CTGGAGGTTG S C T I I (A4) precursor-like protein 2G1066a1 WIAF-13195 HT3538 566 CCKBR, cholecysto-CTTTGGCACC[G/A]TCATCTGCAA M G A V I kinin B receptor G1066a2 WIAF-13196HT3538 607 CCKBR, cholecysto- GGGTGTCTGT[G/A]AGTGTGTCCA S G A V V kininB receptor G1066a3 WIAF-13206 HT3538 864 CCKBR, cholecysto-CTGCTGCTTC[T/A]GCTCTTGTTC M T A L Q kinin B receptor G1067u1 WIAF-12478HT0830 684 KCNA1, potassium AAACGCTGTG[C/T]ATCATCTGGT S C T C Cvoltage-gated channel, shaker- related subfamily, member 1 (episodicataxia with myokymia) G1067u2 WIAF-12479 HT0830 722 KCNA1, potassiumGTGCGCTTCT[T/C]CGCCTGCCCC M T C F S voltage-gated channel, shaker-related subfamily, member 1 (episodic ataxia with myo- kymia) G1067u3WIAF-12480 HT0830 804 KCNA1, potassium ATTTCATCAC[C/C]CTCGCCACCG S C G TT voltage-gated channel, shaker- related subfamily, member 1 (episodicataxia with myo- kymia) G1067u4 WIAF-12509 HT0830 690 KCNA1, potassiumTGTGCATCAT[C/T]TGGTTCTCCT S C T I I voltage-gated channel, shaker-related subfamily, member 1 (episodic ataxia with myo- kymia) G1068u1WIAF-12493 HT0831 774 KCNA2, potassium TGAACATCAT[T/A]GACATTGTGG S T A II voltage-gated channel, shaker- related subfamily, member 2 G1070a1WIAF-13197 HT27728 522 KCNJ6, potassium CACAGTGACC[T/C]GGCTCTTTTT M T CW R inwardly-rectifying channel, subfamily J, member 6 G1070a2WIAF-13201 HT27728 1244 KCNJ6, potassium CCCTGGAGGA[T/C]GGGTTCTACG S T CD D inwardly-rectifying channel, subfamily J, member 6 G1070a3WIAF-13207 HT27728 707 KCNJ6, potassium ATAAATGCCC[C/A]GACCGAATTA S G AP P inwardly-rectifying channel, subfamily J, member 6 G1071u1WIAF-12422 HT48672 1534 KCNJ3, potassium TTCCGGGCAA[C/T]TCAGAACAAA S C TN N inwardly-rectifying channel, subfamily J, member 3 G1073u1WIAF-12461 HT4556 1127 KCNJ1, potassium CACTGTGCCA[T/C]GTGCCTTTAT M T CM T inwardly-rectifying channel, subfamily J, member 1 G1074u1WIAF-12462 HT27804 289 KCNAB2, potassium ACCTCTTCGA[T/C]ACACCAGAAG S T CD D voltage-gated channel, shaker- related subfamily, beta member 2G1079u1 WIAF-12463 HT27383 1130 potassium channel,ACCTGGCCGA[T/A]GAGATCCTGT M T A D E inwardly rectifing (GB:D50582)G1079u2 WIAF-12464 HT27383 1192 potassium channel,CCTTACTCTG[T/G]GGACTACTCC M T G V G inwardly rectifing (GB:D50582)G1079u3 WIAF-12481 HT27383 708 potassium channel,CCTTCCCTCC[A/G]TCTTCATCAA M A G I V inwardly rectifing (GB:D50582)G1079u4 WIAF-12482 HT27383 779 potassium channel,CGGTCATCGC[T/C]CTCCCCCACG S T C A A inwardly rectifing (GB:D50582)G1079u5 WIAF-12483 HT27383 276 potassium channel,GCACCCTGCC[C/A]ACCCCACCTA M G A E K inwardly rectifing (GB:D50582)G1079u6 WIAF-12510 HT27383 489 potassium channel,CTGCCTCATC[C/A]CCTTCCCCCA M G A A T inwardly rectifing (GB:D50582)G1080u1 WIAF-12536 HT4412 1099 KCNJ4, potassiumTCGACTACTC[A/G]CGTTTTCACA S A G S S inwardly rectifying channel,subfamily J, member 4 G1080u2 WIAF-12537 HT4412 1050 KCNJ4, potassiumGGCCACCGCT[T/A]TGAGCCTGTG M T A F Y inwardly-rectifying channel,subfamily J, member 4 G1081u1 WIAF-12538 HT27724 1090 KCNJ2, potassiumGGCCACCGCT[A/T]TGAGCCTGTG M A T Y F inwardly-rectifying channel,subfamily J, member 2 G1082u1 WIAF-12662 HT28319 768 potassium channel,CGCGGGTCAC[C/T]GACGAGGGCG S C T T T inwardly rectify- ing, highconductance, alpha subunit G1082u2 WIAF-12663 HT28319 854 potassiumchannel, CTGGTGTCGC[C/T]CATCACCATC M C T P L inwardly rectify- ing, highconductance, alpha subunit G1082u3 WIAF-12679 HT28319 471 potassiumchannel, TCTCCATCGA[G/C]ACGCAGACCA M G C E D inwardly rectify- ing, highconductance, alpha subunit G1084a1 WIAF-13198 HT0383 2028 KCNB1,potassium CACTCCCCAG[C/A]AAGACTCCGG M C A S R voltage-gated channel,Shab- related subfamily, member 1 G1084a2 WIAF-13199 HT0383 2033 KCNB1,potassium CCCAGCAAGA[C/G]TGGGCGCAGC M C G T S voltage-gated channel,Shab- related subfamily, member 1 G1084a3 WIAF-13200 HT0383 2321 KCNB1,potassium GAGTGTGCCA[C/A]GCTTTTGGAC M C A T K voltage-gated channel,Shab- related subfamily, member 1 G1084a4 WIAF-13208 HT0383 870 KCNB1,potassium ACAACCCCCA[G/A]CTGGCCCACG S C A Q Q voltage-gated channel,Shab- related subfamily, member 1 G1088u1 WIAF-12516 HT0522 1503 KCNA5,potassium TCCTGGGCAA[G/A]ACCTTCCAGC S G A K K voltage-gated channel,shaker- related subfamily, member 5 G1088u2 WIAF-12519 HT0522 1249KCNA5, potassium CGAGCTGCTC[G/A]TGCGCTTCTT M G A V M voltage-gatedchannel, shaker- related subfamily, member 5 G1088u3 WIAF-12520 HT0522973 KCNA5, potassium CTCTGGGTCC[G/A]CGCGGGCCAT M G A A T voltage-gatedchannel, shaker- related subfamily, member 5 G1088u4 WIAF-12521 HT05221013 KCNA5, potassium GTTATCCTCA[T/C]CTCCATCATC M T C I T voltage-gatedchannel, shaker- related subfamily, member 5 G1090u1 WIAF-12651 HT14971836 KCNA5, potassium CAACCAGCCA[G/A]TGGAGGAGGC M G A S N voltage-gatedchannel, shaker- related subfamily, member 6 G1091u1 WIAF-12714 HT0222843 KCNA3, potassium CATCATCTGG[T/C]TCTCCTTCGA M T C F L voltage-gatedchannel, shaker- related subfamily, member 3 G1094a1 WIAF-13218 HT273811280 KCNJ8, potassium GTGTATTCTG[T/A]GGATTACTCC M T a V Einwardly-rectifying channel, subfamily J, member 8 G1095u1 WIAF-12532HT2629 765 KCNMA1, potassium TTCTCTACTT[C/T]GGCTTGCGGT S C T F F largeconductance calcium-activated channel, subfamily M, alpha member 1G1095u2 WIAF-12533 HT2629 2441 KCNMA1, potassiumGTGGTCTGCA[T/C]CTTTGCCCAC M T C I T large conductance calcium-activatedchannel, subfamily M, alpha member 1 G1095u3 WIAF-12534 HT2629 2714KCNMA1, potassium GATGATACTT[C/C]GCTCCACCAC M C G S W large conductancecalcium-activated channel, subfamily M, alpha member 1 G1095u4WIAF-12535 HT2629 2439 KCNMA1, potassium TCGTGGTCTG[C/T]ATCTTTGGCG S C TC C large conductance calcium-activated channel, subfamily M, alphamember 1 G1095u5 WIAF-12539 HT2629 3048 KCNMA1, potassiumCACTCATGAG[C/T]GCGACGTACT S C T S S large conductance calcium-activatedchannel, subfamily M, alpha member 1 G1095u6 WIAF-12544 HT2629 2352KCNMA1, potassium GGATGTTTCA[C/T]TGGTGTGCAC S C T H H large conductancecalcium-activated channel, subfamily M, alpha member 1 G1095u7WIAF-12545 HT2629 2392 KCNMA1, potassium CATCCTGACT[C/T]GAAGTGAAGC N C TR * large conductance calcium-activated channel, subfamily M, alphamember 1 G1095u8 WIAF-12546 HT2629 2295 KCNMA1, potassiumCTGGCAATGA[T/C]CAGATTGACA S T C D D large conductance calcium-activatedchannel, subfamily M, alpha member 1 G1095u9 WIAF-12548 HT2629 2949KCNMA1, potassium AGTTTTTGGA[C/T]CAAGACGATG S C T D D large conductancecalcium-activated channel, subfamily M, alpha member 1 G1095u10WIAF-12549 HT2629 2865 KCNMA1, potassium TGCACGGCAT[G/A]TTACGTCAAC M C AM I large conductance calcium-activated channel, subfamily M, alphamember 1 G1095u1 WIAF-12547 L26318 930 PRKMB, proteinTGCTGGTAAT[A/T]CATCCATCTA S A T I I kinase mitogen activated 8 (MAPkinase) G1098u1 WIAF-12515 L19711 2650 DAG1, dystroglycanTCTACCTGCA[C/T]ACAGTCATTC S C T H H 1 (dystrophin- associatedglycoprotein 1) G110u1 WIAF-10385 HT27392 230 meiosis-specificCAAAGGTATA[C/T]AGATGACAAC N C T Q * recA homolog, HsLim15 G110u2WIAF-10397 HT27392 1050 meiosis-specific CCTGAAAATG[A/G]AGCCACCTTC M A GE G recA homolog, HsLim15 G110u3 WIAF-10399 HT27392 674 meiosis-specificTGAACATCAG[A/G]TGGACCTACT M A G M V recA homolog, HsLim15 G1106u1WIAF-12647 HT5073 5781 MAP1B, microtubule- ACTATGAGAA[G/A]ATAGACAGAA S CA K K associated protein 1B G1106u2 WIAF-12648 HT5073 5916 MAP1B,microtubule- CTGAACAGCG[C/T]GGGTACTCAT S C T G G associated protein 1BG1106u3 WIAF-12650 HT5073 1837 MAP1B, microtubule-AGACAAGCCA[G/A]TAAAAACAGA M G A V I associated protein 1B G1105u4WIAF-12653 HT5073 2476 MAP1B, microtubule- CACCACACCA[G/A]CTGTCATGGC M GA A T associated protein 1B G1106u5 WIAF-12656 HT5073 3913 MAP1B,microtubule- GCCCAATGAG[A/C]TTAAACTCTC M A G I V associated protein 1BG1106u6 WIAF-12667 HT5073 559 MAP1B, microtubule-GATTTTCACC[G/A]ATCAAGAGAT M G A D N associated protein 1B G1106u7WIAF-12668 HT5073 570 MAP1B, microtubule- ATCAAGAGAT[C/T]CCGGAGTTAC S CT I I associated protein 1B G1106u8 WIAF-12669 HT5073 6175 MAP1B,microtubule- TACTTCCACA[T/C]ACTCTTACCA M T C Y H associated protein 1BG1106u9 WIAF-12670 HT5073 1215 MAP1B, microtubule-TCACTCTCCA[C/C]TACCTAAACA M G C Q H associated protein 1B G1106u10WIAF-12672 HT5073 1821 MAP1B, microtubule- AGGTAATGGT[G/A]AAAAAAGACA S GA V V associated protein 1B G1106u11 WIAF-12673 HT5073 2727 MAP1B,microtubule- CTCCTGCCGA[G/T]TCCCCTGATG M G T E D associated protein 1BG1106u12 WIAF-12674 HT5073 2739 MAP1B, microtubule-CCCCTCATGA[G/A]GGAATCACTA S G A E E associated protein 1B G1106u13WIAF-12676 HT5073 3643 MAP1B, microtubule- ACATGCCACT[C/A]ATCCCAAGCA M GA D N associated protein 1B G1106u14 WIAF-12677 HT5073 3609 MAP1B,microtubule- CACCCCTCAA[C/T]CCATTTTCTG S C T N N associated protein 1BG1106u15 WIAF-12682 HT5073 4752 MAP1B, microtubule-TTCCACACCC[A/T]ACAACAGATG S A T p p associated protein 1B G1110u1WIAF-12517 HT1096 1527 myelin associated GCCCCCTCGT[G/C]CTCACCAGCA S G CV V glycoprotein G1110u2 WIAF-12518 HT1096 1678 myelin associatedTGTGCGCCCC[G/T]TGGTCGCCTT M G T V L glycoprotein G1110u3 WIAF-12522HT1096 1271 myelin associated GCCGTGTCAC[C/T]CCACGATGAT M C T P Lglycoprotein G1113u1 WIAF-12523 HT2242 353 myelin transcrip-AATTCCGATC[C/T]GATCCTCACC M C T R L tion factor 1 G1116a1 WIAF-13217HT28451 417 myelin oligodendro- CAACCTTATC[G/A]ACACCCTCTC S G A S S cyteglycoprotein (MOG) G1116a2 WIAF-13219 HT28451 913 myelin oligodendro-GCAGATCACT[C/G]TTGGCCTCGT M C G L V cyte glycoprotein (MOG) G1116a3WIAF-132201 HT28451 922 myelin oligodendro- TCTTGGCCTC[G/A]TCTTCCTCTG MG A V I cyte glycoprotein (MOG) G1120u1 WIAF-12525 HT3695 1200neurofilament, TAGAGATAGC[T/C]GCTTACAGAA S T C A A subunit H G1123u1WIAF-12542 HT2569 2269 OMG, oligodendro- CAGCTGCAAC[T/C]CTAACTATTC S T CT T cyte myelin glycoprotein G1126u1 WIAF-12526 HT28354 626 PSEN2,presenilin 2 GAGCGAAGCA[T/C]GTGATCATGC S T C H H (Alzheimer disease 4)G1126u2 WIAF-12527 HT28354 494 PSEN2, presenilin 2ATGGAGAGAA[T/C]ACTGCCCAGT S T C N N (Alzheimer disease 4) G1126u3WIAF-12528 HT28354 434 PSEN2, presenilin 2 TAATGTCGGC[C/T]GAGAGCCCCA S CT A A (Alzheimer disease 4) G1126u4 WIAF-12543 HT28354 550 PSEN2,presenilin 2 GACCCTGACC[G/A]CTATGTCTGT M G A R H (Alzheimer disease 4)G117u1 WIAF-10391 HT27765 156 GTBP, G/T mismatch-ACTTCTCACC[A/G]GGAGATTTGG S A G P P binding protein G117u2 WIAF-10392HT27765 420 GTBP, G/T mismatch- AACGTGCAGA[T/C]GAAGCCTTAA S T C S Sbinding protein G117u3 WIAF-10407 HT27765 939 GTBP, G/T mismatch-CCCACGTTAG[T/C]GGAGGTGGTG S T C S S binding protein G117u4 WIAF-10411HT27765 1622 GTBP, G/T mismatch- binding proteinCATTGTTCGA[G/A]ATTTAGGACT M G A R K G117u5 WIAF-10412 HT27765 2405 GTBP,G/T mismatch- GACAGCAGGG[C/T]TATAATGTAT M C T A V binding protein G117u6WIAF-10413 HT27765 2387 GTBP, G/T mismatch- AAGAGTCAGA[A/T]CCACCCAGAC MA T N I binding protein G125u1 WIAF-10371 HT28632 1999 ATM, ataxiaCAGTAATTTT[C/T]CTCATCTTGT M C T P S telangiectasia mutated (includescomplementation groups A, C and D) G125u2 WIAF-10372 HT28632 2631 ATM,ataxia TAATGAATGA[C/A]ATTGCAGATA M C A D E telangiectasia mutated(includes complementation groups A, C and D) G125u3 WIAF-10373 HT286323084 ATM, ataxia CAATGGAAGA[T/G]GTTCTTGAAC M T G D E telangiectasiamutated (includes complementation groups A, C and D) G125Su5 WIAF-10375HT28632 4767 ATM, ataxia CACTTATACC[C/T]CTTGTGTATG S C T P Ptelangiectasia mutated (includes complementation groups A, C and D)G125u6 WIAF-10383 HT28632 8713 ATM, ataxia ATTCTTGGAT[C/T]CAGCTATTTG M CT P S telangiectasia mutated (includes complementation groups A, C andD) G125u7 WIAF-10396 HT28632 1825 ATM, ataxia CACTTTGGCA[C/G]TGACCACCAGM C G L V telangiectasia mutated (includes complementation groups A, Cand D) G125u8 WIAF-10398 HT28632 2924 ATM, ataxiaACTACTGCTC[A/G]GACCAATACT M A G Q R telangiectasia mutated (includescomplementation groups A, C and D) G125u9 WIAF-10405 HT28632 8967 ATM,ataxia TTCAACGTGT[C/T]TTCACAAGAT S C T V V telangiectasia mutated(includes complementation groups A, C and D) G125u10 WIAF-10408 HT286326954 ATM, ataxia CCAAACACCT[T/C]GTACAACTCT S T C L L telangiectasiamutated (includes complementation groups A, C and D) G125u11 WIAF-10409HT28632 6855 ATM, ataxia TTCACCACCC[T/C]ATCATCGCTC S T C P Ptelangiectasia mutated (includes complementation groups A, C and D)G125u12 WIAF-10410 HT28632 6801 ATM, ataxia TATATATTAA[G/T]TGGCAGAAAC MG T K N telangiectasia mutated (includes complementation groups A, C andD) G125u13 WIAF-10421 HT28632 335 ATM, ataxia CATTCAGATT[C/C]CAAACAAGCAM C G S C telangiectasia mutated (includes complementation groups A, Cand D) G125u14 WIAF-11607 HT28632 3966 ATM, ataxiaTTCCACATCT[C/A]GTCATTAGAA S G A L L telangiectasia mutated (includescomplementation groups A, C and D) G125a15 WIAF-13130 HT28632 8642 ATM,ataxia CAGAAATATC[A/C]ACTCTTCATG M A C E A telangiectasia mutated(includes complementation groups A, C and D) G136u1 WIAF-10388 HT3337535 MLH1, mutL AGGAGAAAAG[C/T]TTTAAAAAAT M C T A V (E. coli) homolog 1(colon cancer, non- polyposis type 2) G136u2 WIAF-10389 HT3337 769 MLH1,mutL TTCAAAATGA[A/G]TGGTTACATA M A G N S (E. coli) homolog 1 (coloncancer, non- polyposis type 2) G144u1 WIAF-11638 HT3625 1129 FOS, v-fosFBJ CCTCTGCACT[C/T]CGGTCGTCAC M C T P S murine osteo- sarcoma viraloncogene homolog G1461u1 WIAF-12562 HT0329 684 pRB-binding proteinTTGCCAAGAA[C/A]TCCAAGAACC S G A K K G1466u1 WIAF-12571 HT27849 2128API2, apoptosis ATGATCCATG[G/C]GTAGAACATG M G C W C inhibitor 2 G1468u1WIAF-12563 HT4986 1928 apoptosis CCACCAGACC[A/T]GACGAGGGGC S A T P Pinhibitor, neuronal G1468u2 WIAF-12564 HT4986 3057 apoptosisTTTGCAATTC[C/C]TTCAAGGGAG M C G L V inhibitor, neuronal G1472u1WIAF-12565 HT28478 242 BAK1, BCL2- GGCACCAGTC[C/T]GGAGAGCCTG S C T C Cantagonist/killer 1 G1472u2 WIAF-12572 HT28478 509 BAK1, BCL2-TGCACCCCAC[G/A]GCAGAGAATG S G A T T antagonist/killer 1 G1473u1WIAF-12568 HT28606 394 CASP6, caspase 6, GGTGTCAACT[G/C]TTAGCCACGC M G CV L apoptosis-related cysteine protease G1473u2 WIAF-12576 HT28606 411CASP6, caspase 6, ACGCAGATGC[C/T]GATTGCTTTG S C T A A apoptosis relatedcysteine protease G1479u1 WIAF-12550 Y09077 711 ATR, ataxiaACTTTATTAA[T/C]GGTTCTTACT M T C M T telangiectasis and Rad3 relatedG1479u2 WIAF-12551 Y09077 4303 ATR, ataxia TTGCGTATGC[T/C]GATAATAGCC S TC A A telangiectasia and Rad3 related G1479u3 WIAF-12552 Y09077 1894ATR, ataxia ATTCTGATGA[T/C]CCCTGTTTAA S T C D D telangiectasia and Rad3related G1479u4 WIAF-12553 Y09077 1855 ATR, ataxiaATTTATGTGG[T/A]ATGCTCTCAC S T A G G telangiectasia and Rad3 relatedG1479u5 WIAF-12558 Y09077 5287 ATR, ataxia TCATTCATTA[T/C]CATGGTCTAG S TC Y Y telangiectasia and Rad3 related G1479u6 WIAF-12559 Y09077 5539ATR, ataxia CAGCTTTTTA[T/C]GACTCACTGA S T C Y Y telangiectasia and Rad3related G1479u7 WIAF-12569 Y09077 1540 ATR, ataxiaATCCTGTTAT[T/C]GAGATGTTAG S T C I I telangiectasia and Rad3 relatedG1479u8 WIAF-12570 Y09077 2521 ATR, ataxia ATTTAATGGA[A/C]GATCCAGACA S AG E E telangiectasia and Rad3 related G1482u1 WIAF-12560 HT27870 3176BLM, Bloom syndrome AAAATATAAC[G/A]GAATCCAGGA S G A T T G1482u2WIAF-12561 HT27870 3605 BLM, Bloom syndrome GAAATAAAGC[C/A]CAAACTGTAC SC A A A G1482u3 WIAF-12573 HT27870 2677 BLM, Bloom syndromeTATCTATTAC[C/T]GAAAAACCCT M C T P L G1483u1 WIAF-12597 HT1470 1910MYBL2, v-myb avian GGATGAGGAT[C/A]TGAAGCTGAT M G A V M myeloblastosisviral oncogene homolog-like 2 G14B3u2 WIAF-12610 HT1470 244 MYBL2, v-mybavian ATGAGGAGGA[C/T]GAGCAGCTGA S C T D D myeloblastosis viral oncogenehomolog-like 2 G1483u3 WIAF-12611 HT1470 1406 MYBL2, v-myb avianCACTCAGAAT[A/G]GCACCAGTCT M A G S G myeloblastosis viral oncogenehomolog-like 2 G1485u1 WIAF-12581 HT1432 1941 BCR, breakpointTGGAGATGAG[A/G]AAATGGGTCC S A G R R cluster region G1485u2 WIAF-12582HT1432 3144 BCR, breakpoint TGACCATCAA[T/C]AAGGAAGATG S T C N N clusterregion G1485u3 WIAF-12583 HT1432 3777 BCR, breakpointATAACAAGGA[T/C]GTGTCGGTGA S T C D D cluster region G1485u4 WIAF-12603HT1432 2831 BCR, breakpoint CAGATCAAGA[C/A]TGACATCCAG M G A S N clusterregion G1485u5 WIAF-12608 HT1432 4217 BCR, breakpointATCCCTGCCC[C/T]GGACAGCAAG M C T P L cluster region G1486u1 WIAF-12578HT33770 1909 BRCA2, breast ATTGATAATG[G/A]AAGCTGGCCA M G A G E cancer 2,early onset G1486u2 WIAF-12579 HT33770 3623 BRCA2, breastAGTTTAGAAA[A/G]CCAAGCTACA S A G K K cancer 2, early onset G1486u3WIAF-12586 HT33770 1341 BRCA2, breast AAATGTAGCA[A/C]ATCAGAAGCC M A C NH cancer 2, early onset G1486u4 WIAF-12594 HT33770 446 BRCA2, breastCTTATAATCA[G/A]CTGGCTTCAA S G A Q Q cancer 2, early onset G1486u5WIAF-12598 HT33770 3013 BRCA2, breast ACCATGGTTT[T/C]ATATGGAGAC M T C LS cancer 2, early onset G1486u6 WIAF-12599 HT33770 3187 BRCA2, breastGAAAAAAATA[A/T]TGATTACATG M A T N I cancer 2, early onset G1486u7WIAF-12604 HT33770 4971 BRCA2, breast AGCATGTGAG[A/C]CCATTGAGAT M A C TP cancer 2, early onset G1486u8 WIAF-12607 HT33770 4034 BRCA2, breastATGATTCTGT[C/T]GTTTCAATGT S C T V V cancer 2, early onset G1487u1WIAF-12584 HT27632 2536 BRCA1, breast AGTCAGTGTG[C/G]AGCATTTGAA M C G AG cancer 1, early onset G1487u2 WIAF-12587 HT27632 4697 BRCA1, breastCATCTCAAGA[G/C]GAGCTCATTA M G C E D cancer 1, early onset G1487u3WIAF-12595 HT27632 469 BRCA1, breast TCTCCTGAAC[A/G]TCTAAAAGAT M A G H Rcancer 1, early onset G1487u4 WIAF-12600 HT27632 3667 BRCA1, breastAGCGTCCAGA[A/G]AGGAGAGCTT M A G K R cancer 1, early onset G1487u5WIAF-12601 HT27632 3537 BRCA1, breast TATGGGAAGT[A/G]GTCATGCATC M A G SG cancer 1, early onset G1487u6 WIAF-12602 HT27632 4956 BRCA1, breastATCTGCCCAG[A/G]GTCCAGCTGC M A G S G cancer 1, early onset G1487u7WIAF-12605 HT27632 2090 BRCA1,breast AGTACAACCA[A/G]ATGCCAGTCA S A G Q Qcancer 1, early onset G1487u8 WIAF-12614 HT27632 233 BRCA1,breastTCTCCACAAA[G/A]TGTGACCACA S G A K K cancer 1, early onset G1492u1WIAF-12585 HT3506 3912 cell death- TCCAGGTCCG[T/C]GGCCTGGAGA S T C R Rassociated kinase G1492u2 WIAF-12593 HT3506 4352 cell death-TACAACACCA[A/G]TAACGGGGCT M A G N S associated kinase G1492u3 WIAF-12606HT3506 2127 cell death- GCAATTTGGA[C/T]ATCTCCAACA S C T D D associatedkinase G1492u4 WIAF-12612 HT3506 1605 cell death-TCAAATTTCT[C/T]ACTGACAACA S C T L L associated kinase G1494u1 WIAF-12589HT28507 366 cell death-inducing TTCACCACAC[T/C]TAAGGAGAAC M T C L Pprotein Bik G1495u1 WIAF-12580 HT27803 759 CSE1L, chromosomeTTTCTTCCCT[G/C]ATCCTGATCT S G C L L segregation 1 (yeast homolog)- likeG1501u1 WIAF-13502 HT1949 1181 MCC, mutated in CAGCAATGAC[A/C]TTCCCATCGCM A C I L colorectal cancers G1501u2 WIAF-13503 HT1949 1753 MCC, mutatedin CAGCTGAGAA[C/T]GCTGCCAAGG S C T N N colorectal cancers G1501u3WIAF-13504 HT1949 2344 MCC, mutated in TGTCCCTAGC[T/C]GAACTCAGGA S T C AA colorectal cancers G1501u4 WIAF-13521 HT1949 445 MCC, mutated inAGCGAACGAC[G/A]CTTCGCTATG S G A T T colorectal cancers G1501u5WIAF-13522 HT1949 1504 MCC, mutated in AAAGCAATGC[T/C]GAGAGGATGA S T C AA colorectal cancers G1501u6 WIAF-13527 HT1949 2511 MCC, mutated inTTCGTGAATG[A/G]TCTAAAGCGG M A G D G colorectal cancers G1502u1WIAF-12633 HT1547 870 CCND1, cyclin D1 AGTGTGACCC[A/G]GACTGCCTCC S A G PP (PRAD1: para- thyroid adeno- matosis 1) G1503u1 WIAF-13741 U37022 1151CDK4, cyclin- CATGCCAATT[G/A]CATCGTTCAC M G A C Y dependent kinase 4G1503u2 WIAF-13742 U37022 1410 CDK4, cyclin- CTGAAGCCCA[C/T]CAGTTGGGCA SC T D D dependent kinase 4 G1503u3 WIAF-13743 U37022 1328 CDK4, cyclin-TATGCAACAC[C/T]TGTGGACATG M C T P L dependent kinase 4 G1503u4WIAF-13780 U37022 1194 CDK4, cyclin- TTCTGGTCAC[A/G]AGTGGTCCAA S A G T Tdependent kinase 4 G1503u5 WIAF-13781 U37022 1443 CDK4, cyclin-TGATTGGGCT[G/A]CCTCCAGAGG S G A L L dependent kinase 4 G1503u6WIAF-13787 U37022 1633 CDK4, cyclin- CTCTTATCTA[C/T]ATAAGGATGA M C T H Ydependent kinase 4 G1517u1 WIAF-12618 HT1132 3894 ERBB3, v-erb-b2CAGACCTCAG[T/C]GCCTCTCTGG S T C S S avian erythro- blastic leukemiaviral oncogene homolog 3 G152u1 WIAF-11608 HT3854 1673 HSPA1L, heatshock GTGAGTGATG[A/C]AGGTTTCAAG M A C E A 70 kD protein like 1 G152u2WIAF-11629 HT3854 1683 HSPA1L, heat shock AAGGTTTGAA[G/A]GGCAAGATTA S GA K K 70 kD protein like 1 G152u3 WIAF-11609 HT3854 1478 HSPA1L, heatshock GTCACAGCCA[C/T]GGACAAGAGC M C T T M 70 kD protein like 1 G152u4WIAF-11610 HT3854 1443 HSPA1L, heat shock TGACGTTTCA[C/T]ATTGATGCCA S CT D D 70 kD protein like 1 G1520u1 WIAF-12162 HT1175 2211 DNA excisionrepair TGACCGTGGA[C/T]GAGGGTGTCC S C T D D protein ERCC2, 5′ end G1520u2WIAF-12166 HT1175 546 DNA excision repair CCCACTGCCG[A/C]TTCTATGAGG S AC R R protein ERCC2, 5′ end G1527u1 WIAF-12168 HT0086 577 GSTM2,glutathione TCATCTCCCG[A/C]TTTGAGGGCT S A C R R S-transferase M2(muscle) G1527u2 WIAF-12169 HT0086 644 GSTM2, glutathioneACCTGTGTTC[A/T]CAAAGATGGC M A T T S S-transferase M2 (muscle) G1527u3WIAF-12171 HT0086 100 GSTM2, glutathione ACTCAAGCTA[C/T]GAGGAAAAGA S C TY Y S-transferase M2 (muscle) G1527u4 WIAF-12172 HT0086 41 GSTM2,glutathione GGGGTACTGG[A/G]ACATCCGCGG M A G N D S-transferase M2(muscle) G1527u5 WIAF-12173 HT0086 215 GSTM2, glutathioneGATTGATGGG[A/G]CTCACAAGAT M A G T A S-transferase M2 (muscle) G1527u6WIAF-12194 HT0086 238 GSTM2, glutathione CCCAGAGCAA[T/C]GCCATCCTGC S T CN N S-transferase M2 (muscle) G1528u1 WIAF-11950 HT1811 529 GSTM3,glutathione GTATATTTGA[C/G]CCCAAGTGCC M C G D E S-transferase M3 (brain)G1528u2 WIAF-11951 HT1811 674 GSTM3, glutathioneCAACAAGCCT[C/A]TATGCTGAGC M G A V I S-transferase M3 (brain) G1528u3WIAF-11989 HT1811 572 GSTM3, glutathione GGCTTTCATG[T/C]GCCGTTTTGA M T GC G S-transferase M3 (brain) G1528u4 WIAF-13470 HT1811 240 GSTM3,glutathione CAGAGCAATG[C/A]CATCTTGCGC M C A A D S-transferase M3 (brain)G1529u1 WIAF-14146 HT2006 797 GSTM4, glutathioneTGGACGCCTT[C/T]CCAAATCTGA S C T F F S-transferase M4 G153u1 WIAF-12163HT3856 1212 HSPA1B, heat shock TGGGGCTGGA[G/A]ACGGCCGGAG S G A E E 70 kDprotein 1 G153u2 WIAF-12182 HT3856 676 HSPA1B, heat shockGGCCGGGGAC[A/G]CCCACCTGGG M A G T A 70 kD protein 1 G153u3 WIAF-12183HT3856 1695 HSPA1B, heat shock TCAGCGAGGC[C/G]GACAAGAAGA S C G A A 70 kDprotein 1 G153u4 WIAF-12189 HT3856 330 HSPA1B, heat shockACAAGGGGGA[G/C]ACCAAGGCAT M G C E D 70 kD protein 1 G153u5 WIAF-12190HT3856 1053 HSPA1B, heat shock AGCTGCTGCA[A/G]GACTTCTTCA S A G Q Q 70 kDprotein 1 G1530u1 WIAF-11964 HT3010 673 GSTM5, glutathioneATTCCTCCGA[G/A]GTCTTTTGTT M G A G S S-transferase M5 G1530u2 WIAF-11995HT3010 593 GSTM5, glutathione GACGCCTTCC[T/C]AAACTTGAAG M T C L PS-transferase M5 G1530u3 WIAF-13473 HT3010 693 GSTM5, glutathioneTTGGAAAGTC[A/G]GCTACATGGA S A G S S S-transferase M5 G1533u1 WIAF-13458HT27460 543 GSTT2, glutathione CTCTCGGCTA[C/T]GAACTGTTTG S C T Y YS-transferase theta 2 G1533u2 WIAF-13460 HT27460 417 GSTT2, glutathioneGGACTGCCAT[G/A]GACCAGGCCC M G A M I S-transferase theta 2 G1533u3WIAF-13461 HT27460 359 GSTT2, glutathione CAGGTGTTGG[G/A]GCCACTCATT M GA G E S-transferase theta 2 G1533u4 WIAF-13462 HT27460 363 GSTT2,glutathione TGTTGGGGCC[A/C]CTCATTGGGG S A C P P S-transferase theta 2G1533u5 WIAF-13463 HT27460 385 GSTT2, glutathioneCCAGGTGCCC[G/A]AGGAGAAGGT M G A E K S-transferase theta 2 G1535u1WIAF-11952 HT0436 517 HCK, hemopoietic CCGCGTTGAC[T/C]CTCTGGACAC M T C SP cells kinase G1535u2 WIAF-12013 HT0436 783 HCK, hemopoieticTGGACCACTA[C/T]AAGAAGGGGA S C T Y Y cells kinase G1535u3 WIAF-13464HT0436 357 HCK, hemopoietic TCATCGTGGT[T/C]GCCCTGTATG S T C V V cellskinase G1535u4 WIAF-13465 HT0436 387 HCK, hemopoieticCCATTCACCA[C/T]GAAGACCTCA S C T H H cells kinase G1535u5 WIAF-13466HT0436 471 HCK, hemopoietic CCCTGGCCAC[C/G]CGGAAGGACG S C G T T cellskinase G1535u6 WIAF-13467 HT0436 240 HCK, hemopoieticCCAGCGCCAG[C/T]CCACACTCTC S C T S S cells kinase G1535u7 WIAF-13468HT0436 394 HCK, hemopoietic CCACGAAGAC[C/T]TCAGCTTCCA M C T L F cellskinase G1537u1 WIAF-12020 U04045 1514 MSH2, mutSGTGAATTAAG[A/C]GAAATAATCA S A G R R (E. coli) homolog 2 (colon cancer,non- polyposis type 1) G1537u2 WIAF-12044 U04045 599 MSH2, mutSGACTGTGTGA[A/T]TTCCCTGATA M A T E D (E. coli) homolog 2 (colon cancer,non- polyposis type 1) G1537u3 WIAF-12045 U04045 1452 MSH2, mutSAGATATGGAT[C/T]AGGTGGAAAA N C T Q * (E. coli) homolog 2 (colon cancer,non- polyposis type 1) G1537u4 WIAF-12076 U04045 938 MSH2, mutSGACACTTTGA[A/T]CTGACTACTT M A T E D (E. coli) homolog 2 (colon cancer,non- polyposis type 1) G1537u5 WIAF-12077 U04045 1878 MSH2, mutSTCAGCTAGAT[G/A]CTGTTGTCAG M G A A T (E. coli) homolog 2 (colon cancer,non- polyposis type 1) G1543u1 WIAF-13856 J00119 553 MOS, v-mos MoloneyGAGTTTCTGG[G/T]CTGAGCTCAA M G T A S murine sarcoma viral oncogenehomolog G1543u2 WIAF-13857 J00119 621 MOS, v-mos MoloneyGCACGCGCAC[G/A]CCCGCAGGGT S G A T T murine sarcoma viral oncogenehomolog G1544u1 WIAF-12018 U59464 3821 PTCH, patchedCATCCCGAAT[C/T]CAGGCATCAC M C T S F (Drosophila) homolog G1544u2WIAF-12019 U59464 3618 PTCH, patched GCGTGGTCCG[C/T]TTCGCCATGC S C T R R(Drosophila) homolog G1544u3 WIAF-12027 U59464 1761 PTCH, patchedATTTTGCCAT[G/T]GTTCTGCTCA M G T M I (Drosophila) homolog G1544u4WIAF-12029 U59464 4074 PTCH, patched CTGCCATGGG[C/T]AGCTCCGTGC S C T G G(Drosophila) homolog G1544u5 WIAF-12043 U59464 3845 PTCH, patchedCCCTCGAACC[C/T]GAGACAGCAG M C T P L (Drosophila) homolog G1544u6WIAF-12056 U59464 1433 PTCH, patched CTGCTGGTTG[C/T]ACTGTCAGTG M C T A V(Drosophila) homolog G1544u7 WIAF-12058 U59464 3298 PTCH, patchedCACCGTTCAC[G/C]TTGCTTTGGC M G C V L (Drosophila) homolog G1544u8WIAF-12062 U59464 3986 PTCH, patched TCTACTGAAG[G/A]GCATTCTGGC M G A G E(Drosophila) homolog G1544u9 WIAF-13489 U59464 1665 PTCH, patchedCCATCAGCAA[T/C]GTCACAGCCT S T C N N (Drosophila) homolog G1544u10WIAF-13490 U59464 2396 PTCH, patched AAATACTTTT[C/T]TTTCTACAAC M C T S F(Drosophila) homolog G1544u11 WIAF-13491 U59464 2199 PTCH, patchedGGACACTCTC[A/G]TCTTTTGCTG S A G S S (Drosophila) homolog G1544u12WIAF-13492 U59464 2222 PTCH, patched AAGCACTATG[C/T]TCCTTTCCTC M C T A V(Drosophila) homolog G1544u13 WIAF-13500 U59464 1686 PTCH, patchedTCTTCATGGC[C/T]GCGTTAATCC S C T A A (Drosophila) homolog G1545u1WIAF-12032 HT0473 1835 RAG1, recombina- GGACATGGAA[G/A]AAGACATCTT M G AE K tion activating gene 1 G1545u2 WIAF-12035 HT0473 2519 RAG1,recombina- TGACATTGGC[A/G]ATGCAGCTGA M A G N D tion activating gene 1G1545u3 WIAF-12046 HT0473 3045 RAG1, recombina-CGGAAAATGA[A/G]TGCCAGGCAG M A G N S tion activating gene 1 G1545u4WIAF-12047 HT0473 3146 RAG1, recombina- TCATAATGCA[T/C]TAAAAACCTC S T CL L tion activating gene 1 G1545u5 WIAF-12075 HT0473 2513 RAG1,recombina- CCACTGTGAC[A/T]TTGGCAATGC M A T I F tion activating gene 1G1545u6 WIAF-13484 HT0473 1322 RAG1, recombina-GTCGCTGACT[C/T]GGAGAGCTCA M C T R W tion activating gene 1 G1545u7WIAF-13494 HT0473 2571 RAG1, recombina- GAAGTGTATA[A/C]GAATCCCAAT M A GK R tion activating gene 1 G1545u8 WIAF-13498 HT0473 1018 RAG1,recombina- TTCTGGCTGA[C/A]CCTGTGGAGA M C A D E tion activating gene 1G1545u9 WIAF-13499 HT0473 2782 RAG1, recombina-ATCTTTACCT[G/C]AAGATGAAAC S G C L L tion activating gene 1 G1548u1WIAF-12015 HT4999 133 IF127, interferon, CTCTGCCGTA[G/A]TTTTGCCCCT M G AV I alpha-inducible protein 27 G1548u2 WIAF-13482 HT4999 380 IFI27,interferon, ATCCTGGGCT[C/T]CATTGGGTCT M C T S F alpha-inducible protein27 G1548u3 WIAF-13483 HT4999 135 IF127, interferon,CTGCCGTAGT[T/C]TTGCCCCTGG S T C V V alpha-inducible protein 27 G155u1WIAF-11634 HT3962 991 CHCl, chromosome AGCTGGATGT[G/A]CCTGTGGTAA S G A VV condensation 1 G155u2 WIAF-11635 HT3962 1271 CHCl, chromosomeCGGCTTCGGC[C/T]TCTCCAACTA M C T L F condensation 1 G155u3 WIAF-11636HT3962 1192 CHCl, chromosome GCCGGGGCCA[C/T]GTGAGATTCC S C T H Hcondensation 1 G155u4 WIAF-11637 HT3962 1267 CHCl, chromosomeTGTACGGCTT[C/T]GGCCTCTCCA S C T F F condensation 1 G155u5 WIAF-11649HT3962 1657 CHCl, chromosome TGATGGGCAA[A/G]CAGCTGGAGA S A G K Kcondensation 1 G1550u1 WIAF-12057 M16038 611 LYN, v-yes-1 Yama-GCAAAGTCCC[T/G]TTTAACAAAA M T G L R guchi sarcoma viral related oncogenehomolog G1550u2 WIAF-12061 M16038 1371 LYN, v-yes-1 Yama-TGGCATACAT[C/T]GAGCGGAAGA S C T I I guchi sarcoma viral related oncogenehomolog G1550u3 WIAF-12080 M16038 1059 LYN, v-yes-1 Yama-AAAGGCTTGG[C/T]GCTGGGCAGT S C T G G guchi sarcoma viral related oncogenehomolog G1550u4 WIAF-12081 M16038 996 LYN, v-yes-1 Yama-AGCCACAGAA[G/A]CCATGGGATA S G A K K guchi sarcoma viral related oncogenehomolog G1552u1 WIAF-12030 HT4578 2355 PMS1, postmeioticCCTGCTATTT[A/T]AAAGACTTCT N A T K * segregation increased (S.cerevisiae) 1 G1552u2 WIAF-12031 HT4578 2231 PMS1, postmeioticsegregation ACAAAGTTGA[C/T]TTAGAAGAGA S C T D D increased (S.cerevisiae) 1 G1552u3 WIAF-12040 HT4578 617 PMS1, postmeioticTCATGAGCTT[T/C]GGTATCCTTA S T C F F segregation increased (S.cerevisiae) 1 G1552u4 WIAF-12063 HT4578 1723 PMS1, postmeioticTCATGTAACA[A/C]AAAATCAAAT M A G K R segregation increased (S.cerevisiae) 1 G1552u5 WIAF-12064 HT4578 1732 PMS1, postmeioticAAAAAATCAA[A/G]TGTAATAGAT M A G N S segregation increased (S.cerevisiae) 1 G1552u6 WIAF-12065 HT4578 1660 PMS1, postmeioticTTACCATGTA[A/G]AGTAAGTAAT M A G K R segregation increased (S.cerevisiae) 1 G1552u7 WIAF-12066 HT4578 1975 PMS1, postmeioticGAACGATACA[A/G]TAGTCAAATG M A G N S segregation increased (S.cerevisiae) 1 G1552u8 WIAF-12067 HT4578 1881 PMS1, postmeioticTTTAGAGGAT[G/T]CAACACTACA M G T A S segregation increased (S.cerevisiae) 1 G1552u9 WIAF-12068 HT4578 2454 PMS1, postmeioticTTTAGACGTT[T/A]TATATAAAAT M T A L I segregation increased (S.cerevisiae) 1 G1552u10 WIAF-12069 HT4578 2457 PMS1, postmeioticAGACGTTTTA[T/C]ATAAAATGAC M T C Y H segregation increased (S.cerevisise) 1 G1552u11 WIAF-12082 HT4578 2557 PMS1, postmeioticATACCAGGAC[T/C]TTCAATTACT M T C V A segregation increased (S.cerevisiae) 1 G1552u12 WIAF-12083 HT4578 971 PMS1, postmeioticsegregation TTTTCTTTCT[G/T]AAAATCGATG S G T L L increased (S.cerevisiae) 1 G1554u1 WIAF-12028 HT4161 1500 ELK3, ELK3, ETS-CTCAGAAATC[C/T]TGATGACCTC S C T S S domain protein (SRF accessoryprotein 2) NOTE: Symbol and name provisional. G1554u2 WIAF-12059 HT41611380 ELK3, ELK3, ETS- CTGCCAGGCT[G/A]CAAGGGCCAA S G A L L domain protein(SRF accessory protein 2) NOTE: Symbol and name provisional. G1554u3WIAF-12060 HT4161 1436 ELK3, ELK3, ETS- CACATGCCAG[T/C]GCCAATCCCC M T CV A domain protein (SRF accessory protein 2) NOTE: Symbol and nameprovisional. G1562u1 WIAF-12024 HT28220 804 PDCD1, programmedGGGGCTCAGC[T/C]GACGGCCCTC S T C A A cell death 1 G1562u2 WIAF-13488HT28220 644 PDCD1, programmed GACCCCTCAG[C/T]CGTGCCTCTG M C T A V celldeath 1 G1563u1 WIAF-13493 HT1187 1748 EGFR, epidermalCCGGAGCCCA[G/A]GGACTGCGTC M G A R K growth factor receptor (avianerythroblastic leukemia viral (v-erb-b) oncogene homolog) G1563u2WIAF-13497 HT1187 2073 EGFR, epidermal ACGGATGCAC[T/A]GGGCCAGGTC S T A TT growth factor receptor (avian erythroblastic leukemia viral (v-erb-b)oncogene homolog) G1566u1 WIAF-12016 HT27594 235 PDCD2, programmedGCGCCGCTGC[C/G]TGGCCGCCCG M C G P R cell death 2 G1566u2 WIAF-12033HT27594 904 PDCD2, programmed TTGGAATTCC[A/G]GGTCATGCCT M A G Q R celldeath 2 G1566u3 WIAF-12041 HT27594 331 PDCD2, programmedAATCAACTAC[C/T]CAGGAAAAAC M C T P L cell death 2 G1566u4 WIAF-12071HT27594 649 PDCD2, programmed CCTGAGGTTG[T/C]GGAAAAGGAA M T C V A celldeath 2 G1566u5 WIAF-12072 HT27594 633 PDCD2,programmedAGAAGATGAG[A/T]TTATGCCTGA M A T I F cell death 2 G1567u1 WIAF-12042M95936 293 AKT2, v-akt murine GAGAGGCCGC[G/A]ACCCAACACC M G A R Qthymoma viral oncogene homolog 2 G1572u1 WIAF-12212 HT3998 1894proto-oncogene c- TGTTCCAGGA[A/G]TCCAGTATCT S A G E E abl, tyrosineprotein kinase, alt. transcript 2 G1572u2 WIAF-12233 HT3998 3694proto-oncogene c- AGCTTCAGAT[C/T]TGCCCGGCGA S C T I I abl, tyrosineprotein kinase, alt. transcript 2 G1572u3 WIAF-12234 HT3998 3721proto-oncogene c- GCAGTGGTCC[G/A]GCGGCCACTC S G A P P abl, tyrosineprotein kinase, alt. transcript 2 G1573u1 WIAF-12021 HT0642 343 CBL,Cas-Br-M TCATGGACAA[G/C]CTGGTGCGGT M G C K N (murine) ecotropicretroviral transforming sequence G1573u2 WIAF-12022 HT0642 363 CBL,Cas-Br-M TTGTGTCAGA[A/T]CCCAAAGCTG M A T N I (murine) ecotropicretroviral transforming sequence G1573u3 WIAF-12034 HT0642 2364 CBL,Cas-Br-M AATATTCAGT[C/T]CCAGGCGCCA M C T S P (murine) ecotropicretroviral transforming sequence G1573u4 WIAF-12049 HT0642 387 CBL,Cas-Br-M CTAAAGAATA[G/A]CCCACCTTAT M G A S N (murine) ecotropicretroviral transforming sequence G1573u5 WIAF-12050 HT0642 947 CBL,Cas-Br-M AACTCATCCT[G/A]GCTACATGGC M G A G S (murine) ecotropicretroviral transforming sequence G1573u6 WIAF-12070 HT0642 2740 CBL,Cas-Br-M TCGAGAACCT[C/T]ATGAGTCAGG S C T L L (murine) ecotropicretroviral transforming sequence G1573u7 WIAF-12073 HT0642 661 CBL,Cas-Br-M TCTTTCCAAG[T/C]GGACTCTTTC S T C S S (murine) ecotropicretroviral transforming sequence G1573u8 WIAF-12074 HT0642 2569 CBL,Cas-Br-M CTCTGGATGG[T/C]GATCCTACAA S T C G G (murine) ecotropicretroviral transforming sequence G1573u9 WIAF-13486 HT0642 2006 CBL,Cas-Br-M CCGGCACTCA[C/T]TTCCATTTTC M C T L F (murine) ecotropicretroviral transforming sequence G1574u1 WIAF-12037 HT1508 2493 FES,feline sarcoma (Snyder-Theilen) AGCGGCCCAG[C/T]TTCAGCACCA S C T S Sviral (v-fes)/ Fujinami avian sarcoma (PRCII) viral (v- fps) oncogenehomolog G1574u2 WIAF-12051 HT1508 189 FES, feline sarcoma(Snyder-Theilen) CCCAGCGGGT[C/T]AAGAGTGACA S C T V V viral (v-fes)/Fujinami avian sarcoma (pRCII) viral (v- fps) oncogene homolog G1574u3WIAF-12052 HT1508 1441 FES, feline sarcoma GAAGCCCCTG[C/T]ATGAGCAGCT M CT H Y (Snyder-Theilen) viral (v-fes)/ Fujinami avian sarcoma (PRCII)viral (v- fps) oncogene homolog G1574u4 WIAF-12053 HT1508 2202 FES,feline sarcoma GAGAGGAAGC[C/T]GATGGGGTCT S C T A A (Snyder-Theilen)viral (v-fes)/ Fujinami avian sarcoma (PRCII) viral (v-fps) oncogenehomolog G1574u5 WIAF-12054 HT1508 2088 FES, feline sarcomaCTGCTGGCAT[G/T]GAGTACCTGG M G T M I (Snyder-Theilen) viral (v-fes)/Fujinami avian sarcoma (PRCII) viral (v-fps) oncogene homolog G1574u6WIAF-12078 HT1508 1577 FES, feline sarcoma GATGGTCTGC[C/T]CCGGCACTTC M CT P L (Snyder-Theilen) viral (v-fes)/ Fujinami avian sarcoma (PRCII)viral (v-fps) oncogene homolog G1574u7 WIAF-13495 HT1508 579 FES, felinesarcoma GTGACAAGGC[T/C]AAGGACAAGT S T C A A (Snyder-Theilen) viral(v-fes)/ Fujinami avian sarcoma (PRCII) viral (v-fps) oncogene homologG1575u1 WIAF-12079 HT1052 963 FGR, Gardner- TGGGCACCGG[C/T]TGCTTCGGGG SC T G G Rasheed feline sarcoma viral (v-fgr) oncogene homolog G1575u2WIAF-13487 HT1052 232 FGR, Gardner- CAGAAGCTAC[G/A]GGGCAGCAGA M G A G RRasheed feline sarcoma viral (v-fgr) oncogene homolog G1585u1 WIAF-12017HT1675 996 CRK, v-crk avian TGGATCAACA[G/A]AATCCCGATG S G A Q Q sarcomavirus CT10 oncogene homolog G1585u2 WIAF-12036 HT1675 446 CRK, v-crkavian ACTACAACGT[T/C]GATAGAACCA M T C L S sarcoma virus CT10 oncogenehomolog G1587u1 WIAF-12023 HT0590 1473 proto-oncogene dblGGCCAATCCA[A/G]TTTGTGGTAC S A G Q Q G1587u2 WIAF-12025 HT0590 2549proto-oncogene dbl GTCCAGGCTT[C/T]TAATGTAGAT M C T S F G1587u3WIAF-12026 HT0590 2828 proto-oncogene dbl GCATCACAAT[C/T]TGCAGAAATC M CT S F G1587u4 WIAF-12038 HT0590 982 proto-oncogene dblAAATTCTCAG[G/C]AGCTATTATC M G C E Q G1587u5 WIAF-12039 HT0590 2343proto-oncogene dbl AACCAATGCA[G/T]CGACACCTTT M G T Q H G1587u6WIAF-12048 HT0590 683 proto-oncogene dbl GACACTGAAG[G/A]AGCTGTCAGT M G AG E G1587u7 WIAF-12055 HT0590 2686 proto-oncogene dblTTCTCTTCAG[C/T]AGAATGATGA N C T Q * G1587u8 WIAF-13485 HT0590 2136proto-oncogene dbl ACTGTGAAGG[T/A]TCTGCTCTGT S T A G G G1587u9WIAF-13496 HT0590 1566 proto-oncogene dbl AAAATCAGAG[C/T]AACTTAAAAA S CT S S G159u1 WIAF-11616 HT4209 1059 RAD23B, RAD23AGTACTGGGG[C/T]TCCTCAGTCT M C T A V (S. cerevisiae) homolog B G1590u1WIAF-13897 HT2455 1257 ETS2, v-ets avian GCCAGTCTCT[C/G]TGCCTCAATA S C GL L erythroblastosis virus E26 oncogene homolog 2 G1590u2 WIAF-13913HT2455 1107 ETS2, v-ets avian ATTCTGGGAC[T/G]CCCAAAGACC S T G T Terythroblastosis virus E26 oncogene homolog 2 G1590u3 WIAF-13914 HT24551314 ETS2, v-ets avian GGAGTGACCC[A/G]GTGGAGCAAG S A G P Perythroblastosis virus E26 oncogene homolog 2 G1591u1 WIAF-13924 HT2333417 HRAS, v-Ha-ras TCCAGAACCA[T/C]TTTGTGGACG S T C H H Harvey ratsarcoma viral oncogene homolog G1595u1 WIAF-12262 HT33778 1302proto-oncogene GCATACCTCA[G/C]TGGCTACTAA M G C S T 1-myc, alt.transcript 1 G1597u1 WIAF-12243 HT0410 900 MAS1, MAS1 oncogeneCCATCTTGGT[C/T]GTGAAGATCC S C T V V G150u1 WIAF-11630 HT4247 690 RAD23A,RAD23 AGAGCCAGGT[A/G]TCGGAGCAGC S A G V V (S. cerevisiae) homologG1602u1 WIAF-14180 HT1903 1321 proto-oncogene GTCGCCGGGG[C/A]CCAGCAAATAM C A P T pim-1 G1604u1 WIAF-12319 HT2788 1182 REL, v-rel avianCCTCCCAAAG[T/C]GCTGGGATTA S T C S S reticuloendo- theliosis viraloncogene homolog G1609u1 WIAF-12358 HT33646 348 RIPK1, receptorGACGCACGGT[C/T]TCCCATGACC S C T V V (TNFRSF) interact- ing serine-threonine kinase 1 G161u1 WIAF-11654 HT4251 1522 DNA repair andTATGATCCAT[C/T]TTAACTGAGG M C T S F recombination homolog RAD52 G1610a1WIAF-12101 HT27727 501 replication TGCAACTCCT[G/A]CTATTAAGAC M G A A Tprotein Rpa4, 30 kDa G1610a2 WIAF-12102 HT27727 554 replicationTACCGTGTAA[C/T]GTGAACCAGC S C T N N protein Rpa4, 30 kDa G1610u3WIAF-12307 HT27727 450 replication TTCTGCTGCT[G/A]ATGGAGCGAG M G A D Nprotein Rpa4, 30 kDa G1610u4 WIAF-12320 HT27727 1037 replicationTGATTCATGA[G/C]TGTCCTCATC M G C E D protein Rpa4, 30 kDa G1610u5WIAF-12321 HT27727 857 replication TAGAGGACAT[G/A]AACGAGTTCA M G A M Iprotein Rpa4, 30 kDa G1610u6 WIAF-12343 HT27727 539 replicationGAATTCAGGA[C/T]GTTGTACCGT S C T D D protein Rpa4, 30 kDa G1630u1WIAF-12302 HT3563 4312 DCC, deleted in ACTCATGAAG[C/T]AGCTTAATGC N C TQ * colorectal carcinoma G1632u1 WIAF-13572 HT27355 742 tumorsuppressor, TTTATGACAT[G/C]AAGCGGGGCT M G C M I PDGF receptor beta-likeG1632u2 WIAF-13584 HT27355 1102 tumor suppressor,TGGAAGACTT[C/T]GAGACGATTG S C T F F PDGF receptor beta-like G1632u3WIAF-13601 HT27355 258 tumor suppressor, AAGACGCAGT[C/T]TATCATGATG M C TS F PDGF receptor beta-like G1633u1 WIAF-13957 HT1778 1263 FER, fer(fps/ TTCAGGCAAA[T/C]GAGATCATGT S T C N N fes related) tyrosine kinase(phosphoprotein NCP94) G1633u2 WIAF-13958 HT1778 2407 F2R, fer (fps/TATGTTGTAT[C/T]TCGAGAGTAA M C T L F fes related) tyrosine kinase(phosphoprotein NCP94) G1634u1 WIAF-13505 HT3216 1569 ELK1, ELK1, memberTCTCGACCCC[C/T]GTGGTGCTCT S C T P P of ETS oncogene family G1634u2WIAF-13858 HT3216 456 ELK1, ELK1, member GGCTGTGGGG[A/G]CTACGCAAGA S A GG G oncogene family G1634u3 WIAF-13859 HT3216 745 ELK1, ELK1, memberAGGCCCAGGC[G/A]GTTTGGCACG M G A G S of ETS oncogene family G1638u1WIAF-14172 HT1224 98 uracil-DNA GCTGGGACCT[G/C]TTCCACAAAT — G C — —glycosylase G1643u1 WIAF-13517 HT3751 629 DXS648E, DNA seg-TACATCCCCA[G/A]TCGTGGCCCT M G A S N ment on chromosome X (unique) 648expressed sequence G1645u1 WIAF-14087 D21089 363 XPC, xerodermaAAAACCTCAA[G/A]GTTATAAAGG S G A K K pigmentosum, com- plementation groupC G1645u2 WIAF-14088 D21089 2166 XPC, xerodermaTGCATTCCAG[G/A]CACACGTGGC S G A R R pigmentosum, com- plementation groupC G1645u3 WIAF-14089 D21089 1580 XPC, xerodermaGGGAGCCATC[G/A]TAAGGACCCA M G A R H pigmentosum, com- plementation groupC G1645u4 WIAF-14090 D21089 1601 XPC, xerodermaAGCTTGCCAG[T/C]GGCATCCTCA M T C V A pigmentosum, com- plementation groupC G1645u5 WIAF-14091 D21089 2920 XPC, xerodermaCCCATTTGAG[A/C]AGCTGTGAGC M A C K Q pigmentosum, com- plementation groupC G1645u6 WIAF-14103 D21089 405 XPC, xeroderma ATGACCTCAG[G/A]GACTTTCCAAS G A R R pigmentosum, com- plementation group C G1645u7 WIAF-14104D21089 151 XPC, xeroderma GGGACGCGAA[C/G]TGCGCAGCCA M C G L Vpigmentosum, com- plementation group C G1645u8 WIAF-14105 D21089 2133XPC, xeroderma AAGCGGTCTA[C/T]TCCAGGGATT S C T Y Y pigmentosum, com-plementation group C G167u1 WIAF-11632 HT4579 83 PMS2L8, postmeioticCCTATTCATC[G/A]GAAGTCAGTC M G A R Q segregation increased 2-like 8G167u2 WIAF-11633 HT4579 219 PMS2L8, postmeioticGAGTGGATCT[T/C]ATTGAAGTTT S T C L L segregation increased 2-like 8G167u3 WIAF-11644 HT4579 768 PMS2L8, postmeioticTGCCCCCTAG[T/C]GACTCCGTGT S T C S S segregation increased 2-like 8G161u4 WIAF-11622 HT4579 1645 PMS2L8, postmeioticGAAAGCGCCT[G/A]AAACTGACGA M G A E K segregation increased 2-like 8G167u5 WIAF-11645 HT4579 1512 PMS2L8, postmeioticACTCGGGGCA[C/T]GGCAGCACTT S C T H H segregation increased 2-like 8G167u6 WIAF-11646 HT4579 1619 PMS2L8, postmeioticTCGCAGGAAC[A/C]TGTGGACTCT M A G H R segregation increased 2-like 8G167u7 WIAF-11647 HT4579 1432 PMS2L8, postmeioticCGTCCTGAGA[C/T]CTCAGAAAGA M C T P S segregation increased 2-like 8G167u8 WIAF-11625 HT4579 2490 PMS2L8, postmeioticGGACTGCTCT[T/C]AACACAAGCG S T C L L segregation increased 2-like 8G167u9 WIAF-11619 HT4579 804 PMS2L8, postmeioticTGAGCTGTTC[G/C]GATGCTCTGC S G C S S segregation increased 2-like 8G167u10 WIAF-11623 HT4579 1555 PMS2L8, postmeioticCATCCCAGAC[A/G]CGGGCAGTCA M A G T A segregation increased 2-like 8G167u11 WIAF-11624 HT4575 2364 PMS2L8, postmeioticCCTTCGGACC[C/T]CAGGACGTCG S C T P P segregation increased 2-like 8G167u12 WIAF-11626 HT4579 2348 PMS2L8, postmeioticACTAGTAAAA[A/G]CTGGACCTTC M A G N S segregation increased 2-like 8G181u1 WIAF-11697 HT48793 311 ERCC4, excision ATATTTGCGA[C/T]AAGTAGGATAM C T T I repair cross- complementing rodent repair deficiency,complementation group 4 G181u2 WIAF-11698 HT48793 295 ERCC4, excisionCACACAAGGT[G/C]GTGTTATATT M G C G R repair cross- complementing rodentrepair deficiency, complementation group 4 G181u3 WIAF-11699 HT48793 234ERCC4, excision TTGAACACCT[C/T]CCTCCCCCTC S C T L L repair cross-complementing rodent repair deficiency, complementation group 4 G181u4WIAF-11704 HT48793 808 ERCC4, excision TTTGTGGCAC[C/T]AGCTTGGAGC N C TQ * repair cross- complementing rodent repair deficiency,complementation group 4 G181u5 WIAF-11705 HT48793 640 ERCC4, excisionTTCTATGACA[C/T]CTACCATGCT M C T P S repair cross- complementing rodentrepair deficiency, complementation group 4 G181u6 WIAF-11670 HT487931117 ERCC4, excision AGAAAGCAAC[C/T]CAAAGTGGGA M C T P S repair cross-complementing rodent repair deficiency, complementation group 4 G185u1WIAF-11668 HT5122 319 ACVR2B, activin A TCTGCAACGA[G/A]CGCTTCACTC S G AE E receptor, type IIB G185u2 WIAF-11707 HT5122 70 ACVR2B, activin AAGACACGGGA[G/C]TGCATCTACT M G C E D receptor, type IIB G185u3 WIAF-11672HT5122 812 ACVR2B, activin A CCTCACGGAT[T/C]ACCTCAAGGG M T C Y Hreceptor, type IIB G185u4 WIAF-13542 X77533 1109 ACVR2B, activin AGGCTCCTGAG[G/A]TGCTCGAGGG M G A V M receptor, type IIB G185u5 WIAF-13558X77533 997 ACVR2B, activin A TGCTGAAGAG[C/T]GACCTCACAG S C T S Sreceptor, type IIB G187u1 WIAF-11669 HT97400 183 androgenCCAGAGACAG[C/T]GCGACCCGGA M C T R C G191u1 WIAF-10176 AF025375 414CXCR4, chemokine ACCTGGCCAT[C/T]GTCCACGCCA S C T I I (C-X-C motif),receptor 4 (fusin) G193u1 WIAF-10178 D29984 231 CCR2, chemokineAGTGCTTGAC[T/A]GACATTTACC S T A T T (C-C motif) receptor 2 G193u2WIAF-10179 D29984 190 CCR2, chemokine CATGCTGGTC[G/A]TCCTCATCTT M G A VI (C-C motif) receptor 2 G194u1 WIAF-10211 D43767 121 SCYA17, smallACATCCACCC[A/C]GCTCGAGGGA S A C A A inducible cytokine subfamily A(Cys-Cys), member 17 G197u1 WIAF-10167 D50403 1515 NRAMP1, naturalGGTGCTAGTC[T/C]GCGCCATCAA M T C C R resistance- associated macrophageprotein 1 (might include Leishmaniasis) G197u2 WIAF-10173 D50403 1629NRAMP1, natural CACCTACCTG[G/C]TCTGGACCTG M G C V L resistance-associated macrophage protein 1 (might include Leishmaniasis) G20u1WIAF-10249 U14722 896 ACVR1B, activin A CGGTACACAG[T/C]GACAATTGAG M T CV A receptor, type IB G20u2 WIAF-10250 U14722 866 ACVR1B, activin AGAGCACGGGT[C/T]CCTGTTTGAT M C T S F receptor, type IB G20u3 WIAF-10251U14722 1391 ACVR1B, activin A CAGAGTTATG[A/T]GGCACTGCGG M A T E Vreceptor, type IB G20u4 WIAF-10252 U14722 1236 ACVR1B, activin ATATATTGGGA[G/C]ATTGCTCGAA M G C E D receptor, type IB G20u5 WIAF-10261U14722 518 ACVR1B, activin A GAGATGTGTC[T/C]CTCCAAAGAC M T C L Preceptor, type IB G207a1 WIAF-10516 L25259 866 Human CTLA4AGCTGTACTT[C/T]CAACAGTTAT M C T P S counter-receptor (B7-2) mRNA,complete cds. G208u1 WIAF-10204 L31581 85 CCR7, chemokineGGGGAAACCA[A/G]TGAAAAGCGT M A G M V (C-C motif) receptor 7 G211u1WIAF-10213 M24545 174 SCYA2, small, TCACCTGCTG[T/C]TATAACTTCA S T C C Cinducible cytokine A2 (monocyte chemotactic protein 1, homologous tomouse Sig-je) G214u1 WIAF-10191 M27533 452 CD80, CD80 antigenTGAAAGAAGT[G/A]GCAACGCTGT S G A V V (CD28 antigen ligand 1, B7-1antigen) G215u1 WIAF-11659 M28393 822 PRF1, perforin 1GCATCTCTGC[C/T]GAAGCCAAGG S C T A A (preforming protein) G215u2WIAF-11723 M28393 159 PRF1, perform 1 TGACCAGCCT[C/T]CGCCGCTCGG S C T LL (preforming protein) G215u3 WIAF-11724 M28393 96 PRF1, perform 1CAGAGTGCAA[G/A]CGCAGCCACA S G A K K (preforming protein) G215u4WIAF-11725 M28393 1377 PRF1, perform 1 ATAACAACCC[C/T]ATCTGGTCAG S C T PP (preforming protein) G215u5 WIAF-11726 M28393 1326 PRF1, perform 1TGAAGCTCTT[C/T]TTTGGTGGCC S C T F F (preforming protein) G215u6WIAF-11727 M28393 1076 PRF1, perform 1 CGGCGGGAGG[C/T]ACTGAGGAGG M C T AV (preforming protein) G217u1 WIAF-11691 M31932 649 FCGR2B, Fc fragmentGCAGCTCTTC[A/C]CCAATGGGGA S A G S S of IgG, low affinity IIb, receptorfor (CD32) G217u2 WIAF-11692 M31932 625 FCGR2B, Fc fragmentTCACTGTCCA[A/G]GTGCCCAGCA S A G Q Q of IgG, low affinity IIb, receptorfor (CD32) G217u3 WIAF-11712 M31932 332 FCGR2B, Fc fragmentGACTGGCCAG[A/C]CCAGCCTCAG M A C T P of IgG, low affinity IIb, receptorfor (CD32) G217u4 WIAF-11713 M31932 101 FCGR2B, Fc fragmentGGCTTCTGCA[G/T]ACAGTCAAGC M G T D Y of IgG, low affinity IIb, receptorfor (CD32) G218u1 WIAF-10184 M36712 677 CD8B1, CD8 antigen,TTTTACAAAT[A/G]AGCAGAGAAT N A G * * beta polypeptide 1 (p37) G218u2WIAF-10188 M36712 326 CD8B1, CD8 antigen, GCTGTGTTTC[G/C]GGATGCAAGC M GC R P beta polypeptide 1 (p37) G218u3 WIAF-10189 M36712 196 CD8B1, CD8antigen, CAGTAACATG[C/T]GCATCTACTG M C T R C beta polypeptide 1 (p37)G218u4 WIAF-10190 M36712 225 CD8B1, CD8 antigen,AGCGCCAGGC[A/C]CCGAGCAGTG S A C A A beta polypeptide 1 (p37) G218u5WIAF-10194 M36712 583 CD8B1, CD8 antigen, GGTGGCTGGC[G/A]TCCTGGTTCT M GA V I beta polypeptide 1 (p37) G218u6 WIAF-10208 M36712 372 CD8B1, CD8antigen, TGAAGCCGGA[A/G]GACAGTGGCA S A G E E beta polypeptide 1 (p37)G218u7 WIAF-10209 M36712 400 CD8B1, CD8 antigen,CTGCATGATC[G/T]TCGGGAGCCC M G T V F beta polypeptide 1 (p37) G218u8WIAF-10210 M36712 270 CD8B1, CD8 antigen, TCTGGGATTC[C/T]GCAAAAGGGA S CT S S beta polypeptide 1 (p37) G218a9 WIAF-10518 M36712 618 CD8B1, CD8antigen, GAGTGGCCAT[C/G]CACCTGTGCT M C G I M beta polypeptide 1 (p37)G218a10 WIAF-13223 M36712 556 CD8B1, CD8 antigen,TTGTAGCCCC[A/G]TCACCCTTGG M A G I V beta polypeptide 1 (p37) G218a11WIAF-13224 M36712 836 CD8B1, CD8 antigen, CTGTGTGTGA[T/C]GTGCATGGGA — TC — — beta polypeptide 1 (p37) G22u1 WIAF-10301 U86136 6719 Humantelomerase- GGTGGTAACC[G/A]TCGGGCTAGA M G A V I associated protein TP-1mRNA, complete cds. G22u2 WIAF-10302 U86136 7537 Human telomerase-CTGATGGGAT[C/G]CTATGGAACC M C G I M associated protein TP-1 mRNA,complete cds. G22u3 WIAF-10311 U86136 1798 Human telomerase-ATGATGCCAT[T/C]GATGCCCTCG S T C I I associated protein TP-1 mRNA,complete cds. G22u4 WIAF-10312 U86136 2397 Human telomerase-CTGTCTCTGG[C/T]TGGCCAAAGG M C T A V associated protein TP-1 mRNA,complete cds. G22u5 WIAF-10313 U86136 3289 Human telomerase-AGAAAGGGAT[A/C]ACCTGCCGCA S A C I I associated protein TP-1 mRNA,complete cds. G22u6 WIAF-10314 U86136 3242 Human telomerase-AGAGGCCGCA[T/C]GTCGGATCTC M T C C R associated protein TP-1 mRNA,complete cds. G22u7 WIAF-10315 U86136 4482 Human telomerase-CCGTTTGCCT[G/A]CCTCGTCCAG M G A C Y associated protein TP-1 mRNA,complete cds. G22u8 WIAF-10316 U86136 4363 Human telomerase-GTTTGACTGT[G/A]GACCAGCTGC S G A V V associated protein TP-1 mRNA,complete cds. G22u9 WIAF-10317 U86136 4230 Human telomerase-GTGTCTGAGA[G/A]ACTCCGGACC M G A R K associated protein TP-1 mRNA,complete cds. G22u10 WIAF-10318 U86136 4419 Human telomerase-GGGACTAAGA[G/C]CTGGGAAGAA M G C S T associated protein TP-1 mRNA,complete cds. G22u11 WIAF-10319 U86136 5269 Human telomerase-TCTCCGATGA[T/C]ACACTCTTTC S T C D D associated protein TP-1 mRNA,complete cds. G22u12 WIAF-10320 U86136 5015 Human telomerase-GCTGCTCTCC[C/T]GGAGATGGCA M C T R W associated protein TP-1 mRNA,complete cds. G22u13 WIAF-10321 U86136 5133 Human telomerase-GTGGCCTTCT[C/T]CACCAATGGG M C T S F associated protein TP-1 mRNA,complete cds. G22u14 WIAF-10322 U86136 7764 Human telomerase-ACAGCCCTCC[A/G]TGTCCTACCT M A G H R associated protein TP-1 mRNA,complete cds. G22u15 WIAF-10323 U86136 7884 Human telomerase-TGCCTGGAAC[C/T]TTGCCTGGGC M C T P L associated protein TP-1 mRNA,complete cds. G22u16 WIAF-10324 U86136 7744 Human telomerase-AGATTCACTC[C/A]GCCTCTGTCA S G A S S associated protein TP-1 mRNA,complete cds. G22u17 WIAF-10337 U86136 1018 Human telomerase-CCATTGCTGC[T/C]TTCTTGCCGG S T C A A associated protein TP-1 mRNA,complete cds. G22u18 WIAF-10338 U86136 1000 Human telomerase-TGGCCAATAA[C/A]ATCTTGGCCA M C A N K associated protein TP-1 mRNA,complete cds. G22u19 WIAF-10339 U86136 1182 Human telomerase-ATGACGGACA[A/G]ATTTGCCCAG M A G K R associated protein TP-1 mRNA,complete cds. G22u20 WIAF-10340 U86136 1939 Human telomerase-AGCAGCTTCG[T/G]ATGGCAATGA S T G R R associated protein TP-1 mRNA,complete cds. G22u21 WIAF-10341 U86136 2227 Human telomerase-TCACGAGGGC[G/A]GAGCAGGTGG S G A A A associated protein TP-1 mRNA,complete cds. G22u22 WIAF-10342 U86136 2776 Human telomerase-GGCGCAGCAT[C/T]CGGCTTTTCA S C T I I associated protein TP-1 mRNA,complete cds. G22u23 WIAF-10343 U86136 2877 Human telomerase-GCCCCTCACC[C/A]TATCAGCCTT M G A R H associated protein TP-1 mRNA,complete cds. G22u24 WIAF-10344 U86136 3087 Human telomerase-TCAGGGCGCT[C/T]TGTGACAGAG M C T S F associated protein TP-1 mRNA,complete cds. G22u25 WIAF-10345 U86136 3662 Human telomerase-CAAGGTGGCA[C/T]CATTAGTCTT M C T P S associated protein TP-1 mRNA,complete cds. G22u26 WIAF-10346 U86136 4762 Human telomerase-TTTCGAAGTT[C/T]CTTACCAACC S C T F F associated protein TP-1 mRNA,complete cds. G22u27 WIAF-10351 U86136 1737 Human telomerase-CTCCAGCATG[G/C]GAAGTCGGTG M G C G A associated protein TP-1 mRNA,complete cds. G22u28 WIAF-10352 U86136 3543 Human telomerase-ACAGTGCAAC[A/G]GCTGATGCTG M A G Q R associated protein TP-1 mRNA,complete cds. G22u29 WIAF-10353 U86136 4232 Human telomerase-GTCTGAGAGA[C/T]TCCGGACCCT M C T L F associated protein TP-1 mRNA,complete cds. G22u30 WIAF-10354 U86136 4523 Human telomerase-GGAGGGCCCT[C/T]TGGAGCGCCC S C T L L associated protein TP-1 mRNA,complete cds. G22u31 WIAF-10355 U86136 5333 Human telomerase-TGGTTGTCGG[G/T]TGCTGCAGAC M G T V L associated protein TP-1 mRNA,complete cds. G22u32 WIAF-10356 U86136 6208 Human telomerase-AGCTGCTGAC[G/A]CGGCCACACA S G A T T associated protein TP-1 mRNA,complete cds. G22u33 WIAF-10357 U86136 7703 Human telomerase-TAGTCAGCCA[A/G]CACCACATCT M A G T a associated protein TP-1 mRNA,complete cds. G22u34 WIAF-10360 U86136 3881 Human telomerase-CATCGATGGG[G/A]CTGATAGGTT M G A A T associated protein TP-1 mRNA,complete cds. G222u1 WIAF-11700 M57230 697 IL6ST, interleukinTGAGTGGGAT[G/C]GTGGAAGGGA M G C G R 6 signal transducer (gp130,oncostatin M receptor) G222u2 WIAF-11701 M57230 708 IL6ST, interleukinGTGGAAGGGA[A/G]ACACACTTGG S A G E E 6 signal transducer (gp130,oncostatin M receptor) G222u3 WIAF-11702 M57230 677 IL6ST, interleukinGAGGGGAACA[A/G]AATGAGGTGT M A G K R 6 signal transducer (gp130,oncostatin M receptor) G222u4 WIAF-11706 M57230 1616 IL6ST, interleukinAAGAAATATA[T/C]ACTTGAGTGG M T C I T 6 signal transducer (gp130,oncostatin M receptor) G222u5 WIAF-11667 M57230 1444 IL6ST, interleukinTGATCGCTAT[C/G]TAGCAACCCT M C G L V 6 signal transducer (gp130,oncostatin M receptor) G222u6 WIAF-11708 M57230 981 IL6ST, interleukinTCTTAAAATT[G/C]ACATGGACCA M G C L F 6 signal transducer (gp130,oncostatin M receptor) G226u1 WIAF-11714 M85079 869 TGFBR2, transform-CACTGGGAGT[T/C]GCCATATCTG S T C V V ing growth factor, beta receptor II(70-80 kD) G226u2 WIAF-11715 H85079 1749 TGFBR2, transform-ACATTATCAC[C/T]CTCCATTTCC M C T P S ing growth factor, beta receptor II(70-80 kD) G226u3 WIAF-11716 M85079 1601 TGFBR2, transform-TCCCAACTCC[A/C]ACATACATCC S A G A A ing growth factor, beta receptor II(70-80 kD) G226u4 WIAF-11721 H85079 1256 TGFBR2, transform-TACTCCACTT[C/C]CTCACCCCTC M C G F L ing growth factor, beta receptor II(70-80 kD) G226u5 WIAF-11722 M85079 1502 TGFBR2, transform-TCCTCAACAA[C/T]CACCTAACCT S C T N N ing growth factor, beta receptor II(70-80 kD) G226u6 WIAF-11671 M85079 888 TGFBR2, transform-TCTCATCATC[A/C]TCTTCTACTC M A C I L ing growth factor, beta receptor II(70-80 kD) G226u7 WIAF-11674 M85079 1425 TGFBR2, transform-CCTCCACAGT[G/A]ATCACACTCC M G A D N ing growth factor, beta receptor II(70-80 kD) G227u1 WIAF-10197 M86511 685 CD14, CD14 antigenCCTGTCTGAC[A/G]ATCCTGGACT M A G N D G227u2 WIAF-10212 M86511 497 CD14,CD14 antigen GAAGCCACAG[G/A]ACTTGCACTT M G A G E G2278u1 WIAF-14117AF034611 959 CUBN, cubilin ACATAAATAA[T/C]CGCCCCTGTT S T C N N(intrinsic factor- cobalamn receptor) G2278u2 WIAF-14118 AF034611 781CUBN, cubilin CCGTGGATGT[C/T]TTCACCCAAC M C T S F (intrinsic factor-cobalain receptor) G2278u3 WIAF-14119 AF034611 641 CUBN, cubilinCTCAGACGTA[C/T]CCACCCCAGT S C T Y Y (intrinsic factor- cobalaminreceptor) G2278u4 WIAF-14121 AF034611 1185 CUBN, cubilinTCCTTATCCG[C/A]CAAATGCATG M C A P T (intrinsic factor- cobalaminreceptor) G2278u5 WIAF-14133 AF034611 1532 CUBN, cubilinTCTGCGTTAT[C/G]AAAACTGAAA M C G I M (intrinsic factor cobalaminreceptor) G2278u6 WIAF-14134 AF034611 2208 CUBN, cubilinGCCTTTCACT[C/T]ACACCAGGCA M C T H Y (intrinsic factor cobalaminreceptor) G228u1 WIAF-10199 U00672 586 IL10RA, interleukinCCAACGTCCC[G/A]CCAAACTTCA S G A P P 10 receptor, alpha G228u2 WIAF-10200U00672 731 IL10RA, interleukin AGAGCAGTGC[A/G]TCTCCCTCAC M A G I V 10receptor, alpha G2280u1 WIAF-13970 AJ001515 1747 RYR3, ryanodineCAGGTATCTT[G/A]GAAGTTTTGC S G A L L receptor 3 G2280u2 WIAF-13974AJ001515 8593 RYR3, ryanodine TAGAAGCCAT[T/C]GTCAGCAGTG S T C I Ireceptor 3 G2282u1 WIAF-12694 D00726 263 FECH, ACATGGGAGG[C/T]CCTGAAACTGS C T G G ferrochelatase (protoporphyria) G2282u2 WIAF-12695 D00726 514FECH, TACTATATTG[G/A]ATTTCGGTAC M G A G E ferrochelatase(protoporphyria) G2285u1 WIAF-12688 D16611 673 CPO, copropor-AGAAGACGCT[G/A]TCCATTTTCA M G A V I phyrinogen oxidase (coproporphyria,harderoporphyria) G2285u2 WIAF-12689 D16611 783 CPO, copropor-ATCGTGGAGA[G/A]CGGCGGGGCA S G A E E phyrinogen oxidase (coproporphyria,harderoporphyria) G2287u1 WIAF-12687 D28472 502 PTGER4, prosta-GGGCCTCACG[C/T]TCTTTGCAGT M C T L F glandin E receptor 4 (subtype EP4)G2287u2 WIAF-12691 D28472 1309 PTGER4, prosta- TGAAAATGGC[C/T]TTGGAGGCAGM C T L F glandin E receptor 4 (subtype EP4) G2287u3 WIAF-12707 D28472243 PTGER4, prosta- AGGAGACGAC[C/T]TTCTACACGC S C T T T glandin Ereceptor 4 (subtype EP4) G2287u4 WIAF-12710 D28472 1342 PTGER4, prosta-GGTGTGCCTG[G/A]CATGGGCCTG M G A G D glandin E receptor 4 (subtype EP4)G229u1 WIAF-10185 U16752 202 SDF1, stromal cell-CATGTTGCCA[G/A]AGCCAACCTC M G A R K derived factor 1 G2295u1 WIAF-12727D89079 613 LTB4R, leukotriene CTATGTCTGC[G/C]GAGTCAGCAT M G C G R b4receptor (chemo- kine receptor-like 1) G2295u2 WIAF-1272B D89079 1248LTB4R, leukotriene AGGGCACGGG[T/C]TCCGAGGCGT S T C G G b4 receptor(chemo- kine receptor-like 1) G2295u3 WIAF-12753 D89079 1348 LTB4R,leukotriene CCTCACTGCC[T/G]CCAGCCCTCT M T G S A b4 receptor (chemo- kinereceptor-like 1) G230u1 WIAF-10201 U31628 627 IL15RA, interleukinACAGCCAAGA[A/C]CTGGGAACTC M A C N T 15 receptor, alpha alpha G2300u1WIAF-12735 J02959 102 LTA4H, leukotriene ACCTGCACCT[C/T]CGCTGCACGC S G TL L A4 hydrolase G2300u2 WIAF-12738 J02959 1380 LTA4H, leukotrieneCCTGGCTCTA[C/T]TCTCCTGGAC S C T Y Y A4 hydrolase G2302u1 WIAF-12741J03037 627 CA2, carbonic TCCTGAATCC[C/T]TGGATTACTG S C T L L anhydraseII G2302u2 WIAF-12742 J03037 819 CA2, carbonic GCCACTGAAG[A/G]ACAGGCAAATM A G N D anhydrase II G2303u1 WIAF-12751 J03571 304 ALOX5, arachidonateCGCTGAAGAC[G/A]CCCCACGGGG S G A T T 5-lipoxygenase G2303u2 WIAF-12752J03571 794 ALOX5, arachidonate AGAGCTGCCC[G/A]AGAAGCTCCC M G A E K5-lipoxygenase G2304u1 WIAF-12772 J03575 840 PDHA1, pyruvateTCCGAGAGGC[A/C]ACAAGGTTTG S A G A A dehydrogenase (lipoamide) alpha 1G2304u2 WIAF-12779 J03575 1044 PDHA1, pyruvate CCAGTGTGGA[A/C]GAACTAAAGGM A C E D dehydrogenase (lipoamide) alpha 1 G2305u1 WIAF-12763 J03576456 PDHB, pyruvate TCTTCAGGGG[A/G]CCCAATGGTG S A G G G debydrogenase(lipoamide) beta G2305u2 WIAF-12764 J03576 650 PDHB, pyruvateGTTCCTTTTG[A/C]ATTTCTCCCG M A C E A dehydrogenase (lipoamide) betaG231u1 WIAF-10202 U32324 734 IL11RA, interleukinCCAGGGCCTG[C/T]GGGTAGAGTC M C T R W 11 receptor, alpha G2312u1WIAF-12762 J05096 3726 ATP1A2, ATPase, TCAAGAACCA[C/T]ACAGAGATCG S C T HH Na+/K+ transporting, alpha 2 (+) polypeptide G2313u1 WIAF-12760 J052006141 RYR1, ryanodine TGCAATTCAA[A/G]GATGGTACAG S A G K K receptor 1(skeletal) G2313u2 WIAF-12767 J05200 3048 RYR1, ryanodineCGGCGCAGAC[A/G]ACACTGGTGG S A G T T receptor 1 (skeletal) G2313u3WIAF-12768 J05200 3084 RYR1, ryanodine ATGGCCACAA[C/T]GTGTGGGCCC S C T NN receptor 1 (skeletal) G2313u4 WIAF-12777 J05200 5667 RYR1, ryanodineGCATCTTTGG[C/T]GATGAGGATG S C T G G receptor 1 (skeletal) G2313u5WIAF-12780 J05200 6600 RYR1, ryanodine GCTCGCTGCT[C/T]ATCGTGCAGA S C T LL receptor 1 (skeletal) G2313u6 WIAF-12781 J05200 7191 RYR1, ryanodineAGCCTGAGTG[C/T]TTCGHACCCG S C T C C receptor 1 (skeletal) G2313u7WIAF-12782 J05200 7602 RYR1, ryanodine ACCACAAGGC[G/A]TCCATGGTGC S G A AA receptor 1 (skeletal) G2313u8 WIAF-12784 J05200 9288 RYR1, ryanodineCAGACGCCCC[A/G]GCTCTGGTCA S A G P P receptor 1 (skeletal) G2313u9WIAF-12786 J05200 13690 RYR1, ryanodine TCCAAAGAAG[G/A]AGGAAGCTGG M G AE K receptor 1 (skeletal) G2313u10 WIAF-12789 J05200 3147 RYR1,ryanodine ACATCCCAGC[G/A]CGCCCAAACC S G A A A receptor 1 (skeletal)G23144u1 WIAF-12771 J05272 1920 IMPDH1, IMP TGAAGATCGC[A/G]CAGGGTGTCT SA G A A (inosine mono- phosphate) dehydrogenase 1 G2319u1 WIAF-12814K03191 651 CYP1A1, cytochrome CCCCTACAGG[T/C]ATGTGGTGGT M T C Y H P450,subfamily I (aromatic compound inducible), poly- peptide 1 G232u1WIAF-11657 U58917 1490 Homo sapiens IL,-17 TGAACATGAT[C/T]CTCCCGGACT S CT I I receptor mRNA, complete cds. G232u2 WIAF-11677 U58917 1293 Homosapiens IL-17 GCAGGCCATC[T/C]CGGAGGCAGG M T C S P receptor mRNA,complete cds. G232u3 WIAF-11658 U58917 1132 Homo sapiens IL-17GGCCTGCCTG[C/T]GGCTCACCTG M C T A V receptor mRNA, complete cds. G232u4WIAF-11679 U58917 905 Homo sapiens IL-17 GCAGCTGCCT[C/T]AATGACTGCC S C TL L receptor mRNA, complete cds. G232u5 WIAF-11682 U58917 1794 Homosapiens IL-17 GTTCGAATGTE[G/T]AGAACCTCTA N G T E * receptor mRNA,complete cds. G232u7 WIAF-11660 U58917 743 Homo sapiens IL-17TGACCAGTTT[T/C]CCGCACATGG S T C F F receptor mRNA, complete cds. G2322u1WIAF-12853 L01406 1316 GHRHR, growth CTGACATCTA[T/C]GTGCTAGGCT M T C M Thormone releasing hormone receptor G2328u1 WIAF-12845 L20316 1285 GCGR,glucagon TGCGGGCACG[G/C]CAGATGCACC S G C R R receptor G2329u1 WIAF-12850L22214 713 ADORA1, adenosine TGCTGGCAAT[T/C]GCTGTGGACC S T C I I A1receptor G2329u2 WIAF-12851 L22214 716 ADORA1, adenosineTGGCAATTGC[T/G]GTGGACCGCT S T G A A A1 receptor G2335a1 WIAF-12136L32961 265 ABAT, 4-amino- CCTAGATCTC[A/G]GGAGTTAATG M A G Q R butyrateamino- transferase G2335a2 WIAF-12137 L32961 407 ABAT, 4-amino-TCTCCTCTGT[T/C]CCCATAGGTT S T C V V butyrate amino- transferase G2335u3WIAF-12838 L32961 365 ABAT, 4-amino- TTGATGTGGA[C/T]GGCAACCGAA S C T D Dbutyrate amino- transferase G2335u4 WIAF-12839 L32961 583 ABAT, 4-amino-ATCACCATGG[C/T]CTGCGGCTCC M C T A V butyrate amino- transferase G2335u5WIAF-12841 L32961 1082 ABAT, 4-amino- TGGACGAGGT[C/A]CAGACCGGAG S C A VV butyrate amino- transferase G2335u6 WIAF-12852 L32961 227 ABAT,4-amino- ATTATGATGG[C/A]CCTCTGATGA S G A G G butyrate amino- transferaseG2337u1 WIAF-13577 L34820 149 ALDH5A1, aldehydeTGTTCTCGAA[A/C]GAATGCCAAG M A G K R dehydrogenase 5 family, member A1(succinate-semi- aldehyde dehydrogenase) G2342a1 WIAF-12138 M12530 1602TF, transferrin GCCTAAACCT[G/C]TGTGAACCCA S G C L L G2342a2 WIAF-12139M12530 1795 TF, transferrin TACCAGGAAA[C/T]CTGTGGAGGA M C T P S G2346u1WIAF-12829 M13928 234 ALAD, aminolevuli- TGGCCAGGTA[T/C]GGTGTGAAGC S T CY Y nate, delta-, dehydratase G2346u2 WIAF-12830 M13928 529 ALAD,aminolevuli- TGAGGTGGCA[T/C]TGGCGTATGC S T C L L nate, delta-,dehydratase G2346u3 WIAF-12843 M13928 480 ALAD, aminolevuli-TGAGTGAAAA[C/T]GGAGCATTCC S C T N N nate, delta-, dehydratase G2348u1WIAF-12835 M14016 621 UROD, uroporphyrino- CTCTGGTCCC[A/G]TATCTGGTAG S AG P P gen decarboxylase G235u1 WIAF-11678 U83171 100 SCYA22, smallCAGGCCCCTA[C/T]GGCGCCAACA S C T Y Y inducible cytokine subfamily A (Cys-Cys), member 22 G2363a1 WIAF-10519 M37435 596 CSF1, colonyGACAAGGACT[G/T]GAATATTTTC M G T W L stimulating factor 1 (macrophage)G2363a2 WIAF-13225 M37435 498 CSF1, colony AAGAGCATGA[C/T]AAGGCCTGCG S CT D D stimulating factor 1 (macrophage) G2363a3 WIAF-13226 M37435 712CSF1, colony CAGTGACCCG[G/T]CCTCTGTCTC M G T A S stimulating factor 1(macrophage) G2369u1 WIAF-12854 M30773 857 PPP3R1, proteinTTGATTTGCA[C/T]AATTCTCGTT S C T D D phosphatase 3 (formerly 2B),regulatory subunit B (19 kD), alpha isoform (calcineurin B, type I)G2369u2 WIAF-12855 M30773 1274 PPP3R1, proteinATGTGTGACT[C/T]TTATCAGAGA - C T - - phosphatase 3 (formerly 25),regulatory subunit B (19 kD), alpha isoform (calcineurin B, type I)G237u1 WIAF-11662 U86358 311 SCYA25, small CACCACAACA[T/C]GCAGACCTTC M TC M T inducible cytokine subfamily A (Cys- Cys), member 25 G237u2WIAF-11680 U86358 134 SCYA25, small GTGCTCCGGC[G/A]CGCCTGGACT M G A R Hinducible cytokine subfamily A (Cys- Cys), member 25 G237u3 WIAF-11681U86358 133 SCYA25, small TGTGCTCCGG[C/T]GCGCCTGGAC M C T R C induciblecytokine subfamily A (Cys- Cys), member 25 G237u5 WIAF-11661 U86358 302SCYA25, small GCAAAGCTCC[A/G]CCACAACATG M A G H R inducible cytokinesubfamily A (Cys- Cys), member 25 G237u6 WIAF-11663 U86358 378 SCYA25,small AGTTATCATC[A/C]TCCAAGTTTA S A G S S inducible cytokine subfamily A(Cys- Cys), member 25 G2373u1 WIAF-12870 M36035 500 BZRP, benzo-GCTGGCCTTC[G/A]CGACCACACT M G A A T diazapine receptor (peripheral)G2376u1 WIAF-13025 M57414 979 TACR2, tachykininCTGCTGCCCA[T/C]GGGTCACACC M T C W R receptor 2 G238u1 WIAF-10177 X01394239 TNF, tumor necrosis GCTCCAGGCG[G/T]TGCTTGTTCC S G T R R factor (TNFsuper- family, member 2) G2381u1 WIAF-12894 M59941 730 CSF2RB, colonyCAGAGGTTTG[C/T]TGGGACTCCC S C T C C stimulating factor 2 receptor, beta,low-affinity (granulocyte- macrophage) G2381u2 WIAF-12896 M59941 1306CSF2RB, colony GGATCTGGAG[C/T]GAGTGGAGTG S C T S S stimulating factor 2receptor, beta, low-affinity (granulocyte- macrophage) G2381u3WIAF-12900 M59941 1972 CSF2RB, colony CGATGGGACCC[G/A]GGACAGGCCG S G A PP stimulating factor 2 receptor, beta, low-affinity (granulocyte-macrophage) G2381u4 WIAF-12901 M59941 1982 CSF2RB, colonyGGGACAGGCC[G/A]TGGAACTGGA M G A V M stimulating factor 2 receptor, beta,low-affinity (granulocyte- macrophage) G2381u5 WIAF-12942 M59941 773CSF2RB, colony CCAGAACCTG[G/C]AGTGCTTCTT M G C E Q stimulating factor 2receptor, beta, low-affinity (granulocyte- macrophage) G2381u6WIAF-12946 M59941 2458 CSF2RB, colony CCCCACAGCC[C/A]GAGGGCCTCC S C A PP stimulating factor 2 receptor, beta, low-affinity (granulocyte-macrophage) G2384u1 WIAF-12908 M61831 1000 AHCY, S-adenosyl-GCCGTGGAGA[A/C]GGTGAACATC M A C K T homocysteine hydrolase G2387u1WIAF-12910 M63967 2585 ALDH5, aldehyde CTGCTGAACC[T/G]CCTGGCAGAC M T G LR dehydrogenase 5 G2387u2 WIAF-12911 M63967 2996 ALDH5, aldehydeTATGGCCCAA[C/G]AGCAGGTGCG M C G T R dehydrogenase 5 G2387u3 WIAF-12954M63967 2522 ALDH5, aldehyde GCCCGGGAAG[C/T]CTTCCGCCTG M C T A Vdehydrogenase 5 G2387u4 WIAF-12955 M63967 2448 ALDH5, aldehydeACCCTACCAC[C/T]GGGGAGGTCA S C T T T dehydrogenase 5 G2387u5 WIAF-12956M63967 2460 ALDH5, aldehyde GGGAGGTCAT[C/T]GGGCACGTGG S C T I Idehydrogenase 5 G2387u6 WIAF-12957 M63967 2991 ALDH5, aldehydeCGGGGTATGG[C/T]CCAACAGCAG S C T G G dehydrogenase 5 G2387u7 WIAF-12958M63967 3022 ALDH5, aldehyde CGCCCAGCAC[A/G]TGGATGTTGA M A G M Vdehydrogenase 5 G2387u8 WIAF-12959 M63967 2943 ALDH5, aldehydeCCCTCATCAA[G/C]GAGGCAGGCT M G C K N dehydrogenase 5 G2388u1 WIAF-12888M64590 588 GLDC, glycine TGCCACAGAC[G/A]ATTTTGCCGA S C A T Tdehydrogenase (decarboxylating; glycine decarboxyl- ase, glycine cleav-age system protein P) G2388u2 WIAF-12889 M64590 651 GLDC, glycineACCAGCCTGA[G/A]GTGTCTCAGG S G A E E dehydrogenase (decarboxylating;glycine decarboxyl- ase, glycine cleav- age system protein P) G2388u3WIAF-12890 M64590 698 GLDC, glycine CAGACCATGG[T/C]GTGTGACATC M T C V Adehydrogenase (decarboxylating; glycine decarboxyl- ase, glycine cleav-age system protein P) G2388u4 WIAF-12891 M64590 557 GLDC, glycineTATATTGGCA[T/C]GGGCTATTAT M T C M T dehydrogenase (decarboxylating;glycine decarboxyl- ase, glycine cleav- age system protein P) G2388u5WIAF-12938 M64590 587 GLDC, glycine GTGCCACAGA[C/G]GATTTTGCGG M C G T Rdehydrogenase (decarboxylating; glycine decarboxyl- ase, glycine cleav-age system protein P) G2388u6 WIAF-12939 M64590 518 GLDC, glycineCTGCATGCCA[T/C]TTCAAGCAAA M T C I T dehydrogenase (decarboxylating;glycine decarboxyl- ase, glycine cleav- age system protein P) G2388u7WIAF-12940 M64590 810 GLDC, glycine GGAAATTTCT[C/T]GTTGATCCCC S C T L Ldehydrogenase (decarboxylating; glycine decarboxyl- ase, glycine cleav-age system protein P) G2388u8 WIAF-12941 M64590 1481 GLDC, glycineCATTGTGGCT[G/A]CTCAGTGAAG M G A C Y dehydrogenase (decarboxylating;glycine decarboxyl- ase, glycine cleav- age system protein P) G2388u9WIAF-12947 M64590 1841 GLDC, glycine AAACTGAACA[C/A]TTCGTCTGAA M G A S Ndehydrogenase (decarboxylating; glycine decarboxyl- ase, glycine cleavage system protein P) G2388u10 WIAF-12948 M64590 2325 GLDC, glycineGACAGGTCTA[C/T]CTACACCGGG S C T Y Y dehydrogenase (decarboxylating;glycine decarboxyl- ase, glycine cleav- age system protein P) G2388u11WIAF-12949 M64590 2362 GLDC, glycine GGTGGGAATC[T/A]GTCCCCCTGG M T A C Sdehydrogenase (decarboxylating; glycine decarboxyl- ase, glycine cleav-age system protein P) G2388u12 WIAF-12950 M64590 3220 GLDC, glycineTTAGTCCTCT[C/G]TCCCTAAGTT - C G - - dehydrogenase (decarboxylating;glycine decarboxyl- ase, glycine cleav- age system protein P) G2391u1WIAF-12998 M69238 623 ARNT, aryl hydro- TGGTGTATGT[G/C]TCTGACTCCG S G CV V carbon receptor nuclear translocator G2391u2 WIAF-13002 M69238 1072ARNT, aryl hydro- TGCCTAGTGG[C/T]CATTGGCAGA M C T A V carbon receptornuclear translocator G2391u3 WIAF-13021 M69238 966 ARNT, aryl hydro-ACCTCACTTC[G/A]TGGTGGTCCA M G A V M carbon receptor nuclear translocatorG2394u1 WIAF-13003 M73747 2061 TSHR, thyroid TTGCTCGTAC[T/A]CTTCTATCCA MT A L H stimulating hormone receptor G2394u2 WIAF-13004 M73747 2248TSHR, thyroid TTACCCACGA[C/G]ATGAGGCAGG M C G D E stimulating hormonereceptor G2396u1 WIAF-12995 M74542 1027 ALDH3, aldehydeCCCCCAGTCC[C/G]CGGTGATGCA M C G P A dehydrogenase 3 G2396u2 WIAF-13019M74542 1295 ALDH3, aldehyde GGCAACAACA[G/A]CTTCGAGACT M G A S Ndehydrogenase 3 G2403u1 WIAF-13583 M83670 280 CA4, carbonicTACGATAAGA[A/T]GCAAACGTGG M A T K M anhydrase IV G2409u1 WIAF-10010HT2156 1268 AGTR1, angiotensin CCACTCAAAC[C/T9 TTTCAACAAA M C T L Freceptor 1 G2411u1 WIAF-13541 M97759 210 ADORA2B, adenosineTGGCGGGCAA[C/T]GTGCTGGTGT S C T N N A2b receptor G2422u1 WIAF-14077S90469 375 POR, P450 GCAGCCTGCC[A/G]GAGATCGACA S A G P P (cytochrome)oxidoreductase G2422u2 WIAF-14078 S90469 852 POR, P450TCCTGGCTGC[A/G]GTCACCACCA S A G A A (cytochrome) oxidoreductase G2422u3WIAF-14082 S90469 1496 POR, P450 AAGGAGCCTG[T/C]CGCCGAGAAC M T C V A(cytochrome) oxidoreductase G2422u4 WIAF-14099 S90469 1443 POR, P450AGACCAAGGC[C/T]GGCCGCATCA S C T A A (cytochrome) oxidoreductase G2422u5WIAF-14100 S90469 1704 POR, P450 GCCGCCGCTC[G/A]GATGAGGACT S G A S S(cytochrome) oxidoreductase G2427u1 WIAF-14079 U07919 1369 ALDH6,aldehyde ACTATGGACT[C/T]ACAGCAGCCG S C T L L dehydrogenase 6 G2427u2WIAF-14096 U07919 1347 ALDH6, aldehyde ATAAAAAGAG[C/T]GAATACCACC M C T AV dehydrogenase 6 G243u1 WIAF-11684 X57522 926 TAP1, transporterATAGCCAGTG[C/G]AGTGCTGGAG M C G A G 1, ABC (ATP binding cassette) G243u2WIAF-11685 X57522 627 TAP1, transporter ACCCTACCGC[C/T]TTCGTTGTCA S C TA A 1, ABC (ATP binding cassette) G243u3 WIAF-11686 X57522 538 TAP1,transporter CCTGCCGGGA[C/G]TTCCCTTGTT M C G L V 1, ABC (ATP bindingcassette) G243u4 WIAF-11687 X57522 798 TAP1, transporterTGGTGGTCCT[C/G]TCCTCTCTTG S C G L L 1, ABC (ATP binding cassette) G243u5WIAF-11689 X57522 1465 TAP1, transporter TAGTATTTCA[G/T]GTATCCTGCT M G TG C 1, ABC (ATP binding cassette) G243u6 WIAF-11690 X57522 177 TAP1,transporter AGAGTCCCAG[A/G]CCCGGCCGGG S A G R R 1, ABC (ATP bindingcassette) G243u7 WIAF-11693 X57522 1067 TAP1, transporterAACATCATGT[C/T]TCGGGTAACA M C T S F 1, ABC (ATP binding cassette) G243u8WIAF-11665 X57522 1207 TAP1, transporter GGTCACCCTG[A/G]TCACCCTGCC M A GI V 1, ABC (ATP binding cassette) G243u9 WIAF-11664 X57522 1757 TAP1,transporter CCAAACCCCC[C/T]ACATGTCTTA N C T P L 1, ABC (ATP bindingcassette) G244u1 WIAF-10174 X60592 239 TNFRSF5, tumorCTTGCGGTCA[A/C]AGCGAATTCC S A G E E necrosis factor receptor super-family, member 5 G2441u1 WIAF-13682 U30246 1355 SLC12A2, soluteTGCTTAAGGA[A/G]CATTCCATAC S A G E E carrier family 12 (sodium/potassium/chloride trans- porters), member 2 G2441u2 WIAF-13714 U30246 2691SLC12A2, solute AGCCAAATAT[C/G]AGCCATGGCT M C G Q E carrier family 12(sodium/potassium/ chloride trans- porters), member 2 G2443u1 WIAF-14004U37143 1456 CYP2J2, cytochrome CTGAAGTTTA[G/A]AATGGGTATC M G A R K P450,subfamily IIJ (arachidonic acid epoxygenase) polypeptide 2 G2443u2WIAF-14032 U37143 376 CYP2J2, cytochrome TTTAAGAAAA[A/G]TGGATTGATT M A GN S P450, subfamily IIJ (arachidonic acid epoxygenase) polypeptide 2G2443u3 WIAF-14033 U37143 1502 CYP2J2, cytochroneTCTGCGCTGT[T/A]CCTCAGGTGT S T A V V P450, subfamily IIJ (arachidonicacid epoxygenase) polypeptide 2 G2444u1 WIAF-14065 U37519 771 ALDH3,aldehyde CCCGCACGGA[A/G]TTGCCTCGTG M A G N S dehydrogenase 3 G2444u2WIAF-14066 U37519 1698 ALDH3, aldehyde AAGGAGATCC[G/A]CTACCCACCC M G A RH dehydrogenase 3 G2445u1 WIAF-14114 U38178 236 CNP, 2′,3′-cyclicTGCCGGGCGC[C/A]CCTCTCGCTG M G A R H nucleotide 3′ phosphodiesteraseG2445u2 WIAF-14115 U38175 849 CNP, 2′,3′-cyclicGTGCCGCCGA[A/G]GAAAAAGTGC S A G G E nucleotide 3′ phosphodiesteraseG2445u3 WIAF-14122 U38178 1655 CNP, 2′,3′-cyclicGTTATCTTGC[A/T]GAGATCTCTG M A T Q L nucleotide 3′ phosphodiesteraseG2445u4 WIAF-14241 X95520 941 CNP, 2′,3′-cyclicTGCAAAATAT[T/C]CAGGAGACCG ? T C ? ? nucleotide 3′ phosphodiesteraseG2445u5 WIAF-14242 X95520 1057 CNP, 2′,3′-cyclicTCGAGTTGAT[C/T]TTTCAGTGCT ? C T ? ? nucleotide 3′ phosphodiesteraseG2445u6 WIAF-14243 X95520 1583 CNP, 2′,3′-cyclicTCTACTGGCT[C/G]TCTAACTAAT ? C G ? ? nucleotide 3′ phosphodiesteraseG2448u1 WIAF-13973 U46689 1895 ALDH10, aldehydeTTGTCAAGGC[A/T]GAATATTACT S A T A A dehydrogenase 10 (fatty aldehydedehydrogenase) G2457u1 WIAF-13898 U90277 1304 GRIN2A, glutamateGGTCCCGATG[C/T]ACACCTTGCA M C T H Y receptor, iono- tropic, N-methylD-aspartate 2A G2457u2 WIAF-13899 U90277 1934 GRIN2A, glutamateAAGAAGTAAT[G/T]GCACCGTCTC M G T G C receptor, iono- tropic, N-methylD-aspartate 2A G2457u3 WIAF-13900 U90277 2230 GRIN2A, glutamateTCGCTGTCAT[A/G]TTCCTGGCTA M A G I M receptor, iono- tropic, N-methylD-aspartate 2A G2457u4 WIAF-13902 U90277 2916 GRIN2A, glutamateGGCATCTACA[G/A]CTGCATTCAT M G A S N receptor, iono- tropic, N-methylD-aspartate 2A G2457u5 WIAF-13903 U90277 3251 GRIN2A, glutamateCTATGTATTC[C/T]AGGCACAACA N C T Q * receptor, iono- tropic, N-methylD-aspartate 2A G2457u6 WIAF-13917 U90277 2756 GRIN2A, glutamateGGACATTGAC[A/C]ACATCCCGGG M A G N D receptor, iono- tropiC, N-methylD-aspartate 2A G2468u1 WIAF-13642 X04011 1017 CYBB, cytochromeAGGTGTCCAA[G/A]CTGGAGTGGC S G A K K b-245, beta poly- peptide (chronicgranulomatous disease) G2473u1 WIAF-13670 X06990 1417 ICAM1, inter-GGTCACCCGC[G/A]AGGTGACCGT M G A E K cellular adhesion molecule 1 (CD54),human rhinovirus receptor G2473u2 WIAF-13695 X06990 179 ICAM1, inter-GACCAGCCCA[A/T]GTTGTTGGGC M A T K M cellular adhesion molecule 1 (CD54),human rhinovirus receptor G2480u1 WIAF-14148 X55330 800 AGA,aspartylgluco- TTGGCATGGT[T/G]GTAATCCATA S T G V V saminidase G2480u2WIAF-14149 X55330 852 AGA, aspartylgluco- AAATGGTATA[A/T]AATTCAAAAT M AT K * saminidase G2480u3 WIAF-14158 X55330 616 AGA, aspartylgluco-TTATCTACCA[G/C]TGCTTCTCAA M G C S T saminidase G2485u1 WIAF-13612 X595432301 RRM1, ribo- ATTGATCAAA[C/A]CCAATCTTTG M G A S N nucleotidereductase M1 polypeptide G2485u2 WIAF-43613 X59543 2410 RRM1, ribo-ATTTAAGGAC[G/A]AGACCAGCAG S G A T T nucleotide reductase M1 polypeptideG2485u3 WIAF-13651 X59543 548 RRM1, ribo- CAAGTCAACA[T/C]TGGATATTGT S TC L L nucleotide reductase M1 polypeptide G2485u4 WIAF-13652 X59543 199RRM1, ribo- TGCATGTGAT[C/T]AAGCGAGATG S C T I I nucleotide reductase M1polypeptide G2485u5 WIAF-13653 X59543 1037 RRM1, ribo-CAACACAGCT[C/A]GATATGTGGA S C A R R nucleotide reductase M1 polypeptideG2485u6 WIAF-13660 X59543 1955 RRM1, ribo- GAAGATTGCA[A/C]ADTATGGTAT M AC K Q nucleotide reductase M1 polypeptide G2485u7 WIAF-13877 X59543 860RRM1, ribo- GAGTATGAAA[G/C]ATGACAGCAT M G C E Q nucleotide reductase M1polypeptide G2486u1 WIAF-14075 X59618 543 RRM2, ribo-TCAGCACTGG[G/C]AATCCCTGAA M G C E Q nucleotide reductase M2 polypeptideG2486u2 WIAF-14076 X59618 189 RRM2, ribo- TCGCTGCGCC[T/G]CCACTATGCT - TG - - nucleotide reductase M2 polypeptide G2486u3 WIAF-14092 X59618 524RRM2, ribo- TTGACCTCTC[C/G]AACGACATTC S C G S S nucleotide reductase M2polypeptide G2488u1 WIAF-13585 X63563 1633 POLR2B, polymeraseCCTTGATGGC[C/A]TATATTTCAG S G A A A (RNA) II (DNA directed) poly-peptide B (140 kD) G2488u2 WIAF-13586 X63563 2452 POLR2B, polymeraseCTGTAGACCG[C/T]GGCTTCTTCA S C T R R (RNA) II (DNA directed) poly-peptide B (140 kD) G2488u3 WIAF-13587 X63563 2740 POLR2B, polymeraseTCAGAACTAG[T/C]GAGACCGGCA S T C S S (RNA) II (DNA directed) poly-peptide B (140 kD) G2488u4 WIAF-13602 X63563 1411 POLR2B, polymeraseGGGGTGATCA[A/G]AAGAAAGCTC S A G Q Q (RNA) II (DNA directed) poly-peptide B (140 kD) G2488u5 WIAF-13603 X63563 2386 POLR2B, polymeraseCAATTGTGGC[C/T]ATTGCATCAT S C T A A (RNA) II (DNA directed) poly-peptide B (140 kD) G2489u1 WIAF-14181 X63564 1346 POLR2A, polymeraseTGGTGGACAA[T/C]GAGCTGCCTG S T C N N (RNA) II (DNA directed) poly-peptide A (220 kD) G2489u2 WIAF-14236 X63564 1647 POLR2A, polymeraseTGAATCTTAG[C/T]GTGACAACTC ? C T ? ? (RNA) II (DNA directed) poly-peptide A (220 kD) G2489u3 WIAF-14237 X63564 2678 POLR2A, polymeraseCTGAATACAA[C/T]AACTTCAAGT ? C T ? ? (RNA) II (DNA directed) poly-peptide A (220 kD) G2489u4 WIAF-14238 X63564 3059 POLR2A, polymeraseAGCTGCGCTA[C/T]GGCGAACACG ? C T ? ? (RNA) II (DNA directed) poly-peptide A (220 kD) G2489u5 WIAF-14239 X63564 3827 POLR2A, polymeraseTGGGCCAGTC[C/T]GCTCGAGATG ? C T ? ? (RNA) II (DNA directed) poly-peptide A (220 kD) G2489u6 WIAF-14240 X63564 3992 POLR2A, polymeraseTGCCTGACTT[T/C]GATGTGGCCC ? T C ? ? (RNA) II (DNA directed) poly-peptide A (220 kD) G2489u7 WIAF-14245 X63564 3938 POLR2A, polymeraseCCCAGAGCAC[G/A]GTGGTGGCAG ? G A ? ? (RNA) II (DNA directed) poly-peptide A (220 kD) G250u1 WIAF-11696 HT0155 1113 IL3RA, interleukinCTGTGTCTTC[G/C]TGATCTGCAG M G C V L 3 receptor, alpha (low affinity)G251u1 WIAF-11666 HT0240 179 interleukin 1 TGGATAAGAC[C/T]CGAGCTTTGA S CT T T beta convertase G251u2 WIAF-11694 HT0240 973 interleukin 1GATGCTATTA[A/G]GAAAGCCCAC M A G K R beta convertase G251u3 WIAF-11695HT0240 783 interleukin 1 CCCAGATATA[C/T]TACAACTCAA S C T L L betaconvertase G2513u1 WIAF-13736 HT27365 1721 PLCB3, phospho-AACTATCTAT[G/A]AAAAGCCAAA M G A M I lipase C, beta 3 (phosphatidylino-sitol-specific) G2513u2 WIAF-13737 HT27365 1741 PLCB3, phospho-AACTATTGGG[A/T]AATCTGTTCA M A T E V lipase C, beta 3 (phosphatidylino-sitol-specific) G2513u3 WIAF-13738 HT27365 1697 PLCB3, phospho-AATCTGTTCA[A/G]TACACGGATT S A G Q Q lipase C, beta 3 (phosphatidylino-sitol-specific) G2513u4 WIAF-13739 HT27365 1908 PLCB3, phospho-CTGTCAGATT[C/A]TAGCAATGAA M G A V I lipase C, beta 3 (phosphatidylino-sitol-specific) G2513u5 WIAF-13740 HT27365 2172 PLCB3, phospho-TATACAGATA[C/T]ACGGAATTCC M C T H Y lipase C, beta 3 (phosphotidylino-sitol-specific) G2513u6 WIAF-13744 HT27365 3019 PLCB3, phospho-TTGAAGGGCC[A/C]AGGAGATCTG M A G Q R lipase C, beta 3 (phosphatidylino-sitol-specific) G2513u7 WIAF-13745 HT27365 3024 PLCB3, phospho-GGGCCAAGCA[G/A]ATCTGTTGAA M G A D N lipase C, beta 3 (phosphatidylino-sitol-specific) G2513u8 WIAF-13771 HT27365 1079 PLCB3, phospho-ACATTTTTGA[T/C]CCTGAGCAAA S T C D D lipase C, beta 3 (phosphatidylino-sitol-specific) G2513u9 WIAF-13772 HT27365 1546 PLCB3, phospho-AAGTTGCCTT[C/T]TGATCCAGAT M C T S F lipase C, beta 3 (phosphatidylino-sitol-specific) G2513u10 WIAF-13773 HT27365 1514 PLCB3, phospho-AATTAAAAAG[A/T]ATGATCATTG M A T R S lipase C, beta 3 (phosphatidylino-sitol-specific) G2513u11 WIAF-13774 HT27365 1445 PLCB3, phospho-AGGTCTTTGG[C/T]AATAAACTCT S C T G G lipase C, beta 3 (phosphatidylino-sitol-specific) G2513u12 WIAF-13778 HT27365 2087 PLCB3, phospho-TTCATATCAA[G/A]ATCATCAGTG S G A K K lipase C, beta 3 (phosphotidylino-sitol-specific) G2513u13 WIAF-13779 HT27365 2367 PLCB3, phospho-TGAATGTTTG[C/T]ACCCTGGATA N C T Q * lipase C, beta 3 (phosphatidylino-sitol-specific) G2513u14 WIAF-13782 HT27365 2719 PLCB3, phospho-CTCATCACCA[G/A]TGACAATACT M G A S N lipase C, beta 3 (phosphatidylino-sitol-specific) G2513u15 WIAF-13783 HT27365 2567 PLCB3, phospho-TTGATGACAT[C/T]TTTAAAATAG S C T I I lipase C, beta 3 (phosphatidylino-sitol-specific) G2513u16 WIAF-13784 HT27365 2864 PLCB3, phospho-TAGAAATGGC[G/A]GACACACTCC S G A A A lipase C, beta 3 (phosphatidylino-sitol-specific) G2513u17 WIAF-13785 HT27365 2571 PLCB3, phospho-TGACATCTTT[A/T]AAATAGCGGT N A T K * lipase C, beta 3 (phosphatidylino-sitol-specific) G2513u18 WIAF-13786 HT27365 2706 PLCB3, phospho-TCTGTCATCT[C/T]GCCTCATCAC M C T R W lipase C, beta 3 (phosphatidylino-sitol-specific) G252u1 WIAF-10195 HT0425 397 FCER2, Fc fragmentGAGGGCTGCC[C/T]GGAACGTCTC M C T R W of IgE, low affinity II, receptorfor (CD23A) G252u2 WIAF-10206 HT0425 930 FCER2, Fc fragmentATGGGAGCCA[T/C]GTGGACTACA S T C H H of IgE, low affinity II, receptorfor (CD23A) G253u1 WIAF-10175 HT0573 228 IFNB1, interferon,GGCTTGAATA[C/T]TGCCTCAACG S C T Y Y beta 1, fibroblast G254u1 WIAF-10196HT0611 466 IL4R, interleukin TCAGTGCGGA[T/C]AACTATACAC S T C D D 4receptor G254u2 WIAF-10198 HT0611 1474 IL4R, interleukinCATGCCTTCT[T/C]CCACCTTCGG S T C L L 4 receptor G254u3 WIAF-10207 HT06111902 IL4R, interleukin AGTGGCTATC[A/G]GGAGTTTGTA M A G Q R 4 receptorG260u1 WIAF-10186 HT1090 453 IL4R, interleukin TGTTATAATC[C/G]ACAACCCATAM C G A G 1 receptor, type I G261u1 WIAF-10187 HT1101 434 IL7R,interleukin CCTCACTGTC[A/G]TCTATCCCCA M A G I V 7 receptor G261u2WIAF-10203 HT1101 517 IL7R, interleukin TTTTAATCCA[T/C]CATCTAGCTT S T CH H 7 receptor G267u1 WIAF-11735 HT1877 881 IL2RB, interleukinTCCTCGTGGG[C/T]CTCAGCGGGG S C T G G 2 receptor, beta G267u2 WIAF-11759HT1877 379 IL2RB, interleukin AGTCAAGCAT[C/T]CTGCGCCTGC M G T S F 2receptor, beta G268u1 WIAF-11758 HT1985 568 CD19 antigenGCCTCCGTGT[G/C]TCCCACCGAG M G C V L G268u2 WIAF-11734 HT1985 783 CD19antigen ACGATCGCCC[G/T]GCCAGAGATA S G T P P G270u1 WIAF-11736 HT2415 530IL6R, interleukin AGGAGGTGGC[A/G]AGAGCCGTGC S A G A A 6 receptor G270u2WIAF-11760 HT2415 1590 IL6R, interleukin CATTGCCATT[G/A]TTCTGAGGTT M G AV I 6 receptor G270u3 WIAF-11737 HT2415 1510 IL6R, interleukinCCAGTGCAAG[A/C]TTCTTCTTCA M A C D A 6 receptor G270u4 WIAF-11761 HT24151451 IL6R, interleukin CTACTAATAA[A/T]GACGATGATA M A T K N 6 receptorG270u5 WIAF-11766 HT2415 1843 IL6R, interleukinTTCCCCAGAT[A/C]CCTGGCTGGG N A G * W 6 receptor G270u6 WIAF-11767 HT24151829 IL6R, interleukin ATACAGACTA[C/T]TTCTTCCCCA S C T Y Y 6 receptorG271u1 WIAF-11762 HT2531 577 CD2, CD2 antigen TCAGAGGCTC[A/G]TCACACACAAM A G I V (p50), sheep red blood cell receptor G271u2 WIAF-11739 HT2531861 CD2, CD2 antigen GGAAGCCCCA[A/C]CAAATTCCAG M A C X H (p50), sheepred blood cell receptor G271u3 WIAF-11768 HT2531 818 CD2, CD2 antigenCTGGAGACAA[G/A]AGCCCACAGA M G A R K (p50), sheep red blood cell receptorG271u4 WIAF-11738 HT2531 736 CD2, CD2 antigen CCTCTTGATG[G/A]TCTTTGTGGCM G A V I (p50), sheep red blood cell receptor G273u1 WIAF-11763 HT3139667 IL2RA, interleukin ATCATCGTGC[C/T]TGGCTGCCAG M C T P L 2 receptor,alpha G273u2 WIAF-11764 HT3139 956 IL2RA, interleukinAAACTCCAAT[G/C]CACCCACTGC M G C M I 2 receptor, alpha G273u3 WIAF-11765HT3139 701 IL2RA, interleukin ACGATGACCC[G/A]CCAGAGATCC S G A P P 2receptor, alpha G273u4 WIAF-11740 HT3139 1133 IL2RA, interleukinAAATGACCCA[C/T]GGGAAGACAA S C T H H 2 receptor, alpha G273u5 WIAF-11769HT3139 1163 IL2RA, interleukin AGCCCCAGCT[C/A]ATATGCACAG S C A L L 2receptor, alpha G276u1 WIAF-10192 HT3670 644 CD4 antigenCTCCTAGTAG[C/G]CCCTCAGTGC M C G S R G276u2 WIAF-10193 HT3670 1535 CD4antigen CCTGCCAGTG[T/C]CCTCACCGCT S T C C C G276u3 WIAF-10205 HT36701217 CD4 antigen TGATCCTGAC[T/C]TTCAAACTCG S T C S S G277u1 WIAF-10007D10232 851 RENBP, renin- CACGTGATTG[A/G]CAAGTTCCTA M A G D G bindingprotein G277u2 WIAF-10032 D10232 842 RENBP, renin-CTTCGAGCCC[A/G]CGTGATTGAC M A G H R binding protein G277u3 WIAF-10042D10232 634 RENBP, renin- CCTGGCGGCC[A/G]AATACGCAGA M A G K E bindingprotein G279u1 WIAF-10047 K01740 1658 F8C, coagulationACTGATGTCC[G/A]TCCTTTGTAT M G A R H factor VIIIc, procoagulant component(hemophilia A) G279u2 WIAF-10049 K01740 2328 F8C, coagulationCCTTACTGAA[G/A]GTTTCTAGTT S G A K K factor VIIIc, procoagulant component(hemophilia A) G279u3 WIAF-10050 K01740 4650 F8C, coagulationCTGTTCTCCC[G/A]AAACCAGACT S G A P P factor VIIIc, procoagulant component(hemophilia A) G279u4 WIAF-10050 K01740 6919 F8C, coagulationCCAGAAGACA[A/C]TGAAAGTCAC M A G M V factor VIIIc, procoagulant component(hemophilia A) G279u5 WIAF-10080 K01740 480 F8C, coagulationTTAAGAACAT[G/A]GCTTCCCATC M G A M I factor VIIIc, procoagulant component(hemophilia A) G279u6 WIAF-10082 K01740 2129 F8C, coagulationTACATTCTAA[G/A]CATTGGAGCA M G A S N factor VIIIc, procoagulant component(hemophilia A) G279u7 WIAF-10084 K01740 2533 F8C, coagulationGTTTGCACAC[A/G]CAACACCTAT M A G R G factor VIIIc, procoagulant component(hemophilia A) G279u8 WIAF-10086 K01740 6639 F8C, coagulationACCCTCCAAT[T/C]ATTGCTCGAT S T C I I factor VIIIc, procoagulant component(hemophilia A) G279u9 WIAF-10087 K01740 5957 F8C, coagulationGAGAATTATC[G/A]CTTCCATGCA M G A R H factor VIIIc, procoagulant component(hemophilia A) G279a10 WIAF-10495 K01740 5829 F8C, coagulationTGACAGTACA[G/A]GAATTTGCTC S G A Q Q factor VIIIc, procoagulant component(hemophilia A) G279a11 WIAF-10496 K01740 5852 F8C, coagulationTTTTTCACCA[T/G]CTTTCATGAG M T G I S factor VIIIc, procoagulant component(hemophilia A) G279a12 WIAF-10502 K01740 2492 F8C, coagulationACCACAATTC[C/T]AGAAAATGAC M C T P L factor VIIIc, procoagulant component(hemophilia A) G279a13 WIAF-10503 K01740 6906 F8C, coagulationTGCAAGTGGA[C/T]TTCCAGAAGA S C T D D factor VIIIc, procoagulant component(hemophilia A) G279a14 WIAF-13120 K01740 1980 F8C, coagulationCAGAGAATAT[A/C]CAACGCTTTC S A c I I factor VIIIc, procoagulant component(hemophilia A) G279a15 WIAF-13121 K01740 1982 F8C, coagulationGAGAATATAC[A/C]ACGCTTTCTC M A c Q P factor VIIIc, procoagulant component(hemophilia A) G282u1 WIAF-10067 L25615 976 AVPR1A, arginineCGCCTTTCTT[C/A]ATCATCCAGA M C A F F vasopressin receptor 1A G282u2WIAF-10070 L25615 460 AVPR1A, arginine TCGGCATGTT[T/C]GCGTCGGCCT S T C FF vasopressin receptor 1A G282u3 WIAF-10071 L25615 343 AVPR1A, arginineGCCTGGCCGA[C/T]CTGGCCGTGG S C T D D vasopression receptor 1A G282u4WIAF-10072 L25615 68 AVPR1A, arginine TCTCTCCGCC[G/A]GTCCCGACGC M G A GS vasopression receptor 1A G282u5 WIAF-10073 L25615 535 AVPR1A, arginineAGACTCTGCA[A/G]CAGCCCGCGC S A G Q Q vasopressin receptor 1A G282u6WIAF-10092 L25615 1075 AVPR1A, arginine CCTTGAATAG[C/A]TGCTGTAATC M C AS R vasopressin receptor 1A G282a7 WIAF-10499 L25615 1089 AVPR1A,arginine TGTAATCCCT[G/A]GATATACATG N G A W * vasopressin receptor 1AG284u1 WIAF-10182 M16827 1179 ACADM, acyl- AATATCCTGT[A/G]GAAAAACTAA S AG V V Coenzyme A dehydrogenase, C-4 to C-12 straight chain G284a2WIAF-10515 M16827 696 ACADM, acyl- TTGTGGAACC[A/G]GATACCCCAG S A G A ACoenzyme A dehydrogenase, C-4 to C-12 straight chain G285u1 WIAF-10108M28372 258 ZNF9, zinc finger CTCTTCCAGA[T/C]ATTTGTTATC S T C D D protein9 (a cellular retroviral nucleic acid binding protein) G289u1 WIAF-10041M63012 172 PON1, paraoxonase 1 CTCTGAAGAC[A/T]TGGAGATACT M A T M LG290u1 WIAF-10085 M63959 354 LRPAP1, low densityCTCATACGCA[A/G]CCTCAATGTC M A G N S lipoprotein-relatedprotein-associated protein 1 (alpha-2- macroglobulin receptor associatedprotein 1) G290a2 WIAF-13122 M63959 223 LRPAP1, low densityAGCGACTGCA[T/A]CTTCCTCCCG M T A H Q lipoprotein-relatedprotein-associated protein 1 (alpha-2- macroglobulin receptor associatedprotein 1) G292u1 WIAF-10180 M74096 1002 ACADL, acyl-AGTGCAACAT[A/C]AATTAGCAGA M A C K Q Coenzyme A dehydrogenase, long chainG293u1 WIAF-10068 M74775 723 LIPA, lipase A, AAGGACTTAT[T/C]TGGACACAAA MT C F S lysosomal acid, cholesterol esterase (Wolman disease) G293a2WIAF-10497 M74775 107 LIPA, lipase A, TGAGGGGTCT[G/A]GAGGGAAACT M G A GR lysosomal acid, cholesterol esterase (Wolman disease) G293a3WIAF-10498 M74775 86 LIPA, lipase A, GGTTCTCTGG[C/A]CCCTGCATTC M C A P Tlysosomal acid, cholesterol esterase (Wolman disease) G295u1 WIAF-10057U04270 1282 KCNH2, potassium AAAGGAGCGA[A/T]CCCACAATGT M A T T Svoltage-gated channel, subfamily H, member 2 G295u2 WIAF-10062 U042701875 KCNH2, potassium CGCACTGGCT[A/G]GCCTGCATCT S A G L L voltage-gatedchannel, subfamily H, member 2 G295u3 WIAF-10064 U04270 2040 KCNH2,potassium ACTTCACCTT[C/T]AGCAGCCTCA S C T F F voltage-gated channel,subfamily H, member 2 G295u4 WIAF-10088 U04270 1650 KCNH2, potassiumCCGGCCGCAT[C/T]GCCCTCCACT S C T I I voltage-gated channel, subfamily H,member 2 G295u5 WIAF-10090 U04270 2139 KCNH2, potassiumCCCTCATGTA[T/C]GCTAGCATCT S T C Y Y voltage-gated channel, subfamily H,member 2 G2951u1 WIAF-14147 HT0030 1334 ZNF42, zinc fingerCCCTGCTCTG[A/G]TCACCACCCG M A G I V protein 42 (myeloid-specificretinoic acid responsive) G2951u2 WIAF-14157 HT0030 1558 ZNF42, zincfinger ACCAGCTTAC[G/A]CACACCGAGG S G A T T protein 42 (myeloid-specificretinoic acid responsive) G2959u1 WIAF-13501 HT0134 1014 GRLP1, gluco-GTGGAGAGAC[T/C]CTGCATAGCT S T C T T corticoid receptor DNA bindingfactor 1 G2959u2 WIAF-13518 HT0134 1853 GRLF1, gluco-GAGCCATCTT[A/C]CAGCCTGTTT M A C Y S corticoid receptor DNA bindingfactor 1 G296a1 WIAF-10514 U12778 961 ACADSB, acyl-TATTCCATAT[A/G]TTAAAGAAAG M A G I V Coenzyme A dehydrogenase,short/branched chain G2968u1 WIAF-12699 HT0244 1754 SMARCA1, SWI/SNFCAGAACAAAC[C/T]ACTACGTGTA M C T P L related, matrix associated, actindependent regulator of chromatin, sub- family a, member 1 G2968u2WIAF-12716 HT0244 2624 SMARCA1, SWI/SNF TGGGAACGTT[G/T]CAATGAATTA M G TC F related, matrix associated, actinc dependent regulator of chromatin,sub- family a, member 1 G297u1 WIAF-10109 U516660 402 ECH1, enoylACATGGCTTC[G/A]GACATCCTCC S G A S S Coenzyme Ahydratase 1, peroxisomalG297u2 WIAF-10110 U16660 149 ECH1, enoyl GCACAAGAGG[A/C]GGCTTCCGGA M A CE A Coenzyme A hydratase 1, peroxisomal G2970u1 WIAF-12746 HT0281 682BR140: bromodomain- ATGACATGGA[C/T]GAGCAGGACT S C T D D containingprotein, 140 kD (peregrin) G2975U1 WIAF-12729 HT0334 1104B-cell-specific ACTTTTCCGG[G/A]ACTCCCTACA S G A C G transcription factorG2975u2 WIAF-12730 HT0334 1185 B-cell-specific GCTCCCCCTA[C/T]TATTATACCCS C T Y Y transcription factor G2976a1 WIAF-12129 HT0340 1600 SATB1,special GTCCTGCCCC[C/A]CTCATCAGCA S C A P P AT-rich sequence bindingprotein 1 (binds to nuclear matrix/scaf fold- associating DNA's) G2976u2WIAF-12743 HT0340 2116 SATB1, special AT- TGGCCTCTCC[A/G]GCACAGTCAG S AG P P rich sequence binding protein 1 (binds to nuclear matrix/scaffold- associating DNA's) G2978u1 WIAF-12721 HT0346 1140 MSX1, msh(Droso- CATAGAGGGT[C/T]CCAGGTCCCC - C T - - phila) homeo box homolog 1(formerly homeo box 7) G298u1 WIAF-10048 U33837 8995 Human glycoproteinCCGGACAGGA[G/A]GTGCATTCCC M G A R K receptor gp330 precursor, mRNA,complete cds. G298u2 WIAF-10051 U33837 13217 Human glycoproteinATGCAGCCAT[C/T]GAACTGCCTA S C T I I receptor gp330 precursor, mRNA,complete cds. G298u3 WIAF-10077 U33837 6298 Human glycoproteinAACTCTTTCA[T/C]TGTTGTTTCA M T C I T receptor gp330 precursor, mRNA,complete cds. G298u4 WIAF-10078 U33837 6371 Human glycoproteinCCATGGTCCC[G/A]GTGGCAGGCC S G A P P receptor gp330 precursor, mRNA,complete cds. G298u5 WIAF-10079 U33837 6914 Human glycoproteinACTCTGAAGT[G/A]ATTCGTTATG S G A V V receptor gp330 precursor, mRNA,complete cds. G298u6 WIAF-10081 U33837 8718 Human glycoproteinGTTCCAATGC[G/A]CATCTGGGCG M G A A T receptor gp330 precursor, mRNA,complete cds. G298u7 WIAF-10083 U33837 9088 Human glycoproteinACTTGCTCTG[A/G]AAATGAATTC M A G E G receptor gp330 precursor, mRNA,complete cds. G298u8 WIAF-10096 U33837 6949 Human glycoproteinACTCCTTATC[G/C]CATCACTCTT M G C G A receptor gp330 precursor, mRNA,complete cds. G298u9 WIAF-10097 U33837 7149 Human glycoproteinTTCCTTCCAA[A/C]ACAATCGTGG M A G N D receptor gp330 precursor, mRNA,complete cds. G298u10 WIAF-10100 U33837 8590 Human glycoproteinTACACAAAAT [C/A]TCATAATTCA M G A C Y receptor gp330 precursor, mRNA,complete cds. G298u11 WIAF-10101 U33837 12948 Human glycoproteinCATCTTTCAA[G/C]ACCACTTATA M G C D H receptor gp330 precursor, mRNA,complete cds. G2980u1 WIAF-12723 HT0356 437 TLE1, transducin-TCATGGCCAC[G/A]GACCCCCACT M G A G R like enhancer of split 1, homolog ofDrosophila E(sp1) G2980u2 WIAF-12726 HT0356 2044 TLE1, transducin-AGTGGCTGGC[A/G]GTGGGCATGG S A G A A like enhancer of split 1, homolog ofDrosophila E(sp1) G2980u3 WIAF-12747 HT0356 379 TLE1, transducin-CCATGGCAGA[G/A]TTGAATGCCA S G A E E like enhancer of split 1, homolog ofDrosophila E(sp1) G2980u4 WIAF-12748 HT0356 276 TLE1, transducin-ATCGCCAAGA[G/A]ATTGAATACG M G A R K like enhancer of split 1, homolog ofDrosophila E(sp1) G2980u5 WIAF-12749 HT0356 1876 TLE1, transducin-GCCACACAGA[C/T]GGAGCCAGCT S C T D D like enhancer of split 1, homolog ofDrosophila E(sp1) G2980u6 WIAF-12750 HT0356 1759 TLE1, transducin-CCGCCTGCTA[C/T]GCCCTGGCCA S C T Y Y like enhancer of split 1, homolog ofDrosophila E(sp1) G2981u1 WIAF-12720 HT0357 2206 TLE2, transducin-ACAAATACAT[T/C]GTGACAGSCT S T C I I like enhancer of split 2, homolog ofDrosophila E(sp1) G2981u2 WIAF-12737 HT0357 1036 TLE2, transducin-CGGACAGCGT[C/T]GCCCTCACCA S C T V V like enhancer of split 2, homolog ofDrosophila E(sp1) G2981u3 WIAF-12740 HT0357 2181 TLE2, transducin-CTGAGTTGTG[A/T]CATCTCCAGA M A T D V like enhancer of split 2, homolog ofDrosophila E(sp1) G2983u1 WIAF-12833 HT0360 636 TLE3, transducin-TGTCACCCTC[G/C]GAAAGCCTCC S G C S S like enhancer of split 3, homolog ofDrosophila E(sp1) G2983u2 WIAF-12834 HT0360 1944 TLE3, transducin-TGGACAACAC[G/A]GTGCGCTCCT S G A T T like enhancer of split 3, homolog ofDrosophila E(sp1) G2983u3 WIAF-12848 HT0360 1710 TLE3, transducin-ACCTGGCCTC[C/A]CCCACGCCCC S G A S S like enhancer of split 3, homolog ofDrosophila E(sp1) G2985u1 WIAF-12724 HT0421 995 homeotic protein D3CGCTTCGCCA[G/A]CGCCAACCTC M G A S N G2985u2 WIAF-12725 HT0421 1003homeotic protein D3 CACCGCCAAC[C/T]TGCAGGCCAC S C T L L G2986u1WIAF-14124 HT0468 1197 CSDA, cold shock GCCGTGGATA[C/T]CGGCCTCCCT S C TY Y domain protein A G2987u1 WIAF-12758 HT0474 2068 ZNF7, zincAGTGCTTTTA[C/T]GAATATGCGA S C T Y Y finger protein 7 (KOX 4, cloneHF.16) G2987u2 WIAF-12773 HT0474 985 ZNF7, zincGAGAGAAGCC[G/C]TACGAATGTG S G C P P finger protein 7 (KOX 4, cloneHF.16) G2987u3 WIAF-12775 HT0474 1278 ZNF7, zincAGCCAGCAGT[C/T]GCAGCTGGTT M C T S L finger protein 7 (KOX 4, cloneHF.16) G3005a1 WIAF-12133 HT0735 1441 homeotic proteinGAGGCAGCGG[C/T]CCCGGGCCTG S C T G G 5.1 G3008a1 WIAF-12134 HT0753 1850ATF4, activating TAAAAGAGAG[C/A]GCGGATTCCC S G A R R transcriptionfactor 4 (tax- responsive enhancer element B67) G3008u2 WIAF-12798HT0753 946 ATF4, activating CCCTTCGACC[C/A]GTCGGGTTTG M C A P Qtranscription factor 4 (tax- responsive enhancer element B67) G3008u3WIAF-12812 HT0753 1482 ATF4, activating CACTGCTTAC[G/A]TTGCCATGAT M G AV I transcription factor 4 (tax- responsive enhancer element B67)G3008u4 WIAF-12813 HT0753 1847 ATF4, activatingCTCTAAAAGA[G/C]AGGGCGGATT M G C E D transcription factor 4 (tax-responsive enhancer element B67) G301u1 WIAF-10127 U71285 3639 MTR,5-methyltetra- TGTGGAGACT[C/T]GCAGACATCG S C T L L hydrofolate-homocysteine methyltransferase G3012u1 WIAF-12794 HT0873 402 MAD, MAXTGGTGCCACT[C/T]GGACCCGAAT S G T L L dimerization protein G3014u1WIAF-14183 HT0899 274 homeotic protein 2, AAAAGACTCA[G/A]TACTTGGCCT S GA Q Q distal-less G3020u1 WIAF-12797 HT0956 852 MLLT3, myeloid/GTGCCTTCAA[A/G]GAACCTTCCA S A G K K lymphoid or mixed- lineage leukemia(trithorax (Drosophila) homolog); translocated to, 3 G3023u1 WIAF-13724HT0966 381 zinc finger, X- GCTGCAGCAA[G/A]CAATATGACA S G A K K linked,duplicated A G3023u2 WIAF-13725 HT0966 220 zinc finger, X-GGCCAAACTC[G/A]GCGCCCACCA M G A G S linked, duplicated A G3023u3WIAF-13726 HT0966 69 zinc finger, X- AGTCGCACGA[T/C]AAACTGCGGC S T C D Dlinked, duplicated A G3023u4 WIAF-13727 HT0966 249 zinc finger, X-ACTTCGAACC[C/T]CACACCCCTT S C T P P linked, duplicated A G3023u5WIAF-13765 HT0966 661 zinc finger, X- CAGGTTCTCT[G/A]CTCGCAGTAG M G A AT linked, duplicated A G3023u6 WIAF-13766 HT0966 1302 zinc finger, X-TGACTCCTTC[C/T]AGCACCCTTT S G T S S linked, duplicated A G3027u1WIAF-12800 HT1035 124 HOXB7, homeo box B7 TTATGCGAAT[G/A]CTTTATTTTC M GA A T G3027u2 WIAF-12816 HT1035 450 HOXB7, homeo box B7GCCACTCGCA[C/T]TTCGCGCCCC S C T D D G3028u1 WIAF-12806 HT1037 701homeotic protein C8 AGACCCTCGA[A/G]CTCCAGAACC S A G E E G3029u1WIAF-14153 HT1100 441 zinc finger TCAGACTCAG[G/A]CAAAACTCCG S G A R Rprotein 8 G3029u2 WIAF-14155 HT1100 1416 zinc fingerGCCGTCAACA[A/G]TCCTCGACCA S A G Q Q protein 8 G303u1 WIAF-10000 X139164110 LRP1, low density ATGGAGCTGG[C/A]GCCCGACAAC M G A G E lipoprotein-related protein 1 (alpha-2-macro- globulin receptor) G303u2 WIAF-10001X13916 4012 LRP1, low density GCGAGCTCTG[C/T]GACCACTGCT S C T C Clipoprotein- related protein 1 (alpha-2-macro- globulin receptor) G303u3WIAF-10002 X13916 4702 LRP1, low density GCCTGCCCCG[C/T]ATTGAGGCAG S C TR R lipoprotein- related protein 1 (alpha-2-macro- globulin receptor)G303u4 WIAF-10003 X13916 6395 LRP1, low densityCTGGATCGCA[G/A]GCAACATCTA M G A G S lipoprotein- related protein 1(alpha-2-macro- globulin receptor) G303u5 WIAF-10004 X13916 6937 LRP1,low density AAGGCACCAA[C/T]GTGTGCGCGG S C T N N lipoprotein- relatedprotein 1 (alpha-2-macro- globulin receptor) G303u6 WIAF-10005 X139169391 LRP1, low density GGCTGAAGGA[T/C]GACGGCCGCA S T C D D lipoprotein-related protein 1 (alpha-2-macro- globulin receptor) G303u7 WIAF-10011X13916 766 LRP1, low density ACTGCATCGA[C/T]GGCTCAGATG S C T D Dlipoprotein- related protein 1 (alpha-2-macro- globulin receptor) G303u8WIAF-10015 X13916 9040 LRP1, low density ACCCGACCTG[C/T]GGCCCCAGTG S C TC C lipoprotein- related protein 1 (alpha-2-macro- globulin receptor)G303u9 WIAF-10019 X13916 11749 LRP1, low densityCCCTGCGCTG[C/T]AACATGTTCG S C T C C lipoprotein- related protein 1(alpha-2-macro- globulin receptor) G303u10 WIAF-10020 X13916 1917 LRP1,low density GACCAGTATG[G/A]GAAGCCGGGT M G A G E lipoprotein- relatedprotein 1 (alpha-2-macro- globulin receptor) G303u11 WIAF-10021 X139164810 LRP1, low density AGAAGCGCAT[C/T]CTTTGGATTG S C T I I lipoprotein-related protein 1 (alpha-2-macro- globulin receptor) G303u12 WIAF-10022X13916 6367 LRP1, low density TTGGCCGTGT[G/C]GAGGGCATTG S G C V Vlipoprotein- related protein 1 (alpha-2-macro- globulin receptor)G303u13 WIAF-10023 X13916 6247 LRP1, low densityCTGTCCGCAT[C/T]GACTTCCACG S C T I I lipoprotein- related protein 1(alpha-2-macro- globulin receptor) G303u14 WIAF-10024 X13916 8371 LRP1,low density ACGCCTCAGA[T/C]GAGATGAACT S T C D D lipoprotein- relatedprotein 1 (alpha-2-macro- globulin receptor) G303u15 WIAF-10030 X1391611395 LRP1, low density ACGGCAGCGA[C/T]GAGGAGGCCT S C T D D lipoprotein-related protein 1 (alpha-2-macro- globulin receptor) G303u16 WIAF-10031X13916 12763 LRP1, low density ACGTCTTTGA[G/A]GATTACATCT S G A E Elipoprotein- related protein 1 (alpha-2-macro- globulin receptor)G303u17 WIAF-10035 X13916 640 LRP1, low densityACGGATCTGA[C/T]GAGGCCCCTG S C T D D lipoprotein- related protein 1(alpha-2-macro- globulin receptor) G303u18 WIAF-10037 X13916 1609 LRP1,low density GCCGCCTTGT[C/T]TACTGGGCAG S C T V V lipoprotein- relatedprotein 1 (alpha-2-macro- globulin receptor) G303u19 WIAF-10038 X139161629 LRP1, low density GATGCCTATC[T/G]GGACTATATT M T G L R lipoprotein-related protein 1 (alpha-2-macro- globulin receptor) G303u20 WIAF-10039X13916 2210 LRP1, low density CACCAGCTAC[C/T]TCATTGGCCG M C T L Flipoprotein- related protein 1 (alpha-2-macro- globulin receptor)G303u21 WIAF-10043 X13916 7287 LRP1, low densityGATGGCTCCA[G/A]GAGGATCACC M G A R K lipoprotein- related protein 1(alpha-2-macro- globulin receptor) G303u22 WIAF-10044 X13916 8258 LRP1,low density CTCTGACGAC[A/G]TCCCTTGCAA M A G I V lipoprotein- relatedprotein 1 (alpha-2-macro- globulin receptor) G303u23 WIAF-10045 X1391611871 LRP1, low density GTGCGCACCG[A/G]GAAAGCCGCC M A G E G lipoprotein-related protein 1 (alpha-2-macro- globulin receptor) G3031u1 WIAF-14097HT1128 611 PSMC3, proteasome TGGGGATCCA[A/C]CCTCCAAAAG S A G Q Q(prosome, macro- pain) 26S subunit, ATPase, 3 G3034u2 WIAF-12837 HT1182421 TCF12, tran- ATCTTCAATT[A/C]TGGGTTCCTT M A G M V scription factor 12(HTF4, helix-loop- helix transcription factors 4) G3038u1 WIAF-12864HT1373 1700 NFKB1, nuclear AGAGAAGGCT[A/G]TGCAGCTTGC M A G M V factor ofkappa light polypeptide gene enhancer in B-cells 1 (p105) G3038u2WIAF-12881 HT1373 1936 NFKB1, nuclear TGTACCAGAC[G/A]CCCTTGCACT S G A TT factor of kappa light polypeptide gene enhancer in B-cells 1 (p105)G3038u3 WIAF-12882 HT1373 2641 NFKB1, nuclear AGCTGCACCT[G/C]TATAAGTTACS G C L L factor of kappa light polypeptide gene enhancer in B-cells 1(p105) G3039u1 WIAF-13027 HT1375 3761 GLI3, GLI-KruppelAACAGCCCCG[G/T]AACTCCCACC M G T G V family member GLI3 (Greigcephalopoly- syndactyly syndrome) G3039u2 WIAF-13028 HT1375 3963 GLI3,CLI-Kruppel CGCCAAATGA[G/T]TCAGCTGGCA M G T E D family member GLI3(Greig cephalopoly- syndactyly syndrome) G304u1 WIAF-12242 HT637 158FABP3, fatty acid CTCACCCTAA[A/C]AACACACAGC M A G K R binding protein 3,muscle and heart (mammary derived growth inhibitor) G3043u1 WIAF-12867HT1486 842 IRF2, interferon GTGCCGAGGG[G/A]CGGCCACACT S G A G Gregulatory factor 2 G3047u1 WIAF-12875 HT1518 1233 transcriptionTCCGTTTCCT[C/T]GAGAGCCTGC S C T L L factor 1, nucleolar G3047u2WIAF-12876 HT1518 1746 transcription GGATTAAGAA[G/A]GCACCCGAAG S G A K Kfactor 1, nucleolar G3047u3 WIAF-12877 HT1518 1829 transcriptionTCCAAGAAGA[T/C]GAAATTCCAG M T C M T factor 1, nucleolar G3048u1WIAF-12884 HT1530 628 transcription AGTGGAGCGT[C/T]GCCGCCGAGA M C T R Cfactor USF G305u1 WIAF-10150 HT0034 777 prolyl 4-hydroxy-CCCTTGTCAT[C/T]GAGTTCACCG S C T I I lase, beta subunit/ proteindisulfide isomerase/thyroid hormone-binding protein, alt. transcript 1G305u21 WIAF-10154 HT0034 186 prolyl 4-hydroxy-TGGCCGCCCA[C/A]AAGTACCTCC M C A H Q lase, beta subunit/ proteindisulfide isomerase/thyroid hormone-binding protein, alt. transcript 1G305u3 WIAF-10155 HT0034 1428 prolyl 4-hydroxy-GGACGGTCAT[T/C]GATTACAACG S T C I I lase, beta subunit/ proteindisulfide isomerase/thyroid hormone-binding protein, alt, transcript 1G3050u1 WIAF-12860 HT1558 2098 PSRG1: female AACATTGCAA[T/C]GGCATTTTGA ST C N N sterile homeotic related gene 1 (mouse homolog) G3050u2WIAF-12861 HT1558 2845 FSRG1: female TAGGCCCTTC[T/C]GGCTTTGGAC S T C S Ssterile homeotic related gene 1 (mouse homolog) G3050u3 WIAF-12862HT1558 3409 FSRG1: female CCTCGTCGTC[G/A]TCTTCAGACA S G A S S sterilehomeotic related gene 1 (mouse homolog) G3050u4 WIAF-12874 HT1558 1699FSRG1: female TCTCTTCTGT[G/C]TCACACACAG S G C V V sterile homeoticrelated gene 1 (mouse homolog) G3050u5 WIAF-12878 HT1558 2093 FSRG1:female GTTAAAACAT[T/G]GCAATGGCAT M T G C G sterile homeotic related gene1 (mouse homolog) G3050u6 WIAF-12879 HT1558 2746 FSRG1: femaleCTGGGGCCGA[C/T]GAAGATGACA S C T D D sterile homeotic related gene 1(mouse homolog) G3051u1 WIAF-12866 HT1569 1423 MEF2B, MADS boxCTTGGCCGAC[G/A]GCTGGCCCCG S G A T T transcription enhancer factor 2,polypeptide B (myocyte enhancer factor 2B) G3051u2 WIAF-13022 HT1569 661MEF2B, MADS box CAGACTACAG[C/T]GAGCCCCACG S C T S S transcriptionenhancer factor 2, polypeptide B (myocyte enhancer factor 2B) G3057a1WIAF-12142 HT1669 5565 alpha-fetoprotein AGACTGCTCT[T/C]GAGGCTCATA S T CL L enhancer-binding protein G3057a2 WIAF-12143 HT1669 5634alpha-fetoprotein CTCTGTCTGC[C/A]ATGCTCTTAG S G A A A enhancer-bindingprotein G3057a3 WIAF-12144 HT1669 5664 alpha-fetoproteinGGGGACTCCA[G/T]ATGAAAGGAG M G T Q H enhancer-binding protein G3057a4WIAF-12145 HT1669 5703 alpha-fetoprotein GCTTTTCCCA[C/T]CTACCCCCAA S C TH H enhancer-binding protein G3057u5 WIAF-12885 HT1669 2227alpha-fetoprotein TCTGGAGATC[C/T]ATATGAGGTC M C T H Y enhancer-bindingprotein G3057u6 WIAF-12892 HT1669 3720 alpha-fetoproteinAGACCTTGCC[G/A]GCTCAGCTAC S G A P P enhancer-binding protein G3057u7WIAF-12893 HT1669 4137 alpha-fetoprotein CAAGGTTTAC[G/A]GACTACCACC S G AT T enhancer-binding protein G3057u8 WIAF-12897 HT1669 4783alpha-fetoprotein GAAGACCAAC[A/C]CTCCCCAGCA M A C T P enhancer-bindingprotein G3057u9 WIAF-12898 HT1669 5215 alpha-fetoproteinTCCAACCTCC[A/C]CAATGAACAC M A C T P enhancer-binding protein G3057u10WIAF-12904 HT1669 7266 alpha-fetoprotein CCCTGCAGCC[C/TI GCGTTGACTT S CT A A enhancer-binding protein G3057u11 WIAF-12907 HT1669 8345alpha-fetoprotein CCAACACACG[A/C]CTATTCGGAG M A C D A enhancer-bindingprotein G3057u12 WIAF-12943 HT1669 4257 alpha-fetoproteinTGGTGTGGTT[T/C]CAGAATGCCC S T C F F enhancer-binding protein G057u13WIAF-12951 HT1669 7333 alpha-fetoprotein ACCAGGCTTT[T/A]CTCCTTATTA M T AS T enhancer-binding protein G3057u14 WIAF-13030 HT1669 303alpha-fetoprotein GCAHCCTGTC[C/A]GAGGACGAGT S G A S S enhancer-bindingprotein G3057u15 WIAF-13031 HT1669 777 alpha-fetoproteinGCCTTCCAGA[G/A]GACGACGAGG S G A E E enhancer-binding protein G306u1WIAF-10118 HT0040 1618 CPT2, carnitine CTCTACTGCC[C/A]TCCACTTTGA M G A VI palmitoyl- transferase II G307u1 WIAF-10076 HT0114 110 EDN2,endothelin 2 CGTTGCGCTA[G/A]CCCTGCTCGT M G A A T G3070u1 WIAF-12972HT2085 625 pre-B-cell leukemia AGAAATATGA[A/C]CAGGCATGTA S A G E Etranscription factor 3 G3070u2 WIAF-12973 HT2085 841 pre-B-cell leukemiaGTAACTTCAG[T/C]AAACAGGCCA S T C S S transcription factor 3 G3071u1WIAF-12886 HT2086 995 AGER, advanced CCTGCGAGGC[T/C]GTGATGATCC S T C A Aglycosylation end product-specific receptor G3071u2 WIAF-12887 HT20861475 AGER, advanced GAGGCCAGAT[C/G]TACAGCCCAC M C G I M glycosylationend product-specific receptor G3071u3 WIAF-12935 HT2086 933 AGER,advanced ACGCATGGTG[A/G]GCATCATCCA M A G S G glycosylation endproduct-specific receptor G3071u4 WIAF-12936 HT2086 1052 AGER, advancedGTAACTTCAC(C/T]AAACAGGCCA S C T S S glycosylation end product-specificreceptor G3071u5 WIAF-12937 HT2086 836 AGER, advancedAGAAGTATGA[G/A]CAGGCATGTA S G A E E glycosylation end product-specificreceptor G308u1 WIAF-10094 HT0192 484 ANX4, annexin IVATGGACGGAG[C/G]CTTGAAGATG M C G S R (placental anti- coagulant proteinII) G308u2 WIAF-10095 HT0192 333 ANX4, annexin IVGGGATCATGA[C/T]GCCCACGGTC M C T T M (placental anti- coagulant proteinII) G3081u1 WIAF-12997 HT2188 689 PSMC2, proteasomeGGCATTGAGC[C/T]TCCCAAGGGC M C T P L (prosome, macro- pain) 26S subunit,ATPase, 2 G3083u1 WIAF-12976 HT2228 106 IGHMBP2, immuno-TGCTGGAGCT[T/C]GAGAGAGACG S T C L L globulin mu binding protein 2G3083u2 WIAF-12985 HT2228 2260 IGHMBP2, immuno-TGGAGTTCAT[G/C]GCCAGCAAGA M G C M I globulin mu binding protein 2G3083u3 WIAF-12986 HT2228 2060 IGHMBP2, inmuno-GGGACCTGCT[A/G]CGTCCACCAG M A G T A globulin mu binding protein 2G3083u4 WIAF-12987 HT2228 2365 IGHMBP2, immuno-ACGACAGTTC[C/T]GGGGAAGGGA S C T S S globulin mu binding protein 2G3083u5 WIAF-13005 HT2228 411 IGHMBP2, immuno- TTTGATGAGT[C/T]CCACGATTTCM C T S F globulin mu binding protein 2 G3083u6 WIAF-13006 HT2228 272IGHMBP2, immuno- ATACGGGTCC[G/A]CGGCAGCTCT M G A A T globulin mu bindingprotein 2 G3083u7 WIAF-13010 HT2228 2581 IGHMBP2, immuno-TCAGGAGCGC[G/A]CAGGGGCAGC S G A A A globulin mu binding protein 2G3083u8 WIAF-13011 HT2228 2594 IGHMBP2, immuno-GGGGCAGCCC[G/A]CCAGCAAGGA M G A A T globulin mu binding protein 2G3088u1 WIAF-12984 HT2318 884 HIVEP1, human TGTGGCACTA[C/T]GTCCCCCTCC MC T T M immunodeficiency virus type I enhancer-binding protein 1 G3088u2WIAF-12988 HT2318 2469 HIVEP1, human TCTTGTCACC[A/G]CGTCAACACC S A G P Pimmunodeficiency virus type I enhancer-binding protein G3088u3WIAF-12989 HT2318 3066 HIVEP1, human TTCTTGGTAC[T/C]GGACAGTCCC S T C T Timmunodeficiency virus type I enhancer-binding protein 1 G3088u4WIAF-12991 HT2318 4008 HIVEP1, human TTATCCGGCA[G/T]CACAACATCC M G T Q Himmunodeficiency virus type I enhancer-binding protein 1 G3088u5WIAF-12992 HT2318 4880 HIVEP1, human CAAATCCATG[C/G]ACCGCCTAGC M C G A Gimmunodeficiency virus type I enhancer-binding protein 1 G3088u6WIAF-12993 HT2318 5148 HIVEP1, human TTGACAGCAT[G/A]TCTAATTCGC M G A M Iimmunodeficiency virus type I enhancer-binding protein 1 G3088u7WIAF-12999 HT2318 5834 HIVEP1, human CCAGCTGATA[A/C]TTCATCAACA M A G N Simmunodeficiency virus type I enhancer-binding protein 1 G3088u8WIAF-13000 HT2318 6065 HIVEP1, human CAAAGTCAAC[G/A]GCCAGTCACT M G A R Qimmunodeficiency virus type I enhancer-binding protein 1 G3088u9WIAF-13001 HT2318 7652 HIVEP1, human CATAGGAATA[C/T]GGTCACACAA M C T T Mimmunodeficiency virus type I enhancer-binding protein 1 G30B8u10WIAF-13008 HT2318 741 HIVEP1, human TTCTGCAGCA[A/G]CCATCTGAAC S A G Q Qimmunodeficiency virus type I enhancer-binding protein 1 G3088u11WIAF-13009 HT2318 948 HIVEP1, human CAGAACTGAG[C/T]ACCTTGTCAC S C T S Simmunodeficiency virus type I enhancer-binding protein 1 G3088u12WIAF-13012 HT2318 1909 HIVEP1, human TGAAACTTTA[C/T]TAAAATCAAG S C T L Limmunodeficiency virus type I enhancer-binding protein 1 G3088u13WIAF-13013 HT2318 2803 HIVEP1, human TCTTCTGTCT[G/A]TACCTTCACT M G A V Iimmunodeficiency virus type I enhancer-binding protein 1 G3088u14WIAF-13015 HT2318 3342 HIVEP1, human GCGGTCTGCA[A/G]CCTCAGATTC S A G Q Qimmunodeficiency virus type I enhancer-binding protein 1 G3088u15WIAF-13016 HT2318 3542 HIVEP1, human CCTAAACATA[G/A]TGTTACCATA M G A S Nimmunodeficiency virus type I enhancer-binding protein 1 G3088u16WIAF-13017 HT2318 4972 HIVEP1, human TGGGTCTTCT[A/G]AAAGTGAGGA M A G K Eimmunodeficiency virus type I enhancer-binding protein 1 G3095u1WIAF-12994 HT2435 701 TCF2, transcription CCGCTCTGTA[C/T]ACCTGGTACG S CT Y Y factor 2, hepatic; LF-B3; variant hepatic nuclear factor G3095u2WIAF-13018 HT2435 362 TCF2, transcription GGGCCGAGCC[C/T]GACACCAAGC S CT P P factor 2, hepatic; LF-B3; variant hepatic nuclear factor G3095u3WIAF-13020 HT2435 1620 TCF2, transcription CCAGTTCTCC[C/T]AGCAGCTGCA N CT Q * factor 2, hepatic; LF-B3; variant hepatic nuclear factor G3100a1WIAF-12147 HT2483 526 ZNF141, zinc finger GAATGAGTGT[A/G]AGTTGCAGAA M AG K E protein 141 (dione pHZ-44) G3102u1 WIAF-12975 HT2508 259 NRF1,nuclear CGCCTTCTTC[G/T]CCCGAGGACA S G T S S respiratory factor 1 G3103u1WIAF-13617 HT2511 1106 E2F2, E2F CCTTGGACCA[G/T]CTCATCCAGA M H T Q Htranscription factor 2 C3103u2 WIAF-13659 HT2511 1154 E2F2, E2FCTGAGGACAA[G/A]GCCAACAAGA S G A K K transcription factor 2 G311u1WIAF-10291 HT0402 1339 A2M, alpha-2-macro- GTCCCTGTTA[C/T]GGCTACCAGT S CT Y Y globulin G311u2 WIAF-10292 HT0402 1201 A2M, alpha-2-macro-TCATATTCAT[C/T]AGAGGAAATG S C T I I globulin G311u3 WIAF-10293 HT04023041 A2M, alpha-2-macro- TACTCCAGAG[C/A]TCAACTCCAA M G A V I globulinG311u4 WIAF-10294 HT0402 3676 A2M, alpha-2-macro-TGACATCCTA[T/C]GTGCTCCTCC S T C Y Y globulin G311u5 WIAF-10296 HT04023364 A2M, alpha-2-macro- ATATCACCAT[C/T]GCCCTTCTGG S C T I I globulinG311u6 WIAF-10297 HT0402 3203 A2M, alpha-2-macro-CCAAGCTCGA[G/T]CCTACATCTT M G T A S globulin G311a7 WIAF-10494 HT04021122 A2M, alpha-2-macro- TCACACTTTC[G/A]ACAGGGAATT M G A R Q globulinG3119u1 WIAF-13947 HT2654 2876 GLI, glioma- TTTCTGGGCG[G/A]TTCCCAGGTT MG A G D associated oncogene homolog (zinc finger protein) G3119u2WIAF-13959 HT2654 654 GLI, glioma- AGTGCCGGGA[G/A]GAACCCTTGG S G A E Eassociated oncogene homolog (zinc finger protein) G3119u3 WIAF-13965HT2654 3376 GLI, glioma- TGGGGAAACA[G/C]AATTCCTCAA M G C E Q associatedoncogene homolog (zinc finger protein) G312u1 WIAF-10006 HT0428 898PLAU, plasminogen CTCACCACAA[C/T]CACATTCCCT S C T N N activator,urokinase G312u2 WIAF-10029 HT0428 498 PLAU, plasminogenGGCCTAAACC[C/T]GCTTGTCCAA M C T P L activator, urokinase G312a3WIAF-10521 HT0428 767 PLAU, plasminogen TGATTACCCA[A/C]AGAAGGACGA M A CK Q activator, urokinase G3125u1 WIAF-13675 HT2674 740 GTF2F2, generalACATCACAAA[A/G]CAACCTGTGG S A G K K transcription factor hF, poly-peptide 2 (30 kD subunit) G313u1 WIAF-10129 HT0462 3086 platelet-derivedCATGCGTGTG[C/A]ACTCAGACAA M G A D N growth factor, alpha polypeptide(GB:M21574) G313u2 WIAF-10130 HT0462 1078 platelet-derivedATGAGAAAGG[T/C]TTCATTGAAA S T G G G growth factor, alpha polypeptide(CB:M21574) G313u3 WIAF-10133 HT0462 1571 platelet-derivedGGAGATCCAC[T/C]CCCCAGACAG M T C S P growth factor, alpha polypeptide(CB:M21574) G313u4 WIAF-10135 HT0462 2611 platelet-derivedCTCGCAACGT[C/T]CTCCTGGCAC S C T V V growth factor, alpha polypeptide(CB:M21574) C314u1 WIAF-10069 HT0467 1890 ALOX15,TCAGCCAGGA[G/A]CTGGCTGCCC S G A E E arachidonate 15- lipoxygenaseG3141u1 WIAF-13934 HT27498 878 NFATC3, nuclear CCAGAGGATA[G/A]CTGGCTACTCM G A S N factor of activated T-cells, cytoplasmic 3 G3141u2 WIAF-13936HT27498 1189 NFATC3, nuclear GCCTGCCTCA[T/C]GCAATGGGAA M T C C R factorof activated T-cells, cytoplasmic 3 G3141u3 WIAF-13938 HT27498 2241NFATC3, nuclear CTCTGCGGGG[T/C]TTCCCTTCAG S T C G G factor of activatedT-cells, cytoplasmic 3 C3141u4 WIAF-13944 HT27498 702 NFATC3, nuclearATGCCTCTGA[C/T]CACGCAGCCC S C T D D factor of activated T-cells,cytoplasmic 3 G3159u1 WIAF-13891 HT2757 523 SP4, Sp4 tran-CTTCAAAAGA[C/A]AATAACGTTT S G A E E scription factor G3159u2 WIAF-13892HT2757 1514 SP4, Sp4 tran- ACAGAATGTT[C/T]AACTTCAAGC N C T Q * scriptionfactor G3159u3 WIAF-13893 HT2757 2236 SP4, Sp4 tran-TGTTTTGTGG[C/T]AAAAGATTCA S C T G G scription factor G3165u1 WIAF-13860HT27636 437 transcription AGCAGCTCAC[A/G]GAGGAACTGA S A G T T factorB-ATF G3165u2 WIAF-13861 HT27636 512 transcriptionCCACCACGCC[C/G]TCGCCCCCCG S C G P P factor B-ATF G3173u1 WIAF-13556HT2772 1686 ZNF74, zinc finger TGCACAGCGA[G/A]GGGAAGCCCT S G A E Eprotein 74 (Cos52) G3175u1 WIAF-13948 HT2776 2037 transcriptionalTGTTCGGACC[A/G]GAAGCACCCA S A G P P regulator, via glucocorticoidreceptor G3182u1 WIAF-14036 HT2783 1614 MHC2TA, MHC classATCCTAGACG[C/G]CTTCGAGGAG M C G A G II transactivator G3182u2 WIAF-14037HT2783 2791 MHC2TA, MHC class TGAGCGACAC[G/A]GTGGCGCTGT S G A T T IItransactivator C3182u3 WIAF-14059 HT2783 1657 MHC2TA, MHC classTGCACAGCAC[C/A]TGCGGACCGG S G A T T II transactivator G3182u4 WIAF-14060HT2783 1606 MHC2TA, MHC class TTCTGCTCAT[C/T]CTAGACGCCT S C T I I IItransactivator G3183u1 WIAF-13950 HT27861 392 zinc finger proteinTACTCTAGAG[G/A]AGCCTGTTGG M G A E K C2H2-150 G3184u1 WIAF-13864 HT27862271 zinc finger protein GAAACTCCAG[T/G]TCAAAGACTT M T G F V C2H2-171G3184u2 WIAF-13865 HT27862 248 zinc finger proteinCTGCTTGAAT[T/C]CATGTATGAR M T C F S C2H2-171 G320u1 WIAF-10136 HT0791552 ANX7, annexin VII CCAACTTCCA[T/C]GCTATAAGAG S T C D D (synexin)G320u2 WIAF-10137 HT0791 1350 ANX7, annexin VIITTGACCTTGT[A/G]CAAATAAAAC S A G V V (synexin) G3208u1 WIAF-14186 HT27930485 zinc finger GTCACAAGTC[A/C]GCCCTAATTG S A G S S protein ZNF37AG3218u1 WIAF-13526 HT28104 187 zinc finger CCCGACAGCT[C/T]ATTAAGAAAG M CT H Y protein ZNF169, Krueppel-type G323u1 WIAF-10066 HT0915 1361 Homosapiens ACTTCTGTGA[C/T]GTCCAGCGCT S C T D D inducible nitric oxidesynthase (NOS) mRNA, complete cds. G325u1 WIAF-10106 HT0962 3817 FBN1,fibrillin 1 TGTGAATGCC[C/T]GCCTGGCCAT M C T P L (Marfan syndrome) G325u2WIAF-10113 HT0962 722 FBN1, fibrillin 1 AGATACCTCC[T/C]TCCTCTGGCT S T GP P (Marfan syndrome) G325u3 WIAF-10114 HT0962 2022 FBN1, fibrillin 1GATCTGCAAT[A/C]ATGGACGCTG M A C N H (Marfan syndrome) G325u4 WIAF-10116HT0962 3603 FBN1, fibrillin 1 GAACTGCACA[G/C]ACATTGACGA M G C D H(Marfan syndrome) C325u5 WIAF-10117 HT0962 2270 FBN1, fibrillin 1TCTGCATCAA[C/T]GGGCGTTGCG S C T N N (Marfan syndrome) G326u1 WIAF-10036HT1009 1854 KLKB1, kallikreim GCAAACACAA[C/T]GGAATGTGGC S C T N N Bplasma (Fletcher factor) 1 G327u1 WIAF-10052 HT1011 1599 HRG, histidine-AAGCCAGACA[A/T]TCAGCCCTTT M A T N I rich glycoprotein G327u2 WIAF-10054HT1011 1083 HRG, histidine- CCACTATTGC[C/T]CATGTCCTGC M C T P L richglycoprotein G327u3 WIAF-10055 HT1011 1140 HRG, histidine-GCCCAAAGAC[A/G]TTCTCATAAT M A G H R rich glycoprotein G328u1 WIAF-10145HT1087 255 SAA1, serum amyloid GTGCCTGGGC[T/C]GCAGAAGTGA S T C A A A1G328a2 WIAF-10511 HT1087 248 SAA1, serum amyloidCCTGGGGGTC[C/T]CTGGGCTGCA M C T A V A1 G328a3 WIAF-10512 HT1087 305SAA1, serum amyloid TTCTTTGGCC[A/G]TGGTGCGGAC M A G H R A1 G328a4WIAF-13126 HT1087 295 SAA1, serum amyloid TATCCAGAGA[T/C]TCTTTGGCCA M TC F L A1 G328a5 WIAF-13127 HT1087 82 SAA1, serum amyloidCTTGGTCCTG[C/A]GTGTCAGCAG M G A G S A1 G329u1 WIAF-10140 HT1141 2514PLCG1, phospho- CTGACCTTCA[T/C]CAAGAGCGCC M T C I T lipase C, gamma 1(formerly subtype 148) G329u2 WIAF-10162 HT1141 1036 PLCG1, phospho-TATGCCCGGA[C/A]ACCATGAACA M C A D E lipase C, gamma 1 (formerly subtype148) G329u3 WIAF-10163 HT1141 911 PLCG1, phospho-GTTCATGCTC[A/G]GCTTCCTCCG M A G S G lipase C, gamma 1 (formerly subtype148) G3295u1 WIAF-14017 HT3460 1229 FUBP, far upstreamCCATAAAAAG[C/T]ATAACCCAGC S C T S S element binding protein G3296u1WIAF-14168 HT3466 6289 transcription CAGCCTGGAC[G/A]AGAGCCCCAT M G A E Kfactor TFIIIC, RNA polymerase III, alpha subunit G3296u2 WIAF-14179HT3466 235 transcription GGCCATCAGC[T/A]TCTATGAGGA M T A F I factorTFIIIC, RNA polymerase III, alpha subunit G3298u1 WIAF-13523 HT3504 1803DNA-binding protein ACTTTGCCAA[C/T]GTGCAGGAGC S C T N N HRFX2 G3298u2WIAF-13524 HT3504 1743 DNA-binding protein GGGCGGTGCT[G/A]CAGAACACGT S GA L L HRFX2 G3298u3 WIAF-13528 HT3504 2002 DNA-binding proteinGTTCTTGCTG[A/G]AATGGTCCTT M A G K E HRFX2 G33u1 WIAF-10254 X82540 1044INHBC, inhibin, AAGGCCAACA[C/T]AGCTGCAGGC M C T T I beta C G33u2WIAF-10255 X82540 1136 INHBC, inhibin, CAGCAACATT[G/A]TCAAGACTGA M G A VI beta C G33u3 WIAF-10256 X82540 1185 INHBC, inhibin,GGGTGCAGTT[A/G]GTCTATGTGT N A G * W beta C G33u4 WIAF-10259 X82540 892INHBC, inhibin, TTTTTGTGGA[C/T]TTCCGTGAGA S C T D D beta C G3303u1WIAF-13566 HT3523 981 POU6F1, POU CAGGCCAGGA[G/A]ATCACTGAAA S G A E Edomain, class 6, transcription factor 1 G3304u1 WIAF-13932 HT3544 970SP2, Sp2 transcrip- TCAACAACCT[C/T]GTGAACGCCA S C T L L tion factorG3304u2 WIAF-13935 HT3544 1891 SP2, Sp2 transcrip-AGAAGCACGT[T/G]TGCCACATCC S T G V V tion factor G3304u3 WIAF-13943HT3544 920 SP2, Sp2 transcrip- TGTGGTGAAG[T/C]TGACAGGTGG S T C L L tionfactor G3311u1 WIAF-13839 HT3585 757 GATA3, GATA-CCCACTCCCG[T/C]GGCAGCATGA S T C R R binding protein 3 G3311u2 WIAF-13840HT3585 901 GATA3, GATA- TCGGATGCAA[G/A]TCCAGGCCCA S G A K K bindingprotein 3 G3316u1 WIAF-13818 HT3607 282 zinc fingerAAAGAGTTTC[A/G]GTCACACTTC M A G S G protein HKE-T1, Kruppel-like G3319u1WIAF-14214 HT3613 1086 SMARCA3, SWI/SNF AAACTCTTAC[A/C]GCCATTGCAG S A GT T related, matrix associated, actin dependent regulator of chromatin,subfamily a, member 3 G3319u2 WIAF-14221 HT3613 1261 SMARCA3, SWI/SNFTAGATCTAGT[G/C]AACAACCCAG M G C E Q related, matrix associated, actindependent regulator of chromatin, subfamily a, member 3 G3320u1WIAF-13692 HT3622 624 BCL6, B-cell CLL/ ATTTGCGGGA[G/C]GGCAACATCA M G CE D lymphoma 6 (zinc finger protein 51) G3320u2 WIAF-13717 HT3622 1062BCL6, B-cell CLL/ ACAGCCGGCC[C/A]ACTTTGGAGG S G A P P lymphoma 6 (zincfinger protein 51) G3321u1 WIAF-13761 HT3641 235 STAT2, signalTCTTGGATCA[G/C]CTGAACTATG M G C Q H transducer and activator oftranscription 2, 113 kD G3321u2 WIAF-13762 HT3641 774 STAT2, signalCAAAAAGCCT[G/C]CATCAGAGCT M G C C S transducer and activator oftranscription 2, 113 kD G3328u1 WIAF-13543 HT3681 1550 transcriptionCCACAATGGT[A/C]TCAGAGCAGG S A G V V factor znf6 G3328u2 WIAF-13544HT3681 1389 transcription AGAGGATTTA[G/C]AGGAAGATGA M G C E Q factorznf6 G3336u1 WIAF-13848 HT3732 216 XBP1, X-box bindingACCTGAGCCC[C/T]GAGGAGAAGG S C T P P protein 1 G334u1 WIAF-1008 HT1220893 THBS1, thrombo- TACATTCGCC[A/C]CAAGACAAAG M A C H P spondin 1 G334u2WIAF-10009 HT1220 2000 THBS1, thrombo- TCACAGCCCT[T/C]CGGCCAGCCT M T C FS spondin 1 G334u3 WIAF-10016 HT1220 1521 THBS1, thrombo-CCCAGATGAA[T/C]GGCAAACCCT S T C N N spondin 1 G334u4 WIAF-10017 HT12202210 THBS1, thrombo- GGCTGGCCCA[A/G]TGAGAACCTG M A G N S spondin 1G334u5 WIAF-10018 HT1220 2979 THBS1, thrombo- GTGAGACCGA[T/C]TTCCGCCGATS T C D D spondin 1 G334u6 WIAF-10033 HT1220 1136 THBS1, thrombo-TGTCACTGTC[A/G]GAACTCACTT M A G Q R spondin 1 G334u7 WIAF-10034 HT12201859 THBS1, thrombo- AGTGGAAATG[C/A]CATCCAGTGC M G A G D spondin 1G3343u1 WIAF-13545 HT3770 1104 ZNF76, zinc fingerGCACTGCCCA[C/T]GGCGAGCTGG S C T H H protein 76 (expressed in testis)G3343u2 WIAF-13561 HT3770 425 ZNF76, zinc fingerGAGCAGTATG[C/A]CAGCAAGGTT M C A A D protein 76 (expressed in testis)G3343u3 WIAF-13562 HT3770 143 ZNF76, zinc fingerCACCAGGTGA[C/T]GGTACAGAAA M C T T M protein 76 (expressed in testis)G3343u4 WIAF-13563 HT3770 646 ZNF76, zinc fingerGAAGACCCAC[G/T]TTCGTACCCA M G T V F protein 76 (expressed in testis)G3343u5 WIAF-13564 HT3770 611 ZNF76, zinc fingerAGCTGTGGAA[A/G]GGCCTTTGCC M A G K R protein 76 (expressed in testis)G3344u1 WIAF-13664 HT3772 925 zinc finger proteinAGCTCTCGCA[C/T]TCGGACGACA S C T H H HAZ G3345u1 WIAF-13508 HT3823 315TCF6L1, transcrip- TTCGATTTTC[T/C]AAAGAACAAC S T C S S tion factor 6-like 1 (mito- chondrial transcription factor 1-like) G3345u2 WIAF-13509HT3823 167 TCF6L1, transcrip- GGCGTGCTGA[G/CITGCCCTGGGA M G C S T tionfactor 6- like 1 (mito- chondrial transcription factor 1-like) G3345u3WIAF-13531 HT3623 625 TCF6L1, transcrip- TTATAACGTT[T/G]ATGTAGCTGA M T GY D tion factor 6- like 1 (mito- chondrial transcription factor 1-like)G3352u1 WIAF-13589 HT4005 1190 MITF, micro- CTCGGAACTG[G/A]GACTCAGGCC MG A G E phthalmia-associated transcription factor G3352u2 WIAF-13604HT4005 1156 MITF, micro- TCTCACGGAT[G/A]GCACCATCAC M G A G Sphthalmia-associated transcription factor G3353u1 WIAF-13937 HT4010 360GTF2H3, general ATCTAATGAC[C/A]AAAAGTGACA S C A T T transcription factorIIH, polypeptide 3 (34 kD subunit) G3358u1 WIAF-13671 HT4187 398 ETV5,ets variant GATGATGAAC[A/C]GTTTGTCCCA M A G Q R gene 5 (ets-relatedmolecule) G3358u2 WIAF-13672 HT4187 223 ETV5, ets variantTCAGCAAGTC[C/T]CTTTTATGGT M C T P S gene 5 (ets-related molecule)G3358u3 WIAF-13673 HT4187 1236 ETV5, ets variantGACTGGAAGC[C/G]AAAGTCAAAC S C G G G gene 5 (eta-related molecule)G3358u4 WIAF-13674 HT4187 1678 ETV5, ets variantTTACCTCCTC[G/A]ACATGGACCG M G A D N gene 5 (ets-related molecule)G3358u5 WIAF-13706 HT4187 414 ETV5, ets variantTCCCAGATTT[T/C]CAGTCTGATA S T C F F gene 5 (ets-related molecule)G3358u6 WIAF-13707 HT4187 1238 ETV5, ets variantCTGGAAGGCA[A/C]AGTCAAACAG M A G K R gene 5 (ets-related molecule) G336u1WIAF-10152 HT1258 566 ACAT1, acetyl- AGAGCATCTC[C/A]AATGTTCCAT S C A S SCoenzyme A acetyl- transferase 1 (acetoacetyl Coenzyme A thiolase)G3369u1 WIAF-14047 HT4302 614 zinc finger ATCTCAATCG[A/G]CACAAGCTCT S AG R R protein DB1 G337u1 WIAF-10268 HT1259 464 EDNRB, endothelinAAAGCAGACA[G/T]GACGGCAGGA M G T R M receptor type B G337u2 WIAF-10298HT1259 1281 EDNRB, endothelin TGAAGCTCAC[T/A]CTTTATAATC S T A T Treceptor type B G3373u1 WIAF-14203 HT4342 1253 MTF1, metal-CTCAACAGAC[A/G]GCTTCCTTGA S A G T T regulatory transcription factor 1G3390u1 WIAF-14182 HT4483 680 ZNF133, zinc fingerAGAGCCAGAG[C/T]TCTACCTCGA M C T L F protein 133 (clone pHZ-13) G3390u2WIAF-14184 HT4483 1026 ZNF133, zinc finger GCTCACACAG[G/A]GAACCCTGAG M GA G E protein 133 (clone pHZ-13) G3390u3 WIAF-14185 HT4483 1423 ZNF133,zinc finger AAAAGCCTTA[T/C]GTGTGCCGGG S T C Y Y protein 133 (clonepHZ-13) G3390u4 WIAF-14197 HT4483 811 ZNF133, zinc fingerCTGGGGATCC[A/G]GGCCCAGGGG S A G P P protein 133 (clone pHZ-13) G3390u5WIAF-14198 HT4483 1420 ZNF133, zinc finger GGGAAAAGCC[T/G]TATGTCTCCC S TG P P protein 133 (clone pHZ-13) G3390u6 WIAF-14199 HT4483 2143 ZNF133,zinc finger CAGCTCTAAT[C/T]ACACACAAGC S C T I I protein 133 (clonepHZ-13) G3391u1 WIAF-13631 HT4484 391 ZNF136, zinc fingerAGCATTGTAT[A/G]TGGAGAAGTC M A G Y C protein 136 (clone pHZ-20) G3396u1WIAF-13978 HT4491 1283 ZNF135, zinc finger CACACCTCCT[C/T]GCTCAGCCAG M CT S L protein 135 (clone pHZ-17) G3396u2 WIAF-13979 HT4491 1296 ZNF135,zinc finger TCAGCCAGCA[C/T]GAAAGGACGC S C T H H protein 135 (clonepHZ-17) G3396u3 WIAF-13980 HT4491 1028 ZNF135, zinc fingerAGTCACAGCT[C/T]CTCCCTCACC M C T S L protein 135 (clone pHZ-17) G3396u4WIAF-13981 HT4491 1057 ZNF135, zinc finger GCGAATCCAC[A/C]CTGGGGAGAA M AG T A protein 135 (clone pHZ-17) G3396u5 WIAF-13982 HT4491 1152 ZNF135,zinc finger CAGGAGAGAA[A/G]CCCTATGAAT S A G K K protein 135 (clonepHZ-17) G3396u6 WIAF-13983 HT4491 1243 ZNF135, zinc fingerAAAGCCGTAT[G/C]GGTGCAATGA M G C G R protein 135 (clone pHZ-17) G3396u7WIAF-13984 HT4491 1045 ZNF135, zinc finger CACCAAACAT[C/T]AGCGAATCCA N CT Q * protein 135 (clone pHZ-17) G340u1 WIAF-10139 HT1386 459 CYP27A1,cytochrome CCTATGGGCC[G/A]TTCACCACGG S G A P P P450, subfamily XXVIIA(steroid 27- hydroxylase, cerebrotendinous xanthomatosis), polypeptide 1G340u2 WIAF-10160 HT1386 801 CYP27A1, cytochromeTCCCCAAGTG[G/A]ACTCGCCCCG N G A W * P450, subfamily XXVIIA (steroid 27-hydroxylase, cerebrotendinous xanthomatosis), polypeptide 1 G341u1WIAF-10121 HT1388 912 MUT, methylmalonyl GAGCTGGCCT[A/G]TACTTTAGCA M A GY C Coenzyme A mutase G341u2 WIAF-10128 HT1388 2087 MUT, methylmalonylTGCTCTGGGC[G/A]TAAGCACCCT M G A V I Coenzyme A mutase G3410u1 WIAF-13749HT4550 1720 zinc finger TGAGTCCTCT[G/T]TTTCATCAGC M G T V F homeodomainprotein G3410u2 WIAF-13750 HT4550 2843 zinc fingerAAACATCATT[T/C]GATTGAACAC M T C L S homeodonain protein G3410u3WIAF-13751 HT4550 2745 zinc finger AGATATTCCA[A/T]AAGAGTAGTT M A T Q Hhomeodomain protein G3410u4 WIAF-13775 HT4550 236 zinc fingerAGAGAAGGGA[A/C]TGCTAACAAC M A C N T homeodomain protein G3410u5WIAF-13776 HT4550 195 zinc finger TGCCAACAGA[C/T]CAGACAGTGT S C T D Dhomeodomain protein G3410u6 WIAF-13777 HT4550 606 zinc fingerATAACTTTAG[T/C]TGCTCCCTGT S T C S S homeodomain protein G3410u7WIAF-13793 HT4550 2073 zinc finger CAGTTTTACC[A/C]GTGCCATCAA S A G P Phomeodomain protein G343u1 WIAF-10120 HT1552 561 HK1, hexokinase 1CTTGCCAACA[A/C]TCCAAAATAG S A G Q Q C343u2 WIAF-10124 HT1552 159 HK1,hexokinase 1 ACAAGTATCT[G/C]TATGCCATCC S G C L L G348u1 WIAF-10269HT1906 2212 PECAM1, platelet/ TGACGATGTC[A/G]GAAACCATCC S A G G Gendothelial cell adhesion molecule (CD31 antigen) G348u2 WIAF-10277HT1906 1656 PECAM1, platelet/ GCCATTCCCA[C/T]GCCAAAATGT S C T H Hendothelial cell adhesion molecule (CD31 antigen) G348u3 WIAF-10283HT1906 577 PECAM1, platelet/ AGAGTACCAG[C/G]TGTTGGTGGA S C G V Vendothelial cell adhesion molecule (CD31 antigen) G348a5 WIAF-13119HT1906 ? PECAM1, platelet/ ATTCTTCCC[C/G] ? C G endothelial celladhesion molecule (CD31 antigen) G351u1 WIAF-10123 HT1990 1047 OSBP,oxysterol TGCTCGCAGA[C/A]TCAGATGAAT S G A E E binding protein G351u2WIAF-10132 HT1990 1023 OSBP, oxysterol TGGCCAAGGC[C/A]AAAGCTGTGA S C A AA binding protein G355u1 WIAF-10146 HT2143 1670 THBS4,AACTCCCTGA[C/A]TGTCTTAAAT M G A S N thrombospondin 4 G355u2 WIAF-10165HT2143 1186 THBS4, TCGAAATCCA[G/C]CGTGCGTTCC M G C A P thrombospondin 4G355a3 WIAF-10510 HT2143 1962 THBS4, ACTGCCCCAC[C/G]GTCATTAACA S C G T Tthrombospondin 4 G355a4 WIAF-13125 HT2143 1963 THBS4,CTGCCCCACC[G/a]TCATTAACAG M C a V I thrombospondin 4 G3552u1 WIAF-12701HT28101 1006 CLCN2, chloride AAGAGACTAT[T/C]ACAGCCCTCT S T C I I channel2 G3552u2 WIAF-12731 HT28101 1823 CLCN2, chlorideCCGCCACCAG[C/T]AGTACCCGGT N C T Q * channel 2 G3552u3 WIAF-12736 HT281012254 CLCN2, chloride GGAGCGCAGA[G/C]TCGGCAGGCA M G C E D channel 2G3565u1 WIAF-12744 HT2896 334 calcyclin GCCCTCAAGG[G/A]CTGAAAATAA M G AG D G357u1 WIAF-10267 HT2244 4300 C4B, complementATGAGTACGA[T/C]GAGCTTCCAG S T C D D component 4B G357u2 WIAF-10280HT2244 5095 C4B, complement TCATGGGTCT[G/A]GATGGGGCCA S G A L Lcomponent 4B G357u3 WIAF-10295 HT2244 2996 C4B, complementCTCAGATCCA[T/C]TGGACACTTT S T C L L component 4B G359u1 WIAF-10026HT2411 936 PLAT, plasminogen CGCAGGCTCA[A/C]GTGGGAGTAC M A G T Mactivator, tissue G359a2 WIAF-10520 HT2411 1444 PLAT, plasminogenAGGCCTTGTC[T/C]CCTTTCTATT S T C S S activator, tissue G3592u1 WIAF-12759HT4214 743 CLCN4, chloride CTTCTAACGA[C/A]ACCACTTTTG S G A E E channel 4G3592u2 WIAF-12761 HT4214 835 CLCN4, chloride GCTTACATTC[T/G]GAATTACTTAM T G L R channel 4 G361u1 WIAF-10053 HT2479 857 cystathionine betaTGGCTCACTA[C/T]GACACCACCG S C T Y Y synthase, alt. transcript 1 G361u2WIAF-10056 HT2479 1097 cystathionine beta TCATCCCCAC[G/A]GTGCTGGACA S GA T T synthase, alt. transcript 1 G362u1 WIAF-10058 HT2638 223 ADRB2,adrenergic, GGCACCCAAT[G/A]GAACCCATCC M G A G R beta-2-, receptor,surface G362u2 WIAF-10059 HT2638 429 ADRS2, adrenergic,TCATGGGCCT[G/A]CCAGTGGTGC S G A L L beta-2-, receptor, surface G362u3WIAF-10060 HT2638 256 ADRB2, adrenergic, CGTCACGCAG[G/C]AAAGGGACCA M G CE Q beta-2-, receptor, surface G362u4 WIAF-10093 HT2638 1230 ADRB2,adrenergic, AGGCCTATGG[G/C]AATGGCTACT S G C G G beta-2-, receptor,surface G3620u1 WIAF-12808 HT97200 458 ACATN, acetyl-CACTCTCTGG[A/G]TATGAAGAGC M A G D G Coenzyme A transporter G3627u1WIAF-12820 HT97387 347 NAPG, N-ethyl- GCACAAACTA[C/T]CAGAGGCCGT M C T PS maleimide-sensitive factor attachment protein, gamma G366u1 WIAF-10046HT2764 987 BDKRB2, bradykinin GCCTCCTTCA[T/C]CGCCTACAGC M T C M Treceptor B2 G366a2 WIAF-10500 HT2764 820 BDKRB2, bradykininAGATCCAGAC[C/A]GAGAGGAGGG S G A T T receptor B2 G366a3 WIAF-10501 HT2764961 BDKRB2, bradykinin GCATCATCGA[T/C]GTAATCACAC S T C D D receptor B2G367u1 WIAF-10156 HT27685 6965 ACACA, acetyl- ATCATCCATA[T/C]GACGCAGCACN T C * C Coenzyme A carboxylase alpha G370u1 WIAF-10281 HT27888 3250LEPR, leptin AAAATTCTCC[G/A]TTGAAGGATT S G A P P receptor G370u2WIAF-10282 HT27888 3229 LEPR, leptin TCACCAAGTG[C/T]TTCTCTAGCA S C T C Creceptor G370u3 WIAF-10284 HT27888 1005 LEPR, leptinCAATATCAAG[T/C]GAAATATTCA M T C V A receptor G370u4 WIAF-10285 HT278881894 LEPR, leptin CAGAGAATAA[C/TI CTTCAATTCC S C T N N receptor G370u5WIAF-10299 HT27888 1222 LEPR, leptin TTCTGACAAG[T/C]GTTGGGTCTA S T C S Sreceptor G370u6 WIAF-10300 HT27888 2161 LEPR, leptinCTATGAAAAA[G/C]GAGAAAAATG M G C K N receptor G371u1 WIAF-10107 HT27943349 CRAT, carnitine TCATCTACTC[G/C]AGCCCAGGCG S G C S Sacetyltransferase G371a2 WIAF-12093 HT27943 287 CRAT, carnitineGGAGAACTGG[C/T]TGTCTGAGTG S C T L L acetyltransferase G372a1 WIAF-10506HT28247 1099 HADHA, hydroxyacyl- TGGAGCTCCA[C/A]AGAAGGATGT M C A Q KCoenzyme A dehydro- genase dehydro- genase/3-ketoacyl- Coenzyme Athiolase/enoyl- Coenzyme A hydratase (tri- functional protein), alphasubunit G374u1 WIAF-10103 HT28496 4435 FASN, fatty acidCACCTCCCAC[G/A]TCCCGGAGGT M G A V I synthase G374u2 WIAF-10104 HT284965996 FASN, fatty acid CTGGACAGGG[T/C]GACCCGAGAG M T C V A synthaseG374u3 WIAF-10105 HT28496 5644 FASN, fatty acidCAAGAGCTAC[A/G]TCATCGCTGG M A G I V synthase G374u4 WIAF-10115 HT284966387 FASN, fatty acid TGGCACACAT[C/T]CTGGGCATCC S C T I I synthaseG374u5 WIAF-10119 HT28496 567 FASN, fatty acid GGGGCATCAA[C/T]GTCCTGCTGAS C T N N synthase G374a6 WIAF-12094 HT28496 5520 FASN, fatty acidACATGGCCCA[A/G]GGGAAGCACA S A G Q Q synthase G377u1 WIAF-10142 HT2996929 PCCB, propionyl GGACCCGGCT[T/C]CCGTCCGTGA M T C S P Coenzyme Acarboxylase, beta polypeptide G377u2 WIAF-10143 HT2996 1416 PCCB,propionyl CACCTTTGTG[G/A]TGATACCAAC N G A G D Coenzyme A carboxylase,beta polypeptide G380u1 WIAF-10122 HT3159 831 INSR, insulinTCTACCTCCA[C/T]GGCAGGTGTG S C T D D receptor G380u2 WIAF-10126 HT31591698 INSR, insulin GGCAGGATCC[A/G]TGTGGTTCCA S A G A A receptor G380u4WIAF-11605 HT3159 2382 INSR, insulin GCGTGCCCAC[G/A]AGTCCGGAGG S G A T Treceptor G383u1 WIAF-10125 HT33546 3633 phospholipase C,AGCAGCGGGC[G/A]AGGCTCCCCC M G A R Q beta 3, alt. transcript 2 G385u1WIAF-10141 HT3383 1505 PRCP, ATGACAGTGC[A/G]GGAAAGCAGC S A G A Aprolylcarboxy- peptidase (angiotensinase C) G385u2 WIAF-10157 HT33831360 PRCP, ATCACAGACA[C/G]TCTGGTTGCA M C G T S prolylcarboxy- peptidase(angiotensinase C) G387u1 WIAF-11729 HT3439 2697 SREBF2, sterolCACTCTCCAG[G/C]AGCTCCGTGC M G C R S regulatory element binding tran-scription factor 2 G387u2 WIAF-11770 HT3439 1901 SREBF2, sterolGCTGCTGCCC[C/G]CAACCTACAA M C G A G regulatory element binding tran-scription factor 2 G388u1 WIAF-10270 HT3440 245 SELPLG, selectinCTCCAGAAAT[G/A]CTGAGGAACA M G A M I P ligand G390u1 WIAF-10276 HT35682049 NOS3, nitric oxide TTGCTCGTGC[C/G]GTGGACACAC S C G A A synthase 3(endothelial cell) G391u1 WIAF-10013 HT3630 6205 VWF, von WillebrandAGCACCTGCA[G/C]GTGATTCTCC M G C E D factor G391u2 WIAF-10265 HT3630 4554VWF, von Hillebrand GCCCCTCACA[A/C]CAACGCCTTC M A G N S factor G391u3WIAF-10266 HT3630 7489 VWF, von Willebrand TGGCCTCAAC[C/T]GCCACCAATC S CT T T factor C391u4 HIAF-10272 HT3630 2470 VWF, von WillebrandACTGTACCAT[G/A]AGTGCAGTCC M G A M I factor G391u5 WIAF-10273 HT3630 2615VWF, von Willebrand GCTCGAGTGT[A/G]CCAAAACGTG M A G T A factor G391u6WIAF-10274 HT3630 2635 VWF, von Willebrand GCCAGAACTA[T/C]GACCTGGACT S TC Y Y factor G391u7 WIAF-10275 HT3630 4045 VWF, von WillebrandTCTCGGAACC[G/A]CCGTTGCACG S G A P P factor G391u8 WIAF-10278 HT3630 4446VWF, von Willebrand AACTTTGTCC[C/A]CTACGTCCAG M G A R H factor G391u9WIAF-10279 HT3630 5152 VWF, von Willebrand GCCCTAATGC[C/T]AACGTGCACG S CT A A factor G391u10 WIAF-10286 HT3630 3448 VWF, von WillebrandTTACCAGTGA[C/T]GTCTTCCAGG S C T D D factor G391u11 WIAF-10287 HT36304891 VWF, von Willebrand ACATGGTCAC[C/T]GTGGAGTACC S C T T T factorG391u12 WIAF-10288 HT3630 4805 VWF, von WillebrandCAGGAGCAAG[G/A]AGTTCATGGA M G A E K factor G391u13 WIAF-10289 HT36304943 VWF, von Willebrand CCTGCAGCCC[G/T]TGCGAGAGAT M G T V L factorG391u14 WIAF-10290 HT3630 4915 VWF, von WillebrandTCAGCGAGGC[A/C]CAGTCCAAAG S A C A A factor G391a15 WIAF-10517 HT36306194 VWF, von Willebrand AAACAAGGAG[C/T]AGGACCTGGA N C T Q * factorG391a16 WIAF-13222 HT3630 6419 VWF, von WillebrandTCACCTTGGT[C/T]ACATCTTCAC M C T H Y factor G3941u1 WIAF-14123 HT34641265 mannosidase, alpha, CACGTCTGCA[A/G]CCAGCTGGAG M A G N S lysosomalG3941u2 WIAF-14135 HT3464 965 mannosidase, alpha,ACCAACCACA[C/T]TGTGATGACC M C T T I lysosomal G395u1 WIAF-10271 HT41581627 ECE1, endothelin TCACTGCCGA[T/C]CAGCTCAGGA S T C D D convertingenzyme 1 G395a2 WIAF-13110 HT4158 1493 ECE1, endothelinCATCTACAAC[A/T]TGATAGGATA M A T M L converting enzyme 1 G3959u1WIAF-13634 HT4490 250 ADTB1, adaptin, TGAAGAAGCT[G/A]GTATACCTCT S G A LL beta 1 (beta prime) G3959u2 WIAF-13640 HT4490 2029 ADTB1, adaptin,TTCTTGGCGG[T/C]GCCCTTGACA S T C G G beta 1 (beta prime) G3959u3WIAF-13641 HT4490 2395 ADTB1, adaptin, AGGTCCACGC[C/A]CCACTCACCC S G A AA beta 1 (beta prime) G3967u1 WIAF-13997 HT2958 918 ACTC, actin,GAGGCACCAC[T/C]ATGTACCCTG S T C T T alpha, cardiac muscle G3968u1WIAF-14159 HT1986 1747 ACTN3, actinin, CGAGGCTGAC[C/T]GAGAGCGAGG N C TR * alpha 3 G3968u2 WIAF-14164 HT1986 1900 ACTN3, actinin,GGTGCCCAGC[C/T]GTGACCAGAC M C T R C alpha 3 G3968u3 WIAF-14165 HT19862184 ACTN3, actinin, ACACCGTCTA[C/T]AGCATGGAGC S C T Y Y alpha 3 G3968u4WIAF-14167 HT1986 2557 ACTN3, actinin, GATCTTGCCA[G/A]GAGACAAGAA M G A GR alpha 3 G3968u5 WIAF-14175 HT1986 1212 ACTN3, actinin,GGCTGCTCTC[G/A]GAGATCCGGC S G A S S alpha 3 G3979u1 WIAF-13884 HT0623776 GPC1, glypican 1 TGCTGCTGCC[T/G]GATCACTACC S T G P P G3979u2WIAF-13885 HT0623 680 GPC1, glypican 1 TCTACTACCC[C/TI GCTGCCAACC S C TR R G3979u3 WIAF-13886 HT0623 1361 GPC1, glypican 1AGCTGCTCTC[T/C]GAACCCAAGG S T C S S G3979u4 WIAF-13887 HT0623 1163 GPC1,glypican 1 ACAGTCTCAT[C/T]GGCAGCGTCC S C T I I G3979u5 WIAF-13888 HT06231670 GPC1, glypican 1 ACGCCAGTGA[C/T]GACGGCACCG S C T D D G3979u6WIAF-13905 HT0623 1069 GPC1, glypican 1 CTTCCCAACC[A/T]CGCCGACCTG M A TQ L G3979u7 WIAF-13906 HT0623 1514 GPC1, glypican 1TCATCCCTCA[C/T]GCCCTCCCCA S C T D D G3979u8 WIAF-13907 HT0623 1720 GPC1,glypican 1 GACCTCTCCC[G/C]CCCCAAGGTC M G C G A G3979u9 WIAF-13908 HT06231676 GPC1, glypican 1 CTCACCACGG[C/T]AGCGGCTCGG S C T G G G3979u10WIAF-13909 HT0623 1719 GPC1, glypican 1 TGACCTCTCC[G/A]GCCGCAACGT M G AG S G399u1 WIAF-10102 HT48511 450 AQP3, aquaporin 3TCTGGCACTT[T/C]GCCCACAACC S T C A A G399u2 WIAF-10111 HT48511 192 AQP3,aquaporin 3 CCTCCCTCCC[C/T]CAGGTTGTGC S C T A A G399u3 WIAF-10112HT48511 165 AQP3, aquaporin 3 CCCTCATCCT[C/G]GTGATGTTTG S C G L LG3997u1 WIAF-13649 HT27682 473 MFAP2, micro- TGTGTGCCCA[C/T]GAGGAGCTCC SC T H H fibrillar- associated protein 2 G3997u2 WIAF-13650 HT27682 377MFAP2, micro- CCATACACAG[G/T]CCTTCCAAAC M G T R S fibrillar- associatedprotein 2 G3997u3 WIAF-13876 HT27682 453 MFAP2, micro-GGAGATCTGT[G/T]TTCGTACAGT M G T V F fibrillar- associated protein 2G4022u1 WIAF-14020 HT2426 240 TGM1, trans- TGGCTGCTGT[T/C]CATGCCGAAA M TC S P glutaminase 1 (K polypeptide epi- dermal type I,protein-glutamine- gamma glutamyl- transferase) G4022u2 WIAF-14021HT2426 371 TGM1, trans- CCCGGGGCAG[C/TI GGTGTCAATG S C T S S glutaminase1 (K polypeptide epi- dermal type I, protein-glutamine- gamma-glutamyl-transferase) G4022u3 WIAF-14022 HT2426 506 TGM1, trans-ACGAGCTGAT[A/GIGTGCGCCGCG M A G I M glutaminase 1 (K polypeptide epi-dermal type I, protein-glutamine- gamma-glutamyl- transferase) G4022u4WIAF-14031 HT2426 2491 TGM1, trans- GGTGGAGGTG[A/T]CAGTCACTTA M A T D Vglutaminase 1 (K polypeptide epi- dermal type I, protein-glutamine-gamma-glutamyl- transferase) G4038u1 WIAF-13998 HT4211 411 LAMB3,laminin, GGTGGCAGTC[C/A]CAGAATGATG S C A S S beta 3 (nicein (125 kD),kalinin (140 kD), BM600 (125 kD)) G4038u2 WIAF-13999 HT4211 258 LAMB3,laminin, CTTCATCTAC[C/T]TGTGGACTGA S C T T T beta 3 (nicein (125 kD),kalinin (140 kD), BM600 (125 kD)) G4038u3 WIAF-14002 HT4211 1830 LAMB3,laminin, GAGGCTACTG[C/T]AATCGCTACC S C T C C beta 3 (nicein (125 kD),kalinin (140 kD), BM600 (125 kD)) G4038u4 WIAF-14003 HT4211 2668 LAMB3,laminin, GACCACGCAG[A/T]TGATTAGGCC M A T M L beta 3 (nicein (125 kD),kalinin (140 kD), BM600 (125 kD)) G4038u5 WIAF-14018 HT4211 248 LAMB3,laminin, TTTCTCCGAG[C/T]TTCATCTACC M C T A V beta 3 (nicein (125 kD),kalinin (140 kD), BM600 (125 kD)) G4038u6 WIAF-14019 HT4211 887 LAMB3,laminin, CACGGCCATG[C/T]TGATCGCTGC M C T A V beta 3 (nicein (125 kD),kalinin (140 kD), BM600 (125 kD)) G4038u7 WIAF-14023 HT4211 1266 LAMB3,laminin, AGTGTGATCC[G/A]GATGGGGCAG S G A P P beta 3 (nicein (125 kD),kalinin (140 kD), BM600 (125 kD)) G4038u8 WIAF-14025 HT4211 1693 LAMB3,laminin, CTATGGAGAC[G/A]TGGCCACAGG M G A V M beta 3 (nicein (125 kD),kalinin (140 kD), BM600 (125 kD)) G4038u9 WIAF-14026 HT4211 1553 LAMB3,laminin, GGCTGTGAAC[C/T]GTGTGCCTGC M C T P L beta 3 (nicein (125 kD),kalinin (140 kD), BM600 (125 kD)) G4038u10 WIAF-14029 HT4211 3562 LANB3,laminin, CCTGACAGGA[C/T]TGGAGAAGCG S C T L L beta 3 (nicein (125 kD),kalinin (140 kD), BM600 (125 kD)) G4038u11 WIAF-14030 HT4211 3546 LAMB3,laminin, TGCTGCGCTC[A/G]GCGGACCTGA S A G S S beta 3 (nicein (125 kD),kalinin (140 kD), BM600 (125 kD)) G4045u1 WIAF-13571 HT0652 1266adducin, beta sub- TGGAGCAGGA[G/T]AAGCACCGGC M G T E D unit G4050u1WIAF-14106 HT1466 1366 villin CGTTTGCCAG[G/A]GCAGCCAGGC M G A G SG4050u2 WIAF-14107 HT1466 1468 villin GGTCCCAATG[G/A]GCAAGGAGCC M G A GS G4050u3 WIAF-14108 HT1466 1932 villin CCACAGAGAT[C/T]CCTGACTTCA S C TI I G4050u4 WIAF-14110 HT1466 2438 villin TTTGGGATGA[C/T]TCCACCTGCC M CT T I G4057u1 WIAF-13648 HT33633 371 CNN3, calponin 3,TTCAGGCTTA[T/C]GGTATGAAGC S T C Y Y acidic G4066u1 WIAF-13676 HT4301 654troponin T, beta, AGATTGACAA[G/A]TTCGACTTTG S G A K K skeletal G4066u2WIAF-13677 HT4301 774 troponin T, beta, GCAAAGTCGG[C/T]GCGCGCTGGA S C TG G skeletal G4066u3 WIAF-13708 HT4301 625 troponin T, beta,GGAGCTCTGG[G/C]AGACCCTGCA M G C E Q skeletal G4080u1 WIAF-14142 HT139613130 HSPG2, heparan GATTCTCCTC[G/A]GCCATCACAC S G A S S sulfate proteo-glycan 2 (perlecan) G4080u2 WIAF-14150 HT1396 10340 HSPG2, heparanTTGAGTTCCA[C/T]TGTCCTCTGC S C T H H sulfate proteo- glycan 2 (perlecan)G4080u3 WIAF-14151 HT1396 12392 HSPG2, heparan AATGCTATGA[T/C]AGCTCCCCATS T C D D sulfate proteo- glycan 2 (perlecan) G4080u4 WIAF-14152 HT13963416 HSPG2, heparan TCCCTCTGCC [C/T]GAGCAAACCG S C T P P sulfate proteo-glycan 2 (perlecan) G4080u5 WIAF-14154 HT1396 4588 HSPG2, heparanGTGCCGCTGG[T/C]GGCCAGCATC M T C V A sulfate proteo- glycan 2 (perlecan)G4080u6 WIAF-14156 HT1396 9582 HSPG2, heparan GCACAGCCAC[C/A]CCGTGCTGCAM G A A T sulfate proteo- glycan 2 (perlecan) G4096u1 WIAF-13890 HT4237394 motor protein CAAAGAAATC[G/A]ATTCAGTCGC S G A S S G4096u2 WIAF-13910HT4237 455 motor protein ATCTAAACAC[C/T]CTGCCTCACA M C T P S G4096u3WIAF-13911 HT4237 1150 motor protein CTAACCTTGT[A/G]TCTCAGTATC S A G V VG4109u1 WIAF-14034 HT28223 1238 phosphoglucomutase-TACACCGTCC[C/T]GAAGACGCAT M C T A V related protein G4109u2 WIAF-14035HT28223 1043 phosphoglucomutase- ATTATTCCTG[C/A]CCGGAACCAG M C A A Drelated protein G4112u1 WIAF-13615 HT4401 374 KIF5A, kinesinAGATGTCCTT[G/A]CTCGCTACAA M G A A T family member 5A G4112u2 WIAF-13623HT4401 2767 KIF5A, kinesin AGAGAGTTAA[G/T]GCCCTCCACC M G T K N familymember 5A G4114u1 WIAF-14113 HT4160 830 fibrinogen-likeAACTTCACCA[G/A]AACATGGCAA M G A R K protein pT49 G4118u1 WIAF-14010HT0841 564 MYL5, myosin, TCGATGTGGC[G/A]GGCAACCTGG S G A A A lightpolypeptide 5, regulatory G4118u2 WIAF-14011 HT0841 368 MYL5, myosin,TTCACCATGT[T/C]TCTGAACCTG M T C F S light polypeptide 5, regulatoryG4118u3 WIAF-14012 HT0841 533 MYL5, myosin, GAGGTGGACC[A/G]GATGTTCCAG MA G Q R light polypeptide 5, regulatory G4122u1 WIAF-13955 HT97538 161myosin-I TCGAGAACCT[A/G]CGCCCCCGAT S A G L L G4124u1 WIAF-13895 HT09251517 TCM3, transgluta- TCGCTCGCAT[G/A]CTGGCACTAG M G A M I minase 3 (Epoly- peptide, protein- glutamine gamma- glutamyl- transferase) G4124u2WIAF-13896 HT0925 1433 TCM3, transgluta- AACCCAACAC[G/A]CCATTTGCCC S G AT T minase 3 (E poly- peptide, protein- glutamine-gamma- glutamyl-transferase) G4126u1 WIAF-13830 HT2465 1035 myosin bindingACTCGTACTC[C/G]TTCCGGCTCT S C G S S protein H G4126u2 WIAF-13853 HT2465369 myosin binding AGAGAGGCAC[G/C]CTCGGAGTGG M G C G A protein H G4130u1WIAF-13614 HT1657 198 CFL1, cofilin 1 CTGTCCACGA[T/C]CCCTACGCCA S T C DD (non-muscle) G4138u1 WIAF-13598 HT33664 601 MAGP2: Microfibril-GAAAGATGAG[C/T]TTTCCCGTCA M C T L F associated glyco- protein-2 G4138u2WIAF-13599 HT33664 405 MAGP2: Microfibril- ATGACTTGGC[C/T]TCCCTCAGTC S CT A A associated glyco- protein-2 G4138u3 WIAF-13600 HT33664 327 MAGP2:Microfibril- AAGATCCTAA[T/C]CTGCTGAATG S T C N N associated glyco-protein-2 G4159u1 WIAF-14048 HT3443 1119 SNL, singedGCTGCTACTT[T/C]GACATCGACT S T C F F (Drosophila)-like (sea urchin fascinhomolog like) G4170u1 WIAF-13580 HT5069 1131 Golgi protein,GAAATATACC[A/G]TAAGTATCGA M A G I V peripheral, brefeldin A- sensitiveG4170u2 WIAF-13581 HT5069 930 Golgi protein, GTATAATAAA[C/T]TCCTGGACTT MC T L F peripheral, brefeldin A- sensitive G4170u3 WIAF-13582 HT50692312 Golgi protein, AGCAGCCTTA[A/G]GCATCTTGGA N A G * * peripheral,brefeldin A- sensitive G4170u4 WIAF-13596 HT5069 359 Golgi protein,TCAACCACGT[T/G]TCTGTGCCTT S T G L L peripheral, brefeldin A- sensitiveG4170u5 WIAF-13597 HT5069 1007 Golgi protein, AAAAAGCCAA[T/A]ACTGTTCCTGM T A N K peripheral, brefeldin A- sensitive G4171u1 WIAF-13688 HT1587667 KIF5B, kinesin TTTTTAATTA[T/C]ATTTACTCCA S T C Y Y family member 5BG4171u2 WIAF-13689 HT1587 1036 KIF5B, kinesin TTAGTAAAAC[T/C]GGAGCTGAAGS T C T T family member SB G4176u1 WIAF-14204 HT33754 130 TNR, tenascinR GCTCATTGGC[G/A]TCAACCTGAT M G A V I (restrictin, janusin) G4176u2WIAF-14205 HT33754 463 TNR, tenascin R CTGTCCATGT[G/T]CCAGTTCAGC M G T AS (restrictin, janusin) G4176u3 WIAF-14206 HT33754 249 TNR, tenascin RACTACAACAC[G/A]TCCAGCAAAC S G A T T (restrictin, janusin) G4176u4WIAF-14208 HT33754 2009 TNR, tenascin R CTGGTCCCCA[G/A]CGCCATTGGT M G AR K (restrictin, janusin) G4176u5 WIAF-14209 HT33754 2175 TNR, tenascinR CAGCCTCCTC[G/A]GAGACCTCCA S G A S S (restrictin, janusin) G4176u6WIAF-14210 HT33754 3318 TNR, tenascin R AATCCACCGA[C/T]GGAAGCCGCA S C TD D (restrictin, janusin) G4176u7 WIAF-14211 HT33754 3221 TNR, tenascinR CCGGCAAACC[T/C]GACAGCCAGT M T C L P (restrictin, janusin) G4176u8WIAF-14217 HT33754 1635 TNR, tenascim R TCTCGGACAC[C/TI GTGGCTTTTG S C TT T (restrictin, janusin) G4178u1 WIAF-14138 HT0224 2827 ACTN2, actinin,GCTGCGTTCT[C/T]TTCCGCACTC M C T S F alpha 2 G4178u2 WIAF-14139 HT02242818 ACTN2, actinin, CTGGATTACG[C/T]TGCGTTCTCT M C T A V alpha 2 G418u1WIAF-11750 L07594 2370 TGFBR3, trans- GAGTGCACTT[C/T]CCTATCCCGC S C T FF forming growth factor, beta receptor III (betaglycan, 300 kD) G418u2WIAF-11751 L07594 2586 TGFBR3, trans- AGAAGACGTT[C/T]ACCAACCCCC S C T FF forming growth factor, beta receptor III (betaglycan, 300 kD) G418u3WIAF-11752 L07594 2671 TGFBR3, trans- AATTTCTCCA[C/T]CAATTTTCCA M C T PS forming growth factor, beta receptor III (betaglycan, 300 kD) G418u4WIAF-11771 L07594 438 TGFBR3, trans- TGTCTGAACT[C/T]TCACCTCTCA S G T L Lforming growth factor, beta receptor III (betaglycan, 300 kD) G418u5WIAF-11744 L07594 392 TGFBR3, trans- CTGATCAGCT[T/C]CTGTTTAGCC M T C F Sforming growth factor, beta receptor III (betaglycan, 300 kD) G418u6WIAF-11772 L07594 1470 TGFBR3, trans- AGCTACGGAT[C/T]CTGCTGGACC S C T II forming growth factor, beta receptor III (betaglycan, 300 kD) G418u7WIAF-11773 L07594 1170 TGFBR3, trans- TCTTGAAGTG[C/A]AAAAACTCTG N C AC * forming growth factor, beta receptor III (betaglycan, 300 kD) G418u8WIAF-11745 L07594 1463 TGFBR3, trans- CCTCCTGAGC[T/C]ACGGATCCTC M T C LP forming growth factor, beta receptor III (betaglycan, 300 kD) G418u9WIAF-11746 L07594 2211 TGFBR3, trans- ATGTTGAGGT[A/G]TCTGTTACTA S A G VV forming growth factor, beta receptor III (betaglycan, 300 kD) G4181u1WIAF-14207 HT2008 425 SPTBN1, spectrin, CTCTGCGCGG[C/T]TTTTTCAGCG M C TL F beta, non- erythrocytic 1 G4181u2 WIAF-14213 HT2008 3565 SPTBN1,spectrin, ACACAGCGAT[C/T]GCCTCGGAGG S C T I I beta, non- erythrocytic 1G4181u3 WIAF-14218 HT2008 1258 SPTBN1, spectrin,ACCTTCTGGA[A/G]TGCATTGAAC S A G E E beta, non- erythrocytic 1 G4181u4WIAF-14219 HT2008 1780 SPTBN1, spectrin, AGCTCGAGGC[C/T]GAGAATTACC S C TA A beta, non- erythrocytic 1 G4181u5 WIAF-14220 HT2006 3637 SPTBN1,spectrin, ACATCAAGAA[T/C]GAGATCGACA S T C N N beta, non- erythrocytic 1G4183u1 WIAF-13976 HT2640 404 TPM4, tropomyosin 4CCAAGCACAT[T/C]GCGGAAGAGG S T C I I G4185u1 WIAF-13554 HT3451 257 MFAP1,micro- AAGGCCAGAC[T/C]ATGCCCCTAT M T G Y D fibrillar- associated protein1 G4185u2 WIAF-13555 HT3451 1108 MFAP1, micro- CCAACAAAGC[T/C]GTTAAGGGCAS T G A A fibrillar- associated protein 1 G4185u3 WIAF-13570 HT3451 274MFAP1, micro- CTATGCAGTC[C/T]TCAGATCACG S C T S S fibrillar- associatedprotein 1 G4196u1 WIAF-13665 HT97558 941 NUP88, nucleoporinGGGTCCATTG[C/A]CCATGCATCT M C A A D 88 kD G4196u2 WIAF-13666 HT975581092 NUP8B, nucleoporin ATGACCACAC[G/A]TCAGAAAACT S G A T T 88 kDG4196u3 WIAF-13667 HT97558 1551 NUP88, nucleoporinTCCATCCAGC[C/A]TCTCCTCCCC S G A A A 88 kD G4196u4 WIAF-13668 HT975582220 NUP88, nucleoporin AGGGTGAACA[T/C]ATAAGCCAAA S T C H H 88 kDG4196u5 WIAF-13669 HT97558 2205 NUP88, nucleoporinCCATCCTGAA[A/G]GAGGAGGGTG S A G K K 88 kD G4208u1 WIAF-13921 HT1122 1329VCL, vinculin TCATCCTAAA[G/C]AAAGAGATCA M G C E Q G4208u2 WIAF-13922HT1122 2438 VCL, vinculin CCATCTCCCC[A/G]ATGGTGATGC S A G P P G4208u3WIAF-13941 HT1122 818 VCL, vinculin GCCATCAAGA[T/C]GCCTGCGCCA S T C D DG4208u4 WIAF-13942 HT1122 1556 VCL, vinculin AACCACAGCG[C/A]TCGATTGATA SG A R R G4213u1 WIAF-13605 HT2813 163 NUP153, nucleoporinGCCAGGCTCC[T/C]TACAAAGATA S T C L L 153 kD G4213u2 WIAF-13606 HT2813 742NUP153, nucleoporin GAATTCTTCA[A/C]TCCTTAAAAC M A G I V 153 kD G4213u3WIAF-13609 HT2813 1800 NUP153, nucleoporin TTACACCTGC[A/C]GAAATCCTCA S AC A A 153 kD G4213u4 WIAF-13627 HT2813 1829 NUP153,nucleoporinAGTGTTCTAG[A/C]TATTCTCAAA M A C D A 153 kD G4213u5 WIAF-13632 HT28133258 NUP153, nucleoporin CTTTTCCCAA[C/T]GTGGAGCCTC S C T N N 153 kDG4213u6 WIAF-13635 HT2813 4162 NUP153, nucleoporinCTCTGCAACA[A/C]CTCCTAATTC M A G T A 153 kD G4218u1 WIAF-13854 HT16811122 phosphatidyl- AACCTTATTA[T/C]TTTATCTCAC M T C I T inositol glycan,class A G4223u1 WIAF-14160 HT1684 1434 CD36L2, CD36ATTAGATGAC[T/C]TTGTTGAAAC M T C F L antigen (collagen type I receptor,thrombospondin receptor)-like 2 (lysosomal integral membrane protein II)G4223u2 WIAF-14173 HT1684 696 CD36L2, CD36 GTGGTCCCAC[G/A]TGCACTTCCT M GA V M antigen (collagen type I receptor, thrombospondin receptor)-like 2(lysosomal integral membrane protein II) G4223u3 WIAF-14174 HT1684 986CD36L2, CD36 CAGACAAGTC[C/T]AATATCATTA S C T C C antigen (collagen typeI receptor, thrombospondin receptor)-like 2 (lysosomal integral membraneprotein II) G4223u4 WIAF-14176 HT1684 1437 CD36L2, CD36AGATGACTTT[G/A]TTGAAACGCG M G A V I antigen (collagen type I receptor,thrombospondin receptor)-like 2 (lysosomal integral membrane protein II)G4227u1 WIAF-14056 HT1929 912 proteoglycan 2 ATCCCTCCAA[C/A]AAACATCCCC SC A K K G4227u2 WIAF-14057 HT1929 1254 proteoglycan 2CGAACTTTCC[C/A]TACTCCCCTC S C A A A G4227u3 WIAF-14058 HT1929 1321proteoglycan 2 CCCAGCACCC[T/C]ACTCCCCTCC M T C Y H G4229u1 WIAF-13961HT1689 74 SDC4, syndecan 4 CCTGCTCCTC[T/C]TCTTCCTACC M T C F L(amphiglycan, ryudocan) G4230u1 WIAF-13525 HT4995 602 TRAM proteinCCATAACCTC[A/C]TGACATTTCA M A C M L G4243u1 WIAF-14169 HT2901 406 KRT17,keratin 17 ACCTCCACCT[C/A]AACATCCCTC S G A V V G4243u2 WIAF-14170 HT2901478 KRT17, keratin 17 ACACCACAAT[T/C]CACCACCTCC S T C I I G4243u3WIAF-14171 HT2901 389 KRT17, keratin 17 GGAGGAGGCC[A/C]ACACTGAGCT M A GN D G4243u4 WIAF-14178 HT2901 564 KRT17, keratin 17CTGGCTGCTC[A/C]TGACTTCCGC M A C D A G4244u1 WIAF-14086 HT1056 386clathrin, light ATCGATTGCA[G/C]TCAGAGCCTG M G C Q H polypeptide aG4246u1 WIAF-14044 HT97492 259 SLN, sarcolipin GTCCTATCAC[T/C]ACTGAGAGGCM T C Y H G4246u2 WIAF-14045 HT97492 189 SLN, sarcolipinACACCCGGGA[G/A]CTGTTTCTCA S G A E E G4254u1 WIAF-13546 HT3393 86 TNNI2,troponin I, ACCTGAAGAG[C/T]CTGATCCTGC S C T S S skeletal, fast G4254u2WIAF-13553 HT3393 530 TNNI2, troponin I, skeletal, fastTCGAGGAGAA[G/C]TCTGGCATGG M G C K N G4255u1 WIAF-13644 HT2907 562 CRYAB,crystallin, AGTTCCACAG[G/A]AAATACCGGA S G A R R alpha B G4255u2WIAF-13645 HT2907 367 CRYAB, crystallin, CCTCCTTCCT[G/A]CGGCCACCCA S G AL L alpha B G4255u3 WIAF-13872 HT2907 271 CRYAB, crystallin,CCAGCCGCCT[C/T]TTTGACCAGT S C T L L alpha B G4255u4 WIAF-13873 HT2907580 CRYAB, crystallin, GGATCCCAGC[T/C]GATGTAGACC S T C A A alpha BG4257u1 WIAF-14052 HT1694 394 PIGF, TAGAGTTGGC[A/G]TTGGAAACAT S A G A Aphosphatidylinositol glycan, class F G4257u2 WIAF-14053 HT1694 252 PIGF,TATTTAGTAG[T/C]GAAACCAAAT M T C V A phosphatidylinositol glycan, class FG4257u3 WIAF-14069 HT1694 291 PIGF, TCATTATCAC[A/G]CAAGGTAACT M A G H Rphosphatidylinositol glycan, class F G4264u1 WIAF-13519 HT0968 1720TJP1, tight CGGTCAGTGG[C/T]TTCCAGCCAG M C T A V junction protein 1 (zonaoccludens 1) G4264u2 WIAF-13520 HT0968 2272 TJP1, tightCATGCTGATG[A/C]TCACACACCT M A G D G junction protein 1 (zonaoccludens 1) G4264u3 WIAF-13529 HT0968 5408 TJP1, tightAGCCTCCTGA[A/T]GCTGATGGTG M A T E D junction protein 1 (zonaocciudens 1) G434u1 WIAF-11748 M21121 286 SCYA5, smallTACATCAACT[C/T]TTTGGAGATG M C T S F inducible cytokine A5 (RANTES)G434u2 WIAF-11749 M21121 137 SCYA5, small GCTTTGCCTA[C/T]ATTGCCCGCC S CT Y Y inducible cytokine A5 (RANTES) G435u1 WIAF-11741 M31933 754FCGR2B, Fc fragment GTCACTGGGA[T/C]TGCTGTAGCC M T C I T of IgG, lowaffinity IIb, receptor for (CD32) G435u2 WIAF-11743 M31933 395 FCGR2B,Fc fragment GGGAGTACAC[G/A]TGCCAGACTG S G A T T of IgG, low affinityIIb, receptor for (CD32) G435u3 WIAF-11742 M31933 673 FCGR2B, Fcfragment TACACGCTGT[T/A]CTCATCCAAG M T A F Y of IgG, low affinity IIb,receptor for (CD32) G4369u1 WIAF-13728 HT0900 1176 GBE1, glucanTTACGTCCAT[G/A]CTTTATCATC M G A M I (1,4-alpha-), branching enzyme 1(glycogen branching enzyme, Andersen disease, glycogen storage diseasetype IV) G4369u2 WIAF-13729 HT0900 1609 GBE1, glucanGAGTGTCCTG[A/G]CTCCTTTTAC M A G T A (1,4-alpha-), branching enzyme 1(glycogen branching enzyme, Andersen disease, glycogen storage diseasetype IV) G4373u1 WIAF-13559 HT0940 1117 HSD17B2, hydroxy-GCCAGCAAGG[A/T]CTTCTCTCCG M A T D V steroid (17-beta) dehydrogenase 2G4373u2 WIAF-13560 HT0940 1195 HSD17B2, hydroxy-CCAGGGAAAG[G/A]CGCTTACTTG M G A G D steroid (17-beta) dehydrogenase 2G438u1 WIAF-11830 M63121 583 TNFRSF1A, tumor ACCGTGTGTG[G/A]CTGCAGGAAG MG A G D necrosis factor receptor super- family, member 1A G438u2WIAF-11790 M63121 618 TNFRSF1A, tumor TTATTGGACT[G/A]AAAACCTTTT M G A EK necrosis factor receptor super- family, member 1A G440u1 WIAF-11806M74447 261 TAP2, transporter TGCTAAAGCT[A/G]AGAGGGCTGC S A G L L 2, ABC(ATP binding cassette) G440u2 WIAF-11807 M74447 2089 TAP2, transporterCAGGCTGCAG[G/A]CAGTTCAGCG M G A A T 2, ABC (ATP binding cassette) G440u3WIAF-11808 M74447 2155 TAP2, transporter TGCCCAGCTC[C/T]AGGAGGGACA N C TQ * 2, ABC (ATP binding cassette) G440u4 WIAF-11818 M74447 1789 TAP2,transporter GAACAACATT[G/A]CTTATGGGCT M G A A T 2, ABC (ATP bindingcassette) G440u5 WIAF-11819 M74447 1565 TAP2, transporterAAGGGGCTGA[C/T]GTTTACCCTA M C T T M 2, ABC (ATP binding cassette) G440u6WIAF-11820 M74447 1254 TAP2, transporter TGCACTTGGG[G/T[GTCCACATCC S C TG G 2, ABC (ATP binding cassette) G440u7 WIAF-11788 M74447 1231 TAP2,transporter GTACCTGCTC[A/C]TAACCAGGCT M A G I V 2, ABC (ATP bindingcassette) G440u8 WIAF-11821 M74447 1404 TAP2, transporterTGCTCAGCAA[C/T]GTGGGAGCTC S C T N N 2, ABC (ATP binding cassette) G440u9WIAF-11783 M74447 2187 TAP2, transporter CCCGCCTGGT[T/C]CAGCACCGGC S T GV V 2, ABC (ATP binding cassette) G440u10 WIAF-11786 M74447 1825 TAP2,transporter TGATAAGGTG[A/G]TGGCGGCTGC M A G M V 2, ABC (ATP bindingcassette) G4400u1 WIAF-14007 HT97396 839 A33 GCCAATCAAA[G/T]GACGGCTCAC MG T K N G4404u1 WIAF-14013 HT1215 109 ACP2, acidCCGCCCACCC[G/A]GGCCCGGAGT M G A R Q phosphatase 2, lysosomal G4404u2WIAF-14016 HT1215 1271 ACP2, acid ACCGCCACGT[C/T]GCAGATGGGG S C T V Vphosphatase 2, lysosomal G4406u1 WIAF-13661 HT3564 872 ACPP, acidACAAAAAACT[T/C]ATCATGTATT S T C L L phosphatase, prostate G4406u2WIAF-13662 HT3564 839 ACPP, acid ATCACATGAA[G/A]AGAGCAACTC S G A K Kphosphatase, prostate G4406u3 WIAF-13881 HT3564 741 ACPP, acidAGAATTGTCA[G/T]AATTGTCCCT N G T E * phosphatase, prostate G441u1WIAF-10166 M77349 698 TGFBI, transforming GTGCCCGGCT[C/G]CTGAAAGCCG S CG L L growth factor, beta-induced, 68 kD G441u2 WIAF-10168 M77349 1028TGFBI, transforming GCCTCTCTGT[A/G]CAGACCCTGG S A G V V growth factor,beta-induced, 68 kD G441u3 WIAF-10169 M77349 1667 TGFBI, transformingACACAGTCTT[T/C]GCTCCCACAA S T C F F growth factor, beta-induced, 68 kDG441u4 WIAF-10171 M77349 1463 TGFBI, transformingGTAATAGCCT[C/T]TGCATTGAGA S C T L L growth factor, beta-induced, 68 kDG4411u1 WIAF-14005 HT97468 492 acyl-CoA GCTCACCAAT[A/G]AGGCCACCCT M A GK E G4411u2 WIAF-14008 HT97468 1076 acyl-CoA TGCCCCACAC[C/T]GAGGACGAGA SC T T T G4412u1 WIAF-13576 HT1882 657 ACADS, acyl-GCAAAACAAG[G/A]GCATCAGTGC M G A G S Coenzyne A dehydrogenase, C-2 to C-3short chain G4412u2 WIAF-13579 HT1882 1022 ACADS, acyl-TGACCTGGCC[C/T]GCTGCCATGC S C T R R Coenzyme A dehydrogenase, C-2 to C-3short chain G4415u1 WIAF-14080 HT2503 2170 acyl-Coenzyme A:TCATTATATT[C/T]GAGCAGATTC S C T F F cholesterol acyltransferase G4415u2WIAF-14081 HT2503 1993 acyl-Coenzyme A: TTTCAGTTCC[C/T]TATTTTCTGT S C TP P cholesterol acyltransferase G4415u3 WIAF-14098 HT2503 2006acyl-Coenzyme A: TTTTCTGTTT[C/G]AACATTGGCG M C G Q E cholesterolacyltransferase G4415u4 WIAF-14101 HT2503 2365 acyl-Coenzyme A:GGGGTTATGT[C/T]GCTATGAAGT S C T V V cholesterol acyltransferase G4417u1WIAF-13819 HT0542 356 AOAH, acyloxyacyl TCCAGCCAAC[G/A]ATGACCAGTC M G AD N hydrolase (neutro- phil) G4417u2 WIAF-13820 HT0542 340 AOAH,acyloxyacyl TTCAGTCCTC[G/A]GCCTCTCCAG S G A S S hydrolase (neutrophil)G4417u3 WIAF-13824 HT0542 1595 AOAH, acyloxyacylGCTAAATAAA[G/A]ACATGACCTA M G A D N hydrolase (neutrophil) G4417u4WIAF-13841 HT0542 382 AOAH, acyloxyacyl CCAGCCTCTC[G/A]AATGGGCACA S G AS S hydrolase (neutrophil) G4417u5 WIAF-13842 HT0542 458 AOAH,acyloxyacyl CAACTCGACG[G/A]TCCAGGCCTC M G A V I hydrolase (neutrophil)G4417u6 WIAF-13843 HT0542 1201 AOAH, acyloxyacylGATTTCTGGA[C/T]TCCACTGTTG S C T D D hydrolase (neutrophil) G4417u7WIAF-13844 HT0542 1321 AOAH, acyloxyacyl ACCTGAAGAA[A/G]TTTATAGAAA S A GK K hydrolase (neutrophil) G4417u8 WIAF-13845 HT0542 1404 AOAH,acyloxyacyl GATGTCTCCA[G/A]TCGGAACAGT M G A S N hydrolase (neutrophil)G4417u9 WIAF-13846 HT0542 1759 AOAH, acyloxyacylAATTTACAAA[C/T]TTCAATCTTT S C T N N hydrolase (neutrophil) G4417u10WIAF-13847 HT0542 1644 AOAH, acyloxyacyl CTCCAGGTCA[G/A]CCCCTGCCAC M G AS N hydrolase (neutrophil) G442u1 WIAF-11828 M94582 933 IL8RA,interleukin CACATCGACC[G/A]GGCTCTCGAT M G A R Q 8 receptor, alpha G442u2WIAF-11829 M94582 721 IL8RA, interleukin TCATCGTGCC[A/G]CTGCTGATCA S A GP P 8 receptor, alpha G442u3 WIAF-11780 M94582 1027 IL8RA, interleukinGCCATGGACT[C/T]CTCAAGATTC S C T L L 8 receptor, alpha G442u4 WIAF-11792M94582 78 IL8RA, interleukin ATGGACAGTC[A/C]CAGCTTTGAA M A G D G 8receptor, alpha G4423u1 WIAF-13752 HT2216 71 ADSL,GCTATGCCAG[C/T]CCGGAGATGT S C T S S adenylosuccinate lyase G4423u2WIAF-13794 HT2216 126 ADSL, ATGGCGCCAG[C/T]TGTGGCTGTG S C T L Ladenylosuccinate lyase G4423u3 WIAF-13795 HT2216 674 ADSL,AGCTTGACAA[G/A]ATGGTCACAG S G A K K adenylosuccinate lyase G4428u1WIAF-13954 HT97524 57 ADFP, adipose TGGTCAACCT[C/A]CCCTTGGTGA S G A L Ldifferentiation related protein; adipophilin G4434u1 WIAF-13506 HT0863551 ARF3, ADP- TCTGGAGACA[C/T]TACTTCCAGA S C T H H ribosylation factor 3G444u1 WIAF-10172 U28694 398 CCR3, chemokine CGACATCTTT[T/G]TCATAATCCT MT G F V (C-C motif) receptor 3 G444u2 WIAF-10181 U28694 214 CCR3,chemokine TCCTCATAAA[A/C]TACAGGAGGC S A G K K (C-C motif) receptor 3G4440u1 WIAF-14054 HT1392 136 ADRBK1, adrenergic,GCAAGAAGAT[A/C]CTGCTGCCCG S A G I I beta, receptor kinase 1 G445u1WIAF-10183 U40373 319 Human cell TAGAAGGCCA[C/T]CTGGTGATTC S C T H Hsurface glyco- protein CD44 mRNA, complete cds. G4456u1 WIAF-13629HT0626 796 ALDOC, aldolase C, CCCTGCTCAA[G/A]CCCAACATCC S G A K Kfructose- bisphosphate G446u1 WIAF-11832 U64198 754 IL12RB2, inter-TGAACCCTTC[C/G]CATGTAATTT S C G S S leukin 12 receptor, beta 2 G446u2WIAF-11795 U64198 2569 IL12RB2, inter- TTTTCTCAAC[G/A]CATTACTTCC S G A TT leukin 12 receptor, beta 2 G446u3 WIAF-11833 U64198 2500 IL12RB2,inter- TGCAACGTAA[A/C]CCCAATTGCA S A G K K leukin 12 receptor, beta 2G446u4 WIAF-11835 U64198 1918 IL12RB2, inter- CTCCTCGCCA[G/C]CTCTCTGCAAM G C Q H leukin 12 receptor, beta 2 G446u5 WIAF-11793 U64198 991IL12RB2, inter- GTGGAGCAGA[C/A]ATCTTCGTTC S G A E E leukin 12 receptor,beta 2 G446u6 WIAF-11794 U64198 2469 IL12RB2, inter-AGTTCCCACC[G/C]AAATGAGAGG M G C G A leukin 12 receptor, beta 2 G446a7WIAF-13128 U64198 1964 IL12RB2, inter- GGTGACTTGG[C/g]AGCCTCCCAG M C g QE leukin 12 receptor, beta 2 G446a8 WIAF-13129 U64198 2060 IL12RB2,inter- TCTAAACTGG[C/G]TACCCACTCG M C G L V leukin 12 receptor, beta 2G447u1 WIAF-11796 X03663 384 CSF1R, colony CCAGTGTCCC[C/T]GAGCTGGTCG S CT P P stimulating factor 1 receptor, formerly McDonough feline sarcomaviral (v-fms) oncogene homolog G447u2 WIAF-11836 X03663 1026 CSF1R,colony ACAACAACAC[T/C]AAGCTGCCAA S T C T T stimulating factor 1receptor, formerly McDonough feline sarcoma viral (v-fms) oncogenehomolog G447u3 WIAF-11837 X03663 886 CSF1R, colonyCCTCAAAGTG[C/A]ACAAACTCAT M C A Q K stimulating factor 1 receptor,formerly McDonough feline sarcoma viral (v-fms) oncogene homolog G447u4WIAF-11797 X03663 2425 CSF1R, colony GAAGAAATAT[G/A]TCCGCAGGGA M G A V Istimulating factor 1 receptor, formerly McDonough feline sarcoma viral(v-fms) oncogene homolog G4473u1 WIAF-13904 HT1352 860 FUCA1,TTCAAGCCAC[A/G]GAGCTTGCCA M A G Q R fucosidase, alpha-L- 1, tissueG4473u2 WIAF-13916 HT1352 440 FUCA1, ACAAACTGGC[C/T]GAGTCCTGTG M C T P Lfucosidase, alpha-L- 1, tissue G4479u1 WIAF-13637 HT1995 2465 AMPD2,adenosine GCCTCAATGA[G/T]CCTGGTCCAT — G T — — monophosphate deaminase 2(isoform L) G4479u2 WIAF-13866 HT1995 1258 AMPD2, adenosineTGGATGTGCA[T/C]GCGGACAGGA S T C H H monophosphate deaminase 2 (isoformL) G4479u3 WIAF-13867 HT1995 1280 AMPD2, adenosineCACTTTCCAT[C/T]CCTTTGACAA M C T R C monophosphate deaminase 2 (isoformL) G4479u4 WIAF-13868 HT1995 1201 AMPD2, adenosineTGCGGGAGGT[C/T]TTTGAGAGCA S C T V V monophosphate deaminase 2 (isoformL) G4479u5 WIAF-13869 HT1995 1579 AMPD2, adenosineGTACCAAGGG[C/T]CAGCTGGCCA S C T G G monophosphate deaminase 2 (isoformL) G4492u1 WIAF-14084 HT3390 866 ANX11, annexinCCTGGGGAGT[C/T]GCTCCAACAA M C T R C XI (56 kD autoantigen) G4492u2WIAF-14085 HT3390 850 ANX11, annexin AGGCCATCAT[T/C]GACTGCCTGG S T C I IXI (56 kD autoantigen) G450u1 WIAF-10170 X85740 1196 CCR4, chemokineTCCAAATTTA[C/T]TCTGCTGACA S C T Y Y (C-C motif) receptor 4 G4502u1WIAF-13510 HT4840 165 ASS, AAGCCTATGA[C/T]GTCATTGCCT S C T D Dargininosuccinate synthetase G4502u2 WIAF-13511 HT4840 369 ASS,GGCCCTGCAT[C/T]GCCCGCAAAC S C T I I argininosuccinate synthetase G4502u3WIAF-13512 HT4840 73 ASS, AATCCCAGAC[G/A]CTATGTCCAC — G A — —argininosuccinate synthetase G4502u4 WIAF-13513 HT4840 129 ASS,TGGACACCTC[G/C]TGCATCCTCG S G C S S argininosuccinate synthetase G4502u5WIAF-13514 HT4840 285 ASS, AGTTTGTGGA[G/A]GAGTTCATCT S G A E Eargininosuccinate synthetase G4502u6 WIAF-13515 HT4840 234 ASS,AGGCACTGAA[C/A]CTTGGGGCCA S G A K K argininosuccinate synthetase G4502u7WIAF-13516 HT4840 316 ASS, CCAGTCCAGC[G/A]CACTGTATGA N G A A Targininosuccinate synthetase G4502u8 WIAF-13537 HT4840 426 ASS,TGTCCCACGG[C/T]GCCACAGGAA S C T G G argininosuccinate synthetase G4502u9WIAF-13538 HT4840 530 ASS, GAATTCTACA[A/C]CCGGTTCAAG M A G N Sargininosuccinate synthetase G4502u10 WIAF-13539 HT4840 750 ASS,TTCTCGACAT[C/T]GAGTTCAAAA S C T I I argininosuccinate synthetaseG4502u11 WIAF-13540 HT4840 960 ASS, ATGCTCATTT[A/G]GACATCGAGG S A G L Largininosuccinate synthetase G4508u1 WIAF-13663 HT28557 1767 ARSD,CAGTTTTCCA[T/C]GAGCAACATC M T C M T arylsulfatase D G4508u2 WIAF-13693HT28557 433 ARSD, TTCAGTGGAA[C/T]GCAGGCTCAG S C T N N arylsulfatase DG4508u3 WIAF-13694 HT28557 747 ARSD, GGTTTCTTCT[C/G]TGTCTCCGCG M C G S Carylsulfatase D G4508u4 WIAF-13696 HT28557 1012 ARSD,CCAGCACTGC[A/C]TTCCTGGGGA S A G A A arylsulfatase D G4508u5 WIAF-13697HT28557 1302 ARSD, CGAGTGATTG[G/A]AGAGCCCACG M G A G E arylsulfatase DG4508u6 WIAF-13698 HT28557 1285 ARSD, GGGTGCTCCC[G/A]GCCCGCCGAG S G A PP arylsulfatase D G4508u7 WIAF-13699 HT28557 1807 ARSD,AGCCGTGCTG[C/T]GGACATTTCC S C T C C arylsulfatase D G4508u8 WIAF-13718HT28557 483 ARSD, GCAAGAATCT[T/C]GCAGCAGCAT M T C L S arylsulfatase DG4518u1 WIAF-13809 HT3430 515 ASPA, ACAACACCAC[C/T]TCTAACATGG S C T T Taspartoacylase (aminoacylase 2, Canavan disease) G4518u2 WIAF-13810HT3430 851 ASPA, AACTTCATTA[C/T]CCCCGGGATC S C T Y Y aspartoacylase(aminoacylase 2, Canavan disease) G4518u3 WIAF-13811 HT3430 787 ASPA,CATCATTTCA[A/G]TGAAGGAAAA M A G N S aspartoacylase (aminoacylase 2,Canavan disease) G4518u4 WIAF-13837 HT3430 618 ASPA,ACCCTGCTAC[G/A]TTTATCTGAT M G A V I aspartoacylase (aminoacylase 2,Canavan disease) G452a1 WIAF-10509 HT0695 553 APOA4,ACCCAGGTCA[A/C]CACGCAGGCC M A G N S apolipoprotein A-IV G452a2WIAF-13124 HT0695 563 APOA4, ACACGCAGGC[C/T]GAGCAGCTGC S C T A Aapolipoprotein A-IV G4524u1 WIAF-14120 HT1541 726 ATP5A1, ATPCTCAATTGCT[A/G]TTGACACAAT M A G I V synthase, H+ transporting, mito-chondrial F1 complex, alpha subunit, isoform 1, cardiac muscle G4524u2WIAF-14131 HT1541 153 ATP5A1, ATP ATCTTTCATT[G/T]CTGCAAGGAA M G T A Ssynthase, H+ transporting, mito- chondrial F1 complex, alpha subunit,isoform 1, cardiac muscle G4526u1 WIAF-14130 HT4994 400 ATP5D, ATPTCCATCGCAG[T/C]GAACGGCGAC M T C V A synthase, H+ transporting, mito-chondrial F1 complex, delta subunit G453u1 WIAF-10138 HT0768 1747PDGFRB, platelet- CTGCCGCCCA[C/T]GCTGCTGGGG M C T T M derived growthfactor receptor, beta polypeptide G453u2 WIAF-10147 HT0768 2957 PDGFRB,platelet- TTTTGCCTTT[A/G]AAGTGGATGG S A G L L derived growth factorreceptor, beta polypeptide G453u3 WIAF-10148 HT0768 3608 PDGFRB,platelet- AGCCGGAGCC[A/G]GAGCTGGAAC S A G P P derived growth factorreceptor, beta polypeptide G453u4 WIAF-10149 HT0768 457 PDGFRB,platelet- CAGGGCCTGG[T/G]CGTCACACCC M T G V G derived growth factorreceptor, beta polypeptide G453u5 WIAF-10151 HT0768 1505 PDGFRB,platelet- AGCTGACACT[G/C]GTTCGCGTGA S G C L L derived growth factorreceptor, beta polypeptide G453u6 WIAF-10153 HT0768 3446 PDGFRB,platelet- ACCCCAAACC[C/T]GAGCTTGCTG S C T P P derived growth factorreceptor, beta polypeptide G453u7 WIAF-10161 HT0768 2030 PDGFRB,platelet- TTTGGCAGAA[G/A]AAGCCACGTT S G A K K derived growth factorreceptor, beta polypeptide G4533u1 WIAF-13616 HT1618 343 ATP synthase,H+ GTTACATGAT[C/T]GACAACGTGA S C T I I transporting, subunit D, vacuolarG4534u1 WIAF-13569 HT3556 654 ATP6E, ATPase, H+TAAAGGTTTC[C/T]AACACCCTGG S C T S S transporting, lysosomal (vacuolarproton pump) 31 kD G4535u1 WIAF-13747 HT27972 357 ATP50, ATPTCACTACCAA[C/T]CTGATCAATT S C T N N synthase, H+ transporting,mitochondrial F1 complex, O subunit (oligomycin sensitivity conferringprotein) G4535u2 WIAF-13748 HT27972 144 ATP50, ATPAGGTATACGG[T/C]ATTGAAGGTC S T C G G synthase, H+ transporting,mitochondrial F1 complex, O subunit (oligomycin sensitivity conferringprotein) G4535u3 WIAF-13792 HT27972 329 ATP50, ATPATCACAGCAA[A/G]AGAGAGGTTC M A G K R synthase, H+ transporting,mitochondrial F1 complex, O subunit (oligomycin sensitivity conferringprotein) G45439u1 WIAF-13711 HT48520 288 ATPase, 14 kDaTGCCCTGGAC[G/A]CCCACCAGCA M G A A T subunit, vacuolar G4548u1 WIAF-14127HT1574 3138 ATPase, Ca2+ trans- CGCAATGTCT[T/C]TGACGGCATC M T C F Sporting membrane, isoform 2 G4548u2 WIAF-14137 HT1574 2089 ATPase, Ca2+trans- GCACTATCTG[C/T]GTGGCCTACC S C T C C porting membrane, isoform 2G4548u3 WIAF-14140 HT1574 2924 ATPase, Ca2+ trans-CAGGACCATG[A/T]TGAAGAACAT M A T M L porting membrane, isoform 2 G4549u1WIAF-14161 HT1346 524 ATP2B4, ATPase, TGCACTGACC[C/T]AGATTAATGT N C TQ * Ca++ transporting, plasma membrane 4 G4549u2 WIAF-14162 HT1346 715ATP2B4, ATPase, ATGTCACGCT[C/T]ATCATCCTGC S C T L L Ca++ transporting,plasma membrane 4 G4549u3 WIAF-14163 HT1346 508 ATP2B4, ATPase,AGCTGCGTTC[G/A]ACGGATOCAC S G A S S Ca++transporting, plasma membrane 4G4549u4 WIAF-14166 HT1346 1084 ATP2B4, ATPase, TGATCCAACG[G/A]AATGATCTCAS G A G G Ca++ transporting, plasma membrane 4 G4552u1 WIAF-13630 HT0867710 ATP7A, ATPase, TACTAGCACT[A/G]TTGAAGGAAA M A G I V Cu++transporting, alpha polypeptide (Menkes syndrome) G456u1 WIAF-100741HT2834 408 EDN1, endothelin 1 CCTGGCGGCT[T/G]CGCCGGTCCA S T G L L G456u2WIAF-10075 HT2834 585 EDN1, endothelin 1 CAGACCGTGA[A/G]AATAGATGCC S A GE E G456a3 WIAF-10507 HT2834 861 EDN1, endothelin 1TGAAAGGCAA[T/G]CCCTCCAGAG M T G K N G4565u1 WIAF-14041 HT28561 320ATP1G1, ATPase, CGAGGCTGCT[G/A]TTACGGCTCA S G A L L Na+/K+ transporting,gamma 1 polypeptide G4565u2 WIAF-14062 HT28561 216 ATP1G1, ATPase,CAGTGACGGG[G/A]ACAAAGGTCT M G A D N Na+/K+ transporting, gamma 1polypeptide G4565u3 WIAF-14063 HT28561 315 ATP1G1, ATPase,ACCGCCGAGG[C/A]TGCTGTTACG M C A L M Na+/K+ transporting, gamma 1polypeptide G4565u4 WIAF-14064 HT28561 531 ATP1G1, ATPase,TTTCCCCAGG[T/C]GAATGGGCTG N T C * R Na+/K+ transporting, gamma 1polypeptide G4568u1 WIAF-14212 HT0082 717 AMFR, autocrineTGCCTCATGC[A/G]TACGTCCCAC M A G I V motility factor receptor G457a1WIAF-10489 HT2903 321 SELL, selectin L ACAAATCTCT[C/T]ACTGAAGAAG S C T LL (lymphocyte adhesion molecule 1) G457a2 WIAF-10490 HT2903 577 SELL,selectin L CCAGTGTCAG[T/C]TTGTGATTCA M T C F L (lymphocyte adhesionmolecule 1) G457a3 WIAF-10491 HT2903 601 SELL, selectin LTGAGCCTTTG[G/C]AGGCCCCAGA M G C E Q (lymphocyte adhesion molecule 1)G457a4 WIAF-10492 HT2903 637 SELL, selectin L CTGTACTCAC[C/T]CTTTGGGAAAM C T P S (lymphocyte adhesion molecule 1) G4573u1 WIAF-13568 HT28320943 NCAT2, mannosyl CGGACAACCT[G/T]ACCCTGCGCT S G T L L (alpha-1,6-)-glycoprotein beta- 1,2-N-acetylgluco- saminyltransferase G4574u1WIAF-13805 HT0198 163 beta-1,4 N- CGGCCTCCGG[C/G]TACCTCTTGC M C G L Vacetylgalacto- saminyltransferase G4574u2 WIAF-13806 HT0198 415 beta-1,4N- TGCCACAAGA[G/A]AGCAGGAGTT M G A E K acetylgalacto- saminyltransferaseG4574u3 WIAF-13807 HT0196 726 beta-1,4 N- AACTACAACT[G/T]GTCACTTACA S GT L L acetylgalacto- saminyltransferase G4574u4 WIAF-13836 HT0198 559beta-1,4 N- AGGGCTGAGC[C/A]TTCAGGCAGC M C A L I acetylgalacto-saminyltransferase G4575u1 WIAF-13626 HT0341 1251 GCNT1, glucosaminylAGTATGATCT[A/G]TCTGACATGC S A G L L (N-acetyl) transferase 1, core 2(beta-1,6-N- acetylgluco- saminyltransferase) G4577u1 WIAF-13971 HT14951268 SIAT1, sialyl- ATTTCTTTAA[C/T]AACTACAAGA S C T N N transferase 1(beta-galactoside alpha-2, 6- sialytransferase) G458u1 WIAF-10063 HT29681464 ALB, albumin GTGCAGAAGA[C/A]TATCTATCCG M C A D E G458u2 WIAF-10089HT2968 1470 ALB, albumin AAGACTATCT[A/C]TCCGTGGTCC S A C L L G458u3WIAF-10091 HT2968 1707 ALB, albumin TTGTTGAGCT[C/T]GTGAAACACA S C T L LG458a4 WIAF-10504 HT2968 889 ALB, albumin CAGGGCGGAC[C/T]TTGCCAAGTA M CT L F G458a5 WIAF-10508 HT2968 1475 ALB, albuminTATCTATCCG[T/A]GGTCCTGAAC M T A V E G458a6 WIAF-12091 HT2968 1330 ALB,albumin CCAGAATGCG[C/T]TATTAGTTCG S C T L L G458a7 WIAF-12092 HT29681408 ALB, albumin CCTAGGAAAA[G/a]TGGGCAGCAA M G a V M G4592u1 WIAF-14126HT2128 985 branched-chain keto ACCAGCCCTT[T/C]CTCATCGAGG S T C F F aciddehydrogenase E1, alpha poly- peptide G4593u1 WIAF-13574 HT97373 1743BARD1, ERCA1 GCTAGCCACT[G/C]CTCAGTAATG M G C C S associated RING domain1 G4593u2 WIAF-13592 HT97373 1167 BARD1, ERCA1 TGTTCTTCAC[C/T]ACCTTCATGCM C T P L associated RING domain 1 G4593u3 WIAF-13593 HT97373 1591BARD1, ERCA1 AGAATGGGCA[C/TI GTGGATATAG S C T H H associated RING domain1 G4593u4 WIAF-13594 HT97373 2030 BARD1, ERCA1 AAAGTATGAA[A/G]TTCCTGAAGGM A G I V associated RING domain 1 G4593u5 WIAF-13595 HT97373 2006BARD1, ERCA1 AAGAAAAGTA[T/C]GTGAACAGGA M T C C R associated RING domain1 G4599u1 WIAF-13920 HT4273 1803 CDH13, cadherin 13,TCGTACCCGA[C/T]GTCTCCTACG S C T D D H-cadherin (heart) G4614u1WIAF-13733 HT4835 91 S100A3, S100 AGGATGGCCA[G/A]GCCTCTGGAG M G A R Kcalcium-binding protein A3 G4614u2 WIAF-13734 HT4835 203 S100A3, S100TGCTGCAGAA[G/A]GAGCTGGCCA S G A K K calcium-binding protein A3 G4614u3WIAF-13769 HT4835 344 S100A3, S100 TCTACTGCCA[C/T]GAGTACTTCA S C T H Hcalcium-binding protein A3 G462u1 WIAF-10134 HT4753 600 PDGFA, platelet-ACGGGGTCCA[C/T]GCCACTAAGC S C T H H derived growth factor alphapolypeptide G4627u1 WIAF-14042 HT0771 186 ANX6, annexin VIGGAGGCCATA[C/T]TGGACATAAT S C T L L (p68) G4627u2 WIAF-14043 HT0771 1664ANX6, annexin VI CAGACACACC[T/C]AGTGGAGACA S T C P P (p68) G4627u3WIAF-14067 HT0771 1498 ANX6, annexin VI AAGGAGCACT[A/G]TCACAAGTCC M A GY C (p68) G4644u1 WIAF-13801 HT1736 1990 CPS1, carbamoyl-TGGTGGAGAA[G/A]TCAGTGACAG S G A K K phosphate synthetase 1,mitochondrial G4644u2 WIAF-13802 HT1736 1866 CPS1, carbamoyl-ATTGGCTACC[C/T]AGTGATGATC M C T P L phosphate synthetase 1,mitochondrial G4644u3 WIAF-13803 HT1736 1993 CPS1, carbamoyl-TGGAGAAGTC[A/C]GTGACAGGTT S A C S S phosphate synthetase 1,mitochondrial G4644u4 WIAF-13804 HT1736 1860 CPS1, carbamoyl-GACACCATTG[G/A]CTACCCAGTG M G A G D phosphate synthetase 1,mitochondrial G4644u5 WIAF-13831 HT1736 1087 CPS1, carbamoyl-AGCCTGTTTT[C/T]AATATCACAA M G T L F phosphate synthetase 1,mitochondrial G4644u6 WIAF-13835 HT1736 1958 CPS1, carbamoyl-CACAAAGGCC[T/C]TTGCTATGAC M T C F L phosphate synthetase 1,mitochondrial G4644u7 WIAF-13855 HT1736 1332 CPS1, carbamoyl-AAAGCTACCA[C/A]CATTACATCA M C A T N phosphate synthetase 1,mitochondrial G4659u1 WIAF-14143 HT1183 1830 catenin, alphaGTGCCAACGT[T/C]CCTCAACCGT S T C V V G466u1 WIAF-10164 U00968 2403SREBF1, sterol AGCAGTGCCC[C/A]CCAGGCCTGC M G A R H regulatory elementbinding transcrip- tion factor 1 G4662u1 WIAF-13710 HT2142 2183 CTNNB1,catenin TTTTGTTCCG[A/C]ATGTCTGAGG S A C R R (cadherin associatedprotein), beta 1 (88 kD) G467a1 WIAF-13304 X72861 827 ADRB3, adrenergic,GGCCATCGCC[T/C]GGACTCCGAG M T C W R beta-3-, receptor G467a2 WIAF-13305X72861 832 ADRB3, adrenergic, TCGCCTGGAC[T/A]CCGAGACTCC S T A T Tbeta-3-, receptor G467a3 WIAF-13306 X72861 870 ADRB3, adrenergic,TTCGTCACTT[C/T]CCTGGCCGCA M C T S L beta-3-, receptor G467a4 WIAF-13307X72861 1761 ADRB3, adrenergic, TGCGCCGCCG[C/T]CCGCCCCGCC M C T A Vbeta-3-, receptor G467a5 WIAF-13305 X72861 1899 ADRB3, adrenergic,TCTGTTGATC[A/C]GAACCTGTCG — A C — — beta-3-, receptor G4671u1 WIAF-13956HT1925 161 NDUFB7, NADH TGGTGGCCAC[A/C]CAGCAGGACA S A G T Tdehydrogenase (ubiquinone) 1 beta subcomplex, 7 (18 kD, B18) G4673u1WIAF-13889 HT0191 1349 CDC25A, cell TCTCGGGCCA[G/C]CCCCAAAGAC M G C S Tdivision cycle 25A G4674u1 WIAF-13821 HT1393 261 CDC25B, cellACCACCTCCC[C/T]GGGCTCGGCA S C T A A division cycle 25B G4674u2WIAF-13822 HT1393 1297 CDC25B, cell GATGGTCCCC[C/T]TATTCACGGG S C T L Ldivision cycle 25B G4674u3 WIAF-13823 HT1393 1083 CDC25B, cellATAACCCCAG[C/A]CGGAGCCTGA S G A R R division cycle 25B G4674u4WIAF-13827 HT1393 1446 CDC25B, cell AGAGCCCCAT[C/T]CCCCCCTGTA S C T I Idivision cycle 25B G468a1 WIAF-13309 L37019 192 ASIP, agoutiAAATCCAAAC[C/A]CATCGGCACA M C A P Q (mouse)-signaling protein G4691u1WIAF-13753 HT97602 179 CMKBR9, chemokine TATAGCCTGA[T/A]TTTTGTGTTG M T AI N (C-C motif) receptor 9 G4691u2 WIAF-13754 HT97602 134 CMKBR9,chemokine AAGGATGCAG[T/C]GGTCTCCTTT M T C V A (C-C motif) receptor 9G4691u3 WIAF-13755 HT97602 193 CMKBR9, chemokineTGTGTTGGGC[C/T]TCAGCGGGAA M C T L F (C-C motif) receptor 9 G4691u4WIAF-13756 HT97602 770 CMKBR9, chemokine AAAATAGCTC[C/T]AGCCTTGGTG M C TA V (C-C motif) receptor 9 G4691u5 WIAF-13759 HT97602 1130 CMKBR9,chemokine TCTCAGAACT[A/C]CCCTAACAAG M A C Y S (C-C motif) receptor 9G4691u6 WIAF-13796 HT97602 482 CMKBR9, chemokineAGGCTGAGGA[C/A]CCCGGCCAAG M C A T N (C-C motif) receptor 9 G4691u7WIAF-13797 HT97602 259 CMKBR9, chemokine GATGGTTGAG[A/G]TCTATCTGCT M A GI V (C-C motif) receptor 9 G4691u8 WIAF-13798 HT97602 434 CMKBR9,chemokine ATGACCCTGG[A/G]CAAGTACCTG M A G D G (C-C motif) receptor 9G4691u9 WIAF-13799 HT97602 755 CMKBR9, chemokineCAGGGCCGGG[C/T]TTTAAAAATA M C T A V (C-C motif) receptor 9 G4699u1WIAF-14040 HT4277 1426 BAAT, bile acid TTCCAGATGT[C/T]ACCAGTCAAC S G T VV Coenzyme A: amino acid N-acyl- transferase (glycine N-choloyltransferase) G4726u1 WIAF-14128 HT48614 1606 AOC3, amineTCCACCCCAG[T/C]GGGGCCATAG S T C S S oxidase, copper containing 3(vascular adhesion protein 1) G4726u2 WIAF-14129 HT48614 2242 AOC3,amine TTCCTAACAC[A/G]GTGACTGTGG S A G T T oxidase, copper containing 3(vascular adhesion. protein 1) G4726u3 WIAF-14141 HT48614 659 AOC3,amine CCTGCCCTAT[C/T]ACCGACGCCC M C T H Y oxidase, copper containing 3(vascular adhesion protein 1) G4744u1 WIAF-13683 HT2599 564 CTH,cystathionase ATATTGTCCA[T/C]AAGCATGGAG S T C H H (cystathioninegamma-lyase) G4748u1 WIAF-14144 HT1061 242 CYBA, cytochromeGGGACAGAAG[C/T]ACATGACCGC M C T H Y b-245, alpha polypeptide G4748u2WIAF-14145 HT1061 265 CYBA, cytochrome TGGTGAAGCT[G/C]TTCGGGCCCT S G C LL b-245, alpha polypeptide G4750u1 WIAF-14116 HT48417 156 CYB5,cytochrome TGAAGTACTA[C/T]ACCCTAGAGG S C T Y Y b-5 G4751u1 WIAF-13770HT1285 495 UQCRC2, ubiquinol- AGAATTTCGT[C/A]GTTGGGAAGT M C A R Scytochrome c reductase core protein II G4788u1 WIAF-13931 HT28249 1864DSC3, desmocollin 3 CTGTTGATCC[T/C]GATGAACCTG S T C P P G4788u2WIAF-13933 HT28249 2000 DSC3, desmocollin 3 TGGATTTCAA[G/T]AATATACCAT NG T E * G4788u3 WIAF-13945 HT28249 2524 DSC3, desmocollin 3ACACTTACTC[G/A]GAGTGGCACA S G A S S G479u1 WIAF-12567 U36310 894 GPD2,glycerol-3- GGGAAAGTCC[A/G]TGTGACCGGC M A G H R phosphate dehydrogenase2 (mitochondrial) G479u2 WIAF-12574 U36310 1657 GPD2, glycerol-3-CTGGCAAAAG[G/T]TGGCCTATTG M G T R S phosphate dehydrogenase 2(mitochondrial) G479u3 WIAF-12575 U36310 1131 GPD2, glycerol-3-GTTATTTTCT[T/C]CTTACCCTGG M T C F S phosphate dehydrogenase 2(mitochondrial) G480u1 WIAF-12175 HT336 250 GRB2, growthAATGAAACCA[C/A]ATCCGTGGTT M C A H N factor receptor- hound protein 2G4819u1 WIAF-13985 HT97576 1804 EYA1, eyes absentCCCTGCACCA[T/C]GCCTTGGAAC S T C H H (Drosophila) homolog 1 G482u1WIAF-12181 J04501 1186 GYS1, glycogen CTGACGTCTT[T/C]CTGGAGGCAT S T C FF synthase 1 (muscle) G482u2 WIAF-12195 J04501 1406 GYS1, glycogenCCTTCCCGAC[A/G]TGAACAAGAT M A G M V synthase 1 (muscle) G4827u1WIAF-14177 HT97477 68 elongation CGAGCTGGCC[A/G]TCATGGTCAT M A G H RG483a1 WIAF-12113 HT4341 1850 GSY2 TTACCAGCAT[C/T]CCAGACACCT M G T A SG483u2 WIAF-12148 HT4341 1130 GSY2 GTTTTTCATT[A/C]TCCCTGCCAA M A C M LG483u3 WIAF-12149 HT4341 880 GSY2 CCTTCAATGT[T/C]AAGAAATTTT S T G V VG483u4 WIAF-12150 HT4341 1115 GSY2 CATCACACTC[C/A]TGGTGTTTTT M G A V MG483u5 WIAF-12156 HT4341 1230 GSY2 GAAAACTTTG[C/A]AAAAAAACTC M G A G EG483u6 WIAF-12159 HT4341 2033 GSY2 TCACAGATAC[G/A]ATGACGAACA M G A D NG483u7 WIAF-12160 HT4341 1836 GSY2 TACTTACGCA[G/C]ATATTACCAC M G C R TG483u8 WIAF-12161 HT4341 1678 GSY2 CTTACGGTAT[T/C]TACATCGTTG S T C I IG483u9 WIAF-12177 HT4341 790 GSY2 GCGCTCACGT[G/C]TTCACCACGG S G C V VG483u10 WIAF-12188 HT4341 1728 GSY2 TCCAATCACC[T/C]GACTAAGTTT M T C L PG484u1 WIAF-12151 HT5111 487 GSY3 CATCAAAGTG[A/G]TTGGCAATGG M A G I VG484u2 WIAF-12187 HT5111 1141 GSY3 AACCCCGCAA[C/T]AAATCCCAGA N C T Q *G489u1 WIAF-12152 HT2607 1181 IRS1, insulin AAGAAGTGGC[G/A]GCACAAGTCG MG A R Q receptor substrate 1 G489u2 WIAF-12184 HT2607 1031 IRS1, insulinATGGCCAGCC[C/T]TCCGGAGAGC M C T P L receptor substrate 1 G492a1WIAF-13345 L08603 307 MC4R, melanocortin AGAAACCATT[A/C]TCATCACCCT M A GI V 4 receptor G493u1 WIAF-12154 X67594 346 MC1R, melanocortinCGCGCTGGTG[G/T]TGGCCACCAT M G T V L 1 receptor (alpha melanocytestimulating hormone receptor) G493u2 WIAF-12167 X67594 646 MC1R,melanocortin GACCCTGCCG[C/T]GGGCGCGGCA M C T R W 1 receptor (alphamelanocyte stimulating hormone receptor) G493u3 WIAF-12170 X67594 1110MC1R, melanocortin AGGTCCTGAC[A/G]TGCTCCTGGT S A G T T 1 receptor (alphamelanocyte stimulating hormone receptor) G493u4 WIAF-12186 X67594 442MC1R, melanocortin CGGGAGCAAC[C/T]TGCTCGAGAC M G T V L 1 receptor (alphamelanocyte stimulating hormone receptor) G498u1 WIAF-11809 J04127 1305CYP19, cytochrome CTTATAGGTA[C/T]TTTCAGCCAT S C T Y Y P450, subfamilyXIX (aromatization of androgens) G498u2 WIAF-11810 J04127 1377 CYP19,cytochrome TGAAAGCCAT[C/T]CTCGTTACAC S C T I I P450, subfamily XIX(aromatization of androgens) G498u3 WIAF-11811 J04127 1406 CYP19,cytochrome CGATTCCACG[T/C]GAAGACATTG M T C V A P450, subfamily XIX(aromatization of androgens) G498u4 WIAF-11838 J04127 1055 CYP19,cytochrome ATTGCTGACA[G/A]AGACATAAAG M G A R K P450, subfamily XIX(aromatization of androgens) G498u5 WIAF-11800 J04127 1001 CYP19,cytochrome ATTGCAAAGC[A/C]CCCTAATGTT M A G H R P450, subfamily XIX(aromatization of androgens) G499u1 WIAF-11785 HT1439 2142 ESR1,estrogen TCCCTGCCAC[A/G]GTCTGAGAGC S A G T T receptor 1 G499u2WIAF-11801 HT1439 443 ESR1, estrogen CCCCTGAACC[G/A]TCCGCAGCTC M G A R Hreceptor 1 G500u1 WIAF-11803 X99101 793 ESR1, estrogenCATGATCAGC]T/C]GGGCCAAGAA M T C W R receptor 1 G500u2 WIAF-11816 X99101489 ESR1, estrogen GGAAGTGTTA[C/T]GAAGTGGGAA S C T Y Y receptor 1 G500u3WIAF-11817 X99101 474 ESR1, estrogen AGGCCTGCCG[A/G]CTTCGGAAGT S A G R Rreceptor 1 G505u1 WIAF-11824 HT1113 1063 PRLR, prolactinGCTTTCAAGC[C/A]CTATAGCATC M G A G D receptor G505u2 WIAF-11827 HT11132083 PRLR, prolactin GCAACATCAA[C/A]CAAGTCCAGG M G A S N receptor G505u3WIAF-11787 HT1113 582 PRLR, prolactin GAGGACATAC[A/G]TCATGATGGT M A G IV receptor G505u4 WIAF-11802 HT1113 792 PRLR, prolactinCCTGTATGAA[A/C]TTCGATTAAA M A C I L receptor G509u1 WIAF-11789 M32313378 SRD5A1, steroid-S- CACTGTTCGC[A/G]TGTACAATGG S A G A Aalpha-reductase, alpha polypeptide 1 (3-oxo-5 alpha- steroid delta 4-dehydrogenase alpha 1) G510a1 WIAF-13348 U17280 582 STAR, steroidogenicCCAATGTCAA[C/A]GAGATCAAGG S G A K K acute regulatory protein G52u1WIAF-10224 HT0488 1139 inhibin, beta B CCAACATGAT[T/C]GTGGAGGAGT S T C II G520u1 WIAF-13507 D31770 517 ACVR2, activin ACTTATTTTCC[G/A]GAGATGGAAG S G A P P receptor, type II G520u2 WIAF-13532D31770 1177 ACVR2, activin A CAGCTTGCAT[T/G]GCTGACTTTG M T G I Mreceptor, type II G520u3 WIAF-13533 D31770 1189 ACVR2, activin ACTGACTTTGG[G/C]TTGGCCTTAA S G C G G receptor, type II G520u4 WIAF-13534D31770 1024 ACVR2, activin A TCTCTTCGAA[T/C]GAACTGTGTC S T C N Nreceptor, type II G523u1 WIAF-12155 HT4996 538 OXTR, oxytocinTGACGGGGAA[C/T]GCGTGTGTGC S C T N N receptor G523u2 WIAF-12180 HT49961057 OXTR, oxytocin TCTGGCAGAA[C/T]TTGCGGCTCA S C T N N receptor G524a1WIAF-13349 L05144 190 PCK1, phosphoenol- TGGACAGCCT[G/A]CCCCAGGCAG S G AL L pyruvate carboxy- kinase 1 (soluble) G528u1 WIAF-11831 V00572 988PGK1, phospho- AAGCCACTGT[G/C]GCTTCTGGCA S G C V V glycerate kinase 1G53u1 WIAF-10307 HT0508 723 DNA repair protein CCAGCGACCC[G/A]GCAGGACCTAS G A P P XRCC1 G53u2 WIAF-10308 HT0508 746 DNA repair proteinTATGCAGCTG[C/T[TACCCTCCAG M C T A V XRCC1 G53u3 WIAF-10309 HT0508 1884DNA repair protein GGGATCCCAG[C/T]TTTGAGGAGG S C T S S XRCC1 G53u4WIAF-10362 HT0508 425 DNA repair protein AACCCCAACC[G/A]CGTTCGCATG M G AR H XRCC1 G534a1 WIAF-13311 U28281 1284 SCTR, secretinGCTTCCTCAA[T/C]GGGGAGGTGC S T C N N receptor G534a2 WIAF-13311 U282811404 SCTR, secretin AGCACAGCCA[G/A]GGCACCTGCA S G A Q Q receptor G535u1WIAF-12157 HT5001 1158 SHC1 ATGCTCTTCG[G/C]GTGCCTCCAC S G C R R G535u2WIAF-12196 HT5001 774 SHC1 ATGAGGAGGA[G/A]GAAGAGCCAC S G A E E G536u1WIAF-13923 M20747 535 SLC2A4, solute GCCTGCCCAA[C/T]GCTGCTGCCT S C T N Ncarrier family 2 (facilitated glucose transporter), member 4 G538u1WIAF-11812 M55531 438 SLC2A5, solute GCAGCAGAGT[C/T]GCCACATCAT S C T V Vcarrier family 2 (facilitated glucose transporter), member 5 G538u2WIAF-11813 M55531 124 SLC2A5, solute GACGCTTGTG[C/T]TTGCCCTGGC M C T L Fcarrier family 2 (facilitated glucose transporter) member 5 G538u3WIAF-11791 M55531 816 SLC2A5, solute ACAGGGAGGT[C/A]GCCGAGATCC S G A V Vcarrier family 2 (facilitated glucose transporter), member 5 G539u1WIAF-12158 K03195 224 Human (HepG2) glu- TCATGCTGCC[T/C]GTCCGAGGAC S T CA A cose transporter gene mRNA, complete cds. G539u2 WIAF-12191 K031951244 Human (HepG2) glu- CCATCGCGCT[A/C]CCACTCCTGG S A G L L cosetransporter gene mRNA, complete cds. G540a1 WIAF-12114 HT960 1100 SOS1AGTGAAGATC[A/C]ACAACACAAG M A C Q P G540u2 WIAF-12165 HT950 933 SOS1ATGATCGTTT[C/T]CTTAGTCAGT S C T F F G540u3 WIAF-12178 HT960 399 SOS1TACTACCAGT[C/T]TTACAATACA S C T V V G540u4 WIAF-12193 HT960 195 SOS1CTCAGCCCCG[A/C]AGTCCTTCAG S A C R R G540u5 WIAF-12197 HT960 1329 SOS1GTTGTAATCA[A/C]TTTATAATCC S A G E E G540u6 WIAF-12198 HT960 1339 SOS1ATTTATAATC[C/A]AACCAACTCT M G A E K G543a1 WIAF-13312 J00306 1373 SST,somatostatin AACCAGGAAC[T/C]CCCCAACTAC M T C L P G543a2 WIAF-13313J00306 1603 SST, somatostatin ACTATTGTCC[A/G]TATCACACCT — A G — — G544u1WIAF-12174 HT27489 982 SUR, sulfonylurea CCATTGACAT[G/C]GCCACGGAAA M G CM I receptor (hyperinsulinemia) G546u1 WIAF-13618 HT225 426 TKT,transketolase GCTACATTGC[C/T]CAGCAGAACA S C T A A (Wernicke Korsakoffsyndrome) G551u1 WIAF-11709 HT1118 257 TNFRSF1B, tumorGCTGCAGCAA[A/G]TGCTCGCCGG S A G K K necrosis factor receptor super-family, member 1B G551u2 WIAF-11710 HT1118 449 TNFRSF1B, tumorTCTGCACCTG[C/T]AGGCCCGGCT S C T C C necrosis factor receptor super-family, member 1B G551u3 WIAF-11719 HT1118 648 TNFRSF1B, tumorGATCTGTAAC[G/A]TGGTGGCCAT M G A V M necrosis factor receptor super-family, member 1B G551u4 WIAF-11673 HT1118 676 TNFRSF1B, tumorAATGCAACCA[T/C]CCATGCAGTC M T G M R necrosis factor receptor super-family, member 1B G551u5 WIAF-11720 HT1118 808 TNFRSF1B, tumorCCAAGCACCT[C/T]CTTCCTGCTC M C T S F necrosis factor receptor super-family, member 1B G552u1 WIAF-12229 HT5108 384 TRAP3GCCGCTGCCC[G/AICTCATGCTGA S G A P P G555u1 WIAF-12211 U94592 478 UCP2,uncoupling CGCGCTACAG[T/C]CAGCGCCCAG M T C V A protein 2 (mitochondrial,proton carrier) G556u1 WIAF-11804 AF001787 480 UCP2, uncouplingTCGGCCTCTA[T/C]GACTCCCTCA S T C Y Y protein 2 (mitochondrial, protoncarrier) G556u2 WIAF-11805 AF001787 563 UCP2, uncouplingTGCACCACAG[G/A]AGCCATGGCG M G A G E protein 2 (mitochondrial, protoncarrier) G556u3 WIAF-11823 AF001787 1113 UCP2, uncouplingTACGCCAATC[A/C]CCCTTTTGAA S A G S S protein 2 (mitochondrial, protoncarrier) G556u4 WIAF-11782 AF001787 386 UCP2, uncouplingATCCTGACCA[T/C]GGTGCGGACT M T C M T protein 2 (mitochondrial, protoncarrier) G561a1 WIAF-12111 HT1176 2430 IDE, insulin-ACTCTGGCAT[C/A]GAGATATACT S C A I I degrading enzyme G561u2 WIAF-12222HT1176 3099 IDE, insulin- ATATTAACTT[C/G]ATGGCTGCAA M C G F L degradingenzyme GSG2u1 WIAF-12223 HT27503 680 tumor necrosisCCTGTAGTGA[A/C]TCGGCCGCTG M A C N T factor receptor type 1 associatedprotein G562u2 WIAF-12224 HT27503 900 tumor necrosisCGCTCCAGCG[C/A]CTGGTGGAGG S C A R R factor receptor type 1 associatedprotein G573u1 WIAF-12199 HT28094 469 SSTR1, somatostatinGGACCGCTAC[G/C]TGGCCGTGGT M G C V L receptor 1 G573u2 WIAF-12208 HT28094480 SSTR1, somatostatin TGGCCCTGGT[G/A]CATCCCATCA S G A V V receptor 1G573u3 WIAF-12209 HT28094 879 SSTR1, somatostatinTGCAGCTGGT[T/C]AACGTGTTTG S T C V V receptor 1 G574u1 WIAF-11822 HT40581054 SSTR5, somatostatin GCCACGGAGC[C/T]GCGTCCAGAC M C T P L receptor 5G575u1 WIAF-12200 HT28095 99 SSTR3, somatostatinACGTGTCGGC[C/A]GGCCCAAGCC S G A A A receptor 3 G575u2 WIAF-12217 HT28095453 SSTR3, somatostatin CCACCCGGTC[G/A]GCCCGCTGGC S G A S S receptor 3G585u1 WIAF-12204 HT1022 1133 PYGL, AGCTGAATGA[T/C]ACTCACCCTC S T C D Dphosphorylase, glycogen; liver (Hers disease, glycogen storage diseasetype VI) G585u2 WIAF-12205 HT1022 1988 PYGL, AGCTGATCAC[T/C[TCAGTGGCAG ST C T T phosphorylase, glycogen; liver (Hers disease, glycogen storagedisease type VI) G585u3 WIAF-12225 HT1022 1883 PYGL,TGTACAACCC[C/T]ATTAAGAAAG S C T R R phosphorylase, glycogen; liver (Hersdisease, glycogen storage disease type VI) G585u4 WIAF-12226 HT1022 2037PYGL, AAGCAAGTTG[A/G]AAGTCATCTT M A G K E phosphorylase, glycogen; liver(Hers disease, glycogen storage disease type VI) G585u5 WIAF-12231HT1022 1387 PYGL, GATGTGGACC[C/G]TCTGAGAAGG M C G P R phosphorylase,glycogen; liver (Hers disease, glycogen storage disease type VI) G586a1WIAF-12112 HT1878 2410 PFKM, CCGGGGAAGC[T/G]GCCGTCTAAA S T G A Aphosphofructo- kinase, muscle G586u2 WIAF-12206 HT1878 375 PFKM,GGACCACTCC[G/A]AGCTCCCTAC M G A R Q phosphofructo- kinase, muscle G586u3WIAF-12207 HT1878 322 PFKM, TGCGAGGCAC[C/A]GTGATTGGAA S G A T Tphosphofructo- kinase, muscle G586u4 WIAF-12227 HT1878 334 PFKM,TGATTGGAAG[T/C]GCCCGGTGCA S T C S S phosphofructo- kinase, muscle G586u5WIAF-12228 HT1878 408 PFKM, CGTCGGATCA[C/G]CAATCTCTGT M C G T Sphosphofructo- kinase, muscle G586u6 WIAF-12235 HT1878 717 PFKM,CACTGTGGAT[A/G]CCTGGCCCTT M A G Y C phosphofructo- kinase, muscle G587u1WIAF-12615 HT3847 366 phosphofructo- ATGCCAGCCT[T/C]ACAGGTGCCA S T C L Lkinase, liver G589u1 WIAF-12210 L39211 1327 CPT1A, carnitineCAGCGTTCTT[C/T]GTGACGTTAG S C T F F palmitoyl- transferase I, liverG589u2 WIAF-12215 L39211 2080 CPT1A, carnitine AATATCTCGC[T/C]GTGGAGTCCCS T C A A palmitoyl- transferase I, liver G589u3 WIAF-12216 L39211 679CPT1A, carnitine ACTTCAAACG[C/T]ATGACAGCAC S G T R R palmitoyl-transferase I, liver G589u4 WIAF-12218 L39211 1844 CPT1A, carnitineCCTCACATAC[G/C]AGGCCTCCAT M G C E Q palmitoyl- transferase I, liverG592u1 WIAF-11814 X96586 1089 NSMAF, neutral TCCGGGATCT[C/T]AGTAAGCCAG SC T L L sphingomyelinase (N-SMase) activation associated factor G592u2WIAF-11815 X96586 2020 NSMAF, neutral AAGTATATCA[T/G]TTTCAAATAT M T G FV sphingomyelinase (N-SMase) activation associated factor G592u3WIAF-11834 X96586 1673 NSMAF, neutral GTAGCCATGC[T/C]TACGCAAATC M T C LP sphingomyelinase (N-SMase) activation associated factor G592u4WIAF-11784 X96586 1889 NSMAF, neutral CACGAGCACT[A/G]TAAAATCCAC M A C YC sphingomyelinase (N-SMase) activation associated factor G592u5WIAF-11798 X96586 1677 NSMAF, neutral CCATGCTTAC[G/A]CAAATCTTGG S G A TT sphingomyelinase (N-SMase) activation associated factor G592u6WIAF-11799 X96586 2429 NSMAF, neutral TGCCATTCAG[G/C]GATTCTATGT M G C GA sphingomyelinase (N-SMase) activation associated factor G592a7WIAF-13156 X96586 2205 NSMAF, neutral ATTCTGCATC[G/A]TGGGACTCTA S G A SS sphingomyelinase (N-SMase) activation associated factor GS94u1WIAF-10065 HT3921 1153 annexin V, alt. TTGTGAAATC[T/A]ATTCGAAGTA S T A SS transcript 2 G594u2 WIAF-10098 HT3921 567 annexin V, alt.CGAAGTAATG[C/T]TCACCGCCAG M C T A V transcript 2 G594u3 WIAF-10099HT3921 774 annexin V, alt. ATTGCTTCAA[G/C]CACACCTCAA M G C R Ttranscript 2 G594a4 WIAF-10505 HT3921 424 annexin V, alt.GAGTAGTCGC[C/T]ATGCCACACG — C T — — transcript 2 G594a5 WIAF-13123HT3921 571 annexin V, alt. GTAATGCTCA[G/C]CGCCAGGAAA M G C Q Htranscript 2 G595u1 WIAF-12203 HT27983 1008 NRIP1, nuclearTGCAACATTA[C/T]AGGCTGTTGC N C T Q * receptor interacting protein 1G595u2 WIAF-12220 HT27983 785 NRIP1, nuclear CCCTCAGTCA[T/C]GATTCTTTAA ST C H H receptor interacting protein 1 G595u3 WIAF-12232 HT27983 1231NRP1, nuclear GTTGGCAGTT[A/T]CCAGCTCCCA M A T Y F receptor interactingprotein 1 G595u4 WIAF-12261 HT27983 2048 NRIP1, nuclearGCAGTACTCA[G/A]TCTCAAAACC S G A Q Q receptor interacting protein 1C595u5 WIAF-12274 HT27983 2376 NRIP1, nuclear TCCTCAACCA[G/T]GGCTTTCTGGM G T G W receptor interacting protein 1 G595u6 WIAF-12275 HT27983 3498NRIP1, nuclear ACTATATTAC[A/G]TGCTTCAAAA M A G M V receptor interactingprotein 1 G595u7 WIAF-12276 HT27983 3671 NRIP1, nuclearACAATAGCCA[T/C]ATGGGAAATA S T C H H receptor interacting protein 1G595u8 WIAF-12294 HT27983 2020 NRIP1, nuclear ATCAAATGGA[A/G]TTCCCCACCAM A G N S receptor interacting protein 1 G595u9 WIAF-12295 HT27983 3140NRIP1, nuclear ATTTGTCCCC[G/A]CACAGAAGTA S G A P P receptor interactingprotein 1 G596u1 WIAF-10144 HT3537 3299 PC, pyruvateTGCGGTCCAT[C/T]TTGGTCAAGG S C T I I carboxylase G596u2 WIAF-10158 HT35372662 PC, pyruvate ACCAACCTCC[A/C]CTTCCAGGCC M A C H P carboxylase G596u3WIAF-10159 HT3537 2156 PC, pyruvate CCATCTCATA[C/A]ACGGGCGACG N C A Y *carboxylase G598a1 WIAF-12118 HT48666 5585 HERC1, hectGGGACCTATG[C/T]TGATAAACTG M C T A V (homologous to the E6 AP (UBE3A)carboxyl terminus) domain and RCC1 (CHC1)-like domain (RLD) 1 G598u2WIAF-12236 HT48666 4456 HERC1, hect CCTGTTAATA[T/C]TAGGAGTAAG S T C L L(homologous to the E6 AP (UBE3A) carboxyl terminus) domain and RCC1(CHC1)-like domain (RLD) 1 G598u3 WIAF-12237 HT48665 6356 HERC1, hectGGTAATGAAG[G/T]CACGTGTGTT M G T G V (homologous to the E6 AP (UBE3A)carboxyl terminus) domain and RCC1 (CHC1)-like domain (RLD) 1 G598u4WIAF-12240 HT48666 12219 HERC1, hect GTACCTTTGT[C/T]ATCCAGGCCA S C T V V(homologous to the E6 AP (UBE3A) carboxyl terminus) domain and RCC1(CHC1)-like domain (RLD) 1 G598u5 WIAF-12241 HT48666 12480 HERC1, hectCCAGGCAGAT[C/G]GAGGCCTTAC M C G I M (homologous to the E6 AP (UBE3A)carboxyl terminus) domain and RCC1 (CHC1)-like domain (RLD) 1 G598u6WIAF-12244 HT48666 12975 HERC1, hect GAGTAATCAT[T/A]GAAGATGTGG S T A I I(homologous to the E6 AP (UBE3A) carboxyl terminus) domain and RCC1(CHC1)-like domain (RLD) 1 G598u7 WIAF-12245 HT48666 1424 HERC1, hectTCCAATAATC[A/T]GTCAACTTTA M A T Q L (homologous to the E6 AP (UBE3A)carboxyl terminus) domain and RCC1 (CHC1)-like domain (RLD) 1 G598u8WIAF-12250 HT48666 5854 HERC1, hect TTCAAAAGCA[A/T]TTCAATCAAA M A T I F(homologous to the E6 AP (UBE3A) carboxyl terminus) domain and RCC1(CHC1)-like domain (RLD) 1 G598u9 WIAF-12251 HT48666 6754 HERC1, hectTATTCAGCTC[G/A]TCCGTATCCT M G A V I (homologous to the E6 AP (UBE3A)carboxyl terminus) domain and RCC1 (CHC1)-like domain (RLD) 1 G598u10WIAF-12252 HT48666 7535 HERC1, hect ATCTTTACCT[C/T]GGTCCTATGA S C T L L(homologous to the E6 AP (UBE3A) carboxyl terminus) domain and RCC1(CHC1)-like domain (RLD) 1 G598u11 WIAF-12254 HT48666 9189 HERC1, hectGTGGAAATCC[A/G]TACTACCTGT S A G P P (homologous to the E6 AP (UBE3A)carboxyl terminus) domain and RCC1 (CHC1)-like domain (RLD) 1 G598u12WIAF-12255 HT48666 10119 HERC1, hect TTGTGGCATT[G/C]CTAGCAGACA M G C L F(homologous to the E6 AP (UBE3A) carboxyl terminus) domain and RCC1(CHC1)-like domain (RLD) 1 G598u13 WIAF-12257 HT48666 11109 HERC1, hectATCCATCTAT[T/C]GTAAATGGCA S T C I I (homologous to the E6 AP (UBE3A)carboxyl terminus) domain and RCC1 (CHC1)-like domain (RLD) 1 G598u14WIAF-12258 HT48666 13513 HERC1, hect CTATGGACCT[C/T]AGATAACTGT N C T Q *(homologous to the E6 AP (UBE3A) carboxyl terminus) domain and RCC1(CHC1)-like domain (RLD) 1 G5958u15 WIAF-12259 HT48666 13697 HERC1, hectACCATCACAG[A/C]GATGTGCCAG M A G E G (homologous to the E6 AP (UBE3A)carboxyl terminus) domain and RCC1 (CHC1)-like domain (RLD) 1 G598u16WIAF-12255 HT48666 1098 HERC1, hect CCCTTTACGA[G/A]GCAGCATTAT S G A E E(homologous to the E6 AP (UDE3A) carboxyl terminus) domain and RCC1(CHC1)-like domain (RLD) 1 G598u17 WIAF-12272 HT48666 6079 HERC1, hectTATGTGGGAG[A/G]CACCCATTGC M A G T A (homologous to the E6 AP (UHE3A)carboxyl terminus) domain and RCC1 (CHC1)-like domain (RLD) 1 G598u18WIAF-12273 HT48666 9551 HERC1, hect AAGAGCTCCT[C/T]TGGGAGAATA M C T S F(homologous to the E6 AP (UBE3A) carboxyl terminus) domain and RCC1(CHC1)-like domain (RLD) 1 G598u19 WIAF-12277 HT48666 666 HERC1, hectGTCTTTGCAA[C/T]GATGTCATTC S C T N N (homologous to the E6 AP (UBE3A)carboxyl terminus) domain and RCC1 (CHC1)-like domain (RLD) 1 G598u20WIAF-12278 HT48666 882 HERC1, hect GCTCATTGCG[A/G]TATCTTCTTG S A G R R(homologous to the E6 AP (UBE3A) carboxyl terminus) domain and RCC1(CHC1)-like domain (RLD) 1 G598u21 WIAF-12279 HT48666 893 HERC1, hectTATCTTCTTC[A/T]ATGGATAGAA M A T E V (homologous to the E6 AP (UBE3A)carboxyl terminus) domain and RCC1 (CHC1)-like domain (RLD) 1 G598u22WIAF-12280 HT48666 13276 HERC1, hect AGAACTCAGC[A/C]TTCACACGGT M A G I V(homologous to the E6 AP (UBE3A) carboxyl terminus) domain and RCC1(CHC1)-like domain (RLD) 1 G598u23 WIAF-12283 HT48666 6519 HERC1, hectCCTGTCTGTT[A/T]GACATGGAAC M A T L F (homologous to the E6 AP (UBE3A)carboxyl terminus) domain and RCC1 (CHC1)-like domain (RLD) 1 G598u24WIAF-12284 HT48666 8386 HERC1, hect GGGGTTCTCT[C/T]TTCGGCAGAT M C T L F(homologous to the E6 AP (UBE3A) carboxyl terminus) domain and RCC1(CHC1)-like domain (RLD) 1 G598u25 WIAF-12286 HT48666 10266 HERC1, hectCAGCTCAGCA[A/T]CTCGTGCGCA M A T Q H (homologous to the E6 AP (UBE3A)carboxyl terminus) domain and RCC1 (CHC1)-like domain (RLD) 1 G598u26WIAF-12287 HT48666 10099 HERC1, hect CTTTGTTGTA[A/G]CACAGGCCCT M A G T A(homologous to the E6 AP (UBE3A) carboxyl terminus) domain and RCC1(CHC1)-like domain (RLD) 1 G598u27 WIAF-12289 HT48666 11835 HERC1, hectAGAACTGTCT[G/C]CCTGACCCTG S G C L L (homologous to the E6 AP (UBE3A)carboxyl terminus) domain and RCC1 (CHC1)-like domain (RLD) 1 G598u28WIAF-12290 HT48666 12689 HERC1, hect TTAAACCACA[C/T]TTTGGCAGTG M C T T I(homologous to the E6 AP (UBE3A) carboxyl terminus) domain and RCC1(CHC1)-like domain (RLD) 1 G598u29 WIAF-12291 HT48666 14655 HERC1, hectACGTGGACAA[C/T]GCCGAGGGCT S C T N N (homologous to the E6 AP (UBE3A)carboxyl terminus) domain and RCC1 (CHC1)-like domain (RLD) 1 G598u30WIAF-12296 HT48666 393 HERC1, hect ATTCCCCATT[T/C]GCCGGGGCAC S T C F F(homologous to the E6 AP (UBE3A) carboxyl terminus) domain and RCC1(CHC1)-like domain (RLD) 1 G598u31 WIAF-12297 HT48666 479 HERC1, hectGGCAAGGTGA[A/G]GCAGCAGCAG M A G K R (homologous to the E6 AP (UBE3A)carboxyl terminus) domain and RCC1 (CHC1)-like domain (RLD) 1 G598u32WIAF-12298 HT48666 1197 HERC1, hect ATGCTCCCAT[T/C]GTCTCCGAAA S T C I I(homologous to the E6 AP (UBE3A) carboxyl terminus) domain and RCC1(CHC1)-like domain (RLD) 1 G598u33 WIAF-12300 HT48666 3595 HERC1, hectTCCAGAGGAA[C/T]AGCACACTGC N C T Q * (homologous to the E6 AP (UBE3A)carboxyl terminus) domain and RCC1 (CHC1)-like domain (RLD) 1 G598u34WIAF-12301 HT48666 3661 HERC1, hect CACTCCTCAA[T/C]TGGATAAATG S T C L L(homologous to the E6 AP (UBE3A) carboxyl terminus) domain and RCC1(CHC1)-like domain (RLD) 1 G601u1 WIAF-12246 HT27734 106 PRKMK5, proteinTGGAGAACCA[G/A]GTGCTGGTAA S G A Q Q kinase, mitogen- activated, kinase 5(MAP kinase kinase 5) G601u2 WIAF-12247 HT27734 351 PRKMK5, proteinGTAAATGGAC[A/G]GTTAATAGAG M A G Q R kinase, mitogen- activated, kinase 5(MAP kinase kinase 5) G601u3 WIAF-12292 HT27734 617 PRKMK5, proteinAGCATATCAT[G/C]TCCCGAGTGG M G C V L kinase, mitogen- activated, kinase 5(MAP kinase kinase 5) G603u1 WIAF-12248 HT4291 1336 mitogen-activatedAGTCATCAGC[T/C]TTGTGCCACC M T C F L protein (MAP) kinase p38 G603u2WIAF-12281 HT4291 1230 mitogen-activated CTCAGTACCA[C/T]GATCCTGATG S C TH H protein (MAP) kinase p38 G610u1 WIAF-12249 HT48690 1012 proteinkinase, CCGAGCCATA[T/C]GATGAGAGCG S T C V Y mitogen-activated, p38Beta(MAP kinase p38Beta) G610u2 WIAF-12263 HT48690 799 protein kinase,AAATCTCCTC[G/A]GAACACGCCC S G A S S mitogem-activated, p38Beta (MAPkinase p38Beta) GS10u3 WIAF-12264 HT48690 848 protein kinase,GCCCCAGAAG[G/A]ACCTGAGCAG M G A D N mitogen-activated, p38Beta (MAPkinase p38Beta) G610u4 WIAF-12282 HT48690 439 protein kinase,TCCTGGTTTA[C/T]CAGCTCCTGC S C T Y Y mitogen-activated, p38Beta (MAPkinase p38Beta) G612u1 WIAF-12344 HT1436 1513 RAF1, v-raf-1TTTGCATGCA[A/G]AGAACATCAT M A G K E murine leukemia viral oncogenehomolog 1 G614u1 WIAF-12267 HT321 603 BRAF, v-raf murineGACAGTCTAA[A/G]GAAAGCACTG M A G K R sarcoma viral oncogene homolog 51G614u2 WIAF-12268 HT321 2282 BRAF, v-raf murineCCAAACAGAG[G/A]ATTTTAGTCT M G A D N sarcoma viral oncogene homolog 51G614u3 WIAF-12299 HT321 973 BRAF, v-raf murine AGGAAGAGGC[G/A]TCCTTAGCACS G A A A sarcoma viral oncogene homolog 51 G616u1 WIAF-12253 HT48746498 TRAF-interacting AAGAAGACAA[G/T]AGGTTTCTTC N G T E * protein(I-TRAF) G616u2 WIAF-12269 HT48746 1338 TRAF-interactingGCATATACCT[C/G]GAGTATGTGA M C G R G protein (I-TRAF) G616u3 WIAF-12285HT48746 377 TRAF-interacting ATAACAATTA[T/C]GGCTGTGTCC S T C Y Y protein(I-TRAF) G616u4 WIAF-12288 HT48746 1032 TRAF-interactingTGAAATTCAG[G/A]GAATTGACCC M G A G R protein (I-TRAF) G617u1 WIAF-12256HT1614 52 PPP1CA, protein GAAGCTCAAC[C/T]TGGACTCGAT S C T L Lphosphatase 1, catalytic subunit, alpha isoform G617u2 WIAF-12270 HT1614792 PPP1CA, protein AAGACGGCTA[C/T]GAGTTCTTTG S C T Y Y phosphatase 1,catalytic subunit, alpha isoform G618u1 WIAF-12238 HT27508 1598 proteinCATTGAACCA[A/C]CACAGTTCAA M A C T P phosphatase, 2A B56-alpha subunitG618u2 WIAF-12271 HT27508 1135 protein ATCAGAAATT[C/T]GTACAACAGC S C T FF phosphatase, 2A B56-alpha subunit G62u1 WIAF-10369 HT0855 214 ERCC6,excision AGGAGTACCT[G/C]TCCTTTCGTT S G C L L repair cross- complementingrodent repair deficiency, complementation group 6 G62u2 WIAF-10370HT0855 926 ERCC6, excision AAAACTGTCT[T/C]TTGAAAGGAA M T C F L repaircross- complementing rodent repair deficiency, complementation group 6G62u3 WIAF-10428 HT0855 2904 ERCC6, excision AGCACGGACA[C/T]GCAGGCCCGG MC T T M repair cross- complementing rodent repair deficiency,complementation group 6 G62u4 WIAF-10430 HT0855 3368 ERCC6, excisionTGACCCTCAC[A/G]TGAGTAGTAA M A G M V repair cross- complementing rodentrepair deficiency, complementation group 6 G62u5 WIAF-10451 HT0855 1376ERCC6, excision TTCTGGGGAA[G/A]AAGCTGAAGC M G A E K repair cross-complementing rodent repair deficiency, complementation group 6 G62u6WIAF-10452 HT0855 3716 ERCC6, excision TAAGCATTGC[A/G]GACACGCCAA M A G RG repair cross- complementing rodent repair deficiency, complementationgroup 6 G62u7 WIAF-10453 HT0855 3967 ERCC6, excisionCCCTGAAAGC[A/C]CTGAGGCTCT S A C A A repair cross- complementing rodentrepair deficiency, complementation group 6 G62u8 WIAF-10454 HT0855 4016ERCC6, excision TGGTGTTCCC[A/G]CCTGGACTGG M A G T A repair cross-complementing rodent repair deficiency, complementation group 6 G62u9WIAF-10455 HT0855 3979 ERCC6, excision TGAGGCTCTC[T/C]CGTCAGCGGT S T C SS repair cross- complementing rodent repair deficiency, complementationgroup 6 G62u10 WIAF-10456 HT0855 3729 ERCC6, excisionGACCCCAAGT[T/C]TGAAGGAACT M T G F C repair cross- complementing rodentrepair deficiency, complementation group 6 G62u11 WIAF-10476 HT0855 1275ERCC6, excision TCTGGAGATG[G/A]TACTGACTAT M G A G D repair cross-complementing rodent repair deficiency, complementation group 6 G62u12WIAF-10477 HT0855 2017 ERCC6, excision TGATCTTGGA[C/T]GAAGGACACA S C T DD repair cross- complementing rodent repair deficiency, complementationgroup 6 G62u13 WIAF-10479 HT0855 3265 ERCC6, excisionCTAACATATC[T/C]CTAAATCATG S T C S S repair cross- complementing rodentrepair deficiency, complementation group 6 G62u14 WIAF-10481 HT0855 4317ERCC6, excision GGGCACCTGC[A/G]GGAAGCTTCT M A G Q R repair cross-complementing rodent repair deficiency, complementation group 6 G620a1WIAF-12116 HT1943 1256 PPP2CB, protein TATCATGGAA[T/A]TAGATGACAC M T A LI phosphatase 2 (formerly 2A), catalytic subunit, beta isoform G620a2WIAF-12117 HT1943 1326 PPP2CB, protein CCTCATGTTA[C/G]ACGGCGCACC M C G TR phosphatase 2 (formerly 2A), catalytic subunit, beta isoform G620u3WIAF-12239 HT1943 819 PPP2CB, protein TTTTATGATG[A/G]ATGTCTGCGA M A G EG phosphatase 2 (formerly 2A), catalytic subunit, beta isoform G623u1WIAF-12260 HT3979 459 PPP1CB, protein TTCATCGACA[A/G]TATACACATT S A G QQ phosphatase 1, catalytic subunit, beta isoform G625u1 WIAF-12266HT1951 2279 PPP2R2A, protein CATTCTGGAG[A/G]ATTACTAGCA M A G E Gphosphatase 2 (formerly 2A), regulatory subunit (PR 52), alpha isoformG628a1 WIAF-12104 HT2780 1104 PPP1CC, protein AGGGGTATGA[T/A]CACAAAGCAAM T A I N phosphatase 1, catalytic subunit, gamma isoform G628a2WIAF-12105 HT2780 973 PPP1CC, protein CCAATTATTG[C/T]GGACAGTTTG S C T CC phosphatase 1, catalytic subunit, gamma isoform G628u3 WIAF-12311HT2780 888 PPP1CC, protein GATCTTATAT[G/T]TAGAGCCCAT M A T C Pphosphatase 1, catalytic subunit, gamma isoforn G630a1 WIAF-12103 HT5086704 protein phosphatase AAAGATGCAG[A/G]TCTGAACTCT M A G D G 2A, 130 kDaregulatory subunit G630a2 WIAF-12106 HT5086 1015 protein phosphataseCGATGGGAAC[G/T]CCCCATCCTT M G T A S 2A, 130 kDa regulatory subunitG630a3 WIAF-12107 HT5086 1024 protein phosphataseCGCCCCATCC[T/c]TTGGTTTACT M T c F L 2A, 130 kDa regulatory subunitG630a4 WIAF-12108 HT5086 837 protein phosphataseACTTAAAGGA[T/C]ATTGCAGGAG S T C D D 2A, 130 kDa regulatory subunitG630u5 WIAF-12325 HT5086 1200 protein phosphataseTAAAGATGTG[C/T]TTGGACATCT S C T C C 2A, 130 kDa regulatory subunitG630u6 WIAF-12326 HT5086 2810 protein phosphataseATGTTCAGGG[C/TITGCAGGGGGA M C T A V 2A, 130 kDa regulatory subunitG630u7 WIAF-12351 HT5086 512 protein phosphatase ATTATGGCAG[C/T]AACTTACAGA M C T A V 2A, 130 kDa regulatory subunit G630u8WIAF-12352 HT5086 703 protein phosphatase CAAACATGCA[G/A]ATCTGAACTC M GA D N 2A, 130 kDa regulatory subunit G630u9 WIAF-12353 HT5086 1069protein phosphatasa ACCTTTGTCT[C/T]ATAGAAACTC M C T H Y 2A, 130 kDaregulatory subunit G634u1 WIAF-11825 X04434 2283 IGF1R, insulin-TGCAAGTGGC[C/T]AACACCACCA S C T A A like growth factor 1 receptor G634u2WIAF-11826 X04434 2279 IGF1R, insulin- GTCATGCAAG[T/C]GGCCAACACC M T C VA like growth factor 1 receptor G634u3 WIAF-11781 X04434 1731 IGF1R,insulin- ACAAGGACGT[G/AIGAGCCCGGCA S G A V V like growth factor 1receptor G634a4 WIAF-13106 X04434 948 IGF1R, insulin-TCCACGACGG[C/A]GAGTGCATGC S C A G G like growth factor 1 receptor G634a5WIAF-13107 X04434 1089 IGF1R, insulin- CTTCTGCTCA[G/C]ATGCTCCAAG M G C QH like growth factor 1 receptor G634a6 WIAF-13108 X04434 2539 IGF1R,insulin- AGAAGGAGCA[G/A]ATGACATTCC M G A D N like growth factor 1receptor G634a7 WIAF-13109 X04434 2606 IGF1R, insulin-AAGTGGCCGG[A/C]ACCTGACAAT M A C E A like growth factor 1 receptor G634a8WIAF-13111 X04434 1543 IGF1R, insulin- CTCCACCACC[A/T]CGTCGAAGAA M A T TS like growth factor 1 receptor G634a9 WIAF-13112 X04434 1549 IGF1R,insulin- CACCACGTCG[A/G]AGAATCGCAT M A G K E like growth factor 1receptor G634a10 WIAF-13113 X04434 1596 IGF1R, insulin-CCCCTGACTA[C/T]AGGGATCTCA S C T Y Y like growth factor 1 receptor G645u1WIAF-12332 HT5191 1127 retinoic acid- TCTGCAGACT[C/T]TTCAGGAGAG M C T LF binding protein II G645u2 WIAF-12333 HT5191 1048 retinoic acid-AAGCATTAGA[G/A]GCCTTACAGA S G A E E binding protein II G646u1 WIAF-12303X81479 1204 EMR1, egf-like CAAATATCCA[T/C]GTGGACTAAA M T C M T modulecontaining, mucin-like, hormone receptor- like sequence 1 G646u2WIAF-12304 X81419 1919 EMR1, egf-like TTCTGCTGTG[T/G]CGCTCCATCC M T G CW module containing, mucin-like, hormone receptor- like sequence 1G646u3 WIAF-12316 X81479 590 EMR1, egf-like CTTGCCCAGA[G/T]CATGCAACTT MG T E D module containing, mucin-like, hormone receptor- like sequence 1G646u4 WIAF-12317 X81479 799 EMR1, egf-like GCACCAAGCA[G/A]TGGACAGTTG MG A S N module containing, mucin-like, hormone receptor- like sequence 1G646u5 WIAF-12318 X81479 558 EMR1, egf-like TGAAGACGTG[A/G]ATGAATGTGC MA G N D module containing, mucin-like, hormone receptor- like sequence 1G646u6 WIAF-12334 X81479 207 EMR1, egf-like TTACTATTGC[A/G]CTTGCAAACA MA G T A module containing, mucin-like, hormone receptor- like sequence 1G646u7 WIAF-12335 X81479 458 EMR1, egf-like TCACCAGCAG[G/C]GTCTGCCCTG MG C R S module containing, mucin-like, hormone receptor- like sequence 1G646u8 WIAF-12336 X81479 1308 EMR1, egf-like CTCAGCAAAT[G/A]TCACTCCGGC MG A V I module containing, mucin-like, hormone receptor- like sequence 1G646u9 WIAF-12337 X81479 1285 EMR1, egf-like ACACTGGCAT[C/T]TTTTTGGAAA MC T S F module containing, mucin-like, hormone receptor- like sequence 1G646u10 WIAF-12338 X81479 2026 EMR1, egf-like GACAACAAGA[C/T]GGGCTGCGCCM C T T M module containing, mucin-like, hormone receptor- like sequence1 G647u1 WIAF-12339 HT5190 174 RARA, retinoic acidTGCCTCCCTA[C/T]GCCTTCTTCT S C T Y Y receptor, alpha G648a1 WIAF-13332HT0070 469 retinoic acid AACCTGAGCC[A/G]CGACCAGCGT — A G — — receptor,beta G648a2 WIAF-13333 HT0070 532 retinoic acidATTGTTTTTA[A/G]GGTGAGAAAT — A G — — receptor, beta G6S0u1 WIAF-12323X52773 862 RXRA, retinoid X CTCGCCGAAC[G/A]ACCCTGTCAC M G A D Nreceptor, alpha G650u2 WIAF-12341 X5277 3102 RXRA, retinoid XTCCTGCCGCT[C/T]GATTTCTCCA S C T L L receptor, alpha G650u3 WIAF-12348X5277 3673 RXRA, retinoid X GGCCATCGGC[A/C]TGAAGCGGCA M A G M Vreceptor, alpha G650u4 WIAF-12349 X52773 902 RXRA, retinoid XGACAAACACC[T/C]TTTCACCCTC M T C L P receptor, alpha G653a1 WIAF-13326HT1458 439 RARB, retinoic AGGACAAAGC[T/C]CTCAAAGCAT S T C A A acidreceptor, beta G655a1 WIAF-13327 J05252 1158 PCSK2, proproteinCCTTCACGAA[C/T]GGGAGGAAAA S C T N N convertase subtilisin/kexin type 2G655a2 WIAF-13334 J05252 678 PCSK2, proprotein CCTATCCTTA[C/A]CCTCCCTACAN C A Y * convertase subtilisin/kexin type 2 G655a3 WIAF-13335 J05252744 PCSK2, proprotein TTTCTGCTCC[C/T]GCCAACAACA S C T A A convertasesubtilisin/kexin type 2 G658u1 WIAF-11856 J02943 971 CBG, corticosteroidTCTATGACCT[T/C]CGAGATGTCC S T C L L binding globulin G658u2 WIAF-13407J02943 771 CBG, corticosteroid CCTTCATGAC[T/C]CACAGCTCCC M T G S Abinding globulin G658u3 WIAF-13408 J02943 773 CBG, corticosteroidTTCATCACTC[A/G]GAGCTCCCCT S A G S S binding globulin G658u4 WIAF-13409J02943 1046 CBG, corticosteroid TCACCCAGGA[C/T]GCCCAGCTCA S C T D Dbinding globulin G663u1 WIAF-13400 HT3157 1202 TPO, thyroidCGCCACGCGC[G/A]CCTGCGGCCT S G A A A peroxidase G663u2 WIAF-13401 HT31571282 TPO, thyroid GGCCGCGCCA[G/C]CGAGGTCCCC M G C S T peroxidase G668a1WIAF-13350 U53506 350 DI02, deiodinase, TCGATGCCTA[C/A]AAACAGGTGA N C AY * iodothyronine, type II G668a2 WIAF-13351 U53506 354 DI02,deiodinase, TGCCTACAAA[C/A]AGGTGAAATT M C A Q K iodothyronine, type IIG668a3 WIAF-13352 U53506 408 DI02, deiodinase, TGTCTCGACT[A/G]CAGAAGGAGGM A G T A iodothyronine, type II G673a1 WIAF-13328 M57464 1723 Human retproto- CGAGCCTGGC[C/A]AGCCCCGGGG M G A E K oncogene mRNA for tyrosinekinase. G673a2 WIAF-13338 M57464 1186 Human ret proto-GGCTCGCCCA[T/A[TTGCCCAGAT M T A F I oncogene mRNA for tyrosine kinase.G673a3 WIAF-13337 M57464 1227 Hunan ret proto- ACTGCCAGGC[G/A]TTCACTCGGAS G A A A oncogene mRNA for tyrosine kinase. G673a4 WIAF-13338 M574642118 Human ret proto- TTGGAAAAAC[T/A]CTAGGAGAAG S T A T T oncogene mRNAfor tyrosine kinase. G673a5 WIAF-13339 M57464 2238 Human ret proto-CGAGTGAGCT[T/C]CGAGACCTGC S T G L L oncogene mRNA for tyrosine kinase.G678a1 WIAF-13353 D49492 1439 GDF10, growth TCGGCTGGAA[T/A]GAATGCATAA MT A N K differentiation factor 10 G55u1 WIAF-10434 HT1115 1214 ERCC3,excision CTGTGGAGCA[G/A]TGGAAAGCCC S G A Q Q repair cross- complementingrodent repair deficiency, complementation group 3 (xeroderma pigmentosumgroup B complementing) G68u2 WIAF-10435 HT1115 1155 ERCC3, excisionTGTGACTGCT[G/C]CATGCACTGT M G C A P repair cross- complementing rodentrepair deficiency, complementation group 3 (xeroderma pigmentosum groupB complementing) G68u3 WIAF-10436 HT1115 1327 ERCC3, excisionAGCACCTACT[C/T]CATCCTGGGC M C T S F repair cross- complementing rodentrepair deficiency, complementation group 3 (xeroderma pigmentosum groupB complementing) G68u4 WIAF-10461 HT1115 926 ERCC3, excisionAGGAAATCAT[T/C]CACGAACTCC S T C I I repair cross- complementing rodentrepair deficiency, complementation group 3 (xeroderma pigmentosum groupB complementing) G68u5 WIAF-10464 HT1115 1430 ERCC3, excisionAAGTGCACAC[C/T]ATACCAGCCA S C T T T repair cross- complementing rodentrepair deficiency, complementation group 3 (xeroderma pigmentosum groupB complementing) G684a1 WIAF-13359 X51801 712 BMP7, bone morpho-GTTTATCACG[T/G]GCTCCACCAG M T G V G genetic protein 7 (osteogenicprotein 1) G684a2 WIAF-13360 X51801 719 BMP7, bone morpho-AGGTCCTCCA[G/A]GAGCACTTGG S G A Q Q genetic protein 7 (osteogenicprotein 1) G684a3 WIAF-13361 X51801 796 BMP7, bone morpho-GGCTGGCTGG[T/G]GTTTCACATC M T G V G genetic protein 7 (osteogenicprotein 1) G684a4 WIAF-13362 X51803 862 BMP7, bone morpho-GGCCTGCAGC[T/G]CTCGGTGGAG M T G L R genetic protein 7 (osteogenicprotein 1) G684a5 WIAF-13363 X51801 658 BMP7, bone morpho-ATCTACAAGG[A/G]CTACATCCGC M A G D G genetic protein 7 (osteogenicprotein 1) G684u6 WIAF-13834 X51801 1421 BMP7, bone morpho-GCCACTAGCT[C/T]CTCCCAGAAT — C T — — genetic protein 7 (osteogenicprotein 1) G685a1 WIAF-13329 D89675 882 BMPR1B, boneGTTCCCTTTA[T/G]GATTATCTGA N T G Y * morphogenetic protein receptor, typeIB G685a2 WIAF-13330 D89675 920 BMPR1B, bone GCTAAATCAA[T/C]GCTGAAGTTA MT C M T morphogenetic protein receptor, type IB G685a3 WIAF-13331 D89675770 BMPR1B, bone TATCACACAG[T/C]GTTCATGAGG M T G V G morphogeneticprotein receptor, type IB G685a4 WIAF-13340 D89675 1303 BMPR1B, boneTCCTTATCAT[C/A]ACCTACTGCC M G A D N morphogenetic protein receptor, typeIB G685a5 WIAF-13341 D89675 1372 BMPR1B, bone GTTACCCCCC[T/G]CATTCCCAAAM T G S A morphogenetic protein receptor, type IB G685a6 WIAF-13342D89675 1173 BMPR1B, bone TGTTGGACGA[C/A]AGCTTGAACA S G A E Emorphogenetic protein receptor, type IB G686u1 WIAF-13816 Z48923 2705BMPR2, bone AAATTTGGCA[G/A]CAAGCACAAA M G A S N morphogenetic proteinreceptor, type II (serine/ threonine kinase) G686u2 WIAF-13817 Z489232749 BMPR2, bone TGGAGTTGCC[A/T]AGATGAATAC N A T K * morphogeneticprotein receptor, type II (serine/threonine kinase) G687a1 WIAF-13343HT1455 626 CALB1, calbindin 1, ATGATCACGA[C/T]GGCAATCCAT S C T D D (28kD) G696u1 WIAF-11839 HT27700 1075 calcium-sensingGCCCACAATT[G/C]CACCTGATGA M G C A P receptor G696u2 WIAF-11840 HT277001551 calcium-sensing TACCTGTGGA[C/T]ACCTTTCTGA S C T D D receptor G696u3WIAF-11841 HT27700 1688 calcium-sensing TTACGGATAT[C/T]CTACAATGTG M C TS F receptor G696u4 WIAF-11842 HT27700 1698 calcium-sensing CCTACAATGT[G/T]TACTTACCAG S G T V V receptor G696u5 WIAF-11858 HT27700 1767calcium-sensing GGAGAGGGCT[C/T]TTCACCAATG S C T L L receptor G696u6WIAF-118S9 HT27700 1689 calcium-sensing TACGCATATC[C/T]TACAATGTGT S C TS S receptor G696u7 WIAF-11860 HT27700 2541 calcium-sensingTCGTCCTCTG[C/T]ATCTCATCCA S C T C C receptor G696u8 WIAF-11861 HT277002581 calcium-sensing TGTCCTCCTG[G/A]TGTTTGAGGC M G A V M receptor G696u9WIAF-11863 HT27700 3159 calcium-sensing TCTCCCGCAA[G/C]CGGTCCAGCA M G CK N receptor G696u10 WIAF-11872 HT27700 562 calcium-sensingTCCTATTCAT[T/AJTTCGAGTACC M T A F I receptor G696u11 WIAF-11878 HT277002941 calcium-sensing CATTCCAGCC[T/G]ATGCCAGCAC M T G Y D receptorG696u12 WIAF-13386 HT27700 1145 calcium-sensingAGGGATATCT[G/A]CATCGACTTC M G A C Y receptor G696u13 WIAF-13395 HT27700670 calcium-sensing CATATTTGCC[A/GJTAGAGGACAT M A G I V receptor G696u14WIAF-13396 HT27700 2243 calcium-sensing TTCTGGTCCA[A/G]TGAGAACCAC M A GN S receptor G696u15 WIAF-13397 HT27700 2742 calcium-sensingAGCTGGAGGA[T/C]GAGATCATCT S T C D D receptor G698u1 WIAF-13547 X61598393 CBP1, collagen- TCAGCAACTC[G/C]ACGGCGCGCA S G C S S binding protein1 G698u2 WIAF-13549 X61598 628 CBP1, collagen- CGGCGCCCTG[C/T]TAGTCAACGCS C T L L binding protein 1 G698u3 WIAF-13550 X61598 1230 CBP1,collagen- GCGGCTCCCT[G/A]CTATTCATTG S G A L L binding protein 1 G701u1WIAF-12382 HT27657 706 CGRP type I AACGATGTTG[C/A]AGCAGGAACT M C A A Ereceptor G701u2 WIAF-12391 HT27657 841 CGRP type ITGGACAAATT[A/T]TACCCAGTGT M A T Y F receptor G704u1 WIAF-14046 X603821396 COL10A1, collagen, AGGCATTCCA[G/A]GATTCCCTGG M G A G R type X,alpha 1 (Schmid meta- physeal chondro- dysplasia) G704u2 WIAF-14070X60382 1648 COL10A1, collagen, TGCCAACCAG[G/C]CGGTAACAGC M G C G R typeX, alpha 1 (Schmid meta- physeal chondro- dysplasia) G704u3 WIAF-14071X60382 1824 COL10A1, collagen, CATACCACGT[G/C]CATCTGAAAG S G C V V typeX, alpha 1 (Schmid meta- physeal chondro- dysplasia) G704u4 WIAF-14072X60382 1582 COL10A1, collagen, AGTCATCCCT[C/C]ACGGTTTTAT M G C E Q typeX, alpha 1 (Schmid meta- physeal chondro- dysplasia) G705a1 WIAF-13228J04177 686 COL11A1, collagen, ACAACAAAAC[T/A]GTCACAATCA S T A T T typeXI, alpha 1 G705a2 WIAF-13229 J04177 698 COL11A1, collagen,TGACAATCAT[T/A]GTTGATTGTA S T A I I type XI, alpha 1 G705a3 WIAF-13230J04177 8881 COL11A1, collagen, TACTCCACAC[T/A]CTGACTCTTC M T A C S typeXI, alpha 1 G705a4 WIAF-13231 J04177 894 COL11A1, collagen,AGACTGTGAC[T/A]CTTCAGCACC M T A S T type XI, alpha 1 G705a5 WIAF-13232J04177 651 COL11A1, collagen, TGACCGCAAG[T/A]CCCATCCCCT M T A W R typeXI, alpha 1 G705a6 WIAF-13233 J04177 661 COL11A1, collagen,TGGCATCGGG[T/A]AGCAATCAGC M T A V E type XI, alpha 1 G705a7 WIAF-13234J04177 1597 COL11A1, collagen, CGTCCTGGCT[T/C]ACCAGGGGCT M T C L S typeXI, alpha 1 G705a8 WIAF-13235 J04177 2745 COL11A1, collagen,TGGGTTTCCA[C/A]GTGCCAATGG M G A G S type XI, alpha 1 G705a9 WIAF-13236J04177 4385 COL11A1, collagen, GTCCAGAAGG[T/A]CTTCGGGGCA S T A G G typeXI, alpha 1 G705a10 WIAF-13237 J04177 4576 COL11A1, collagen,GAAAAAGGTG[A/T]CCGAGGGGTC M A T D V type XI, alpha 1 G705a11 WIAF-13238J04177 4306 COL11A1, collagen, GCTAAGGGGG[A/C]AGCAGGTCCA M A C E A typeXI, alpha 1 G705a12 WIAF-13239 J04177 4837 COL11A1, collagen,AGACATACTG[A/G]AGGCATGCAA M A G E G type XI, alpha 1 G705a13 WIAF-13240J04177 4931 COL11A1, collagen, AACAAGACAT[C/T]CACCATATGA S C T I I typeXI, alpha 1 G705a14 WIAF-13346 J04177 299 COL11A1, collagen,AAGCACTAGA[T/G]TTTCACAATT M T G D E type XI, alpha 1 G705a15 WIAF-13347J04177 2225 COL11A1, collagen, GGGAGCCTGG[G/C]CCTCCAGGTC S G C G G typeXI, alpha 1 G705u16 WIAF-13679 J04177 5493 COL11A1, collagen,AATTCATCAA[G/A]TACCTATTGT M G A V I type XI, alpha 1 G705u17 WIAF-13700J04177 3484 COL11A1, collagen, GGACTTCAAG[G/A]TCCTGTTGGT M G A G D typeXI, alpha 1 G705u18 WIAF-13709 J04177 5392 COL11A1, collagen,GACATGTCCT[A/T]TGACAATAAT M A T Y F type XI, alpha 1 G707u1 WIAF-12363U32169 4996 COL11A2, collagen, TCCCCTGAGA[C/T]TCCGTGGGGC M C T L F typeXI, alpha 2 G707u2 WIAF-12374 U32169 3580 COL11A2, collagen,CAATGGCCCT[C/A]ATGGCCCACA M G A D N type XI, alpha 2 G707u3 WIAF-12385U32169 2059 COL11A2, collagen, GCCTGGCTCA[C/A]ACGGACCCCC M G A D N typeXI, alpha 2 G708a1 WIAF-13354 U73778 1885 COL12A1, collagen,GCCTCTCCTC[C/T]TCCACAGACC M C T P L type XII, alpha 1 G708a2 WIAF-13355U73778 3630 COL12A1, collagen, TGTTGGACAA[C/A]AAATGACAAC M G A E K typeXII, alpha 1 G708a3 WIAF-13356 U73778 3905 COL12A1, collagen,GCTTCTTGCA[A/T]GCTCTGGCAA M A T Q H type XII, alpha 1 G708a4 WIAF-13357U73778 7051 COL12A1, collagen, ATTCCACCAG[C/A]CCGGGATGTA M C A A D typeXII, alpha 1 G708a5 WIAF-13358 U73778 8036 COL12A1, collagen,AAGAAGTAAA[C/A]ACATTATTTT S G A K K type XII, alpha 1 G708a6 WIAF-13364U73778 1461 COL12A1, collagen, TGGCTCCTAT[A/T]GCATTGGGAT M A T S C typeXII, alpha 1 G708a7 WIAF-13365 U73778 2344 COL12A1, collagen,ATTACTTGGA[C/T]TCAAGCTCCA M C T T I type XII, alpha 1 G708a8 WIAF-13366U73778 5207 COL12A1, collagen, CAGATAAGAT[C/A]GAGACCATCT M G A M I typeXII, alpha 1 G708a9 WIAF-13367 U73778 6592 COL12A1, collagen,GAGCCCATGG[A/T]AGCCTTTGTT M A T E V type XII, alpha 1 G708a10 WIAF-13368U73778 7434 COL12A1, collagen, CCAGGATGAG[G/A]TCAACAAGGC M G A V I typeXII, alpha 1 G708a11 WIAF-13369 U73778 9108 COL12A1, collagen,ACCTCGGGGG[C/G]TGCCTGGGCC M C G L V type XII, alpha 1 G708a12 WIAF-13370U73778 9111 COL12A1, collagen, TCGGGGGCTG[C/T]CTGGGCCCCC M C T P S typeXII, alpha 1 G708a13 WIAF-13371 U73778 9196 COL12A1, collagen,CCCCCTGGCC[G/A]TCCTGGAAAC M G A R H type XII, alpha 1 G708u14 WIAF-13972U73778 3044 COL12A1, collagen, CAGTATTTGC[C/A]ACTTACAGCA S C A A A typeXII, alpha 1 G708u15 WIAF-13977 U73778 5853 COL12A1, collagen,TCTGACTCTA[G/C]TTCCCGTTTA M G C V L type XII, alpha 1 G710u1 WIAF-12371D38163 3082 COL19A1, collagen, AGGAAACAAG[C/T]GCTCCATGGG M G T G C typeXIX, alpha 1 G710u2 WIAF-12388 D38163 2089 COL19A1, collagen,TCCAGGGACT[C/T]CAGGCAATGA M C T P S type XIX, alpha l C711u1 WIAF-12360L25286 1449 COL15A1, collagen, TGTGGGTCCA[A/C]GCACTCAACA M A G S G typeXV, alpha 1 C711u2 WIAF-12372 L25286 4001 COL15A1, collagen,ATATTCCAAT[A/C]TACTCCTTTC M A G I M type XV, alpha 1 G711u3 WIAF-12373L25286 3867 COL15A1, collagen, CCATTTGCAA[G/T]ATCTGTCCAC M G T D Y typeXV, alpha 1 C711a4 WIAF-13372 L25286 395 COL15A1, collagen,CCACCAGCAC[C/T]CGTGCTGCCG S C T T T type XV, alpha 1 C711a5 WIAF-13373L25286 3101 COL15A1, collagen, AAGGCGACCA[G/A]GGACCCCAGG S G A Q Q typeXV, alpha 1 G712u1 WIAF-13619 M92642 3608 COL16A1, collagen,GGCGACCAGG[C/A]ATTTCAAGGC M G A G E type XVI, alpha 1 G712u2 WIAF-13620M92642 4944 COL16A1, collagen, CCATGAAAAC[C/T]ATGAAGGGGC S C T T T typeXVI, alpha 1 G712u3 WIAF-13621 M92642 4707 COL16A1, collagen,CCAAACGTCA[A/C]AAAGGGGACA M A C E D type XVI, alpha 1 G712u4 WIAF-13654M92642 421 COL16A1, collagen, GCCCACGCCA[C/A]GAGTATTCCC S C A R R typeXVI, alpha 1 G712u5 WIAF-13655 M92642 444 COL16A1, collagen,GGGGTCTCCC[G/A]GAGGAGTTTG S G A P P type XVI, alpha 1 G712u6 WIAF-13656M92642 338 COL16A1, collagen, CTCATGAAGA[A/C]GTCTGCCATC M A C K T typeXVI, alpha 1 G712u7 WIAF-13862 M92642 3227 COL16A1, collagen,CCTGGTCCTC[C/T]GGGATTCCCA M C T P L type XVI, alpha 1 G712u8 WIAF-13863M92642 3199 COL16A1, collagen, TCCTGGCTGT[G/T]TTGGGAGCCC M G T V F typeXVI, alpha 1 G712u9 WIAF-13878 M92642 318 COL16A1, collagen,ACCTCATCCA[C/T]CGACTCAGCC S C T H H type XVI, alpha 1 G712u10 WIAF-13882M92642 1346 COL16A1, collagen, ACAGGCGAGA[A/G]GGGCCAGAAA M A G K R typeXVI, alpha 1 G712u11 WIAF-13883 M92642 1309 COL16A1, collagen,GTCACGACCT[C/T]TGGGACCCTC S C T L L type XVI, alpha 1 G715a1 WIAF-13344Z74615 3504 COL1A1, collagen, TCCTGGTGAA[C/G]AAGGTCCCTC M C G Q E typeI, alpha 1 G717u1 WIAF-12639 Z74616 3988 COL1A2, collagen,ATGAGGAGAC[T/C]GGCAACCTGA S T C T T type I, alpha 2 G720u1 WIAF-12367X14420 3494 COL3A1, collagen, GGTGCAATCG[G/A]CAGTCCAGGA M G A G D typeIII, alpha 1 (Ehlers-Danlos syndrome type IV, autosomal dominant) G720u2WIAF-12383 X14420 3035 COL3A1, collagen, GGTGTCAAGG[G/A]TGAAAGTGGG M G AG D type III, alpha 1 (Ehlers-Danlos syndrome type IV, autosomaldominant) G720a3 WIAF-13374 X14420 214 COL3A1, collagen,TCTTGGTCAG[T/C]CCTATGCGGA M T C S P type III, alpha 1 (Ehlers-Danlossyndrome type IV, autosomal dominant) G720a4 WIAF-13375 X14420 1953COL3A1, collagen, CTGGACCTCA[A/G]GGACCCCCAG S A G Q Q type III, alpha 1(Ehlers-Danlos syndrome type IV, autosomal dominant) G720a5 WIAF-13376X14420 2194 COL3A1, collagen, TAGAGGTGGA[G/A]CTGGTCCCCC M G A A T typeIII, alpha 1 (Ehlers-Danlos syndrome type IV, autosomal dominant) G720a6WIAF-13377 X14420 3731 COL3A1, collagen, GGGATTGGAG[G/A]TGAAAAAGCT M G AG D type III, alpha 1 (Ehlers-Danlos syndrome type IV, autosomaldominant) G722u1 WIAF-14132 HT3162 140 COL4A2, collagen,GAGATTGGCG[C/T]GACTGGTGAT M C T A V type IV, alpha 2 G724a1 WIAF-12120X81053 3892 COL4A4, collagen, CTCGTGGAAA[G/A]AAAGGTCCCC S G A K K typeIV, alpha 4 G724a2 WIAF-12121 X81053 4187 COL4A4, collagen,GAAAGGACCA[A/G]TGGGATTCCC M A G H V type IV, alpha 4 G724a3 WIAF-12122X81053 3802 COL4A4, collagen, ATGATGTGGG[G/A]CCACCTGGTC S G A G G typeIV, alpha 4 G724a4 WIAF-12123 X81053 1838 COL4A4, collagen,ACCAGGAAAG[C/A]ATGGTGCCTC M C A H N type IV, alpha 4 G724u5 WIAF-12364X81053 376 COL4A4, collagen, CTGTTTGCCA[C/T[TGTCTTCCTG S C T H H typeIV, alpha 4 G724u6 WIAF-12365 X81053 2018 COL4A4, collagen,TCCAGGGGAT[C/G]ATGAACATGC M C G H D type IV, alpha 4 G724u7 WIAF-12366X81053 4756 COL4A4, collagen, GCCTTCCCCT[A/G]TTTACCACGC S A G V V typeIV, alpha 4 G724u8 WIAF-12377 X81053 3595 COL4A4, collagen,CTGGACCACC[A/G]GGGTGCCCAG S A G P P type IV, alpha 4 G724u9 WIAF-12378X81053 3516 COL4A4, collagen, GGAGCATCCG[C/C]ACACCAGGGC M G C G A typeIV, alpha 4 G724u10 WIAF-12379 X81053 4288 COL4A4, collagen,CTGGTCTTCC[A/G]GCTCCCAGAG S A G P P type IV, alpha 4 G724u11 WIAF-12380X81053 5140 COL4A4, collagen, GCCACTTTTT[C/A]GCAAATAAGT M C A F L typeIV, alpha 4 G724u12 WIAF-12387 X81053 207 COL4A4, collagen,GACTTCCCTG[C/T]GATGTGGTCT — C T — — type IV, alpha 4 G727u1 WIAF-12362D90279 5135 COL5A1, collagen, TTCAACGTTT[A/T]CTGCAACTTC M A T Y F typeV, alpha 1 G727u2 WIAF-12369 D90279 4686 COL5A1, collagen,AACAGGGTAT[C/T]ACTGCTCCTT S C T I I type V, alpha 1 G727u3 WIAF-12370D90279 4608 COL5A1, collagen, TCGGTCCTCC[G/C]GCTGAACAGG S G C P P typeV, alpha 1 G727a4 WIAF-13300 D90279 2034 COL5A1, collagen,ACGGCCTGGC[T/A]GGGTTGCCAG S T A A A type V, alpha 1 G727a5 WIAF-13301D90279 2073 COL5A1, collagen, GTGACCCTGG[T/C]CCTTCCGGCC S T C G G typeV, alpha 1 G727a6 WIAF-13302 D90279 3763 COL5A1, collagen,CGGGCACAAA[G/A]GTGATGAAGG M G A G S type V, alpha 1 G729u1 WIAF-11844L02870 2345 COL7A1, collagen, ATGGACTGGA[G/A]CCAGATACTG S G A E E typeVII, alpha 1 (epidermolysis bullosa, dys- trophic, dominant andrecessive) G729u2 WIAF-11845 L02870 3083 COL7A1, collagen,TATCCTGGCG[G/A]CCACTCAGAG S G A R R type VII, alpha 1 (epidermolysisbullosa, dys- trophic, dominant and recessive) G729u3 WIAF-11846 L028103031 COL7A1, collagen, GACTCGGTGA[C/T]TTTGGCCTGG M C T T I type VII,alpha 1 (epidermolysis bullosa, dys- trophic, dominant and recessive)G729u4 WIAF-11851 L02870 1289 COL7A1, collagen,CGGACTATGA[G/T]GTGACCGTGA M G T E D type VII, alpha 1 (epidermolysisbullosa, dys- trophic, dominant and recessive) G729u5 WIAF-11852 L028701032 COL7A1, collagen, CCAAGTGACT[G/T]TGATTGCCCT M G T V L type VII,alpha 1 (epidermolysis bullosa, dys- trophic, dominant and recessive)G729u6 WIAF-11853 L02870 1897 COL7A1, collagen,CGCCGGGAGC[C/T]GGAAACTCCA M C T P L type VII, alpha 1 (epidermolysisbullosa, dys- trophic, dominant and recessive) G729u7 WIAF-11854 L028701827 COL7A1, collagen, GCTTAGCTAC[A/T]CTGTGCGGGT M A T T S type VII,alpha 1 (epidermolysis bullosa, dys- trophic, dominant and recessive)G729u8 WIAF-11855 L02870 1893 COL7A1, collagen,TGTCCGCCGG[G/A]AGCCCGAAAC M G A E K type VII, alpha 1 (epidermolysisbullosa, dys- trophic, dominant and recessive) G729u9 WIAF-11864 L028702142 COL7A1, collagen, GGGCCCTGCT[G/A]CAGTCATCGT M G A A T type VII,alpha 1 (epidermolysis bullosa, dys- trophic, dominant and recessive)G729u10 WIAF-11865 L02870 2353 COL7A1, collagen,GAGCCAGATA(C/T]TGAGTATACG M C T T I type VII, alpha 1 (epidermolysisbullosa, dys- trophic, dominant and recessive) G729u11 WIAF-11866 L028702221 COL7A1, collagen, TCATCTGTCA[C/T]CATTACCTGG M C T T I type VII,alpha (epidermolysis bullosa, dys- trophic, dominant and recessive)G729u12 WIAF-11869 L02870 6585 COL7A1, collagen,ACCAGGAGAG[C/T]GTGGTATGGC M C T R C type VII, alpha 1 (epidermolysisbullosa, dys- trophic, dominant and recessive) G729u13 WIAF-11870 L028708169 COL7A1, collagen, GGGTGACCGA[G/T]GCTTTGACGG M G T G C type VII,alpha 1 (epidermolysis bullosa, dys- trophic, dominant and recessive)G729u14 WIAF-11877 L02870 438 COL7A1, collagen,CGCCATCCGT[G/A]AGCTTAGCTA M G A E K type VII, alpha 1 (epidermolysisbullosa, dys- trophic, dominant and recessive) G729u15 WIAF-11882 L028703481 COL7A1, collagen, AGGATCCGTG[A/T]CATGCCCTAC M A T D V type VII,alpha 1 (epidermolysis bullosa, dys- trophic, dominant and recessive)G729u16 WIAF-11883 L02870 5654 COL7A1, collagen,ACGGAGAACC[T/C]GGGGACCCTG S T C P P type VII, alpha 1 (epidermolysisbullosa, dys- trophic, dominant and recessive) G729u17 WIAF-11884 L028707124 COL7A1, collagen, TGCCAGGGCC[G/C]CGAGGCCAGA S G C P P type VII,alpha 1 (epidermolysis bullosa, dys- trophic, dominant and recessive)G729u18 WIAF-11885 L02870 7757 COL7A1, collagen,CCTTGGATGG[T/C]GACAAAGGAC S T C G C type VII, alpha 1 (epidermolysisbullosa, dys- trophic, dominant and recessive) G729u19 WIAF-13389 L028701615 COL7A1, collagen, ACCGTGGTTC[C/T]CACTGGACCA M C T P L type VII,alpha 1 (epidermolysis bullosa, dys- trophic, dominant and recessive)G729u20 WIAF-13390 L02870 2930 COL7A1, collagen,TCCTAGGGCC[G/A]GCTGGAGAAG S G A P P type VII, alpha 1 (epidermolysisbullosa, dys- trophic, dominant and recessive) G729u21 WIAF-13399 L028705145 COL7A1, collagen, CCAGCGACAT[C/T]CTGGACAGGA M C T P S type VII,alpha 1 (epidermolysis bullosa, dys- trophic, dominant and recessive)G729u22 WIAF-13411 L02870 3472 COL7A1, collagen,ATCTTGCAAA[G/A]GATCCCTGAC M G A R K type VII, alpha 1 (epidermolysisbullosa, dys- trophic, dominant and recessive) G730a1 WIAF-13303 X57527305 COL8A1, collagen, ATGGGCAAGG[A/G]AGCCGTTCCC M A G E G type VIII,alpha 1 G732u1 WIAF-l26l6 M95610 936 COL9A2, collagen,CACGGGCCAC[A/G]GCCCGGAACT S A G T T type IX, alpha 2 G732u2 WIAF-12617M95610 696 COL9A2, collagen, AAGGGAGAGA[C/T]GGGCCCTCAT S C T D D typeIX, alpha 2 G732u3 WIAF-12619 M95610 1288 COL9A2, collagen,AACTCGGTCA[C/T]CCAGCGCTCG H C T P S type IX, alpha 2 G732u4 WIAF-12620M95610 962 COL9A2, collagen, CCACCAGCCC[C/G]TAGCGCCTCT M C G P R typeIX, alpha 2 G737u1 WIAF-13394 M13436 ? INHBA, inhibin, TGCTCCCTG[G/T] ?G T beta A (activin A, activin AB alpha polypeptide) G738a1 WIAF-13383M58549 183 MGP, matrix Gla ATGGAGAGCT[A/G]AAGTCCAAGA M A G K E proteinG738a2 WIAF-13384 M58549 330 MGP, matrix Gla GCGCCGAGGG[A/G]CCAAATGAGA MA G T A protein G739u1 WIAF-11867 U94332 862 TNFRSF11B, tumorTGCTGAAGTT[A/G]TGGAAACATC S A G L L necrosis factor receptor super-family, member 11b (osteoprotegerin) G739u2 WIAF-11874 U94332 1244TNFRSP11B, tumor GTATCACAAG[T/C]TATTTTTAGA S T C L L necrosis factorreceptor-super- family, member 11b (osteoprotegerin) G743u1 WIAF-13402HT847 1669 PTHR1, parathyroid CCCTGGAGAC[C/A]CTCGAGACCA S C A T Thormone receptor 1 G747u1 WIAF-12414 J03040 123 SPARC, secretedCTCAGCAAGA[A/G]GCCCTGCCTG S A G E E protein, acidic, cysteine-rich(osteonectin) G748u1 WIAF-12628 HT0157 117 VDR, vitamin DCCTTCAGGGA[T/C]GGAGGCAATG M T C M T (1,25-dihydroxy- vitamin D3)receptor G748u2 WIAF-12629 HT0157 1171 VDR, vitamin DCCGCGCTGAT[T/C]GAGGCCATCC S T C I I (1,25-dihydroxy- vitamin D3)receptor G748u3 WIAF-12640 HT0157 172 VDR, vitamin DTTGACCGGAA[C/T]GTGCCCCGGA S C T N N (1,25-dihydroxy- vitamin D3)receptor G749u1 WIAF-11862 HT3734 679 osteopontin, alt.ATCACCTCAC[A/T]CATGGAAAGC M A T H L transcript 1 G749u2 WIAF-11875HT3734 386 osteopontin, alt. AAGATGATGA[A/G]GACCATGTGG S A G D Dtranscript 1 G749u3 WIAF-11876 HT3734 419 osteopontin, alt.CCATTGACTC[C/A]AACCACTCTC S G A S S transcript 1 G749a4 WIAF-12084HT3734 171 osteopontin, alt. TAAACAGGCT[G/A]ATTCTCGAAC M G A D Ntranscript 1 G749u5 WIAF-13387 HT3734 738 osteopontin, alt.CCAGGACCTG[A/C]ACGCGCCTTC M A C N H transcript 1 G749u6 WIAF-13388HT3734 716 osteopontin, alt. CATACAAGGC[C/A]ATCCCCGTTC S C A A Atranscript 1 G751u1 WIAF-12631 HT5036 410 ADM, GACAGCAGTC[C/G]GGATGCCGCCM C G P R adrenomedullin G752u1 WIAF-11843 HT1782 1405 CHGA,chromogranin CGGCCATTGA[A/G]GCAGAGCTGG S A G E E A (parathyroidsecretory protein 1) G752u2 WIAF-11873 HT1782 1187 CHGA, chromograninGGACAACCCG[C/A]ACAGTTCCAT M G A D N A (parathyroid secretory protein 1)G754a1 WIAF-13382 K02043 663 NPPA, natriuretic GTACAATGCC[C/A]TGTCCAACGCM G A V M peptide precursor A G756u1 WIAF-12395 HT3508 2086 SCNN1A,sodium CAGTTCCTCC[A/G]CCTGTCCTCT ? A G T A channel, non- voltage-gated 1alpha G757u1 WIAF-12420 HT28563 797 SCNN1B, sodiumCCTGCAGGCC[A/C]CCAACATCTT M A C T P channel, non- voltage-gated 1, beta(Liddle syndrome) G757u2 WIAF-12421 HT28563 1006 SCNN1B, sodium channel,non- voltage-gated 1, beta (Liddle syndrome) G757u3 WIAF-12430 HT285631768 SCNN1B, sodium TCATCGACTT[T/C]GTGTGGATCA S T C F F channel, non-voltage-gated 1, beta (Liddle syndrome) G757u4 WIAF-12494 HT28563 662SCNN1B, sodium AAGCAGCTCA[G/C]CATCAGAAAA M G C A P channel, non-voltage-gated 1, beta (Liddle syndrome) G757u5 WIAF-12506 HT28563 1091SCNN1B, sodium GATGCTTCAC[G/C]AGCAGAGCTC M G C E Q channel, non-voltage-gated 1, beta (Liddle syndrome) G757u6 WIAF-12507 HT28563 1452SCNN1B, sodium ACCTGCATTC[C/T]CATCTGCAAG M G T G V channel, non-voltage-gated 1, beta (Liddle syndrome) G758u1 WIAF-12621 HT27856 415SCNN1D, sodium CGGGAACCCA[C/T]GTCGGCCGAG M C T R C channel, non-voltage-gated 1, delta G758u2 WIAF-12632 HT27856 325 SCNN1D, sodiumCCTCTTTGAG[C/T]GTCACTGCCA M C T R C channel, non- voltage-gated 1, deltaG758u3 WIAF-12634 HT27856 879 SCNN1D, sodium ATGGCGTCTG[C/A]ACAGCTCAGC NG A W * channel, non- voltage-gated 1, delta G758u4 WIAF-12635 HT278561138 SCNN1D, sodium CGTGGAGGTG[G/C]AGCTCCTACA M G C E Q channel, non-voltage-gated 1, delta G762u1 WIAF-12622 HT27531 1850 NPR3, natriureticTAGGACCTGG[C/T]TTGCTAATGG S C T G G peptide receptor C/guanylate cyclaseC (atrionatriuretic peptide receptor C) G762u2 WIAF-12623 HT27531 1926NPR3, natriuretic AGAAGAAAGT[A/G]ACCTTGGAAA M A G N D peptide receptorC/guanylate cyclase C (atrionatriuretic peptide receptor C) C) G762u3WIAF-12624 HT27531 1791 NPR3, natriuretic CAAATCATCA[G/T]GTGGCCTAGA M GT G C peptide receptor C/guanylate cyclase C (atrionatriuretic peptidereceptor G762u4 WIAF-12636 HT27531 1963 NPR3, natriureticGAAGATTCCA[T/C]CAGATCCCAT M T C I T peptide receptor C/guanylate cyclaseC (atrionatriuretic peptide receptor C) G763u1 WIAF-12659 HT3183 1633NPR2, natriuretic CTGGGCCCTT[C/T]CCTGATGAAC M C T S F peptide receptorB/guanylate cyclase B (atrionatriuretic peptide receptor B) G763u2WIAF-12678 HT3183 668 NPR2, natriuretic TGCCATCACT[T/C]CTGCTGTTGG S T CL L peptide receptor B/guanylate cyclase B (atrionatriuretic peptidereceptor B) G763u3 WIAF-12684 HT3183 2354 NPR2, natriureticTGTTTGAACT[C/T]AAACATATGA S C T L L peptide receptor B/guanylate cyclaseB (atrionatriuretic peptide receptor B) G764u1 WIAF-12698 HT1221 3021NPR1, natriuretic CCCCGTTACT[C/T]TCTCTTTGGG M G T C F peptide receptorA/guanylate cyclase A (atrionatriuretic peptide receptor A) G764u2WIAF-12706 HT1221 588 NPR1, natriuretic GAGCGCCAAG[C/T]GCTCATGCTC M C TA V peptide receptor A/guanylate cyclase A (atrionatriuretic peptidereceptor A) G764u3 WIAF-12709 HT1221 1897 NPR1, natriureticGTCCCCGTGG[G/A]AGCCTGCAGG S G A G G peptide receptor A/guanylate cyclaseA (atrionatriuretic peptide receptor A) G765u1 WIAF-10012 HT2456 604DCP1, dipeptidyl GCTGGCACAA[A/G]GCTGCGGGCA S A G N N carboxypeptidase 1(angiotensin I converting enzyme) G765u2 WIAF-10014 HT2456 2350 DCP1,dipeptidyl TGATGGCCAC[A/G]TCCCGCAAAT S A G T T carboxypeptidase 1(angiotensin I converting enzyme) G765u3 WIAF-10025 HT2456 1688 DCP1,dipeptidyl CCCACTGCAC[C/A]AGTGTCACAT M C A Q K carboxypeptidase 1(angiotensin I converting enzyme) G765u4 WIAF-10027 HT2456 3220 DCP1,dipeptidyl TCCCCTTCAG[C/T]TACCTCGTCG S C T S S carboxypeptidase 1(angiotensin I converting enzyme) G765u5 WIAF-10028 HT2456 3409 DCP1,dipeptidyl TCAGGTACTT[T/C]GTCAGCTTCA S T C F F carboxypeptidase 1(angiotensin I converting enzyme) G765u6 WIAF-10040 HT2456 775 DCP1,dipeptidyl AGCCCCTCTA[C/T]CTGAACCTCC S C T Y Y carboxypeptidase 1(angiotensin I converting enzyme) G772u1 WIAF-12626 HT2121 1064 AVPR2,arginine TCAGCAGCAC[C/T]GTGTCCTCAG S C T S S vasopressin receptor 2(nephrogenic diabetes insipidus) G772u2 WIAF-12627 HT2121 998 AVPR2,arginine CCTTTGTGCT[A/G]CTCATGTTGC S A G L L vasopressin receptor 2(nephrogenic diabetes insipidus) G773u1 WIAF-12644 HT2141 163 SLC6A6,solute CTAGCAAGAT[C/T]GACTTTGTGC S C T I I carrier family 6(neurotransmitter transporter, taurine), member 6 G773u2 WIAF-12645HT2141 445 SLC6A6, solute TCGTCATCCT[G/C]GCCTGGGCCA S G C L L carrierfamily 6 (neurotransmitter transporter, taurine), member 6 G773u3WIAF-12665 HT2141 289 SLC6A6, solute TCTTTGGGAG[C/T]GGCCTGCCTG S C T S Scarrier family 6 (neurotranemitter transporter, taurine), member 6G773u4 WIAF-12666 HT2141 382 SLC6A6, solute CCTTGTTCTC[T/C]GGTATCGGCT ST C S S carrier family 6 (neurotransmitter transporter, taurine), member6 G776u1 WIAF-11857 U66088 1457 SLC6A6, solute TAGAACACCT[C/T]ATCAAACCTCS C T L L carrier family 5 (sodium iodide symporter), member 5 G776u2WIAF-11871 U66088 2039 SLC5A5, solute GATTGTTGTG[G/C]TGGGACCTCG M G C WC carrier family 5 (sodium iodide symporter), member 5 G776u3 WIAF-13398U66088 1379 SLC5A5, solute GGCTTTTCCT[G/A]GCCTGTGCTT S G A L L carrierfamily 5 (sodium iodide symporter), member 5 G777u1 WIAF-12646 HT278434348 SMRT ATACAATATC[A/G]GCCACCCTGG M A G S G G777u2 WIAF-12654 HT278432031 SMRT CTGAGCTGGG[T/C]AACCCGCGCC S T C G G G777u3 WIAF-12655 HT276432052 SMRT ACACCCCCCT[C/A]ACCTATCACC S G A L L G777u4 WIAF-12675 HT278432205 SMRT CTCGTGACAT[C/T]GCCAAGTCCC S C T I I G778u1 WIAF-14093 HT14498212 TG, thyroglobulin ATCTCCTCTC[T/C]GAACACATCT M T C L P G778u2WIAF-14111 HT1449 6033 TG, thyroglobulin ATGTCAACGA[C/T]CGTGCGATGC M C TR W G778u3 WIAF-14112 HT1449 6894 TG, thyroglobulinGTATCTCAAT[G/T]TGTTCATCCC M G T V L G778u4 WIAF-14125 HT1449 2375 TG,thyroglobulin ATGGCCCTCC[T/C]GAGCACCTCT S T C P P G778u5 WIAF-14136HT1449 1931 TG, thyroglobulin ACCATCTCCA[A/C]TCCTTTTCCC S A G Q Q G783u1WIAF-12649 X97674 4008 H. sapiens mRNA for CTACTGGTAT[G/C]CCAGCAACTA M GC M I transcriptional intermediary factor 2. G783u2 WIAF-12658 X976742566 H. sapiens mRNA for GCCTGCCACT[G/A]AGCTGCACAA M G A E Ktranscriptional intermediary factor 2. G783u3 WIAF-12671 X97674 3828 H.sapiens mRNA for CTCTGAGCCC[T/C]GGACTACCAA S T C P P transcriptionalintermediary factor 2. G785u1 WIAF-13385 HT1291 386 TTR, transthyretinCCAACCACTC[C/T]GCCCCCCGCC S C T S S (prealbumin, amyloidosis type I)G787u1 WIAF-12652 HT27477 468 TRIP15: thyroid GAAAATTATA[T/C]TTAGAACGAGS T C Y Y receptor interacting protein 15 G792u1 WIAF-12661 HT27476 265thyroid receptor CAGCTGGAAC[G/A]TGAACAGGGC M G A V M interactor 14G793u1 WIAF-12643 HT5152 458 thyroid receptor GGAACCTTTT[C/G]AAAGAATGTTN C G S * interactor 8 G794u1 WIAF-12664 HT5136 1110 PSMC5, proteasomeGCGTGTCCAC[G/A]GAACCTGGCA S G A T T (prosome, macro- pain) 26S subunit,ATPase, 5 G797u1 WIAF-11847 HT3919 140 glutamate receptorCTCACGGAGG[A/G]TTCCCCAACA S A G G G 3, flip isoform G797u2 WIAF-11848HT3919 759 glutamate receptor GGTTGTGATC[C/T]TAGGGAAACA S C T L L 3,flip isoform G797u3 WIAF-11849 HT3919 1253 glutamate receptorGCTACTCCAA[C/T]GACTATGAAA S C T N N 3, flip isoform G797u4 WIAF-11850HT3919 1770 glutamate receptor TCTTTTCCTA[C/A]TCAGCACGTT M G A V I 3,flip isoform G797u5 WIAF-13404 HT3919 2711 glutamate receptorGCTACAACGT[G/A]TATGGAACAG S G A V V 3, flip isoform G797u6 WIAF-13405HT3919 2376 glutamate receptor CTCAGCATTA[G/A]GAACGCCTGT M G A G R 3,flip isoform G798u1 WIAF-11868 X77748 2655 GRM3, glutamateTGCAGACGAC[A/G]ACCATGTGCA S A G T T receptor, metabo- tropic 3 G798u2WIAF-11879 X77748 2771 GRM3, glutamate CACAGACTCC[A/G]CCTCAACAGG M A G HR receptor, metabotropic 3 G798a3 WIAF-12085 X77748 2699 GRM3, glutamateGTGGTCTTGG[G/C]CTGTTTGTTT M G C G A receptor, metabotropic 3 G798a4WIAF-12086 X77748 2738 GRM3, glutamate ATCCTGTTTC[A/G]ACCCCAGAAG M A G QR receptor, metabotropic 3 G798a5 WIAF-12087 X77748 2072 GRM3, glutamateACACCCTTGG[T/C]CAAAGCATCG M T C V A receptor, metabotropic 3 G798a6WIAF-12088 X77748 2235 GRM3, glutamate CCCTGCTCAC[C/TI AAGACAAACT S C TT T receptor, metabotropic 3 G798u7 WIAF-13391 X77748 1131 GRM3,glutamate GCGCCAATGC[C/T]TCCTTCACCT S C T A A receptor, metabotropic 3G799u1 WIAF-11880 M81883 2000 GAD1, glutamate CAACAAATGC[C/T]TGGAACTGGCS C T L L decarboxylase 1 (brain, 67 kD) G799u2 WIAF-11881 M81883 1822GAD1, glutamate AGGGTATACT[C/T]CAAGGATCCA S C T L L decarboxylase 1(brain, 67 kD) G799u3 WIAF-13392 M81883 661 GAD1, glutamateGCGTGGCCCA[T/C]GGATGCACCA S T C H H decarboxylase 1 (brain, 67 kD)G799u4 WIAF-13393 M81883 556 GAD1, glutamate AGCTGATGGC[G/A]TCTTCGACCC SG A A A decarboxylase 1 (brain, 67 kD) G799u5 WIAF-13410 M81883 1229GAD1, glutamate CCTCATGGAA[C/T]AAATAACACT N C T Q * decarboxylase 1(brain, 67 kD) G801u1 WIAF-13403 D49394 1596 HTR3, 5-hydroxy-TTTACCTGCT[A/G]GCGGTGCTGG S A G L L tryptamine (serotonin) receptor 3G803a1 WIAF-13118 U66406 1446 EFNB3, ephrin-B3 CTGGGCCTGG[G/A]GGGTGGAGGTM G A G E G804u1 WIAF-11887 Z26653 7237 LAMA2, laminin,TCACTGATGG[G/T]CACATAAAAG S G T G G alpha 2 (merosin, congenitalmuscular dystrophy) G804u2 WIAF-11901 Z26653 9351 LAMA2, laminin,GCAAGCCACT[G/C]GAGGTTAATT M G C W S alpha 2 (merosin, congenitalmuscular dystrophy) G804u3 WIAF-11924 Z26653 8740 LAMA2, laminin,ACACTACCCG[A/G]AGAATTGGTC S A G R R alpha 2 (merosin, congenitalmuscular dystrophy) G804u4 WIAF-11943 Z26653 8577 LAMA2, laminin,ACCAAAATCA[A/G]TGATGGCCAG M A G N S alpha 2 (merosin, congenitalmuscular dystrophy) G804a5 WIAF-12089 Z26653 3372 LAMA2, laminin,CTCTGTGACT[G/A]CTTCCTCCCT M G A C Y alpha 2 (merosin, congenitalmuscular dystrophy) G804a6 WIAF-13227 Z26653 7047 LAMA2, laminin,GTCAGTCCTC[A/G]GGTGGAAGAT M A g Q R alpha 2 (nerosin, congenitalmuscular dystrophy) G804u7 WIAF-13437 Z26653 6791 LAMA2, laminin,TGTGAGAGCC[C/T]TGGATGGACC S C T L L alpha 2 (merosin, congenitalmuscular dystrophy) G805u1 WIAF-13416 U14755 799 LHX1, LIMAAGTAACAGC[A/G]GTGTTGCCAA M A G S G homeobox protein 1 G805u2 WIAF-13417U14755 743 LHX1, LIM GGCGAGGAAC[T/C]CTACATCATC M T C L P homeoboxprotein 1 G805u3 WIAF-13428 U14755 639 LHX1, LIMGCCGTCAGGG[C/A]ATCTCCCCTA S C A G G homeobox protein 1 G806u1 WIAF-11886AF026547 2656 CSPG3, chondroitin TTGGAGTTCC[A/G]GCCATGTCTA S A G P Psulfate proteo- glycan 3 (neurocan) G606u2 WIAF-11895 AF026547 529CSPG3, chondroitin TGACCTTCGC[T/C]GAGGCCCAGG S T C A A sulfate proteo-glycan 3 (neurocan) G806u3 WIAF-11896 AF026547 477 CSPG3, chondroitinCAGGTGACAG[G/A]TGTTGTGTTC M G A G D sulfate proteo- glycan 3 (neurocan)G806u4 WIAF-11917 AF026547 89 CSPG3, chondroitinACAGGATATC[A/G]CCGATGCCAG M A G T A sulfate proteo- glycan 3 (neurocan)G806u5 WIAF-11918 AF026547 213 CSPG3, chondroitinAGCGCAGCCC[G/C]AGATCCCCCT M G C R P sulfate proteo- glycan 3 (neurocan)G806u6 WIAF-11929 AF026547 769 CSPG3, chondroitinGCTTTGCCCG[G/A]GAGCTGGGGG S G A R R sulfate proteo- glycan 3 (neurocan)G806u7 WIAF-11931 AF026547 3148 CSPG3, chondroitinACATTGATGA[C/T]TGCCTCTGCA S C T D D sulfate proteo- glycan 3 (neurocan)G806u8 WIAF-11949 AF026547 209 CSPG3, chondroitinGCCAAGCGCA[G/A]CCCGAGATGC M G A A T sulfate proteo- glycan 3 (neurocan)G806a9 WIAF-13114 AF026547 3430 CSPG3, chondroitinATGAAAACAC[G/A]TGGATCGGCC S G A T T sulfate proteo- glycan 3 (neurocan)G806u10 WIAF-13420 AF026547 2113 CSPG3, chondroitinCCAGGGCAGA[C/G]TTCAGAGAAA M C G D S sulfate proteo- glycan 3 (neurocan)C806u11 WIAF-13431 AF026547 94 CSPG3, chondroitinATATCACCGA[T/C]CCCACCCAAA M T C P E sulfate proteo- glycan 3 (neurocan)G806u12 WIAF-13432 AF026547 275 CSPG3, chondroitinACAGGACTTC[C/T]CCATCCTGGT M C T P S sulfate proteo- glycan 3 (neurocan)G808a1 WIAF-13117 Y13276 177 TLX, tailless GCATGAGCAA[G/a]CCAGCCCGAT S Ga K K homolog (Drosophila) G810u1 WIAF-11890 X98248 990 SORT1, sortilin1 ATAACGATAC[C/A]ACAAGAAGGA S C A T T G810u2 WIAF-11891 X98248 1093SORT1, sortilin 1 GGCAGCAAAT[G/T]ATGACATCGT M G T D Y G810u3 WIAF-11907X98248 1683 SORT1, sortilin 1 CAGACGAAGG[T/C]CAATGCTGGC S T G G G G810u4WIAF-11908 X98248 1433 SORT1, sortilin 1 ATCTCCCAGA[A/C]ACTGAATGTT M A CK T G810u5 WIAF-11909 X98248 1354 SORT1, sortilin 1GAAGCCTGAA[A/G]ACAGTGAATG M A G N D G810u6 WIAF-11910 X98248 2180 SORT1,sortilin 1 TACCGGAAAA[T/A]TCCAGGGGAC M T A I N G810u7 WIAF-11911 X982482264 SORT1, sortilin 1 AACTTTTTGA[G/A]TCCGGAAAAA M G A S N G810u8WIAF-11925 X98248 1993 SORT1, sortilin 1 TCGAGACTAT[G/A]TTGTGACCAA M G AV I G810u9 WIAF-11939 X98248 1351 SORT1, sortilin 1GAGGAAGCCT[G/C]AAAACAGTGA M G C E Q G810u10 WIAF-11940 X98248 2232SORT1, sortilin 1 AACTAAAAGA[C/T]TTCAAAAAGA S C T D D G810a11 WIAF-13115X98248 1769 SORT1, sortilin 1 TCCATCAATA[T/A]CACCATTTGC M T A I NG810a12 WIAF-13116 X98248 1757 SORT1, sortilin 1CCTGGAGCTA[G/A]GTCCATGAAT M G A R K G811u1 WIAF-11893 HT3676 900synapsin I, alt, TGACCAAGAC[G/A]TATGCCACTG S G A T T transcript 1 G811u2WIAF-11894 HT3676 758 synapsin I, alt, ACCTTCTACC[C/T]CAATCACAAA M C T PL transcript 1 G811u3 WIAF-11927 HT3676 996 synapsin I, alt,CGTCAGTGTC[A/T]GGGAACTGGA S A T S S transcript 1 G811u4 WIAF-11928HT3676 1054 synapsin I, alt, CATGTCTCAC[A/G]CATACAAGCT M A G R Gtranscript 1 G811u5 WIAF-13418 HT3676 249 synapsin I, alt,TGTCCAACGC[G/A[GTCAAGCAGA S G A A A transcript 1 G811u6 WIAF-13419HT3676 432 synapsin I, alt, TTAAAGTAGA[G/A]CAGGCCGAAT S G A E Etranscript 1 G812u1 WIAF-11898 HT4564 163 STX1A, syntaxinCCAACCCCCA[T/C]GAGAAGACGA S T C D D 1A (brain) G812u2 WIAF-11942 HT4564604 STX1A, syntaxin TACAGGACAT[C/T]TTCATCGACA M G T M I 1A (brain)G813u1 WIAF-11934 U72508 939 Human B7 mRNA, TATGACACAG[G/A]ACACAGGATG MG A G E complete cds. G813u2 WIAF-11946 U72508 619 Human B7 mRNA,GCATCCACAT[G/C]CTCACAGGTC M G C M I complete cds. G816u1 WIAF-11897HT4230 151 HTR2B, 5-hydroxy- CTAACTGGTC[T/C]GCATTACAGA S T G S Stryptamine (serotonin) receptor 2B G816u2 WIAF-11930 HT4230 189 HTR2B,5-hydroxy- GAAATGAAAC[A/G]CATTGTTGAC M A G Q R tryptamine (serotonin)receptor 2B G818u1 WIAF-11902 HT2694 753 TPH, tryptophanGAGTTTTTCA[C/T]TCCACTCAAT S C T H H hydroxylase (tryptophan5-monooxygenase) G818u2 WIAF-11903 HT2694 775 TPH, tryptophanTGTGAGACAC[A/G]GTTCACATCC M A G S G hydroxylase (tryptophan5-monooxygenase) G818u3 WIAF-11904 HT2694 1211 TPH, tryptophanTATAATCCAT[A/C]TACACGCAGT M A C Y S hydroxylase (tryptophan5-monooxygenase) G818u4 WIAF-11905 HT2694 1081 TPH, tryptophanGATTACCTGC[A/C]AACAGGAATG M A C K Q hydroxylase (tryptophan5-monooxygenase) G818u5 WIAF-11933 HT2694 795 TPH, tryptophanCCTTCTATAC[C/T]CCAGAGCCAG S C T T T hydroxylase (tryptophan5-monooxygenase) G818u6 WIAF-11935 HT2694 1239 TPH, tryptophanTCCTGAAAGA[C/T]ACCAAGAGCA S C T D D hydroxylase (tryptophan5-monooxygenase) G822u1 WIAF-11906 HT0207 936 ASMT, acetyl-CAGACGGAAA[G/T]TGCTCACACC M G T K N serotonin N- methyltransferaseG822u2 WIAF-11919 HT0207 637 ASMT, acetyl- TGGTGCGACA[C/T]CGATAAAGCT M CT R W serotonin N- methyltransferase G822u3 WIAF-11936 HT0207 318 ASMT,acetyl- GAAAAGCTTT[C/T]TATCGAAACA S C T F F serotonin N-methyltransferase G822u4 WIAF-11937 HT0207 116 ASMT, acetyl-AATGACTACG[C/T]CAACGGCTTC M C T A V serotonin N- methyltransferaseG822u5 WIAF-11938 HT0207 930 ASMT, acetyl- ACTGGGCAGA[C/T]GGAAAGTGCT S CT D D serotonin N- methyltransferase G822u6 WIAF-13427 HT0207 120 ASMT,acetyl- ACTACGCCAA[C/A]GGCTTCATGG M C A N K serotonin N-methyltransferase G825u1 WIAF-11888 HT4974 236 ADAR, adenosineGCTCAGATAC[C/T]AGCAGCCTGG N C T Q * deaminase, RNA- specific G825u2WIAF-11900 HT4974 3076 ADAR, adenosine TCTTTGACAA[A/G]TCCTGCAGCG S A G KK deaminase, RNA specific G825u3 WIAF-11912 HT4974 2537 ADAR, adenosineCTTGATTGGG[G/C]AGAACGAGAA M G C E Q deaminase, RNA- specific G825u4WIAF-11941 HT4974 3558 ADAR, adenosine GATGGCTATG[A/G]CCTGGAGATC M A G DG deaminase, RNA- specific G825a5 WIAF-12090 HT4974 1305 ADAR, adenosineCCTGAGACCA[A/G]AAGAAACGCA M A G K R deaminase, RNA- specific G825u6WIAF-13426 HT4974 3683 ADAR, adenosine CCGCAGGGAT[C/T]TACTGAGACT S C T LL deaminase, RNA- specific G826u1 WIAF-12554 X99383 2109 ADARB1,adenosine AGATTACCAA[A/G]CCCAACGTGT S A G K K deaminase, RNA- specific,B1 (homolog of rat RED1) G826u2 WIAF-12566 X99383 1698 ADARB1, adenosineTGTCCTCCAG[T/G]GACAAGATTG M T G S R deaminase, RNA- specific, B1(homolog of rat RED1) G829u1 WIAF-13735 U49262 1404 DVL3, dishevelled 3GGGTTGGAGG[T/C]CCGTGACTGC M T C V A (homologous to Drosophila dsh) G83u1WIAF-10449 HT1576 1338 DNMT1, DNA ATGATGACCC[G/A]TCTCTTGAAG S G A P P(cytosine-5-)- methyltransferase 1 G83u2 WIAF-10450 HT1576 1871 DNMT1,DNA AAGCTGGTCT[A/C]CCAGATCTTC M A G Y C (cytosine-5-)- methyltransferase1 G83u3 WIAF-10468 HT1576 928 DNMT1, DNA AAATCCACAG[A/G]TTTCTGATGA M A GI V (cytosine-5-)- methyltransferase 1 G83u4 WIAF-10469 HT1576 1562DNMT1, DNA AATTCCGACT[C/T]CACCTATGAG M C T S L (cytosine-5-)-methyltransferase 1 G83u5 WIAF-10471 HT1576 2424 DNMT1, DNAGGGCCACGTC[G/A]GACCCTCTGC S G A S S (cytosine-5-)- methyltransferase 1G83u6 WIAF-10473 HT1576 3790 DNMT1, DNA GTTCTTCCTC[C/T]TGGACAATGT S C TL L (cytosine-5-)- methyltransferase 1 G83u7 WIAF-10486 HT1576 1581DNMT1, DNA AGGACCTGAT[C/A]AACAAGATCG S C A I I (cytosine-5-)-methyltransferase 1 G832u1 WIAF-12577 L13387 1129 PAFAH1B1, platelet-AGACATTCAC[A/T]GGACACAGAG S A T T T activating factor acetylhydrolase,isoform Ib, alpha subunit (45 kD) G835u1 WIAF-12555 U38276 1311 SEMA3F,sema CCTCTGGCTC[C/A]GTGTTCCGAG S C A S S domain, immuno- globulin domain(Ig), short basic domain, secreted, 3F G835u2 WIAF-12556 U38276 1229SEMA3F, sema ACTCACTTTG[A/T]TGACCTCCAG M A T D V domain, immuno-globulin domain (Ig), short basic domain, secreted, 3F G835u3 WIAF-12557U38276 1473 SEMA3F, sema GAACCTTCAC[G/A]CCATCTATGA S G A T T domain,immuno- globulin domain (Ig), short basic domain, secreted, 3F G835a4WIAF-13138 U38276 1726 SEMA3F, sema TGACCACCAC[A/T]TCGACCAGCT M A T M Ldomain, immuno- globulin domain (Ig), short basic domain, secreted, 3FG836u1 WIAF-12592 U28369 1056 SEMA3B, sema AACGACGTGC[G/A]CGGCCAGCGC M GA G D domain, immuno- globulin domain (Ig), short basic domain,secreted, 3B G836u2 WIAF-12609 U28369 1479 SEMA3B, semaGTCCTCCCCA[C/T]TGGGGGGCGC M C T T I domain, immuno- globulin domain(Ig), short basic domain, secreted, 3B G838u1 WIAF-12590 U72671 1107ICAM5, inter- CGCAGCTGGG[A/G]CCCAAGCTCT M A G T A cellular adhesionmolecule 5, telencephalin G838u2 WIAF-12591 U72671 966 ICAM5, inter-CAGGCAGCTG[A/G]TCTGCAACGT M A G I V cellular adhesion molecule 5,telencephalin G840a1 WIAF-12109 HT961 2232 SOS1, son of seven-CTCAGGCAAA[T/C]GGACTAAGCC S T C N N less (Drosophila) homolog 1 G840a2WIAF-12110 HT961 2404 SOS1, son of seven- ACCGTCTGAA[C/G]TTGTAGGGAG M CG L V less (Drosophila) homolog 1 G840u3 WIAF-12213 HT961 3813 SOS1, sonof seven- CAAGGGTACC[G/A]CGTCGATGCT S G A P P less (Drosophila) homolog1 G841u1 WIAF-12153 HT97420 1372 SMOH, smoothenedTTTTGGCTTC[C/G]TGGCCTTTGG M C G L V (Drosophila) homolog G841u2WIAF-12179 HT97420 858 SMOH, smoothened CCCAGTTCAT[G/T]GATCCTGCCC M G TM I (Drosophila) homolog G841u3 WIAF-12185 HT97420 1164 SMOH, smoothenedCTCTGAGTGG[G/C]ATTTGTTTTG S C G G G (Drosophila) homolog G847u1WIAF-12588 L41939 2019 EPHB2, EphB2 GGTCTGCAGT[G/T]GCCACCTGAA M G T G CG847u2 WIAF-12596 L41939 1806 EPHB2, EphB2 GTGTAACAGA[A/C]GACCGGCCTT S AC R R G847u3 WIAF-12613 L41939 2885 EPHB2, EphB2AGGCCATCAA[G/C]ATGGGGCAGT M G C K N G848u1 WIAF-12685 L40636 2484 EPHB1,EphB1 GTCAACAGTA[A/C]CCTGGTCTGC M A G N S G848u2 WIAF-12690 L40636 2020EPHB1, EphB1 CCTTCACTTA[T/C]GAGGATCCCA S T C Y Y G849u1 WIAF-11920D83492 1544 EPHB6, EphB6 ACCTGTGTGG[C/T]TCATCCACAC M C T A V G849u2WIAF-11921 D83492 3301 EPHB6, EphB6 CTTTGGGATA[C/T]TCATGTGGCA M C T L FG849u3 WIAF-13412 D83492 1139 EPHB6, EphB6 GAGACCTTCA[C/T]CCTTTACTAC M CT T I G849u4 WIAF-13413 D83492 1895 EPHB6, EphH6TTTGAGGTGC[A/C]AGGCTCAGCA M A C Q P G849u5 WIAF-13414 D83492 2338 EPHB6,EphB6 CTATGACCAG[G/A]CAGAAGACGA M G A A T G849u6 WIAF-13415 D83492 2567EPHB6, EphB6 GGGGCTTTGG[G/C]CTTCCTCCTG M C G A G G849u7 WIAF-13422D83492 2860 EPHB6, EphB6 GGCCATCCAG[G/A]CCCTCTGGGC M G A A T G849u8WIAF-13423 D83492 2782 EPHB6, EphB6 GGAGGTCATT[G/C]GGACAGGCTC M A C G RG849u9 WIAF-13424 D83492 3038 EPHB6, EphB6 TTCCTCAGGC[A/C]GCGGGAGGGC M AG Q R G849u10 WIAF-13425 D83492 3637 EPHB6, EphB6AGCCATTGGA[C/T]TGGAGTGCTA S C T L L G856u1 WIAF-12625 D45906 1323 LIMK2,LIM domain AGCTCAACCT[G/C]CTGACAGAGT S G C L L kinase 2 G858u1WIAF-12630 U65019 864 MADH2, MAD (mothers TTTGGTGTTC[G/A]ATAGCATATT S GA S S against decapenta- plegic, Drosophila) homolog 2 G86u1 WIAF-10437HT1701 263 RAD51, RAD51 TGAAGCAAAT[G/C]CAGATACTTC M G C A P (S.cerevisiae) homolog (E coli RecA homolog) G86u2 WIAF-10465 HT1701 861RAD51, RAD51 GCATCAGCCA[T/C]GATGGTAGAA M T C M T (S. cerevisiae) homolog(E coil RecA homolog) G86u3 WIAF-10466 HT1701 924 RAD51, RAD51TACAGAACAC[A/G]CTACTCGGGT M A G D G (S. cerevisiae) homolog (E coli RecAhomolog) G864a1 WIAF-13139 X82324 183 POU3F4, POU domain,CAGCAATCGG[C/t]ATCCCCTCCG M C t H Y class 3, tran- scription factor 4G866u1 WIAF-12637 HT0101 2576 glutamate receptorAAATCCCGTA[G/A]TCAATCCAAG M G A S N (GB:M64752) G866u2 WIAF-12638 HT01011131 glutamate receptor TAACAGGAAA[C/T]GTGCAGTTTA S C T N N (GB:M64752)G869u1 WIAF-13406 HT33620 3627 GRIN2C, glutamateAGATCAGCAG[G/T]GTACCCCCTC M G T R S receptor, iono- tropic, N-methylD-aspartate 2C G870u1 WZAF-11889 HT4468 714 SLC1A1, soluteCAGAAGAGTC[C/G]TTCACAGCTG S C G S S carrier family 1 (neuronal/epithelial high affinity glutamate transporter, system Xag), member 1G870u2 WIAF-11913 HT4468 314 SLC1A1, solute CTACAGAAAT[T/A]CTACTTTGCT MT A F Y carrier family 1 (neuronal/ epithelial high affinity glutamatetransporter, system Xag), member 1 G870u3 WIAF-11914 HT4468 579 SLC1A1,solute AAGTCAGTAC[G/A]CTCGATGCCA S G A T T carrier family 1 (neuronal/epithelial high affinity glutamate transporter, system Xag), member 1G870u4 WIAF-11922 HT4468 706 SLC1A1, solute GAACATGACA[G/A]AAGAGTCCTT MG A E K carrier family 1 (neuronal/ epithelial high affinity glutamatetransporter, system Xag), member 1 G870u5 WIAF-11923 HT4468 978 SLC1A1,solute GGAAGATCAT[A/G]GAAGTTGAAG M A G I M carrier family 1 (neuronal/epithelial high affinity glutamate transporter, system Xag), member 1G871ul WIAF-11892 HT3187 1004 SLC1A3, solute TTCTCTTAAC[G/C]AAGCCATCAT MG C E Q carrier family 1 (glial high affinity glutamate transporter),member 3 G871u2 WIAF-11915 HT3187 1154 SLC1A3, soluteTGTTGGCTTA[C/T]TCATTCACGC M C T L F carrier family 1 (glial highaffinity glutamate transporter), member 3 G871u3 WIAF-11926 HT3187 1412SLC1A3, solute GGCTGCCATT[T/G]TCATTGCTCA M T G F V carrier family 1(glial high affinity glutamate transporter), member 3 G871u4 WIAF-11944HT3187 1217 SLC1A3, solute AAACCCTTGG[G/A]TTTTTATTCC M G A V I carrierfamily 1 (glial high affinity glutamate transporter), member 3 G872u1WIAF-13433 HT4077 1271 SLC1A2, solute CTGTTGGAGC[A/C]ACCATTAACA S A C AA carrier family 1 (glial high affinity glutamate transporter), member 2G879u1 WIAF-11899 HT28317 1273 GRM2, glutamate GACTTTGTGC[T/C]CAACGTCAAGM T C L P receptor, metabo- tropic 2 G879u2 WIAF-11932 HT28317 2349GRM2, glutamate CTTCTATGTC[A/C]CCTCCAGTGA M A G T A receptor, metabo-tropic 2 G879u3 WIAF-13421 HT28317 2186 GRM2, glutamateATGCAAGTAT[G/T]TTGGGCTCGC M G T M I receptor, metabo- tropic 2 G879u4WIAF-13429 HT28317 2567 GRM2, glutamate CCCAGTTTGT[C/T]CCCACTGTTT S C TV V receptor, metabo- tropic 2 G879u5 WIAF-13436 HT28317 2046 CRM2,glutamate ACAGGTGGCC[A/G]TCTGCCTGGC M A G I V receptor, metabo- tropic 2G879u6 WIAF-13438 HT28317 2425 GRM2, glutamate GTCCTTGGCT[C/T]CCTCTTTGCGM G T C F receptor, metabo- tropic 2 G879u7 WIAF-13439 HT28317 2463GRM2, glutamate CCTCTTCCAG[C/T]CGCAGAAGAA M C T P S receptor, metabo-tropic 2 G880u1 WIAF-12164 HT33719 2117 GRM4, glutamateAGCCCGACCT[T/G]GGCACCTGCT S T G L L receptor, metabo- tropic 4 G880u2WIAF-12176 HT33719 2427 GRM4, glutamate GGACCTGTCG[C/T]TCATCTGCCT M C TL F receptor, metabo- tropic 4 G880u3 WIAF-12192 HT33719 2372 GRM4,glutamate ACCAGCGGAC[A/G]CTCGACCCCC S A G T T receptor, metabo- tropic 4G883a1 WIAF-13140 HT48863 1408 GRM7, glutamate ATCGCAAATC[C/a]ACAGGACAGGN C a C * receptor, metabo- tropic 7 G883a2 WIAF-13141 HT48863 2027GRM7, glutamate TCCTGTCTTC[C/t]TGGCAATGTT S C t L L receptor, metabo-tropic 7 G883a3 WIAF-13147 HT48863 1813 GRM7, glutamateTGTGCACACT[A/g]CCATGTAAGC S A g L L receptor, metabo- tropic 7 G883a4WIAF-13148 HT48863 1536 GRM7, glutamate TGTGCTGACT[A/t]CCGGGCTCTC M A tY F receptor, metabo- tropic 7 G883a5 WIAF-13149 HT48863 2473 GRM7,glutamate AAGCCAGAGG[G/a]GTTCTCAAGT S G a G G receptor, metabo- tropic 7G883a6 WIAF-13150 HT48863 2434 GRM7, glutamate TCATAGACTA[C/t]GATGAACACAS C t Y Y receptor, metabo- tropic 7 G884u1 WIAF-11916 U95025 1052 GRM8,glutamate CGAACTCTTG[C/A]CAATAATCGA M C A A D receptor, metabotropic 8G884u2 WIAF-11945 U95025 2016 GRM8, glutamate AAACAAACCG[T/C]ATCCACCGAAS T C R R receptor, metabo- tropic 8 G884u3 WIAF-11946 U95025 1852 GRM8,glutamate CAGGGCTTCA[G/A]GACGCGAACT M G A G R receptor, metabo- tropic 8G884u4 WIAF-11947 U95025 2078 GRM8, glutamate ATTAGTCCAG[C/G]ATCTCAGCTGM C G A G receptor, metabo- tropic 8 G884u5 WIAF-13430 U95025 1897 GRM8,glutamate TTTTCTCTGT[T/G]ATTCAATCAC M T G Y D receptor, metabo- tropic 8G884u6 WIAF-13435 U95025 2364 GRM8, glutamate TTACCATGTA[T/C]ACCACCTGCAS T C Y Y receptor, metabo- tropic 8 G885u1 WIAF-13434 AF002700 1363GFRA2, GDNF family AACTCAGGCC[C/A]CAGCACAGCC M C A P H receptor alpha 2G886a1 WIAF-13142 U95847 497 GFRA1, GDNF familyGAAGTCCCTC[T/a]ACAACTGCCG M T a Y N receptor alpha 1 G886a2 WIAF-13143U95847 1385 GFRA1, GDNF family GTCTGAGAAT[G/a]AAATTCCCAC M G a E Kreceptor alpha 1 G886a3 WIAF-13151 U95847 781 GFRA1, GDNF familyGCGTGTCCAA[T/C]GATGTCTGCA S T c N N receptor alpha 1 G892u1 WIAF-11956U12140 798 NTRK2, neuro- TGGGCAATCC[A/C]TTTACATGCT S A G P P trophictyrosine kinase, receptor, type 2 G892u2 WIAF-11957 U12140 834 NTRK2,neuro- GGATCAAGAC[T/A]CTCCAACAGC S T A T T trophic tyrosine kinase,receptor, type 2 G892u3 WIAF-11958 U12140 956 NTRK2, neuro-GCAAATCTGG[C/T]CGCACCTAAC M C T A V trophic tyrosine kinase, receptor,type 2 G892u4 WIAF-11960 U12140 1738 NTRK2, neuro-CTCCAAGTTT[G/A]GCATCAAAGG M G A G S trophic tyrosine kinase, receptor,type 2 G892u5 WIAF-11962 U12140 2486 NTRK2, neuro-GTCGGTGGCC[A/C]CACAATGCTG M A G H R trophic tyrosine kinase, receptor,type 2 G892u6 WIAF-11965 U12140 1106 NTRK2, neuro-TCCTTAAGGA[T/C]AACTAACATT M T C I T trophic tyrosine kinase, receptor,type 2 G892u7 WIAF-11966 U12140 2085 NTRK2, neuro-AGGATGCCAG[T/C]GACAATGCAC S T C S S trophic tyrosine kinase, receptor,type 2 G892u8 WIAF-11967 U12140 2230 NTRK2, neuro-GGACCTCAAC[A/C]AGTTCCTCAG M A C K Q trophic tyrosine kinase, receptor,type 2 G892u9 WIAF-11968 U12140 2223 NTRK2, neuro-AGCATGGGGA[C/T]CTCAACAAGT S C T D D trophic tyrosine kinase, receptor,type 2 G892u10 WIAF-11992 U12140 1602 NTRK2, neuro-GTAATCAAAT[C/T]CCTTCCACAG S C T I I trophic tyrosine kinase, receptor,type 2 G892u11 WIAF-11998 U12140 1354 NTRK2, neuro-TACTAAAATA[C/T]ATGTTACCAA M C T H Y trophic tyrosine kinase, receptor,type 2 G892u12 WIAF-11999 U12140 1944 NTRK2, neuro-CATTTGTTCA[G/C]CACATCAAGC M G C Q H trophic tyrosine kinase, receptor,type 2 G892u13 WIAF-12000 U12140 2103 NTRK2, neuro-CACGCAAGGA[C/T]TTCCACCGTG S C T D D trophic tyrosine kinase, receptor,type 2 G892u14 WIAF-12001 U12140 1860 NTRK2, neuro-CTGTCATTAT[T/C]GGAATGACCA S T C I I trophic tyrosine kinase, receptor,type 2 G892a15 WIAF-13144 U12140 1868 NTRK2, neuro-ATTGGAATGA[C/G]CAAGATCCCT M C G T S trophic tyrosine kinase, receptor,type 2 G892a16 WIAF-13145 U12140 1903 NTRK2, neuro-CCAGTACTTT[C/T]GCATCACCAA M G T G C trophic tyrosine kinase, receptor,type 2 G892a17 WIAF-13146 U12140 1965 NTRK2, neuro-GACATAACAT[T/G]GTTCTGAAAA M T G I M trophic tyrosine kinase, receptor,type 2 G892u18 WIAF-13442 U12140 958 NTRK2, neuro-AAATCTGGCC[G/T]CACCTAACCT M G T A S trophic tyrosine kinase, receptor,type 2 G892u19 WIAF-13446 U12140 2502 NTRK2, neuro-TGCTGCCCAT[T/C]CGCTGGATGC S T C I I trophic tyrosine kinase, receptor,type 2 G892u20 WIAF-13447 U12140 2317 NTRK2, neuro-GATGCTGCAT[A/T]TAGCCCAGCA M A T I L trophic tyrosine kinase, receptor,type 2 G892u21 WIAF-13448 U12140 2364 NTRK2, neuro-CGTCCCAGCA[C/A]TTCGTGCACC M C A H Q trophic tyrosine kinase, receptor,type 2 G892u22 WIAF-13449 U12140 2507 NTRK2, neuro-CCCATTCGCT[G/A]GATCCCTCCA N G A W * trophic tyrosine kinase, receptor,type 2 G892u23 WIAF-13471 U12140 2389 NTRK2, neuro-TTTGCCCACC[A/C]CGAACTCCCT S A C R R trophic tyrosine kinase, receptor,type 2 G892u24 WIAF-13472 U12140 2416 NTRK2, neuro-GGAGAACTTG[C/T]TCGTGAAAAT S C T L L trophic tyrosine kinase, receptor,type 2 G892u25 WIAF-13474 U12140 359 NTRK2, neuro-GGGATCTCGT[C/T]CTGGATAAGG M C T S F trophic tyrosine kinase, receptor,type 2 G892u26 WIAF-13479 U12140 1044 NTRK2, neuro-TGTATTGGGA[T/C]GTTGGTAACC S T C D D trophic tyrosine kinase, receptor,type 2 G9u1 WIAF-10222 J03826 1130 FDXR, ferredoxinGGTATAAGAG[C/T]CGCCCTGTCG S C T S S reductase G9u2 WIAF-10258 J03826 388FDXR, ferredoxin CCGGAGCTGC[A/C]GGAGGCCTAC M A G Q R reductase G900u1WIAF-11970 HT3470 497 STX4A, syntaxin 4A TGCAATTCAA[T/C]GCACTCCGAA M T CM T (placental) G901u1 WIAF-11969 HT27792 758 STX3A, syntaxin 3ATGCACACAGT[G/A]GACCACGTGG S G A V V G901u2 WIAF-11971 HT27792 317 STX3A,syntaxin 3A ACGTCCGGAA[C/A]AAACTGAAGA M C A N K G901u3 WIAF-12002HT27792 611 STX3A, syntaxin 3A AGCAAGCCCT[C/T]AGTGAGATTG S C T L LG901u4 WIAF-12003 HT27792 909 STX3A, syntaxin 3ACCTCAATTAA[C/A]ACTCCCCTAA — G A — — G901u5 WIAF-12004 HT27792 163 STX3A,syntaxin 3A ATTGAGGAAA[C/T]TCGGCTTAAC M C T T I G901a6 WIAF-13152HT27792 82 STX3A, syntaxin 3A CAGCTGACAC[A/C]GGATGATGAT M A G Q R G901u7WIAF-13453 HT27192 828 STX3A, syntaxin 3A CCGGAAGAAA[T/C]TGATAATTAT S TC L L G901u8 WIAF-13455 HT27792 226 STX3A, syntaxin 3ATACAGTATCA[T/C]TCTCTCTGCA M T C I T G902u1 WIAF-13454 HT27744 848 STX5A,syntaxin 5A ACTTCCAGTC[T/A]GTCACCTCCA S T A S S G902u2 WIAF-13456HT27744 338 STX5A, syntaxin 5A ATTTCGTGAG[A/G]GCCAAGGGCA S A G R RG905u1 WIAF-12202 HT27789 487 CREBL1, cAMP TCCAGATCAA[C/T]GTTATCCCCA S CT N N responsive element binding protein- like 1 G905u2 WIAF-12219HT27789 151 CREBL1, cAMP ATTCTGCCCT[A/T]GATCAAGTGG S A T L L responsiveelement binding protein- like 1 G905u3 WIAF-12230 HT27789 649 CREBL1,cAMP AGTCCCTGTC[C/G]CCTTCAGGAT S C G S S responsive element bindingprotein- like 1 G906u1 WIAF-12214 HT4372 2127 N-ethylmaleimide-AAGGGAAGAA[G/A]GTCTGGATAG S G A K K sensitive factor G906u2 WIAF-12221HT4372 514 N-ethylmaleimide- GGGAGAGCCT[G/A]CGACAGGGAA M G A A Tsensitive factor G908u1 WIAF-12201 HT3665 98 RAB5A, RAB5A,GCCCAAATAC[T/G]GGAAATAAAA S T G T T member RAS oncogene family G91u1WIAF-10438 HT1848 496 ERCC1, excision TCGTGCGCAA[C/T]GTGCCCTGGG S C T NN repair cross- complementing rodent repair deficiency, com-plementation group 1 (includes over- lapping antisense sequence) G91u2WIAF-10439 HT1848 367 ERCC1, excision CTGGCGCCAC[G/A]TGCCCCACAG S C A TT repair cross- complementing rodent repair deficiency, complementationgroup 1 (includes overlapping anti- sense sequence) G914a1 WIAF-13210HT3672 252 synaptobrevin 1 GCAGTGCTGC[C/A]AAGCTAAAGA S G A A A G915a1WIAF-12115 D63506 1390 Homo sapiens mRNA TTACCTTGGT[G/A]TTCCCATTGT M G AV I for unc- 18homologue, complete cds. G915u2 WIAF-12293 D63506 685Homo sapiens mRNA ACAGCTTGTT[G/A]AAAAAAAGCT M G A E K for unc-18homologue, complete cds. G916a1 WIAF-13209 HT28523 308 HuntingtinGAGCACTTTT[C/T]GGAGGCCAGC M C T S L associated protein 1-like proteinG916a2 WIAF-13211 HT28523 762 Huntingtin CGGAGGACTT[G/C]GTCCCCCACG M G CL F associated protein 1-like protein G916a3 WIAF-13212 HT28523 560Huntingtin GAGCTCAGAA[C/T]GTCTCTAAGG M C T T N associated protein 1-likeprotein G917u1 WIAF-11972 U79734 1075 HIP1, huntingtinAGAGCCAGCG[G/A]GTTGTGCTGC S G A R R interacting protein 1 G917u2WIAF-11973 U79734 1005 HIP1, huntingtin GACCACTTAA[T/C]TGAGCGACTA M T CI T interacting protein 1 G917u3 WIAF-11977 U79734 1539 HIP1, huntingtinCTGCAAGGCA[G/A]CCTGGAAACT M G A S N interacting protein 1 G917u4WIAF-12005 U79734 817 HIP1, huntingtin TGGTGGTGAT[C/T]CCTGCAGAGG S C T II interacting protein 1 G917u5 WIAF-12006 U79734 1906 HIP1, huntingtinGCTGGAGCCA[G/C]TATCTGGCCT M G C Q H interacting protein 1 G917a6WIAF-13157 U79734 993 HIP1, huntingtin AAGGATGAGA[A/G]GGACCACTTA M A G KR interacting protein 1 G919u1 WIAF-11974 D30742 707 CAMK4, calcium/ACTGCGCACC[T/C]GAAATTCTTA S T C P P calmodulin dependent protein kinaseIV G919u2 WIAF-11991 D30742 1139 CAMK4, calcium/AGAGCCACAA[G/A]GCTAGCCGAG S G A K K calmodulin dependent protein kinaseIV G919u3 WIAF-12007 D30742 834 CAMK4, calcium/CATGTTCAGG[A/T]GAATTCTGAA N A T R * calmodulin dependent protein kinaseIV G919u4 WIAF-13443 D30742 1088 CAMK4, calcium/TGGCCTCTTC[C/G]CGCCTGGGAA S C G S S calmodulin- dependent protein kinaseIV G920u1 WIAF-11979 X78520 1952 CLCN3, chlorideATGACATTCC[T/C]GATCGTCCAG S T C P P channel 3 G920u2 WIAF-11980 X785201819 CLCN3, chloride ATAGCCTTCC[C/T]TAATCCATAC M C T P L channel 3G920u3 WIAF-11981 X78520 2094 CLCN3, chloride CATTGGAGCG[A/C]TCGCAGCGAAGM A G I V channel 3 G920u4 WIAF-11983 X78520 2822 CLCN3, chlorideATATTTTCCG[A/G]AAGCTGGGAC S A G R R channel 3 G920u5 WIAF-11984 X785202745 CLCN3, chloride GCCATTGAAG[C/T]TTCCAAGCAT M C T L F channel 3G920u6 WIAF-11987 X78520 2499 CLCN3, chloride TCCCTTACCT[C/T]TCCTGACACAM G T V F channel 3 G920u7 WIAF-12008 X78520 1251 CLCN3, chlorideCATCATCACA[G/A]GTTACTTGGC M G A G S channel 3 G920u8 WIAF-12011 X78520888 CLCN3, chloride AGTACTAACA[C/T]TAACACGATT S C T L L channel 3 G920u9WIAF-13459 X78520 2804 CLCN3, chloride CAATCGACAT[T/C]GTCCTCCATA S T C II channel 3 G921u1 WIAF-11954 J02908 931 CLU, clusterinGAGACCTTGA[C/T]CAGGAAATAC M C T T I (complement lysis inhibitor, SP-40,40, sulfated glyco- protein 2, testosterone- repressed prostate message2, apolipoprotein J) G921u2 WIAF-11955 J02908 880 CLU, clusterinCCCTCCCAGG[C/T]TAAGCTCCGG M C T A V (complement lysis inhibitor, SP-40,40, sulfated glyco- protein 2, testosterone- repressed prostate message2, apolipoprotein J) G921u3 WIAF-11990 J02908 1051 CLU, clusterinCTCACCCAAG[G/C]CGAACACCAG M G C G A (complement lysis inhibitor, SP-40,40, sulfated glyco- protein 2, testosterone- repressed prostate message2, apolipoprotein J) G921u4 WIAF-13469 J02908 986 CLU, clusterinTCAACACCTC[C/T]TCCTTCCTGG S C T S S (complement lysis inhibitor, SP-40,40, sulfated glyco- protein 2, testosterone- repressed prostate message2, apolipoprotein J) G923u1 WIAF-11993 M19650 1059 Human 2′,3′-cyclicGAGCTAAGCC[G/A]GGGCAAGCTC M G A R Q nucleotide 3′- phosphodiesterasemRNA, complete cds. G923u2 WIAF-11994 M19650 1062 Human 2′,3′-cyclicCTAAGCCGGG[G/T]CAAGCTCTAT M G T G V nucleotide 3′- phosphodiesterasemRNA, complete cds. G923u3 WIAF-13445 M19650 1141 Human 2′,3′-cyclicTCTTCACGGG[C/A]TACTACGGGA S G A G G nucleotide 3′- phosphodiesterasemRNA, complete cds. G925u1 WIAF-11953 L11315 666 CAK, cell adhesionGGGTCATGAG[T/C]GTCTCTCTGC S T C S S kinase G925u2 WIAF-11959 L11315 2562CAK, cell adhesion TGCTGCCCAT[C/T]CGCTGGATCC S C T I I kinase G925u3WIAF-11996 L11315 2049 CAK, cell adhesion AAGATCTCCT[T/C]AGTCTTCATT S TC V V kinase G925u4 WIAF-13440 L11315 1601 CAK, cell adhesionTACCAGGAGC[C/T]CCGGCCTCGT M C T P L kinase G925u5 WIAF-13441 L11315 1629CAK, cell adhesion CGCCCCACTC[C/T]GCTCCCTGTG S C T S S kinase G925u6WIAF-13451 L11315 2262 CAK, cell adhesion TGGACAACGG[C/T]GACCTCAACC S CT G G kinase G926u1 WIAF-11961 AF018956 577 NRP1, neuropilin 1TGAAAGCTTT[C/T]ACCTGGACCC M G T D Y G926u2 WIAF-11963 AF018956 1683NRP1, neuropilin 1 CCACCCGATT[G/C]ATCAGGATCT M C G F L G926u3 WIAF-11975AF018956 2176 NRP1, neuropilin 1 GACCTTCTGG[T/C]ATCACATGTC M T C Y HG926u4 WIAF-11976 AF018956 2092 NRP1, neuropilin 1TTCCCAAGCT[G/T]ACGAAAATCA M G T D Y G926a5 WIAF-13158 AF018956 747 NRP1,neuropilin 1 TTTTTTACAC[C/T]GACAGCGCGA S C T T T G926a6 WIAF-13159AF018956 996 NRP1, neuropilin 1 ACTTGGGCCT[T/C]CTGCGCTTTC S T C L LG926u7 WIAF-13444 AF018956 644 NRP1, neuropilin 1GAAATCTGGG[A/C]TGGATTCCCT M A C D A G926u8 WIAF-13450 AF018956 1738NRP1, neuropilin 1 CAGAATGGAG[C/G]TGCTCGGCTG M C C L V G926u9 WIAF-13452AF018956 537 NRP1, neuropilin 1 TTGTCTTTCC[C/A]CCAAAGATGT S C A A AG926u10 WIAF-13457 AF018956 2197 NRP1, neuropilin 1TGGCTCCCAC[G/A]TCGGCACACT M G A V I G927u1 WIAF-11978 AF022860 870 NRP2,neuropilin 2 GGATTCCTAA[T/C]GAACAGATCA S T C N N G927u2 WIAF-11982AF022860 1674 NRP2, neuropilin 2 ATCACACCCC[T/G]GACATCCGAA S T G P PG927u3 WIAF-11985 AF022860 1250 NRP2, neuropilin 2TGGCACTCAG[C/A]TATCGCCCTC M G A G D G927u4 WIAF-11986 AF022860 1071NRP2, neuropilin 2 ATGGCTACTA[C/T]GTCAAATCCT S C T Y Y G927u5 WIAF-12009AF022860 726 NRP2, neuropilin 2 GTTCATCCAC[G/A]GCGATCCTCT S G A T TG927u6 WIAF-12010 AF022860 2522 NRP2, neuropilin 2GCAACCTCAG[G/T]GTCTGGCGCC M G T C V G927u7 WIAF-12012 AF022860 123 NRP2,neuropilin 2 GCTATATCAC[C/T]TCTCCCCGTT S C T T T G927a8 WIAF-13160AF022860 2427 NRP2, neuropilin 2 CTTTTCCAGT[G/T]CACATCCCAG S C T V VG927a9 WIAF-13161 AF022860 2430 NRP2, neuropilin 2TTGCAGTGGA[C/G]ATCCCAGAAA M C G D E G927a10 WIAF-13162 AF022860 2463NRP2, neuropilin 2 AACCATATCA[A/G]GATCAAATTG S A G E E G927a11WIAF-13163 AF022860 2473 NRP2, neuropilin 2 AGATGAAATT[G/T]ATCATCAATA MG T D Y G927u12 WIAF-13480 AF022860 724 NRP2, neuropilin 2TCGTTCATCG[A/T]CGGGGATCCT M A T T S G927u13 WIAF-13481 AF022860 767NRP2, neuropilin 2 ATGCCCGTGC[C/T]CAAGGATGCC M C T A V G930a1 WIAF-13164HT2608 609 GABRA2, gamma- ACAATGGGAA[G/a]AAATCAGTAG S G a K Kaminobutyric acid (GASA) A receptor, alpha 2 G931a1 WIAF-13153 HT26091111 GABRA3, gamma- ACTGGTTCAT[A/g]GCCCTCTGTT M A g I M aminobutyricacid (GABA) A receptor, alpha 3 G931a2 WIAF-13165 HT2609 1448 GABRA3,gamma- TGTCAGCAAG[G/A]TTCACAAAAT M G A V I aminobutyric acid (GASA) Areceptor, alpha 3 G932a1 WIAF-13154 HT27773 1077 GABRA4, gamma-CAAAAGAAAG[A/G]CATCAAACCC M A G T A aminobutyric acid (GABA) A receptor,alpha 4 G932a2 WIAF-13155 HT27773 1189 GABRA4, gamma-AGAACAAATG[C/A]TTTGGTTCAC M C A A D aminobutyric acid (GABA) A receptor,alpha 4 G936u1 WIAF-12308 HT3432 1027 GABRB2, gamma-AATTACGATG[C/T]TTCACCTGCA M C T A V aminobutyric acid (GABA) A receptor,beta 2 G936u2 WIAF-12327 HT3432 362 GABRB2, gamma-AAGGCTATGA[C/T]ATTCGTCTGA S C T D D aminobutyric acid (GABA) A receptor,beta 2 G936u3 WIAF-12328 HT3432 571 GABRB2, gamma-CTCTGGGTG[C/T]TGATACCTAT M C T P L aminobutyric acid (GABA) A receptor,beta 2 G939u1 WIAF-12330 HT2236 1219 GABRR2, gamma-CTGGATGGAA[G/C]CTACAGTGAG M G C S T aminobutyric acid (GABA) receptor,rho 2 G939u2 WIAF-12355 HT2236 1003 GABRR2, gamma-ACCACCATCA[T/C]CACGGGCGTG M T C I T aminobutyric acid (GABA) receptor,rho 2 G939u3 WIAF-12356 HT2236 1041 CABRR2, gamma-CGTCTCCTAC[G/A]TCAAGGCCGT M G A V I aminobutyric acid (GABA) receptor,rho 2 G950u1 WIAF-13622 U64871 725 Human putative GGTCCTGCTCC[A/C]GTTCACCACT M A C Q P protein-coupled receptor (GPR19)gene, complete cds. G950u2 WIAF-13624 U64871 443 Human putative GGATAACAGCA[A/C]GCCACATTTG M A C K T protein-coupled receptor (GPR19)gene, complete cds. G950u3 WIAF-13625 U64871 818 Human putative GCTGGGTAGTG[C/T]AACGTGCAAG M C T A V protein-coupled receptor (GPR19)gene, complete cds. G955a1 WIAF-13166 HT3860 5110 calcium channel,CTGGCCTCTT[T/c]ACCGTGGAGA S T c F F voltage-gated, alpha 1 subunit, Ltype, alt. transcript 1 G955a2 WIAF-13167 HT3860 3842 calcium channel,CTACCCCAAC[C/a]CAGAAACTAC M C a P T voltage-gated, alpha 1 subunit, Ltype, alt. transcript 1 G955a3 WIAF-13168 HT3860 5624 calcium channel,GTGTGCCCCA[G/a]AGTCCGAGCC M G a E K voltage-gated, alpha 1 subunit, Ltype, alt. transcript 1 G955a4 WIAF-13169 HT3860 5703 calcium channel,ATCAGCTTCT[A/g]CATGCTCTGT M A g Y C voltage-gated, alpha 1 subunit, Ltype, alt. transcript 1 G955a5 WIAF-13170 HT3860 5809 calcium channel,ACCACCTGGA[T/c]GAGTTTAAAA S T c D D voltage-gated, alpha 1 subunit, Ltype, alt. transcript 1 G955a6 WIAF-13171 HT3860 6616 calcium channel,CCGGCTCCAA[C/t]GCCAACATCA S C t N N voltage-gated, alpha 1 subunit, Ltype, alt. transcript 1 G956u1 WIAF-14187 HT2199 1334 calcium channel,CTTCACATAG[C/T]CCTTTTGGTA M C T A V voltage-gated, alpha 1D subunit,DHP-sensitive G956u2 WIAF-14188 HT2199 1452 calcium channel,AAGAGGACCC[A/T]GCTCCATGTG S A T P P voltage-gated, alpha 1D subunit,DHP-sensitive G956u3 WIAF-14189 HT2199 1614 calcium channel,GCTGGACAGA[C/T]GTGCTCTACT S C T D D voltage-gated, alpha 1D subunit,DHP-sensitive G956u4 WIAF-14190 HT2199 2540 calcium channel,GGCAAGTTTA[A/T]TTTTGATGAA M A T N I voltage-gated, alpha 1D subunit,DHP-sensitive. G956u5 WIAF-14191 HT2199 3210 calcium channel,TGCTGACCAC[T/C]GCTCCCCTGG S T C S S voltage-gatad, alpha 1D subunit,DHP-sensitive G956u6 WIAF-14192 HT2199 3326 calcium channel,TTGAAGATGA[C/T]AACTTTTGGA M C T T I voltage-gated, alpha 1D subunit,DHP-sensitive G956u7 WIAF-14193 HT2199 3274 calcium channel,ACTGGGTTAC[T/C]TTGACTATGC M T C F L voltage-gated, alpha 1D subunit,DHP-sensitive G956u8 WIAF-14194 HT2199 5127 calcium channel,TGCCTCTCAA[C/T)AGTGACGGGA S C T N N voltage-gated, alpha 1D subunit,DHP-sensitive G956u9 WIAF-14195 HT2199 5173 calcium channel,TGCTTTGGTT[C/T]GAACCGCTCT N C T R * voltage-gated, alpha 1D subunit,DHP-sensitive G956u10 WIAF-14200 HT2199 1437 calcium channel,CAGATATCGT[A/G]GCTGAAGAGG S A G V V voltage-gated, alpha 1D subunit,DHP-sensitive G956u11 WIAF-14201 HT2199 2567 calcium channel,ACCAAGCGCA[G/T]CACCTTTGAC M G T S I voltage-gated, alpha 1D subunit,DHP-sensitive G956u12 WIAF-14202 HT2199 4464 calcium channel,TCACCTTTTT[C/T]CGTCTTTTCC S C T F F voltage-gated, alpha 1D subunit,DHP-sensitive G956u13 WIAF-14215 HT2199 6927 calcium channel,GCTACAGCGA[C/T]GAAGAGCCAG S C T F F voltage-gated, alpha 1D subunit,DHP-sensitive G956u14 WIAF-14216 HT2199 6858 calcium channel,CCCGAGCCAA[C/T]GCGGATGTGG S C T N N voltage-gated, alpha 1D subunit,DHP-sensitive G957u1 WIAF-12306 HT4229 915 calcium channel,TACATCGAGC[G/A]TGCTTCATGA M G A ? R voltage-gated, alpha 1E subunit,alt. transcript 2 G957u2 WIAF-12309 HT4229 3555 calcium channel,GCCACTACAT[C/T]GTGAACCTGC S C T I I voltage-gated, alpha 1E subunit,alt. transcript 2 G957u3 WIAF-12310 HT4229 4116 calcium channel,ATGTAGATCA[C/T]GAGAAAAACA S C T H H voltage-gated, alpha 1E subunit,alt. transcript 2 G957u4 WIAF-12313 HT4229 5181 calcium channel,AGAACGACAA[T/C]GAACGCTGCG S T C N N voltage-gated, alpha 1E subunit,alt. transcript G957u5 WIAF-12314 HT4229 5971 calcium channel,TATGGACCCC[C/A]CCCATGACGG S G A T T voltage-gated, alpha 1E subunit,alt. transcript 2 G957u6 WIAF-12315 HT4229 5985 calcium channel,ATGACGGACA[G/T]TTCCAACAAC M G T Q H voltage-gated, alpha 1E subunit,alt. transcript 2 G957u7 WIAF-12329 HT4229 3100 calcium channel,GCTGGCAGCA[C/A]GCCTTGATGA M G A G S voltage-gated, alpha 1E subunit,alt. transcript 2 G957u8 WIAF-12331 HT4229 6492 calcium channel,CCCTCCTTTC[C/T]TACAGCTCCC M C T ? R voltage-gated, alpha 1E subunit,alt. transcript 2 G957u9 WIAF-12354 HT4229 3839 calcium channel,AACGCTTTGC[G/C]AACCAACAAA M G C G A voltage-gated, alpha 1E subunit,alt. transcript 2 G957u10 WIAF-12357 HT4229 4753 calcium channel,TGACTTCATC[A/G]CCCTCATTCG M A G T A voltage-gated, alpha 1E subunit,alt. transcript 2 G960u1 WIAF-12305 HT3336 1246 CACNB3, calciumTTGATCCCCT[C/T]TCATGAGCCC M C T S F channel, voltage dependent, beta 3subunit G960u2 WIAF-12340 HT3336 1288 CACNB3, calciumTGGACAGGAT[C/T]TTCACAGCGT M C T S F channel, voltage dependent, beta 3subunit G960u3 WIAF-12345 HT3336 641 CACNB3, calciumAGGCTCTCTT[C/T]CACTTCCTCA S C T F F channel, voltage dependent, beta 3subunit G960u4 WIAF-12346 HT3336 576 CACNB3, calciumCATCCCGCCT[G/A]TGGTCCTCCT M G A V M channel, voltage dependent, beta 3subunit C961u1 WIAF-12322 U95019 2037 CACNB2, calciumACTCTCCCTA[C/T]GTAGAGCCAA S C T Y Y channel, voltage dependent, beta 2subunit G961u2 WIAF-12347 U95019 2007 CACNB2, calciumCATTTGACTC[G/A]GAAACCCAGG S G A S S channel, voltage dependent, beta 2subunit G962u1 WIAF-12324 U95020 1423 CACNB4, calciumCCAATTGAAA[G/A]ACGAAGTCTA M G A R K channel, voltage dependent, beta 4subunit G962u2 WIAF-12342 U95020 167 CACNB4, calciumGGACCAGGTT[G/T]AAAAGATCCG M G T L F channel, voltage dependent, beta 4subunit G962u3 WIAF-12350 U95020 1571 CACNB4, calciumACACTTACAA[A/C]CCCCATAGGA S A G K K channel, voltage dependent, beta 4subunit G965u1 WIAF-12312 U40583 1276 CHRNA7, cholinergicTCCTGCACGC[T/C]GGCCAACCCC S T C G G receptor, nicotinic, alphapolypeptide 7 G968a1 WIAF-12119 HT27592 1008 CHRNA1, cholinergicACACACACCA[C/T]CGCTCACCCA S C T H H receptor, nicotinic, alphapolypeptide 1 (muscle) G968u2 WIAF-12368 HT27592 1136 CHRNA1,cholinergic AAGATTTTTA[C/T]AGAACACATT M C T T I receptor, nicotinic,alpha polypeptide 1 (muscle) G973a1 WIAF-13172 HT48774 800 CHRNA2,cholinergic ACACTTCAGA[C/t]GTGGTGATTG S C t D D receptor, nicotinic,alpha polypeptide 2 (neuronal) G973a2 WIAF-13173 HT48774 927 CHRNA2,cholinergic CTGGAACCCC[G/a]CTCATTTTGC M G a A T receptor, nicotinic,alpha polypeptide 2 (neuronal) G977u1 WIAF-13949 Y08419 366 CHRNA5,cholinergic AACTTATACC[T/C]CTTCCTTCAC S T C R R receptor, nicotinic,alpha polypeptide 5 G978a1 WIAF-13179 Y08417 1331 CHRNB3, cholinergicCCATTAGATA[C/a]ATTTCCACAC N C a Y * receptor, nicotinic, betapolypeptide 3 G983a1 WIAF-13214 HT0374 236 NPY, neuropeptide YCATACTACTC[C/A]CCCCTCCGAC S G A S S G983a2 WIAF-13215 HT0374 290 NPY,neuropeptide Y CAAAACGATC[C/T]AGCCCAGAGA S C T S S G983a3 WIAF-13216HT0374 111 NPY, neuropeptide Y GCCACTCCCC[C/T]TCTCCGCACT S C T L LG987a1 WIAF-13174 HT27830 159 PPYR1, pancreaticTGGTCTTCAT[C/T]GTCACTTCCT S C T I I polypeptide receptor 1 G987a2WIAF-13175 HT27830 222 PPYR1, pancreatic TGATCTGTGT[G/A]ACTGTGAGGC S G AV V polypeptide receptor 1 G987a3 WIAF-13176 HT27830 322 PPYR1,pancreatic GCCGCTGACC[C/T]CCCTCTACAC M G T A S polypeptide receptor 1G987a4 WIAF-13177 HT27830 1074 PPYR1, pancreaticTGGACGACTC[G/A]GACCATCTCC S G A S S polypeptide, receptor 1 G987a5WIAF-13178 HT27830 975 PPYR1, pancreatic CCTCCACCTG[C/T]GTCAACCCAT S C TC C polypeptide receptor 1 G987a6 WIAF-13180 HT27830 615 PPYR1,pancreatic AGTTCCTCCC[A/g]GATAAGCTGC S A g A A polypeptide receptor 1G987a7 WIAF-13181 HT27830 718 PPYR1, pancreaticGGGCTTCATC[C/T]TGGTCTGTTA S C T L L polypeptide receptor 1 G987a8WIAF-13182 HT27830 745 PPYR1, pancreatic CATCTACCGG[C/t]GCCTGCAGAG M C tR C polypeptide receptor 1 G987a9 WIAF-13183 HT27830 842 PPYR1,pancreatic GTGATGCTCC[T/A]GGCCTTTGCC M T A V E polypeptide receptor 1G987a10 WIAF-13184 HT27830 852 PPYR1, pancreaticTCGCCTTTGC[C/T]GTGCTCTGGC S C T A A polypeptide receptor 1 G987a11WIAF-13185 HT27830 889 PPYR1, pancreatic CAACAGCCTG[G/a]AACACTCGCA M G aE K polypeptide receptor 1 G987a12 WIAF-13186 HT27830 924 PPYR1,pancreatic CCATCTGCCA[C/T]CCGAACCTCA S C T H H polypeptide receptor 1G989u1 WIAF-13573 D86519 891 NPY6R, neuro- TGACTCATGC[C/T]TACTGGGCCA S CT A A peptide Y receptor Y6 G989u2 WIAF-13588 D86519 465 NPY6R, neuro-ACCACCCAGC[A/C]TCTAATACAA S A G A A peptide Y receptor Y6 G989u3WIAF-13591 D86519 980 NPY6R, neuro- GAGCCCTTCC[G/A]CAACCTCTCT M G A R Hpeptide Y receptor Y6 G991u1 WIAF-12390 HT97376 336 Notch2AAGCTACTTG[C/T]GTTCAGAAAA S C T C C G993u1 WIAF-12359 U95299 1343NOTCH4, Notch TCCACACTCT[G/T]CCTGTGTCAG H G T C F (Drosophila) homolog 4G993u2 WIAF-12361 U95299 2020 NOTCH4, Notch TAACCACCAC[A/C]AACACAACCC HA G K E (Drosophila) homolog 4 G993u3 WIAF-12384 U95299 5775 NOTCH4,Notch CCGCCTATTC[G/T]CATTGCCGGA S C T S S (Drosophila) homolog 4 G996a1WIAF-13213 HT3329 356 OPRM1, opioid CTTAGATCCC[A/G]ACCTCTCCCA M A G N Dreceptor, mu 1 LPLa4 WIAF-13314 HT1320 443 LPL, lipoproteinATGTATGACA[C/T]TTGCCTGCCA M C T S I lipase LPLa5 WIAF-13315 HT1320 579LPL, lipoprotein GACAGCATCT[G/A]GCCCGGTTTA S G A V V lipase LPLa6WIAF-13316 HT1320 609 LPL, lipoprotein TGGACGAGCA[C/A]TTTAACTACC S C A EE lipase LPLa7 WIAF-13317 HT1320 1338 LPL, lipoproteinCAAATAAGAC[C/A]TACTCCTTCC S C A T V lipase LPLa8 WIAF-13318 HT1320 1117LPL, lipoprotein CAATCTGCCC[T/C]ATGAGATCAA M T C Y D lipase LPLa9WIAF-13319 HT1320 715 LPL, lipoprotein CAGAATTACT[G/A]GCCTCCATCC M C A CS lipase LPLa10 WIAF-13320 HT1320 834 LPL, lipoproteinCTGGTCGAAC[C/A]ATTGGAATCC M C A S R lipase LPLa11 WIAF-13321 HT1320 951LPL, lipoprotein GACTTGCACA[T/A]CTCCACCAGC M T A D E lipase LPLa12WIAF-13322 HT1320 1595 LPL, lipoprotein AATAACAACT[C/C]AGCCTCAAAC N C GS * lipase LPLa13 WIAF-13323 HT1320 1597 LPL, lipoproteinTAAGAAGTCA[G/A]GCTGAAACTG M G A G S lipase LPLa14 WIAF-13324 HT1320 1606LPL, lipoprotein AGGCTGAAAC[T/C]CGGCGAATCT T C — — lipase LPLa15WIAF-13325 HT1320 1611 LPL, lipoprotein GAAACTGGGC[G/A]AATcTACAGA — G A— — lipase

While this invention has been particularly shown and described withreferences to preferred embodiments thereof, it will be understood bythose skilled in the art that various changes in form and details may bemade therein without departing from the scope of the inventionencompassed by the appended claims.

1. A method of diagnosing or aiding in the diagnosis of a vasculardisease in an individual comprising a) obtaining a nucleic acid samplefrom the individual; and b) determining the nucleotide present atnucleotide position 2210 of the thrombospondin-1 gene, wherein presenceof a G at nucleotide position 2210 is indicative of increased likelihoodof a vascular disease in the individual as compared with an individualhaving an A at nucleotide position 2210, and wherein presence of an A atnucleotide position 2210 is indicative of decreased likelihood of avascular disease in the individual as compared with an individual havinga G at nucleotide position
 2210. 2. The method of claim 1, wherein thethrombospondin-1 gene has the nucleotide sequence of SEQ ID NO:
 1. 3.The method of claim 1, wherein the vascular disease is selected from thegroup consisting of atherosclerosis, coronary heart disease, myocardialinfarction, stroke, peripheral vascular diseases, venous thromboembolismand pulmonary embolism.
 4. A method for predicting the likelihood thatan individual will have a vascular disease, comprising the steps of: a)obtaining a DNA sample from an individual to be assessed; and b)determining the nucleotide present at nucleotide position 2210 of thethrombospondin-1 gene, wherein presence of a G at nucleotide position2210 is indicative of increased likelihood of a vascular disease in theindividual as compared with an individual having an A at nucleotideposition
 2210. 5. The method according to claim 4, wherein thethrombospondin-I gene has the nucleotide sequence of SEQ ID NO:
 1. 6.The method according to claim 4, wherein the individual is an individualat risk for development of a vascular disease.
 7. The method accordingto claim 4, wherein the vascular disease is selected from the groupconsisting of atherosclerosis, coronary heart disease, myocardialinfarction, stroke, peripheral vascular diseases, venous thromboembolismand pulmonary embolism.
 8. A nucleic acid molecule comprising all or aportion of the nucleic acid sequence of SEQ ID NO: 1 wherein saidnucleic acid molecule is at least 10 nucleotides in length and whereinthe nucleic acid sequence comprises a polymorphic site at nucleotideposition 2210 of SEQ ID NO:
 1. 9. The nucleic acid molecule according toclaim 8, wherein the nucleotide at the polymorphic site is differentfrom a nucleotide at the polymorphic site in a corresponding referenceallele.
 10. An allele-specific oligonucleotide that hybridizes to thenucleic acid molecule of claim
 8. 11. A peptide of SEQ ID NO: 2 which isat least ten contiguous amino acids, wherein the peptide comprises theserine at amino acid position 700 of SEQ ID NO:
 2. 12. A method ofdiagnosing or aiding in the diagnosis of a vascular disease in anindividual comprising a) obtaining a biological sample comprisingthrombospondin-1 protein or relevant portion thereof from theindividual; and b) determining the amino acid present at amino acidposition 700 of the thrombospondin-1 protein, wherein presence of anasparagine at amino acid position 700 is indicative of increasedlikelihood of a vascular disease in the individual as compared with anindividual having a serine at amino acid position 700, and whereinpresence of a serine at amino acid position 700 is indicative of reducedlikelihood of a vascular disease in the individual as compared with anindividual having an asparagine at amino acid position
 700. 13. Themethod of claim 12, wherein the thrombospondin-1 protein has the aminoacid sequence of SEQ ID NO:
 2. 14. The method of claim 12, wherein thevascular disease is selected from the group consisting ofatherosclerosis, coronary heart disease, myocardial infarction, stroke,peripheral vascular diseases, venous thromboembolism and pulmonaryembolism.
 15. A nucleic acid molecule comprising all or a portion of thenucleic acid sequence of SEQ ID NO: 3 wherein said nucleic acid moleculeis at least 10 nucleotides in length and wherein the nucleic acidsequence comprises a polymorphic site at nucleotide position 1186 of SEQID NO:
 3. 16. The nucleic acid molecule according to claim 15, whereinthe nucleotide at the polymorphic site is different from a nucleotide atthe polymorphic site in a corresponding reference allele.
 17. Anallele-specific oligonucleotide that hybridizes to the nucleic acidmolecule of claim
 15. 18. A peptide of SEQ ID NO: 4 which is at leastten contiguous amino acids, wherein the peptide comprises the proline atamino acid position 387 of SEQ ID NO:
 4. 19. A method of diagnosing oraiding in the diagnosis of a vascular disease in an individualcomprising a) obtaining a biological sample comprising thrombospondin-4protein or relevant portion thereof from the individual; and b)determining the amino acid present at amino acid position 387 of thethrombospondin-4 protein, wherein presence of an alanine at amino acidposition 387 is indicative of increased likelihood of a vascular diseasein the individual as compared with an individual having a proline atamino acid position 387, and wherein presence of a proline at amino acidposition 387 is indicative of reduced likelihood of a vascular diseasein the individual as compared with an individual having an alanine atamino acid position
 387. 20. The method of claim 19, wherein thethrombospondin-4 protein has the amino acid sequence of SEQ ID NO: 4.21. The method of claim 19, wherein the vascular disease is selectedfrom the group consisting of atherosclerosis, coronary heart disease,myocardial infarction, stroke, peripheral vascular diseases, venousthromboembolism and pulmonary embolism.
 22. A nucleic acid moleculeselected from the group consisting of the genes listed in the Table,wherein said nucleic acid molecule is at least 10 nucleotides in lengthand comprises a polymorphic site identified in the Table, wherein anucleotide at the polymorphic site is different from a nucleotide at thepolymorphic site in a corresponding reference allele.
 23. A nucleic acidmolecule according to claim 22, wherein said nucleic acid molecule is atleast 15 nucleotides in length.
 24. A nucleic acid molecule according toclaim 22, wherein said nucleic acid molecule is at least 20 nucleotidesin length.
 25. A nucleic acid molecule according to claim 22, whereinthe nucleotide at the polymorphic site is the variant nucleotide for thegene listed in the Table.
 26. An allele-specific oligonucleotide thathybridizes to a portion of a gene selected from the group consisting ofthe genes listed in the Table, wherein said portion is at least 10nucleotides in length and comprises a polymorphic site identified in theTable, wherein a nucleotide at the polymorphic site is different from anucleotide at the polymorphic site in a corresponding reference allele.27. An allele-specific oligonucleotide according to claim 26 that is aprobe.
 28. An allele-specific oligonucleotide according to claim 26,wherein a central position of the probe aligns with the polymorphic siteof the portion.
 29. An allele-specific oligonucleotide according toclaim 26 that is a primer.
 30. An allele-specific oligonucleotideaccording to claim 29, wherein the 3′ end of the primer aligns with thepolymorphic site of the portion.
 31. An isolated gene product encoded bya nucleic acid molecule according to claim
 22. 32. A method of analyzinga nucleic acid sample, comprising obtaining the nucleic acid sample froman individual; and determining a base occupying any one of thepolymorphic sites shown in the Table.
 33. A method according to claim32, wherein the nucleic acid sample is obtained from a plurality ofindividuals, and a base occupying one of the polymorphic positions isdetermined in each of the individuals, and wherein the method furthercomprising testing each individual for the presence of a diseasephenotype, and correlating the presence of the disease phenotype withthe base.